var images_info;if (!images_info) images_info =[]; images_info["66"]={"66000":{"type":"graphic_diagnosticimage","displayName":"Radiograph of foreign body associated with hand infection","title":"Radiograph of foreign body associated with hand infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of foreign body associated with hand infection</div><div class=\"cntnt\"><img style=\"width:354px; height:540px;\" src=\"images/SURG/66000_Radiogr_foreign_body_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A radiograph of the hand should be obtained to document the presence of any foreign bodies. This lateral view radiograph demonstrates embedded pieces of glass.</div><div id=\"graphicVersion\">Graphic 66000 Version 3.0</div></div></div>"},"66004":{"type":"graphic_table","displayName":"Changes in pregnancy and heart transplant concerns","title":"Normal physiologic changes during pregnancy and associated concerns in the heart transplant recipient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal physiologic changes during pregnancy and associated concerns in the heart transplant recipient</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Physiologic changes</td> <td class=\"subtitle1\">Associated concern in the pregnant heart transplant recipient</td> </tr> <tr> <td>Increased blood volume</td> <td>Hemodilution may affect serum drug levels.</td> </tr> <tr> <td>Increased heart rate</td> <td>Exacerbation is possible due to cyclosporine. The denervated heart does not respond to the autonomic nervous system.</td> </tr> <tr> <td>Increased cardiac output</td> <td>In a denervated heart, the cardiac output increases result primarily from volume changes and circulating catecholamines.</td> </tr> <tr> <td>Increased stroke volume</td> <td>Rejection may create systolic/diastolic dysfunction.</td> </tr> <tr> <td>Right ventricular enlargement/tricuspid regurgitation</td> <td>In patients requiring serial endomyocardial biopsies there is the potential for worsened tricuspid regurgitation.</td> </tr> <tr> <td>Sodium retention</td> <td>Increased edema; exacerbation of edema by prednisone.</td> </tr> <tr> <td>Decreased T-lymphocytes and T-helper cells</td> <td>Increased risk of infection; decreased risk of rejection.</td> </tr> <tr> <td>Decreased glucose tolerance</td> <td>Increased risk of diabetogenesis for patients on prednisone.</td> </tr> <tr> <td>Decreased gastrointestinal motility and tone</td> <td>Exacerbation of gastrointestinal symptoms with use of immunosuppressants. Exacerbation of reflux due to ulcerogenic effects of chronic steroids.</td> </tr> <tr> <td>Increased risk of urinary tract infections</td> <td>Risk increased secondary to immunosuppressive drugs.</td> </tr> <tr> <td>Hyperemic/edematous gums</td> <td>Worsened with immunosuppressive agents.</td> </tr> <tr> <td>Increased risk of cholelithiasis</td> <td>Exacerbated with use of azathioprine.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66004 Version 3.0</div></div></div>"},"66006":{"type":"graphic_table","displayName":"Parkinson disease organizations","title":"Parkinson disease organizations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parkinson disease organizations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">American Parkinson Disease Association</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>135 Parkinson Avenue</p> <p>Staten Island, NY 10305</p> <p><a href=\"http://www.apdaparkinson.org/\" target=\"_blank\">www.apdaparkinson.org</a></p> <p><a href=\"mailto:apda&#64;apdaparkinson.org\">apda&#64;apdaparkinson.org</a></p> <p>Tel: 1-800-223-2732</p> <p>Fax: 718-981-4399</p> </td> </tr> <tr> <td class=\"subtitle2_left\">European Parkinson's Disease Association</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>1 Cobden Road</p> <p>Sevenoaks</p> <p>Kent</p> <p>TN13 3UB</p> <p>United Kingdom</p> <p><a href=\"http://www.epda.eu.com/\" target=\"_blank\">www.epda.eu.com</a></p> <p><a href=\"mailto:info&#64;epda.eu.com\" title=\"info&#64;epda.eu.com\" class=\"oLinkEmail\">info&#64;epda.eu.com</a></p> </td> </tr> <tr> <td class=\"subtitle2_left\">National Parkinson Foundation, Inc.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>200 SE 1st Street</p> <p>Suite 800</p> <p>Miami, FL 33131</p> <p><a href=\"http://www.parkinson.org/\" target=\"_blank\">www.parkinson.org</a></p> <p><a href=\"mailto:contact&#64;parkinson.org\">contact&#64;parkinson.org</a></p> <p>Tel: 1-800-473-4636</p> <p>Fax: 305-537-9901</p> </td> </tr> <tr> <td class=\"subtitle2_left\">Parkinson's Disease Foundation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>1359 Broadway, Suite 1509</p> <p>New York, NY 10018</p> <p><a href=\"http://www.pdf.org/\" target=\"_blank\">www.pdf.org</a></p> <p><a href=\"mailto:info&#64;pdf.org\">info&#64;pdf.org</a></p> <p>Tel: 1-800-457-6676</p> <p>Fax: 212-923-4778</p> </td> </tr> <tr> <td class=\"subtitle2_left\">Parkinson Society Canada</td> </tr> <tr> <td class=\"indent1\"> <p>4211 Yonge Street, Suite 316</p> <p>Toronto, ON M2P 2A9</p> <p>Canada</p> <p><a href=\"http://www.parkinson.ca/\" target=\"_blank\">www.parkinson.ca</a></p> <p><a href=\"mailto:info&#64;parkinson.ca\" spellcheck=\"true\">info&#64;parkinson.ca</a></p> <p>Tel: 1-800-565-3000</p> <p>Fax: 416-227-9600</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Updated November 2016.</div><div id=\"graphicVersion\">Graphic 66006 Version 6.0</div></div></div>"},"66007":{"type":"graphic_diagnosticimage","displayName":"Metacarpal neck fracture with minimal angulation","title":"Metacarpal neck fracture with minimal angulation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metacarpal neck fracture with minimal angulation</div><div class=\"cntnt\"><img style=\"width:309px; height:360px;\" src=\"images/EM/66007_Metacarpal_neck_fx_min_angu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This fracture of the neck of the&nbsp;fifth metacarpal is nondisplaced and minimally angulated.&nbsp;A faint radiolucent fracture line can be seen (arrow).</div><div class=\"graphic_reference\">Courtesy of Josh Bloom, MD, MPH.</div><div id=\"graphicVersion\">Graphic 66007 Version 4.0</div></div></div>"},"66008":{"type":"graphic_picture","displayName":"Secondary syphilis - oral fissure","title":"Secondary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Secondary syphilis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/66008_Sec_syphilis_oral_fissure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fissured papule is present at the oral commissure in this patient with secondary syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66008 Version 3.0</div></div></div>"},"66009":{"type":"graphic_figure","displayName":"Positive SAECG predicts outcomes with NSVT","title":"The signal averaged ECG predicts outcome in patients with nonsustained ventricular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">The signal averaged ECG predicts outcome in patients with nonsustained ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:496px; height:304px;\" src=\"images/CARD/66009_SAECGoutcomeNSVT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a trial of 1925 patients with coronary artery disease, asymptomatic nonsustained ventricular tachycardia, and left ventricular dysfunction, the signal averaged ECG (SAECG) predicted outcome, particularly in those with a left ventricular ejection fraction (LVEF) &lt;30 percent. The two- and five-year event rates for patients with filtered QRS duration &gt;114 ms were 17 and 36 percent, respectively, compared with 10 and 23 percent, respectively, with a QRS ≤114 ms (p = 0.0001). In patients with an LVEF ≥30 percent, the two- and five-year event rates were 6 and 13 percent, respectively and 11 and 22 percent, respectively, for a QRS ≤ or &gt;114 ms (p = 0.01).</div><div class=\"graphic_reference\">Data from: Gomes JA, Cain ME, et al. Circulation 2001; 104:436.</div><div id=\"graphicVersion\">Graphic 66009 Version 5.0</div></div></div>"},"66011":{"type":"graphic_table","displayName":"Classification of pancreatic fistulas","title":"Classification of pancreatic fistulas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of pancreatic fistulas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td rowspan=\"2\">1. External </td> <td>High output (&#62;200 mL/day)</td> </tr> <tr> <td>Low output (&#60;200 mL/day)</td> </tr> <tr> <td>Internal</td> <td>Pancreatic ascites, pleural effusion, communication with other viscera or retroperitoneum or mediastinum</td> </tr> <tr> <td rowspan=\"4\">2. Based on underlying disease process </td> <td>Acute pancreatitis</td> </tr> <tr> <td>Chronic pancreatitis</td> </tr> <tr> <td>Pancreatic cancer and other pancreatic neoplasms</td> </tr> <tr> <td>Normal pancreas</td> </tr> <tr> <td rowspan=\"3\">3. Based on the immediate predisposing cause </td> <td>Postoperative (pancreatoduodenectomy, distal pancreatectomy, surgery on organs adjacent to pancreas)</td> </tr> <tr> <td>Percutaneous drainage of pancreatic fluid collections</td> </tr> <tr> <td>Trauma</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Dia T Simmons, MD, Santhi Swaroop Vege, MD, and Suresh T Chari, MD.</div><div id=\"graphicVersion\">Graphic 66011 Version 2.0</div></div></div>"},"66013":{"type":"graphic_picture","displayName":"Normal fundus appearance","title":"Normal fundus appearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal fundus appearance</div><div class=\"cntnt\"><img style=\"width:396px; height:328px;\" src=\"images/NEURO/66013_Normal_fundus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66013 Version 2.0</div></div></div>"},"66014":{"type":"graphic_algorithm","displayName":"Occult SUI flowchart","title":"Risk of developing postoperative stress urinary incontinence in women undergoing surgery for pelvic organ prolapse","html":"<div class=\"graphic\"><div style=\"width: 1172px\" class=\"figure\"><div class=\"ttl\">Risk of developing postoperative stress urinary incontinence in women undergoing surgery for pelvic organ prolapse</div><div class=\"cntnt\"><img style=\"width:1152px; height:615px;\" src=\"images/OBGYN/66014_Occult_SUI_flowchart.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SUP: suburethral plication; TVT: tension-free vaginal tape; RPU: retropubic urethropexy; NS: needle suspension; PS: pubovaginal sling; MUS: midurethral sling.<br />* Symptoms recorded per patient report.<br />&para; Denotes abdominal procedures, all other procedures were performed vaginally.</div><div id=\"graphicVersion\">Graphic 66014 Version 6.0</div></div></div>"},"66017":{"type":"graphic_diagnosticimage","displayName":"Pneumopericardium in a neonate","title":"Pneumopericardium in a neonate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumopericardium in a neonate</div><div class=\"cntnt\"><img style=\"width:368px; height:276px;\" src=\"images/PEDS/66017_Pneumopericardium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pericardium is clearly delineated by air surrounding heart and air in lung.</div><div class=\"graphic_reference\">Courtesy of Gerardo Cabrera-Meza, MD.</div><div id=\"graphicVersion\">Graphic 66017 Version 3.0</div></div></div>"},"66018":{"type":"graphic_figure","displayName":"Blocks measurement kyphosis","title":"Blocks measurement of kyphosis","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Blocks measurement of kyphosis</div><div class=\"cntnt\"><img style=\"width:493px; height:499px;\" src=\"images/PC/66018_Blocks_measurement_kyphosis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66018 Version 1.0</div></div></div>"},"66019":{"type":"graphic_figure","displayName":"Macroscopic magnetic moment","title":"Creation of macroscopic magnetic moment in MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Creation of macroscopic magnetic moment in MRI</div><div class=\"cntnt\"><img style=\"width:339px; height:210px;\" src=\"images/PULM/66019_Macroscopic_magnetic_moment.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Excess of magnetic moments aligned parallel to the main magnetic field (B<sub>0</sub>) creates a macroscopic magnetic moment (M<sub>0</sub>). The random phases of the individual magnetic vectors cause cancellation of the transverse component of magnetization.</div><div id=\"graphicVersion\">Graphic 66019 Version 1.0</div></div></div>"},"66021":{"type":"graphic_diagnosticimage","displayName":"Radiation field stage I HL","title":"Involved-node radiation for a patient with stage I Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Involved-node radiation for a patient with stage I Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:483px; height:246px;\" src=\"images/HEME/66021_RadiatfieldstgIHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with stage I Hodgkin lymphoma involving the left neck. The gross tumor volume (PET + node) is displayed in red.</div><div class=\"graphic_footnotes\">PET: positron emission tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Yahalom J, Hoppe RT, Mauch PM. Principles and Techniques of Radiation Therapy for Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al, (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 66021 Version 7.0</div></div></div>"},"66023":{"type":"graphic_figure","displayName":"Mallet finger mechanism","title":"Mallet finger mechanism","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Mallet finger mechanism</div><div class=\"cntnt\"><img style=\"width:454px; height:342px;\" src=\"images/EM/66023_Mallet_finger_mechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mallet finger injuries involve disruption of the insertion of the extensor tendon, usually caused by a direct blow to the fingertip.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company, Upper Extremity Disorders. Copyright &#169;2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66023 Version 1.0</div></div></div>"},"66024":{"type":"graphic_figure","displayName":"Probability of ovulation","title":"Probability of ovulation relative to midpoint of the cycle","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Probability of ovulation relative to midpoint of the cycle</div><div class=\"cntnt\"><img style=\"width:455px; height:248px;\" src=\"images/OBGYN/66024_Probability_of_ovulation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Analysis of WHO 1981 data.</div><div class=\"graphic_reference\">Reproduced with permission from the Institute for Reproductive Health, Georgetown University.</div><div id=\"graphicVersion\">Graphic 66024 Version 1.0</div></div></div>"},"66025":{"type":"graphic_figure","displayName":"United States TB incidence 2002-2016","title":"Tuberculosis incidence overall and among United States- and foreign-born persons* — United States, 2002 to 2016","html":"<div class=\"graphic\"><div style=\"width: 864px\" class=\"figure\"><div class=\"ttl\">Tuberculosis incidence overall and among United States- and foreign-born persons* — United States, 2002 to 2016</div><div class=\"cntnt\"><img style=\"width:844px; height:378px;\" src=\"images/ID/66025_US_TB_incidence_2002_2016.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TB: tuberculosis.<br />* United States-born persons are those persons who were born in the United States or a United States island area, or were born abroad to a United States citizen parent or parents. All others, including naturalized United States citizens, are considered foreign-born persons.</div><div class=\"graphic_reference\">Reproduced from: Schmit KM, Wansaula Z, Pratt R, et al. Tuberculosis — United States, 2016. MMWR Morb Mortal Wkly Rep 2017; 66:289.</div><div id=\"graphicVersion\">Graphic 66025 Version 9.0</div></div></div>"},"66027":{"type":"graphic_picture","displayName":"Accessory auricle","title":"Accessory auricular appendage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Accessory auricular appendage</div><div class=\"cntnt\"><img style=\"width:259px; height:293px;\" src=\"images/PEDS/66027_Accssry_auricular_appendage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the accessory hillock (composed of skin, subcutaneous fat, and/or cartilage) near the border of the sternocleidomastoid muscle.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 66027 Version 1.0</div></div></div>"},"66029":{"type":"graphic_picture","displayName":"Mandibular gingivitis","title":"Mandibular gingivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mandibular gingivitis</div><div class=\"cntnt\"><img style=\"width:396px; height:273px;\" src=\"images/PEDS/66029_Mandibular_gingivitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heavy plaque accumulations and gingivitis with papillary edema and marginal erythema can be seen on the mandibular teeth of this child with orthodontic appliances. Oral hygiene has been better on the maxillary anterior teeth, and the gingiva appears healthy.</div><div class=\"graphic_reference\">Courtesy of Ann Griffen, DDS, MS.</div><div id=\"graphicVersion\">Graphic 66029 Version 1.0</div></div></div>"},"66030":{"type":"graphic_figure","displayName":"Change in FEV1 with aging","title":"Change in FEV1 with aging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Change in FEV1 with aging</div><div class=\"cntnt\"><img style=\"width:414px; height:258px;\" src=\"images/PULM/66030_Change_in_FEV1_with_aging.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A general theoretical model of growth and decline of lung function with time. Curve A (red) shows normal change over time. Curve B (blue) indicates reduced lung growth and therefore a decrease in the peak level of lung function. Curve C (green) shows a premature decline in lung function, while Curve D (orange) depicts an accelerated decline in lung function. The horizontal gray line represents the development of COPD.</div><div class=\"graphic_reference\">Adapted from Weiss, ST, Sparrow, D (Eds), Airways Responsiveness and Atopy in the Development of the Obstructive Airways Diseases, Raven Press, New York, 1989.</div><div id=\"graphicVersion\">Graphic 66030 Version 1.0</div></div></div>"},"66032":{"type":"graphic_figure","displayName":"Nocturnal asthma - effect of prednisone on BAL","title":"Effect of prednisone on BAL cellularity in nocturnal asthma","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Effect of prednisone on BAL cellularity in nocturnal asthma</div><div class=\"cntnt\"><img style=\"width:477px; height:245px;\" src=\"images/PULM/66032_Prednisone_BAL_nocturnal_as.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of a 3 PM prednisone dose on 4 AM bronchoalveolar lavage finding in nocturnal asthma. Prednisone (red column) led to a significant fall in the number of total white blood cells, neutrophils, eosinophils, lymphocytes, and macrophages when compared to placebo (blue column).</div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage.</div><div class=\"graphic_reference\">Redrawn from: Beam WR, Weiner DE, Martin RJ, Am Rev Respir Dis 1992; 146:1524.</div><div id=\"graphicVersion\">Graphic 66032 Version 3.0</div></div></div>"},"66035":{"type":"graphic_table","displayName":"Rx chancroid","title":"Treatment options for chancroid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment options for chancroid</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Drugs of choice</td> </tr> <tr> <td class=\"indent1\">Azithromycin 1 g orally&nbsp;in a single dose&nbsp;<strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Ceftriaxone 250 mg IM in a single dose</td> </tr> <tr> <td class=\"subtitle1_single\">Alternatives</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin* 500 mg orally twice daily for three days <strong>OR</strong> </td> </tr> <tr> <td class=\"indent1\">Erythromycin<sup><span style=\"font-size: 13px;\">&#182;</span></sup> base 500 mg orally&nbsp;three times daily for seven days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscular.<br />* Not recommended in pregnancy or breastfeeding.<br />¶&nbsp;Erythromycin is rarely used given gastrointestinal toxicity. Erythromycin ethylsuccinate 800 mg may be substituted for erythromycin base 500 mg.</div><div class=\"graphic_reference\">Adapted from: Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</div><div id=\"graphicVersion\">Graphic 66035 Version 4.0</div></div></div>"},"66037":{"type":"graphic_figure","displayName":"Safi modification of Crawford TAA classification","title":"Safi modification of Crawford TAA classification","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Safi modification of Crawford TAA classification</div><div class=\"cntnt\"><img style=\"width:525px; height:358px;\" src=\"images/SURG/66037_Crawford_classification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Crawford classification of thoracoabdominal aortic aneurysm is based upon the extent of aortic involvement.&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Type I arises from above the sixth intercostal space, usually near the left subclavian artery, and extends to include the origins of the celiac axis and superior mesenteric arteries. Although the renal arteries can also be involved, the aneurysm does not extend into the infrarenal aortic segment. </li>&#xD;&#xA;    <li>Type II aneurysm also arises above the sixth intercostal space, and may include the ascending aorta, but extends distal to include the infrarenal aortic segment, often to the level of the aortic bifurcation. </li>&#xD;&#xA;    <li>Type III aneurysm arises in the distal half of the descending thoracic aorta, below the sixth intercostal space, and extends into the abdominal aorta. </li>&#xD;&#xA;    <li>Type IV aneurysm generally involves the entire abdominal aorta from the level of the diaphragm to the aortic bifurcation.</li>&#xD;&#xA;    <li>Type V aneurysm arises in the distal half of the descending thoracic aorta, below the sixth intercostal space, and extends into the abdominal aorta, but is limited to the visceral segment.</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Adapted from: Safi HJ, Winnerkvist A, Miller CC 3rd, et al. Effect of extended cross-clamp time during thoracoabdominal aortic aneurysm repair. Ann Thorac Surg 1998; 66:1204.</div><div id=\"graphicVersion\">Graphic 66037 Version 8.0</div></div></div>"},"66038":{"type":"graphic_picture","displayName":"Congenital HSV 1","title":"Congenital herpes simplex viral disease-1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital herpes simplex viral disease-1</div><div class=\"cntnt\"><img style=\"width:396px; height:261px;\" src=\"images/OBGYN/66038_Congenital_HSV_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Congenital herpes simplex viral disease with wedge shaped involvement of the adrenal cortex in a markedly autolyzed 28 week fetus. Calcified infarcts in this region are nearly pathognomotic for herpes infection, which mostly go clinically unsuspected and silent in the mother.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 66038 Version 1.0</div></div></div>"},"66040":{"type":"graphic_diagnosticimage","displayName":"Jefferson fracture","title":"Jefferson fracture","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Jefferson fracture</div><div class=\"cntnt\"><img style=\"width:483px; height:241px;\" src=\"images/PEDS/66040_Jefferson_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note how the lateral masses of C1 (arrows) are lateral to the lateral masses of C2 (triangles).</div><div class=\"graphic_reference\">Reproduced with permission from: Graber, MA, Kathol, M. Cervical spine radiographs in the trauma patient. Am Fam Physician 1999; 59:331. A: Copyright © 1999 Mark Graber, MD. B: Copyright © 1999 David Klemm.</div><div id=\"graphicVersion\">Graphic 66040 Version 2.0</div></div></div>"},"66041":{"type":"graphic_algorithm","displayName":"Diagnostic approach to isolated neutropenia in children","title":"Diagnostic approach to isolated neutropenia in children","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to isolated neutropenia in children</div><div class=\"cntnt\"><img style=\"width:568px; height:388px;\" src=\"images/HEME/66041_Diag_appr_isolated_neut_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBC: complete blood count; PE: physical examination; ESR: erythrocyte sedimentation rate; FTT: failure to thrive.</div><div id=\"graphicVersion\">Graphic 66041 Version 3.0</div></div></div>"},"66042":{"type":"graphic_table","displayName":"Verification level","title":"Trauma center verification level: setting and capability for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Trauma center verification level: setting and capability for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Freestanding children's hospital or comprehensive pediatric care unit within general hospital organization</td> <td class=\"subtitle1\">Peds LI</td> <td class=\"subtitle1\">Peds LII</td> </tr> <tr> <td>Pediatric trauma service</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric surgeon as pediatric medical director</td> <td class=\"centered\">E</td> <td class=\"centered\">D</td> </tr> <tr> <td>Pediatric surgeon</td> <td class=\"centered\">E (At least 2)</td> <td class=\"centered\">E&ndash; (At least 1)</td> </tr> <tr> <td>Pediatric emergency medicine physicians</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric critical care medicine physicians</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Other surgical specialists with pediatric specialty experience</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric-specific trauma continuing medical education for pediatric medical director and liaisons</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric emergency department area</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric intensive care unit</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric acute care unit</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric rehabilitation</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric resuscitation equipment in all appropriate patient care areas</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric trauma program manager</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric trauma registrar</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Child life and family support programs</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric social work child protective services</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Child maltreatment assessment capability</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Injury prevention and community outreach programs (pediatric trauma education programs)</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> <tr> <td>Pediatric trauma research</td> <td class=\"centered\">E</td> <td class=\"centered\">D</td> </tr> <tr> <td>Minimum number of annual trauma admissions of children younger than 15 years</td> <td class=\"centered\">200</td> <td class=\"centered\">100</td> </tr> <tr> <td>Pediatric trauma performance improvement program</td> <td class=\"centered\">E</td> <td class=\"centered\">E</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">E: expected; D: desired.</div><div class=\"graphic_reference\">Reproduced with permission from: Committee on Trauma. Resources for optimal care of the injured patient, 6th edition. American College of Surgeons. Chicago, Illinois, 2014. Copyright &copy; 2014 American College of Surgeons.</div><div id=\"graphicVersion\">Graphic 66042 Version 2.0</div></div></div>"},"66043":{"type":"graphic_picture","displayName":"Washing catheter chromoendosc","title":"Washing catheter used during chromoendoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Washing catheter used during chromoendoscopy</div><div class=\"cntnt\"><img style=\"width:446px; height:230px;\" src=\"images/GAST/66043_Washing_catheter_chromoendo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Washing catheter for chromoendoscopy (A) creates a fine mist spray (B) necessary for optimal application of reagents to the gastrointestinal mucosa.</div><div class=\"graphic_reference\">Courtesy of Marcia I Canto, MD, MHS.</div><div id=\"graphicVersion\">Graphic 66043 Version 2.0</div></div></div>"},"66044":{"type":"graphic_table","displayName":"Cytokines radiation exposure","title":"Cytokine doses after radiation exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytokine doses after radiation exposure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cytokine</td> <td class=\"subtitle1\">Adult dose*</td> <td class=\"subtitle1\">Precautions</td> </tr> <tr> <td>G-CSF</td> <td>5 &#181;g/kg per day SQ until ANC &#62;1000/microL</td> <td>Sickle cell disease, significant coronary art disease, ARDS<sup>&#182;</sup></td> </tr> <tr> <td>Pegylated G-CSF</td> <td>6 mg SQ as a single dose </td> <td>as with G-CSF</td> </tr> <tr> <td>GM-CSF</td> <td>250 &#181;g/m2/day SQ until ANC &#62;1000/microL</td> <td>as with G-CSF</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating factor; ARDS: acute respiratory distress syndrome; ANC: absolute neutrophil count.<br />* Recommended doses of G-CSF and GM-CSF are similar for adults, pregnant women, and children. Dose for pegylated G-CSF for adolescents &gt;45 kg is the same as that for adults.<br />&para; Consider discontinuation of cytokines if pulmonary infiltrates develop at the time of neutrophil recovery.</div><div class=\"graphic_reference\">Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Intern Med 2004; 140:1037. Copyright &copy; 2004 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 66044 Version 17.0</div></div></div>"},"66045":{"type":"graphic_table","displayName":"PE AUB adolescent","title":"Physical examination of the adolescent with abnormal uterine bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical examination of the adolescent with abnormal uterine bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Examination finding</td> <td class=\"subtitle1\">Potential diagnosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vital signs</td> </tr> <tr> <td class=\"indent1\">Tachycardia, hypotension, orthostasis</td> <td>Life-threatening pregnancy complication (eg, ectopic pregnancy); bleeding disorder; severe anovulatory uterine bleeding; eating disorder</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fever</td> <td>Infection (PID, endometritis)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Growth parameters</td> </tr> <tr> <td class=\"indent1\">Short stature</td> <td>Turner syndrome, hypothalamic-pituitary disease</td> </tr> <tr> <td class=\"indent1\">Obesity (BMI &#62;30 kg/m<sup>2</sup>)</td> <td>PCOS</td> </tr> <tr> <td class=\"indent1\">Underweight (BMI &#60;18.5)</td> <td>Hypothalamic amenorrhea secondary to eating disorder, exercise, or weight loss from systemic disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Arm span &#62; height plus 5 cm</td> <td>Delayed epiphyseal closure secondary to hypogonadism</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Eyes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Visual field defects</td> <td>Pituitary tumor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin and hair</td> </tr> <tr> <td class=\"indent1\">Acanthosis nigricans</td> <td>PCOS, insulin resistance</td> </tr> <tr> <td class=\"indent1\">Abnormal bleeding (bruises, petechiae)</td> <td>Bleeding diathesis</td> </tr> <tr> <td class=\"indent1\">Striae</td> <td>Cushing syndrome</td> </tr> <tr> <td class=\"indent1\">Hyperpigmentation, vitiligo</td> <td>Adrenal insufficiency</td> </tr> <tr> <td class=\"indent1\">Low hair line</td> <td>Turner syndrome</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hirsutism, acne, male-pattern balding</td> <td>Hyperandrogenism (PCOS, CAH, androgen-secreting tumor, presence of Y chromosome)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neck</td> </tr> <tr> <td class=\"indent1\">Thyroid enlargement</td> <td>Hypothyroidism, hyperthyroidism</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Webbed neck</td> <td>Turner syndrome</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Thorax/breasts</td> </tr> <tr> <td class=\"indent1\">Shield chest, widely spaced nipples</td> <td>Turner syndrome</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Galactorrhea</td> <td>Hyperprolactinemia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Abdomen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Abdominal/pelvic mass</td> <td>Ovarian tumor, hematocolpos</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tanner staging</td> </tr> <tr> <td class=\"indent1\">Low for both breast and pubic hair</td> <td>Delayed sexual development (ie, constitutional delay of puberty)</td> </tr> <tr> <td class=\"indent1\">High for both breast and pubic hair</td> <td>Normal progression of puberty</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Divergent</td> <td>Asynchrony between estrogen- and androgen-dependent aspects of puberty (eg, androgen excess)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">External genitalia</td> </tr> <tr> <td class=\"indent1\">Imperforate hymen</td> <td>May be the cause of primary amenorrhea</td> </tr> <tr> <td class=\"indent1\">Clitoromegaly</td> <td>Hyperandrogenism (PCOS, CAH, androgen-secreting tumor, presence of Y chromosome)</td> </tr> <tr> <td class=\"indent1\">Perineal trauma</td> <td>Sexual abuse/assault</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vaginal discharge, genital ulcer, condyloma lata</td> <td>Sexually transmitted infection</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pelvic examination</td> </tr> <tr> <td class=\"indent1\">Depth of vagina, presence of cervix, uterus, ovaries</td> <td>Congenital vaginal or uterine anomalies</td> </tr> <tr> <td class=\"indent1\">Uterine enlargement</td> <td>Pregnancy or mass (eg, leiomyoma)</td> </tr> <tr> <td class=\"indent1\">Ovarian enlargement</td> <td>Ovarian cyst, possibly related to PCOS; ovarian mass</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PID: pelvic inflammatory disease; BMI: body mass index; PCOS: polycystic ovary syndrome; CAH: congenital adrenal hyperplasia.</div><div id=\"graphicVersion\">Graphic 66045 Version 2.0</div></div></div>"},"66046":{"type":"graphic_table","displayName":"The \"Get up and go\" test","title":"The \"Get up and go\" test for gait assessment in older adult patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The \"Get up and go\" test for gait assessment in&nbsp;older adult&nbsp;patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">The \"Get up and go\" test for gait assessment in&nbsp;older adult&nbsp;patients<sup>[1]</sup></td> </tr> <tr> <td colspan=\"2\">Have the patient sit in a straight-backed high-seat chair</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Instructions for patient:</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Get up (without use of armrests, if possible)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Stand still momentarily</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Walk forward 10 feet (3 meters)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Turn around and walk back to chair</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Turn and be seated</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Factors to note:</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Sitting balance</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Transfers from sitting to standing</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Pace and stability of walking</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Ability to turn without staggering</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Modified qualitative scoring<sup>[2]</sup></td> </tr> <tr> <td class=\"centered\">(1) No fall risk</td> <td class=\"centered\">Well-coordinated movements, without walking aid</td> </tr> <tr> <td class=\"centered\">(2) Low fall risk</td> <td class=\"centered\">Controlled, but adjusted movements</td> </tr> <tr> <td class=\"centered\">(3) Some fall risk</td> <td class=\"centered\">Uncoordinated movements</td> </tr> <tr> <td class=\"centered\">(4) High fall risk</td> <td class=\"centered\">Supervision necessary</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">(5) Very high fall risk</td> <td class=\"centered\">Physical support of stand by physical support necessary</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Timed test (record time from initial rising to re-seating)<sup>[3]</sup></td> </tr> <tr> <td class=\"subtitle3\">Age (years)</td> <td class=\"subtitle3\">Mean time (seconds)</td> </tr> <tr> <td class=\"centered\">60 to 69</td> <td class=\"centered\">8.1 (7.1 to 9.0)</td> </tr> <tr> <td class=\"centered\">70 to 79</td> <td class=\"centered\">9.2 (8.2 to 10.2)</td> </tr> <tr> <td class=\"centered\">80 to 99</td> <td class=\"centered\">11.3 (10.0 to 12.7</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Sources:<br /><OL>&#xD;&#xA;<LI>Reproduced with permission from: Fleming KC, Evand JM, Weber DC, Chutka DS. Practical Functional Assessment of Elderly Persons: A Primary-Care Approach [Symposium on Geriatrics-Part III]. Mayo Clinic Proceedings 1995; 70:890. Copyright © 1995 Mayo Foundation.</LI>&#xD;&#xA;<LI>From: Nordin E, Lindelöf N, Rosendahl E. Prognostic validity of the Timed Up-and-Go test, a modified Get-Up-and-Go test, staff's global judgement and fall history in evaluating fall risk in residential care facilities. Age Ageing 2008; 37:442. By permission of the British Geriatrics Society. Copyright © 2013 Oxford University Press.</LI>&#xD;&#xA;<LI>Data from: Bohannon RW. Reference Values for the Timed Up and Go Test: A Descriptive Meta-Analysis. J Geriatr Phys Ther 2006; 29:64.</LI></OL></div><div id=\"graphicVersion\">Graphic 66046 Version 9.0</div></div></div>"},"66047":{"type":"graphic_picture","displayName":"Neuroendocrine carcinoma stain","title":"Large cell neuroendocrine carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large cell neuroendocrine carcinoma</div><div class=\"cntnt\"><img style=\"width:389px; height:261px;\" src=\"images/PULM/66047_Neuroendocrine_carcinoma_st.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Synaptophysin immuno-peroxidase stain showing diffuse reactivity confirming that this tumor has neuroendocrine differentiation.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 66047 Version 1.0</div></div></div>"},"66048":{"type":"graphic_picture","displayName":"Bullous lupus","title":"Bullous lupus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous lupus</div><div class=\"cntnt\"><img style=\"width:504px; height:245px;\" src=\"images/RHEUM/66048_Bullous_lupus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple blisters in a young woman with bullous systemic lupus erythematosus.</div><div class=\"graphic_reference\">Courtesy of Samuel L Moschella, MD.</div><div id=\"graphicVersion\">Graphic 66048 Version 2.0</div></div></div>"},"66049":{"type":"graphic_picture","displayName":"Perivascular staining retina","title":"Perivascular staining on fluorescein angiography in retinal vasculitis ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perivascular staining on fluorescein angiography in retinal vasculitis </div><div class=\"cntnt\"><img style=\"width:377px; height:288px;\" src=\"images/RHEUM/66049_Perivascular_staining_retin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorescein angiogram in a patient with retinal vasculitis and systemic lupus erythematosus shows perivascular staining.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 66049 Version 3.0</div></div></div>"},"66051":{"type":"graphic_diagnosticimage","displayName":"Aortic root aneurysm in Marfan syndrome on chest film","title":"Aortic root aneurysm in Marfan syndrome on chest film","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic root aneurysm in Marfan syndrome on chest film</div><div class=\"cntnt\"><img style=\"width:283px; height:368px;\" src=\"images/CARD/66051_Aortic_root_aneurysm_Marfan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This aortogram in a young patient with Marfan syndrome demonstrates significant dilation of the aortic root (white arrows). There is also opacification of the left ventricle as a result of aortic regurgitation (black arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 66051 Version 4.0</div></div></div>"},"66052":{"type":"graphic_table","displayName":"Features of Mansonella spp I","title":"Features of <EM>Mansonella</EM> species causing human infection - I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of <EM>Mansonella</EM> species causing human infection - I</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&nbsp;</td> <td class=\"subtitle1\"><em>M. streptocera</em></td> <td class=\"subtitle1\"><em>M. ozzardi</em></td> <td class=\"subtitle1\"><em>M. perstans</em></td> </tr> <tr> <td class=\"subtitle2_left\">Geographic distribution</td> <td>Western and Central Africa</td> <td>Central and South America, Caribbean</td> <td>Sub-Saharan and North Africa, South America</td> </tr> <tr> <td class=\"subtitle2_left\">Transmission</td> <td>Transmitted via bite of infected <em>Culicoides</em> species (midge)</td> <td>Transmitted via bite of infected <em>Culicoides</em> species (midge) or by <em>Simulium amazonicum</em> (black fly)</td> <td>Transmitted via bite of infected <em>Culicoides </em>species (various species)</td> </tr> <tr> <td class=\"subtitle2_left\">Clinical features</td> <td>Usually asymptomatic but can cause chronic papulonodular dermatitis, pruritis, pigmentation changes, dermal thickening, and lymphadenopathy. May be difficult to distinguish from onchocerciasis.</td> <td>Usually asymptomatic but can be associated with urticaria, pruritic rash, edema, lymphadenopathy, arthralgias, fever, headache, vertigo, or pulmonary symptoms.</td> <td>Usually asymptomatic but can cause transient angioedema, urticaria, and pruritus and may be difficult to distinguish from loiasis. Other manifestations include headache, arthralgias, pericarditis, pleuritis, hepatitis, meningoencephalitis, and ocular symptoms.</td> </tr> <tr> <td class=\"subtitle2_left\">Site of adult parasites</td> <td>Dermal layers of the trunk and upper shoulder girdle</td> <td>Lymphatics and thoracic and peritoneal cavities</td> <td>Pericardial, pleural and peritoneal cavities; mesenteric, perirenal, and retroperitoneal tissues</td> </tr> <tr> <td class=\"subtitle2_left\">Site of microfilariae</td> <td>Skin</td> <td>Blood and skin</td> <td>Blood</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66052 Version 5.0</div></div></div>"},"66055":{"type":"graphic_picture","displayName":"Post radiation atypia benign","title":"Post-radiation atypia in benign prostatic epithelium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Post-radiation atypia in benign prostatic epithelium</div><div class=\"cntnt\"><img style=\"width:359px; height:285px;\" src=\"images/ONC/66055_Post_radiation_atypia_benig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Benign epithelial cells in an irradiated prostate gland show degenerative atypia and a &quot;streaming&quot; appearance (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 66055 Version 1.0</div></div></div>"},"66056":{"type":"graphic_table","displayName":"Bladder retraining PI","title":"Bladder training instructions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bladder training instructions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>These methods are to help you regain bladder control; think of it as \"mind over bladder.\"</td> </tr> <tr> <td>1.&nbsp;Start by going to the toilet and trying to urinate as often as your shortest interval (the length of time between trips to the bathroom) based on your bladder diary. For example, go every hour if that is what your diary shows as the shortest interval. Make these regular trips to the toilet while you are awake. You do not have to get up during the night!</td> </tr> <tr> <td>2. You must try to urinate whether you feel the need or not, even if you have just leaked urine.</td> </tr> <tr> <td class=\"sublist1_start\">3. If you get a strong urge to go to the bathroom before your scheduled time, use distraction or relaxation: </td> </tr> <tr> <td class=\"sublist1\">Stop, don't run to the bathroom! </td> </tr> <tr> <td class=\"sublist1\">Stand still or sit down if you can. </td> </tr> <tr> <td class=\"sublist1\">RELAX. Take a deep breath and let it out slowly. </td> </tr> <tr> <td class=\"sublist1\">Concentrate on making the need to urinate decrease or even go away, any way you can.&nbsp;(For example, you could imagine the pressure becoming less and less.) You can also try doing quick contractions (squeezes) of your pelvic floor muscles.</td> </tr> <tr> <td class=\"sublist1\">DISTRACT yourself, for example by doing math problems in your head.</td> </tr> <tr> <td class=\"sublist1\">When you feel IN CONTROL OF YOUR BLADDER, walk slowly to the bathroom, and then go.</td> </tr> <tr> <td>4. Keep this schedule until you can go one day without urine leakage. Then, increase the time between scheduled trips to the toilet by 15 minutes. When you can go one&nbsp;day on this new schedule without urine leakage, extend the time between bathroom trips again by 15 minutes.</td> </tr> <tr> <td>5. Keep this up until you can go four hours between trips to the toilet (which is NORMAL), or until you are comfortable. This may take several weeks.</td> </tr> <tr> <td>6. DON'T GET DISCOURAGED! Bladder training takes time and effort, but it is an effective way to get rid of incontinence without medication or surgery.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66056 Version 3.0</div></div></div>"},"66057":{"type":"graphic_picture","displayName":"Alopecia areata eyebrow","title":"Alopecia areata involving the eyebrow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia areata involving the eyebrow</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/66057_Alopecia_areata_eyebrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of eyebrow hair is present in this patient with alopecia areata.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66057 Version 4.0</div></div></div>"},"66058":{"type":"graphic_figure","displayName":"Slit lamp","title":"Slit lamp","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Slit lamp</div><div class=\"cntnt\"><img style=\"width:453px; height:493px;\" src=\"images/EM/66058_Slit_lamp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A basic slit lamp with typical features is illustrated.</div><div id=\"graphicVersion\">Graphic 66058 Version 1.0</div></div></div>"},"66059":{"type":"graphic_table","displayName":"Risk of recurrent systemic allergic reaction after stopping VIT","title":"Risk of recurrent systemic allergic reaction after stopping venom immunotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of recurrent systemic allergic reaction after stopping venom immunotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Elevated in:</td> </tr> <tr> <td class=\"indent1\">Adults compared with children</td> </tr> <tr> <td class=\"indent1\">Patients allergic to honey bee venom compared with those with vespid venom allergy</td> </tr> <tr> <td class=\"indent1\">Patients with severe pretreatment SARs</td> </tr> <tr> <td class=\"indent1\">Patients with SARs during VIT to treatment injections or re-stings</td> </tr> <tr> <td class=\"indent1\">VIT duration less than five years of maintenance VIT</td> </tr> <tr> <td class=\"indent1\">Elevated baseline serum tryptase</td> </tr> <tr> <td class=\"indent1\">Mastocytosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Patients with frequent exposure, such as gardeners, farmers, and beekeepers</td> </tr> <tr> <td class=\"subtitle1_single\">Possibly elevated in:</td> </tr> <tr> <td class=\"indent1\">Persistent high sensitivity on intradermal skin testing or in vitro testing for venom-specific IgE</td> </tr> <tr> <td class=\"indent1\">Patients with underlying cardiovascular or respiratory disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Patients taking medications, such as ACE inhibitors and/or beta-blockers</td> </tr> <tr> <td class=\"subtitle1_single\">Not influenced by:</td> </tr> <tr> <td class=\"indent1\">Sex</td> </tr> <tr> <td class=\"indent1\">Atopy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Venom-specific IgG level at discontinuation of VIT</td> </tr> <tr> <td class=\"subtitle1_single\">Diminished if:</td> </tr> <tr> <td class=\"indent1\">Skin tests and venom-specific IgE negative at discontinuation of VIT</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SAR: systemic allergic reaction; VIT: venom immunotherapy; IgE: immunoglobulin E; ACE: angiotensin-converting enzyme; IgG: immunoglobulin G.</div><div class=\"graphic_reference\">Adapted from: Golden DB, Demain J, Freeman T, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol 2017; 118:28.</div><div id=\"graphicVersion\">Graphic 66059 Version 6.0</div></div></div>"},"66062":{"type":"graphic_movie","displayName":"Fasciculations deltoid and triceps ALS","title":"Fasciculations of right deltoid and triceps in amyotrophic lateral sclerosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fasciculations of right deltoid and triceps in amyotrophic lateral sclerosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/66062_alsarfscconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:324px; height:243px;\" src=\"images/NEURO/66062_alsarfsc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lower motor neuron sign, fasciculations are apparent in the right deltoid (white arrow), biceps and triceps muscles.</div><div class=\"graphic_reference\">Courtesy of Nestor Galvez-Jimenez, MD, FACP.</div><div id=\"graphicVersion\">Graphic 66062 Version 3.0</div></div></div>"},"66064":{"type":"graphic_table","displayName":"US scheds controlled drugs","title":"Schedules of controlled substances in the United States*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Schedules of controlled substances in the United States*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Schedule</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Medical use?</td> <td class=\"subtitle1\">Potential for abuse/dependence</td> <td class=\"subtitle1\">Prescription</td> </tr> <tr class=\"divider_bottom\"> <td>I</td> <td>Heroin, marijuana, LSD<sup>&#182;</sup></td> <td>No</td> <td>High</td> <td>Not applicable</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">II</td> <td class=\"sublist1_start\">Narcotics:</td> <td class=\"divider_bottom\" rowspan=\"6\">Yes</td> <td class=\"divider_bottom\" rowspan=\"6\">High</td> <td class=\"divider_bottom\" rowspan=\"6\">Require a written prescription by a licensed practitioner. Refilling of individual prescriptions is prohibited.</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Codeine </li> <li>Fentanyl </li> <li>Hydrocodone and hydrocodone combinations (eg, with acetaminophen) </li> <li>Hydromorphone </li> <li>Morphine </li> <li>Methadone </li> <li>Oxycodone and oxycodone combinations (eg, with acetaminophen) </li> </ul> </td> </tr> <tr> <td class=\"sublist1_start\">Stimulants: </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Amphetamine </li> <li>Methamphetamine </li> <li>Methylphenidate </li> </ul> </td> </tr> <tr> <td class=\"sublist1_start\">Other: </td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\"> <ul> <li>Cocaine </li> <li>Pentobarbital, secobarbital </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">III</td> <td class=\"sublist1_start\">Narcotics:</td> <td class=\"divider_bottom\" rowspan=\"4\">Yes</td> <td class=\"divider_bottom\" rowspan=\"4\">Less than with Schedule I and II drugs</td> <td rowspan=\"9\">A prescription for a drug in Schedules III through V must be issued by a practitioner and may be communicated orally, in writing, or by facsimile to the pharmacist; may be refilled up to five times</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Buprenorphine </li> <li>Combination products with &#60;90 mg codeine/unit (eg, acetaminophen with codeine) </li> </ul> </td> </tr> <tr> <td class=\"sublist1_start\">Non-narcotics:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\"> <ul> <li>Dronabinol </li> <li>Ketamine </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">IV</td> <td class=\"sublist1_start\">Narcotics:</td> <td class=\"divider_bottom\" rowspan=\"4\">Yes</td> <td class=\"divider_bottom\" rowspan=\"4\">Less than with Schedule III drugs</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Tramadol and combinations (eg, with acetaminophen) </li> </ul> </td> </tr> <tr> <td class=\"sublist1_start\">Others:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\"> <ul> <li>Alprazolam </li> <li>Diazepam </li> <li>Clonazepam </li> <li>Lorazepam </li> <li>Midazolam </li> </ul> </td> </tr> <tr> <td>V</td> <td>Preparations containing limited quantities of certain narcotic and stimulant drugs used for antitussive, antidiarrheal, and analgesic purposes (eg, cough preparation with &#60;200 mg codeine/100 mL [eg, Robitussin AC])</td> <td>Yes</td> <td>Lower than with Schedule IV drugs</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Drugs and other substances that are considered controlled substances under the Controlled Substances Act are divided into five schedules based upon whether they have a currently accepted medical use in the United States and their relative abuse potential and likelihood of causing dependence when abused.<br />¶ Lysergic acid diethylamide.</div><div class=\"graphic_reference\">United States Department of Justice; Drug Enforcement Administration website <A spellcheck=true href=\"http://www.deadiversion.usdoj.gov/schedules/#list\" target=_blank>http://www.deadiversion.usdoj.gov/schedules/#list</A>.</div><div id=\"graphicVersion\">Graphic 66064 Version 5.0</div></div></div>"},"66065":{"type":"graphic_table","displayName":"Ddx intestinal atresia","title":"Differential diagnosis of intestinal obstruction in a newborn infant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of intestinal obstruction in a newborn infant</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Intestinal atresia (duodenal, jejunal, ileal, or colonic)&nbsp;</td> </tr> <tr> <td>Antral web</td> </tr> <tr> <td>Pyloric web</td> </tr> <tr> <td>Annular pancreas</td> </tr> <tr> <td>Malrotation&nbsp;(with volvulus, or obstruction due to Ladd's bands)</td> </tr> <tr> <td>Intussusception*</td> </tr> <tr> <td>Duodenal stenosis</td> </tr> <tr> <td>Ileal stenosis</td> </tr> <tr> <td>Internal hernia</td> </tr> <tr> <td>Congenital bands</td> </tr> <tr> <td>Meconium ileus</td> </tr> <tr> <td>Hirschsprung's disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Intussusception is very rare during the neonatal period. When it does occur, it is often associated with a pathological lead point, such as an intestinal duplication, Meckel diverticulum, or intestinal atresia. Indeed, intestinal atresia may be caused by intrauterine intussusception.</div><div id=\"graphicVersion\">Graphic 66065 Version 2.0</div></div></div>"},"66067":{"type":"graphic_figure","displayName":"Laryngeal cleft class","title":"Classification of laryngotracheal clefts","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Classification of laryngotracheal clefts</div><div class=\"cntnt\"><img style=\"width:461px; height:698px;\" src=\"images/PEDS/66067_Laryngeal_cleft_class.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Based on the Benjamin classification. Benjamin B, Inglis A. Minor congenital laryngeal clefts: Diagnosis and classification. Ann Otol Rhinol Laryngol 1989; 98:417.</div><div id=\"graphicVersion\">Graphic 66067 Version 3.0</div></div></div>"},"66068":{"type":"graphic_table","displayName":"Ogilvies syndrome associations","title":"Common clinical conditions associated with Ogilvie's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common clinical conditions associated with Ogilvie's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Trauma, especially fractures</td> </tr> <tr> <td>Obstetrical surgery, especially involving spinal anesthesia</td> </tr> <tr> <td>Pelvic, abdominal, or cardiothoracic surgery</td> </tr> <tr> <td>Major orthopedic surgery</td> </tr> <tr> <td>Severe medical illness, such as pneumonia, myocardial infarction, or heart failure</td> </tr> <tr> <td>Neurologic conditions</td> </tr> <tr> <td>Chemotherapy (eg, <span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">all-trans retinoic acid, methotrexate, vincristine)</span></td> </tr> <tr> <td>Retroperitoneal pathology, such as malignancy or hemorrhage</td> </tr> <tr> <td>One of the above <strong>plus</strong> metabolic imbalance or medication administration (eg, narcotics, phenothiazines, calcium channel blockers, alpha-2-adrenergic agonists, epidural analgesics)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66068 Version 2.0</div></div></div>"},"66071":{"type":"graphic_picture","displayName":"PVOD interstitial fibrosis","title":"Alveolar infiltration and interstitial fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alveolar infiltration and interstitial fibrosis</div><div class=\"cntnt\"><img style=\"width:367px; height:277px;\" src=\"images/PULM/66071_PVOD_interstitial_fibrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is interstitial fibrosis and lymphocytic infiltration of the alveolar walls surrounding an obliterated vein (thick arrow). Abundant brown granular hemosiderin is present in alveoli (thin arrow). Hematoxylin-eosin; original magnification: x10.</div><div class=\"graphic_reference\">Reproduced with permission from: Mandel, J, Mark, E, Hales, C. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162:1964. Official Journal of the American Thoracic Society © American Lung Association.</div><div id=\"graphicVersion\">Graphic 66071 Version 2.0</div></div></div>"},"66072":{"type":"graphic_figure","displayName":"Overview of the mevalonate pathway","title":"Simplified schematic overview of the mevalonate pathway, which is distributed at the level of mevalonate kinase in mevalonate kinase deficiency","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Simplified schematic overview of the mevalonate pathway, which is distributed at the level of mevalonate kinase in mevalonate kinase deficiency</div><div class=\"cntnt\"><img style=\"width:590px; height:694px;\" src=\"images/RHEUM/66072_Cholesterol_synthesis_path2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bold text in dashed boxes are enzymes. Italicized text in solid-line boxes are drugs/agents that block the enzymatic pathways.</div><div class=\"graphic_footnotes\">HMG: 3-hydroxy-3-methyl-glutaryl; CoA: coenzyme A.</div><div class=\"graphic_reference\">From: Stoffels M, Simon A. Hyper-IgD syndrome or mevalonate kinase deficiency. Curr Opin Rheumatol 2011; 23:419. DOI: <a href=\"http://journals.lww.com/co-rheumatology/pages/articleviewer.aspx?year=2011&amp;issue=09000&amp;article=00003&amp;type=abstract\" target=\"_blank\">10.1097/BOR.0b013e328349c3b1</a>. Copyright &copy; 2011. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 66072 Version 5.0</div></div></div>"},"66073":{"type":"graphic_figure","displayName":"TEP hernia reduction for direct inguinal hernia repair","title":"TEP hernia reduction for direct inguinal hernia repair","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">TEP hernia reduction for direct inguinal hernia repair</div><div class=\"cntnt\"><img style=\"width:460px; height:559px;\" src=\"images/SURG/66073_TEP_hernia_reduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a small direct hernia viewed from the extraperitoneal space.&nbsp;Gentle traction on &nbsp;the peritoneum with one hand and pressure on the abdominal wall with the other facilitates reduction of the direct hernia sac.</div><div class=\"graphic_footnotes\">TEP: total extraperitoneal hernia repair</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Maithel SK, Schneider BE. Atlas of minimally invasive surgery. Ciné-Med, Woodbury, CT 2006. Copyright © 2006 Ciné-Med, Inc.</div><div id=\"graphicVersion\">Graphic 66073 Version 8.0</div></div></div>"},"66074":{"type":"graphic_figure","displayName":"2D TTE Suprasternal notch view aorta","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the suprasternal notch view showing the aorta and major branch vessels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the suprasternal notch view showing the aorta and major branch vessels</div><div class=\"cntnt\"><img style=\"width:256px; height:498px;\" src=\"images/CARD/66074_Suprasternal_notch_recordin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the transducer at the suprasternal notch (panel A), the long axis of the aortic arch can be visualized (panel B). The circular right pulmonary artery (RPA) is seen under the arch just inferior to the air filled right bronchus (RB). Relative to the aorta, the RPA is one half the diameter.</div><div class=\"graphic_footnotes\">RSA: right subclavian artery; RCC: right common carotid artery; LCC: left common carotid artery; LSA: left subclavian artery; IN: inominate vein. The inominate artery is not labled.</div><div class=\"graphic_reference\">Image courtesy of Dr. Norman Silverman</div><div id=\"graphicVersion\">Graphic 66074 Version 2.0</div></div></div>"},"66075":{"type":"graphic_diagnosticimage","displayName":"L femur with Paget disease of bone","title":"Left femur with Paget disease of bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left femur with Paget disease of bone</div><div class=\"cntnt\"><img style=\"width:361px; height:540px;\" src=\"images/RHEUM/66075_R_femur_Paget_disease_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a radiograph of the&nbsp;left femur. Note the advancing lytic lesion, the thickening of the femoral diaphysis, and the grossly abnormal remodeling evident there.</div><div class=\"graphic_reference\">Courtesy of Margaret Seton, MD.</div><div id=\"graphicVersion\">Graphic 66075 Version 3.0</div></div></div>"},"66076":{"type":"graphic_figure","displayName":"Cancer incidence in males in more and less developed countries","title":"Cancer incidence in males in more and less developed countries*","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Cancer incidence in males in more and less developed countries*</div><div class=\"cntnt\"><img style=\"width:553px; height:449px;\" src=\"images/GAST/66076_Cancer_incidence_men_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Comparison of the most common cancers in more and less developed countries in 2000.</div><div class=\"graphic_reference\">Reproduced with permission from: Stewart B, Kleihues P. World Cancer Report, IARC Press, Lyon 2003.&nbsp;Copyright © 2003 IARC Press.</div><div id=\"graphicVersion\">Graphic 66076 Version 14.0</div></div></div>"},"66077":{"type":"graphic_picture","displayName":"Nasal stenting","title":"Nasal stenting after transnasal choanal atresia repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal stenting after transnasal choanal atresia repair</div><div class=\"cntnt\"><img style=\"width:140px; height:240px;\" src=\"images/PEDS/66077_Nasal_stenting_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nasal stenting after transnasal choanal atresia repair.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 66077 Version 4.0</div></div></div>"},"66078":{"type":"graphic_diagnosticimage","displayName":"Tarsal coalition","title":"Tarsal coalition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tarsal coalition</div><div class=\"cntnt\"><img style=\"width:432px; height:388px;\" src=\"images/PEDS/66078_Tarsal_coalition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Congenital coalition of the tarsal navicular, the cuboid bone, and the calcaneus causing &quot;Peroneal flatfoot.&quot;</div><div class=\"graphic_reference\">Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 66078 Version 2.0</div></div></div>"},"66081":{"type":"graphic_table","displayName":"Heparin protocol I","title":"Example of a non-weight-based intravenous heparin protocol: Part I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of a non-weight-based intravenous heparin protocol: Part I</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Initial intravenous heparin bolus: 5000 units.</td> </tr> <tr> <td class=\"sublist1_start\">Continuous intravenous heparin infusion: commence at 42 mL/hour of 20,000 units (1680 units/hour) in 500 mL of two-thirds dextrose and one-third saline (a 24-hour heparin dose of 40,320 units), except in the following patients, in whom heparin infusion will be commenced at a rate of 31 mL/hour (1240 units/hour) (ie, a 24-hour dose of 29,760 units).</td> </tr> <tr> <td class=\"sublist1\">Patients who have undergone surgery within the previous two weeks.</td> </tr> <tr> <td class=\"sublist1\">Patients with a previous history of peptic ulcer disease, gastrointestinal or genitourinary bleeding.</td> </tr> <tr> <td class=\"sublist1\">Patients with (thrombotic) stroke within the previous two weeks.</td> </tr> <tr> <td class=\"sublist1\">Patients with a platelet count &#60;150,000/microL.</td> </tr> <tr> <td class=\"sublist1\">Patients with miscellaneous reasons for a high risk of bleeding (eg, hepatic failure, renal failure, or vitamin K deficiency).</td> </tr> <tr> <td class=\"sublist1_start\">Heparin dose adjusted using the aPTT. The aPTT is performed in all patients as outlined below:</td> </tr> <tr> <td class=\"sublist1\">4 to 6 hours after commencing heparin; the heparin dose is then adjusted according to the nomogram shown in Heparin Protocol-II until the aPTT is within the therapeutic range.</td> </tr> <tr> <td class=\"sublist1\">Thereafter, the aPTT will be performed once daily. If the value is outside the therapeutic range, the heparin dose is then adjusted according to the nomogram shown in Heparin Protocol-II until the aPTT is within the therapeutic range.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152:1589.</div><div id=\"graphicVersion\">Graphic 66081 Version 6.0</div></div></div>"},"66083":{"type":"graphic_table","displayName":"Hepatocellular jaundice","title":"Differential diagnosis of hepatocellular jaundice","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hepatocellular jaundice</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Neoplasms</td> </tr> <tr> <td>Hepatocellular carcinoma</td> </tr> <tr> <td>Cholangio carcinoma</td> </tr> <tr> <td>Metastases (bronchogenic, GI tract, breast, GU tract)</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Hemangioendothelioma</td> </tr> <tr> <td>Hepatoblastoma</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic/hereditary</td> </tr> <tr> <td>Wilson disease</td> </tr> <tr> <td>Alpha-1 antitrypsin deficiency</td> </tr> <tr> <td>Hemochromatosis</td> </tr> <tr> <td>Porphyrias</td> </tr> <tr> <td>Congenital hepatic fibrosis</td> </tr> <tr> <td>Fibropolycystic disease</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic</td> </tr> <tr> <td>Acute ischemia</td> </tr> <tr> <td>Severe heart failure</td> </tr> <tr> <td>Tricuspid insufficiency</td> </tr> <tr> <td>Constrictive pericarditis</td> </tr> <tr> <td>Budd-Chiari syndrome</td> </tr> <tr> <td>Venoocclusive disease</td> </tr> <tr> <td>Telangiectasias</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Amyloidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Secondary biliary cirrhosis</td> </tr> <tr> <td>Cryptogenic cirrhosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"subtitle2_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Hepatitis viruses</td> </tr> <tr> <td class=\"indent1\">Herpes viruses</td> </tr> <tr> <td class=\"indent1\">\"Hemorrhagic\" viruses: yellow fever, Ebola, Marburg, Lassa</td> </tr> <tr> <td class=\"indent1\">Adenoviruses, enteroviruses, etc</td> </tr> <tr> <td class=\"subtitle2_single\">Bacterial</td> </tr> <tr> <td class=\"indent1\">Tuberculosis, leptospirosis, syphilis, pyogenic abscess, <em>Brucella</em>, <em>Rickettsia</em>, <em>Tropheryma whippeli</em>, <em>Rochalimea</em></td> </tr> <tr> <td class=\"subtitle2_single\">Parasitic</td> </tr> <tr> <td class=\"indent1\">Helminths: <em>Ascaris</em>, <em>Fasciola</em>, <em>Clonorchis</em>, schistosomiasis, echinococcosis</td> </tr> <tr> <td class=\"indent1\">Protozoa: amebiasis, plasmodia, babesiosis, toxoplasmosis, leishmaniasis</td> </tr> <tr> <td class=\"subtitle2_single\">Fungal</td> </tr> <tr> <td class=\"indent1\"><em>Candida</em>, <em>Blastomyces</em>, <em>Coccidioides</em>, <em>Histoplasma</em>, <em>Cryptococcus</em></td> </tr> <tr> <td class=\"subtitle1_single\">Toxic/immunologic</td> </tr> <tr> <td>Medications (allergic, idiosyncratic)</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Chlorinated hydrocarbons (carbon tetrachloride, chloroform)</td> </tr> <tr> <td><em>Amanita phalloides</em> toxin</td> </tr> <tr> <td>Aflatoxin B1</td> </tr> <tr> <td>Vitamin A</td> </tr> <tr> <td>Pyrrolizidine alkaloids</td> </tr> <tr> <td>Arsenic</td> </tr> <tr> <td>Phosphorous</td> </tr> <tr> <td>Autoimmune hepatitis</td> </tr> <tr> <td>Primary biliary cholangitis</td> </tr> <tr> <td>Primary sclerosing cholangitis</td> </tr> <tr> <td>Overlap syndrome</td> </tr> <tr> <td>Autoimmune cholangiopathy</td> </tr> <tr> <td>Nonalcoholic steatohepatitis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">GI: gastrointestinal; GU: genitourinary.</div><div id=\"graphicVersion\">Graphic 66083 Version 2.0</div></div></div>"},"66085":{"type":"graphic_table","displayName":"B19 symptoms in children","title":"Range of parvovirus B19 symptoms and signs in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Range of parvovirus B19 symptoms and signs in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Symptom or sign</td>\n\n      <td class=\"subtitle1\">Percent affected</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fever</td>\n\n      <td>14 to 53</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Headache</td>\n\n      <td>12 to 53</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sore throat</td>\n\n      <td>12 to 60</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pruritus</td>\n\n      <td>0 to &#62;50</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cough </td>\n\n      <td>5 to 40</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diarrhea</td>\n\n      <td>0 to 40</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nausea and/or vomiting</td>\n\n      <td>0 to 33</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Coryza and/or conjunctivitis</td>\n\n      <td>4 to 27</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Arthralgia and/or arthritis</td>\n\n      <td>0 to 9</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Anderson, LJ. Pediatr Infect Dis J 1987; 6:711.</div><div id=\"graphicVersion\">Graphic 66085 Version 1.0</div></div></div>"},"66087":{"type":"graphic_picture","displayName":"Mucous patch secondary syphilis","title":"Secondary syphilis: Mucous patch","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Secondary syphilis: Mucous patch</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/ID/66087_Mucous_patch_second_syph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mucous patches of secondary syphilis may appear on a variety of mucous membranes. They are teeming with organisms and are therefore highly infectious.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66087 Version 10.0</div></div></div>"},"66092":{"type":"graphic_table","displayName":"Conditions peliosis hepatis","title":"Conditions associated with peliosis hepatis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with peliosis hepatis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">Drugs and chemicals</td>\n   </tr>\n   <tr>\n   <td>2-Chloro-3'-deoxyadenosine</td>\n   </tr>\n   <tr>\n   <td>6-mercaptopurine</td>\n   </tr>\n   <tr>\n   <td>6-thioguanine</td>\n   </tr>\n   <tr>\n   <td>Androgenic-anabolic steroids</td>\n   </tr>\n   <tr>\n   <td>Arsenic</td>\n   </tr>\n   <tr>\n   <td>Azathioprine</td>\n   </tr>\n   <tr>\n   <td>Cadmium</td>\n   </tr>\n   <tr>\n   <td>Contraceptive steroids</td>\n   </tr>\n   <tr>\n   <td>Danazol</td>\n   </tr>\n   <tr>\n   <td>Glucocorticoids</td>\n   </tr>\n   <tr>\n   <td>Tamoxifen</td>\n   </tr>\n   <tr>\n   <td>Thorium dioxide</td>\n   </tr>\n   <tr>\n   <td>Urethane</td>\n   </tr>\n   <tr>\n   <td>Vinyl chloride</td>\n   </tr>\n   <tr>\n   <td>Vitamin A toxicity</td>\n   </tr>\n\n   <tr>\n   <td  class=\"subtitle1_single\">Infections</td>\n   </tr>\n   <tr>\n   <td>Bacterial endocarditis</td>\n   </tr>\n   <tr>\n   <td>Bartonella henselae and Bartonella quintana</td>\n   </tr>\n   <tr>\n   <td>Human immunodeficiency virus infection</td>\n   </tr>\n   <tr>\n   <td>Leprosy</td>\n   </tr>\n   <tr>\n   <td>Pyelonephritis</td>\n   </tr>\n   <tr>\n   <td>Syphilis</td>\n   </tr>\n   <tr>\n   <td>Tuberculosis</td>\n   </tr>\n\n   <tr>\n   <td  class=\"subtitle1_single\">Hematologic</td>\n   </tr>\n   <tr>\n   <td>Agnogenic myeloid metaplasia</td>\n   </tr>\n   <tr>\n   <td>Anaplastic anemia</td>\n   </tr>\n   <tr>\n   <td>Castelman's disease</td>\n   </tr>\n   <tr>\n   <td>Fanconi disease</td>\n   </tr>\n   <tr>\n   <td>Hodgkin disease</td>\n   </tr>\n   <tr>\n   <td>Lymphoma</td>\n   </tr>\n   <tr>\n   <td>Malignant histiocytosis</td>\n   </tr>\n   <tr>\n   <td>Multiple myeloma</td>\n   </tr>\n   <tr>\n   <td>Waldenstr&#246;m macroglobulinemia</td>\n   </tr>\n\n\n\n\n   <tr>\n   <td  class=\"subtitle1_single\">Malignancies</td>\n   </tr>\n   <tr>\n   <td>Colorectal adenocarcinoma</td>\n   </tr>\n   <tr>\n   <td>Gastric adenocarcinoma</td>\n   </tr>\n   <tr>\n   <td>Hepatocellular carcinoma</td>\n   </tr>\n   <tr>\n   <td>Pancreatic cancer</td>\n   </tr>\n   <tr>\n   <td>Prostate cancer</td>\n   </tr>\n   <tr>\n   <td>Renal cell carcinoma</td>\n   </tr>\n   <tr>\n   <td>Seminoma</td>\n   </tr>\n\n   <tr>\n   <td  class=\"subtitle1_single\">Other conditions</td>\n   </tr>\n   <tr>\n   <td>Cardiac transplantation</td>\n   </tr>\n   <tr>\n   <td>Chronic hemodialysis</td>\n   </tr>\n   <tr>\n   <td>Crohn's disease</td>\n   </tr>\n   <tr>\n   <td>Diabetes mellitus</td>\n   </tr>\n   <tr>\n   <td>Idiopathic restrictive cardiomyopathy</td>\n   </tr>\n   <tr>\n   <td>Liver transplant</td>\n   </tr>\n   <tr>\n   <td>Marasmus</td>\n   </tr>\n   <tr>\n   <td>Pregnancy</td>\n   </tr>\n   <tr>\n   <td>Renal transplantation</td>\n   </tr>\n   <tr>\n   <td>Rheumatoid arthritis</td>\n   </tr>\n   <tr>\n   <td>Systemic lupus erythematosus</td>\n   </tr>\n\n </table></div><div id=\"graphicVersion\">Graphic 66092 Version 1.0</div></div></div>"},"66095":{"type":"graphic_diagnosticimage","displayName":"Aspergillus sinusitis","title":"<em>Aspergillus</em> sinusitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Aspergillus</em> sinusitis</div><div class=\"cntnt\"><img style=\"width:242px; height:275px;\" src=\"images/ID/66095_Aspergillus_sinusitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An 87-year-old man with diabetes mellitus and biopsy-proved aspergillosis of paranasal sinuses. Coronal T1-weighted&nbsp;magnetic resonance&nbsp;image (MRI) obtained after injection of contrast material shows abnormal soft tissue filling ethmoidal air cell complex, nasal cavity, and maxillary sinus. Note subfrontal intracranial extension with dural thickening and abnormal enhancement (arrows).</div><div class=\"graphic_reference\">From: Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol 1994; 162:155. Reprinted with permission from the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 66095 Version 12.0</div></div></div>"},"66096":{"type":"graphic_figure","displayName":"Laryngeal mask insertion by standard technique","title":"Laryngeal mask insertion by standard technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laryngeal mask insertion by standard technique</div><div class=\"cntnt\"><img style=\"width:339px; height:523px;\" src=\"images/EM/66096_Laryn_mask_ins_stan_tech.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The LMA is held in the operator's dominant hand like a pen or pencil, with the index finger at the cuff as shown.<br />(B) The patient's mouth is opened, and the LMA is pressed against the patient's hard palate. The wrist of the operator should remain flexed. If neck movement is not prohibited, placement of the operator's nondominant hand as shown can increase leverage and facilitate placement.<br />(C) The LMA mask is pressed inward by extension of the index finger. Contact with the palate is maintained.<br />(D) The index finger is pressed toward the nondominant hand to exert counterpressure.<br />(E) The LMA cuff is advanced into the hypopharynx until resistance is felt. The operator maintains gentle downward pressure on the tube while removing the index finger from the patient's mouth.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Image courtesy of LMA North America, Inc. Originally published in: King BR, Hagberg CA. Management of the difficult airway. In: Textbook of Pediatric Emergency Medicine Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 66096 Version 2.0</div></div></div>"},"66097":{"type":"graphic_picture","displayName":"Acute graft-versus-host disease erythroderma","title":"Acute graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/66097_Acute_GVHD_erythroderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread erythema, desquamation, and postinflammatory hyperpigmentation are evident in this patient with acute graft-versus-host disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66097 Version 5.0</div></div></div>"},"66098":{"type":"graphic_table","displayName":"Ideal body weight lean body weight approximation table","title":"Ideal body weight and approximate lean body weight in obesity (adult)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ideal body weight and approximate lean body weight in obesity (adult)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Height (in)</td> <td class=\"subtitle1\">Height (cm)</td> <td class=\"subtitle1\">IBW* (kg)</td> <td class=\"subtitle1\">Approximate LBW in class III obesity<sup>&#182;</sup> (kg) </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Female (adult)</strong></td> <td>60</td> <td>152</td> <td>46</td> <td>52</td> </tr> <tr> <td>65</td> <td>165</td> <td>57</td> <td>60</td> </tr> <tr> <td>70</td> <td>178</td> <td>68</td> <td>70</td> </tr> <tr class=\"divider_bottom\"> <td>75</td> <td>191</td> <td>80</td> <td>80</td> </tr> <tr> <td rowspan=\"5\"><strong>Male (adult)</strong></td> <td>60</td> <td>152</td> <td>50</td> <td>63</td> </tr> <tr> <td>65</td> <td>165</td> <td>62</td> <td>73</td> </tr> <tr> <td>70</td> <td>177</td> <td>76</td> <td>85</td> </tr> <tr> <td>75</td> <td>191</td> <td>89</td> <td>97</td> </tr> <tr> <td>80</td> <td>203</td> <td>103</td> <td>112</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IBW: ideal body weight; LBW: lean body weight; TBW: total body weight; BMI: body mass index<br />* IBW male = 50 + (2.3 x height in inches over 5 feet); IBW female = 45.5 + (2.3 x height in inches over 5 feet).<br />¶ Approximate LBW in class III obesity (BMI 40-45 kg/m2) for dosing emergency drugs; LBW estimate (kg) = (9270 x TBW)/(A + B x BMI) where A and B are 6680 and 216 respectively for males and 8780 and 244 respectively for females.</div><div class=\"graphic_reference\">Formulas from: Devine BJ. Drug Intell Clin Pharm 1974; 8:560 and Hanley, MJ et al. Clin Pharmacokinet 2010; 49:71.</div><div id=\"graphicVersion\">Graphic 66098 Version 4.0</div></div></div>"},"66099":{"type":"graphic_figure","displayName":"Anatomy of the distal humerus in the child","title":"Anatomy of the distal humerus in the child","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Anatomy of the distal humerus in the child</div><div class=\"cntnt\"><img style=\"width:493px; height:383px;\" src=\"images/EM/66099_Supracondylar_anatomy_child.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66099 Version 4.0</div></div></div>"},"66100":{"type":"graphic_table","displayName":"Estimating calories","title":"Estimating calories for weight maintenance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimating calories for weight maintenance</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Men:</td> </tr> <tr> <td>662 - (9.53 x age [year]) + PA* x (15.91 x weight [kg] + 539.6 x height [m])</td> </tr> <tr> <td class=\"sublist1_start\">* The PA coefficient is:</td> </tr> <tr> <td class=\"sublist1\">Sedentary = 1.0</td> </tr> <tr> <td class=\"sublist1\">Low active = 1.11</td> </tr> <tr> <td class=\"sublist1\">Active = 1.25</td> </tr> <tr> <td class=\"sublist1\">Very active = 1.48</td> </tr> <tr> <td class=\"subtitle1_single\">Women:</td> </tr> <tr> <td>354 - (6.91 x age [year]) + PA<sup>&#182;</sup> x (9.36 x weight [kg] + 726 x height [m])</td> </tr> <tr> <td class=\"sublist1_start\">&#182;&nbsp;The PA coefficient is:</td> </tr> <tr> <td class=\"sublist1\">Sedentary = 1.0</td> </tr> <tr> <td class=\"sublist1\">Low active = 1.12</td> </tr> <tr> <td class=\"sublist1\">Active = 1.27</td> </tr> <tr> <td class=\"sublist1\">Very active = 1.45</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PA: physical activity.</div><div class=\"graphic_reference\">Data from: Institutes of Medicine, Food and Nutrition Board. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington, DC: National Academy Press 2002.</div><div id=\"graphicVersion\">Graphic 66100 Version 3.0</div></div></div>"},"66101":{"type":"graphic_picture","displayName":"Optic disk","title":"Glaucoma","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Glaucoma</div><div class=\"cntnt\"><img style=\"width:516px; height:200px;\" src=\"images/PC/66101_Opticdisk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Extensive cupping of the optic disk typical of glaucoma.<br />(B) Compared&nbsp;with a normal optic disk.</div><div class=\"graphic_reference\">Courtesy of the W.K. Kellogg Eye Center, University of Michigan.</div><div id=\"graphicVersion\">Graphic 66101 Version 2.0</div></div></div>"},"66102":{"type":"graphic_picture","displayName":"Tinea corporis 3","title":"Tinea corporis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea corporis</div><div class=\"cntnt\"><img style=\"width:324px; height:324px;\" src=\"images/PC/66102_Tinea_corporis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This annular lesion with a raised erythematous border, central clearing, and slight scale was consistent with tinea corporis.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66102 Version 2.0</div></div></div>"},"66104":{"type":"graphic_diagnosticimage","displayName":"Disseminated cryptococcosis","title":"Disseminated cryptococcosis in a lung transplant recipient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated cryptococcosis in a lung transplant recipient</div><div class=\"cntnt\"><img style=\"width:444px; height:390px;\" src=\"images/ID/66104_Disseminated_cryptococcosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Magnetic resonance imaging (MRI) of the brain showing brain abscess, (B) micronodules in the transplanted lung, and (C) mucicarmine stain of the lung tissue showing <EM>Cryptococcus neoformans</EM>.</div><div class=\"graphic_reference\">Reproduced with permission from: Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66104 Version 11.0</div></div></div>"},"66105":{"type":"graphic_table","displayName":"Estimated global incidence","title":"Estimated annual incidence (000) of fire-related burn injuries* in 2004, by World Health Organization region","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated annual incidence (000) of fire-related burn injuries* in 2004, by World Health Organization region</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Africa</td> <td class=\"subtitle1\">The Americas</td> <td class=\"subtitle1\">EMR<sup>&#182;</sup></td> <td class=\"subtitle1\">Europe</td> <td class=\"subtitle1\">SEAR<sup>&#916;</sup></td> <td class=\"subtitle1\">WPR<sup>&#9674;</sup></td> <td class=\"subtitle1\">World</td> </tr> <tr> <td><strong>Population (000)</strong></td> <td>689,632</td> <td>874,380</td> <td>519,688</td> <td>883,311</td> <td>1,671,904</td> <td>1,738,457</td> <td>6,436,826</td> </tr> <tr> <td><strong>Burns (000)</strong></td> <td>982</td> <td>163</td> <td>970</td> <td>523</td> <td>4069</td> <td>388</td> <td>7105</td> </tr> <tr> <td><strong>Incidence rate (000)</strong></td> <td>1.33</td> <td>0.19</td> <td>1.87</td> <td>0.59</td> <td>0.243</td> <td>0.22</td> <td>1.1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Includes only burns covering 20 percent or more of total body surface area.<br />¶ Eastern Mediterranean region.<br />Δ Southeast Asia region.<br /><FONT class=lozenge>◊</FONT> Western Pacific region.</div><div class=\"graphic_reference\">Data from: World Health Organization. Disease and injury estimates for 2004. Morbidity and Mortality. Incidence. Annual incidence (000s) for selected causes, in WHO regions, estimates for 2004. www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html.</div><div id=\"graphicVersion\">Graphic 66105 Version 3.0</div></div></div>"},"66106":{"type":"graphic_table","displayName":"Microbiology of IAI","title":"Organisms isolated in the amniotic fluid of 404 patients with intraamniotic infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Organisms isolated in the amniotic fluid of 404 patients with intraamniotic infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Number</td> <td class=\"subtitle1\">Percent</td> </tr> <tr> <td><em>Ureaplasma urealyticum</em></td> <td>190</td> <td>47.0</td> </tr> <tr> <td>Any gram-negative anaerobe</td> <td>155</td> <td>38.4</td> </tr> <tr> <td><em>Mycoplasma hominis</em></td> <td>123</td> <td>30.4</td> </tr> <tr> <td><em>Bacteroids bivius</em></td> <td>119</td> <td>29.5</td> </tr> <tr> <td><em>Gardnerella vaginalis</em></td> <td>99</td> <td>24.5</td> </tr> <tr> <td>Group B <em>Streptococcus</em></td> <td>59</td> <td>14.6</td> </tr> <tr> <td><em>Peptostreptococcus</em> spp</td> <td>38&nbsp;</td> <td>9.4</td> </tr> <tr> <td><em>Escherichia coli</em></td> <td>33</td> <td>8.2</td> </tr> <tr> <td><em>Enterococci</em></td> <td>22</td> <td>5.4</td> </tr> <tr> <td><em>Fusobacterium</em> spp</td> <td>22</td> <td>5.4</td> </tr> <tr> <td><em>Bacteroides fragilis</em></td> <td>14</td> <td>3.5</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Sperling RS, Newton E, Gibbs RS. Intraamniotic infection in low-birth-weight infants. J Infect Dis 1988; 157:113.</div><div id=\"graphicVersion\">Graphic 66106 Version 4.0</div></div></div>"},"66107":{"type":"graphic_diagnosticimage","displayName":"US Y funnel cervix","title":"Ultrasound Y funnel cervix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound&nbsp;Y funnel cervix</div><div class=\"cntnt\"><img style=\"width:450px; height:394px;\" src=\"images/OBGYN/66107_US_Y_funnel_cervix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Funneling cervix, with walls of funnel in &quot;Y-shaped&quot; configuration. Membranes are not visible separately, and there is no evidence of prolapsed membranes beyond internal os.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Johnson, MD.</div><div id=\"graphicVersion\">Graphic 66107 Version 3.0</div></div></div>"},"66108":{"type":"graphic_table","displayName":"Gr3 chemo tox elderly pts","title":"Grade 3 or worse chemotherapy toxicity in fit older patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grade 3 or worse chemotherapy toxicity in fit older patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\" rowspan=\"3\">Toxicity in percent</td>\n\t    <td class=\"subtitle1\" colspan=\"8\">Regimen</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2\" colspan=\"2\">FOLFOX<sup>[1]</sup></td>\n\t    <td class=\"subtitle2\" colspan=\"2\">Irinotecan/FU/LV<sup>[2]</sup></td>\n\t    <td class=\"subtitle2\" colspan=\"2\">FU/LV<sup>[2]</sup></td>\n\t    <td class=\"subtitle2\" colspan=\"2\">FU/LV<sup>[3]</sup></td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle3\">&#8805;70 years</td>\n\t    <td class=\"subtitle3\">&#60;70 years</td>\n\t    <td class=\"subtitle3\">&#8805;70 years</td>\n\t    <td class=\"subtitle3\">&#60;70 years</td>\n\t    <td class=\"subtitle3\">&#8805;70 years</td>\n\t    <td class=\"subtitle3\">&#60;70 years</td>\n\t    <td class=\"subtitle3\">&#8805;70 years</td>\n\t    <td class=\"subtitle3\">&#60;70 years</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Leukopenia</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t    <td>19</td>\n\t    <td>17</td>\n\t    <td>6</td>\n\t    <td>7</td>\n\t    <td>8*</td>\n\t    <td>4</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Neutropenia</td>\n\t    <td>49*</td>\n\t    <td>43</td>\n\t    <td>30</td>\n\t    <td>29</td>\n\t    <td>20</td>\n\t    <td>16</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Infection</td>\n\t    <td>4</td>\n\t    <td>5</td>\n\t    <td>2</td>\n\t    <td>1</td>\n\t    <td>3</td>\n\t    <td>1</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Thrombocytopenia</td>\n\t    <td>5*</td>\n\t    <td>2</td>\n\t    <td>1</td>\n\t    <td>2</td>\n\t    <td>1</td>\n\t    <td>1</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Stomatitis</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t    <td>4</td>\n\t    <td>3</td>\n\t    <td>4</td>\n\t    <td>3</td>\n\t    <td>15</td>\n\t    <td>11</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Diarrhea</td>\n\t    <td>13</td>\n\t    <td>11</td>\n\t    <td>23</td>\n\t    <td>21</td>\n\t    <td>13</td>\n\t    <td>11</td>\n\t    <td>15</td>\n\t    <td>15</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Nausea/vomiting</td>\n\t    <td>7</td>\n\t    <td>9</td>\n\t    <td>11/10</td>\n\t    <td>11/10</td>\n\t    <td>4/3</td>\n\t    <td>6/5</td>\n\t    <td>2</td>\n\t    <td>5</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Fatigue</td>\n\t    <td>7</td>\n\t    <td>4</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Neurotoxicity</td>\n\t    <td>12</td>\n\t    <td>14</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t    <td>-</td>\n\t  </tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">-: not reported; FU: fluorouracil; LV: leucovorin.<br> * p value &#8805;70 versus &lt;70 statistically significant.</div><div class=\"graphic_reference\">1. Goldberg, R, et al. J Clin Oncol 2006; 24:4085.<br> 2. Folprecht, J, et al. J Clin Oncol 2008; 26:1443.<br> 3. Sargent, D, et al. N Engl J Med 2001; 345:1091.</div><div id=\"graphicVersion\">Graphic 66108 Version 2.0</div></div></div>"},"66109":{"type":"graphic_picture","displayName":"Prostate adenocarcinoma light","title":"Prostate cancer, Gleason pattern 3","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prostate cancer, Gleason pattern 3</div><div class=\"cntnt\"><img style=\"width:369px; height:278px;\" src=\"images/ONC/66109_Prostate_adenocarcinoma_lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power photomicrograph of an hematoxylin- and eosin-stained core biopsy of the prostate. The entire biopsy is involved with prostate adenocarcinoma, Gleason pattern 3, characterized by haphazardly infiltrating, well-formed malignant glands.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 66109 Version 3.0</div></div></div>"},"66110":{"type":"graphic_figure","displayName":"Digestive system adult PI","title":"Digestive system","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Digestive system</div><div class=\"cntnt\"><img style=\"width:500px; height:680px;\" src=\"images/PI/66110_Digestive_tract_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the organs in the body that process food. Together these organs are called &quot;the digestive system,&quot; or &quot;digestive tract.&quot; As food travels through this system, the body absorbs nutrients and water.</div><div id=\"graphicVersion\">Graphic 66110 Version 4.0</div></div></div>"},"66111":{"type":"graphic_picture","displayName":"Anterior tibiofibular ligament","title":"Anterior tibiofibular ligament","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Anterior tibiofibular ligament</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/66111_Anterior_tibiofibular_ligam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With a syndesmosis sprain, pain occurs in the region of the ruptured anterior tibiofibular ligament (location indicated by the tip of the pen). Also shown are the locations of the anterior talofibular ligament (A) and the calcaneofibular ligament (B).</div><div class=\"graphic_reference\">Courtesy of Karen Maughan, MD.</div><div id=\"graphicVersion\">Graphic 66111 Version 2.0</div></div></div>"},"66114":{"type":"graphic_diagnosticimage","displayName":"Color Doppler severe TR","title":"Color flow Doppler in severe tricuspid regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color flow Doppler in severe tricuspid regurgitation</div><div class=\"cntnt\"><img style=\"width:308px; height:238px;\" src=\"images/CARD/66114_Color_Doppler_severe_TR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The color flow Doppler obtained from the apical four chamber view shows that the tricuspid regurgitation (TR) jet has a large PISA and broad vena contracta (A to B), suggesting that the TR is severe.</div><div class=\"graphic_footnotes\">RV: right ventricle; RA: right atrium.</div><div id=\"graphicVersion\">Graphic 66114 Version 2.0</div></div></div>"},"66116":{"type":"graphic_table","displayName":"Down syndrome screening PI","title":"Select the statement that best describes your values and preferences to help decide which screening test is best for you","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Select the statement that best describes your values and preferences to help decide which screening test is best for you</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Statement</td> <td class=\"subtitle1\">Screening test to consider</td> </tr> <tr> <td>1. \"I want the result of my screening test as early as possible in the pregnancy, while the pregnancy is still private and I have options of early prenatal diagnosis (chorionic villus sampling) because I would terminate an affected pregnancy.\"</td> <td>First-trimester or cfDNA screening</td> </tr> <tr> <td>2. \"I want to have the test with the lowest chance of a screen positive result.\"</td> <td>cfDNA screening</td> </tr> <tr> <td>3. \"I would consider an amniocentesis if my test result shows a high chance of Down syndrome, but not a CVS because it has a higher risk for procedure-related complications.\"</td> <td>Integrated or cfDNA screening</td> </tr> <tr> <td>4. \"I have been very anxious and want my results as soon as possible, whether or not I would terminate an affected pregnancy.\"</td> <td>First-trimester or cfDNA&nbsp;screening</td> </tr> <tr> <td>5. \"I am already in my second trimester of pregnancy.\"</td> <td>Quad or cfDNA&nbsp;screening</td> </tr> <tr> <td>6. \"Nuchal translucency ultrasound is not available in my area.\"</td> <td>Serum-only integrated or cfDNA screening</td> </tr> <tr> <td>7. \"Chorionic villus sampling is not available in my area.\"</td> <td>Integrated or cfDNA screening</td> </tr> <tr> <td>8. \"My pregnancy is considered high risk for a chromosomal abnormality because of my age, my family history, a finding on my ultrasound exam, or a positive result on a screening test done on my blood.\"</td> <td>cfDNA screening</td> </tr> <tr> <td>9. \"I am carrying twins.\"</td> <td>First-trimester or quad or integrated screening</td> </tr> <tr> <td>10. \"I am concerned about having a financial responsibility for my screening.\"</td> <td>First-trimester or quad or integrated screening</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">cfDNA: cell-free DNA.</div><div id=\"graphicVersion\">Graphic 66116 Version 6.0</div></div></div>"},"66117":{"type":"graphic_picture","displayName":"Papillon-Lefèvre syndrome dental effects","title":"Dental effects of Papillon-Lefèvre syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dental effects of Papillon-Lefèvre syndrome</div><div class=\"cntnt\"><img style=\"width:354px; height:240px;\" src=\"images/PEDS/66117_PapillonLefevresyndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Near loss of the right central incisor in an eight-year-old child with Papillon-Lefèvre syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright © 2000 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 66117 Version 4.0</div></div></div>"},"66119":{"type":"graphic_diagnosticimage","displayName":"Pediatric hip fracture treatment","title":"Delbet type III fracture after operative fixation with cannulated screws","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delbet type III fracture after operative fixation with cannulated screws</div><div class=\"cntnt\"><img style=\"width:432px; height:339px;\" src=\"images/EM/66119_Hip_fx_rx_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ten-year-old girl who fell from a tree. She required arthrotomy, open reduction, and internal fixation with cannulated screws.</div><div class=\"graphic_reference\">Courtesy of Klane White, MD.</div><div id=\"graphicVersion\">Graphic 66119 Version 3.0</div></div></div>"},"66120":{"type":"graphic_table","displayName":"Metabolic syndrome definitions in children and adolescents","title":"Definitions of metabolic syndrome in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of metabolic syndrome in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Parameters</td>\n\t\t\t\t\t<td class=\"subtitle1\">Modified ATP III</td>\n\t\t\t\t\t<td class=\"subtitle1\">IDF (10 to 16 years)</td>\n\t\t\t\t\t<td class=\"subtitle1\">NHANES III</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"4\">Required</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Waist circumference</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&#8805;90th percentile*</td>\n\t\t\t\t\t<td>&#8805;90th percentile</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Number of abnormalities</td>\n\t\t\t\t\t<td>&#8805;3</td>\n\t\t\t\t\t<td>&#8805;2</td>\n\t\t\t\t\t<td>All</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Triglyceride</td>\n\t\t\t\t\t<td>&#62;95th percentile</td>\n\t\t\t\t\t<td>&#8805;150 mg/dL (1.7 mmol/L)</td>\n\t\t\t\t\t<td>&#8805;110 mg/dL (1.24 mmol/L)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">HDL</td>\n\t\t\t\t\t<td>&#60;5th percentile</td>\n\t\t\t\t\t<td>&#60;40 mg/dL (1.03 mmol/L)</td>\n\t\t\t\t\t<td>&#8804;40 mg/dL (1.03 mmol/L)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">BP</td>\n\t\t\t\t\t<td>Either</td>\n\t\t\t\t\t<td>Either</td>\n\t\t\t\t\t<td rowspan=\"3\">&#8805;90th percentile</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Systolic</td>\n\t\t\t\t\t<td>&#62;95th percentile</td>\n\t\t\t\t\t<td>&#62;130 mmHg</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Diastolic</td>\n\t\t\t\t\t<td>&#62;95th percentile</td>\n\t\t\t\t\t<td>&#8805;85 mmHg</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Glucose</td>\n\t\t\t\t\t<td>Impaired glucose tolerance</td>\n\t\t\t\t\t<td>&#8805;100 mg/dL (5.6 mmol/L)</td>\n\t\t\t\t\t<td>Fasting &#8805;110 mg/dL (6.1 mmol/L)</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">ATP III: Adult Treatment Panel; IDF: International Diabetes Federation; NHANES: National Health and Nutrition Examination Survey; HDL: high-density lipoprotein; BP: blood pressure.<BR>* Ethnic-specific waist circumference (see Fernandez JR, Redden DT, Pietrobelli A, et al. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 2004; 145:439).</div><div id=\"graphicVersion\">Graphic 66120 Version 4.0</div></div></div>"},"66122":{"type":"graphic_table","displayName":"Etiology of massive hemoptysis","title":"Etiologies of massive hemoptysis in several series","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of massive hemoptysis in several series</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">South Africa&#8226;\n1983-1990</td>\n\n      <td class=\"subtitle1\">New York City&#916;\n1991-1992</td>\n\n      <td class=\"subtitle1\">Jerusalem&#9674; 1980-1995</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bronchiectasis</td>\n\n      <td>51 percent*</td>\n\n      <td>25 percent</td>\n\n      <td>20 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tuberculosis</td>\n\n      <td>73 percent</td>\n\n      <td>16 percent</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bronchogenic carcinoma</td>\n\n      <td>5 percent</td>\n\n      <td>12 percent</td>\n\n      <td>15 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aspergilloma</td>\n\n      <td>0</td>\n\n      <td>12 percent</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pneumonia</td>\n\n      <td>4 percent</td>\n\n      <td>5 percent</td>\n\n      <td>23 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bleeding diathesis</td>\n\n      <td>0</td>\n\n      <td>0</td>\n\n      <td>15 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Other</td>\n\n      <td>10 percent</td>\n\n      <td>5 percent</td>\n\n      <td>20 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Undefined</td>\n\n      <td>8 percent</td>\n\n      <td>19 percent</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\"Bronchitis\"</td>\n\n      <td>0</td>\n\n      <td>5 percent</td>\n\n      <td>7 percent</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* All patients with bronchiectasis had tuberculosis.</div><div class=\"graphic_reference\">&#8226; Data from Knott-Craig, CJ, Oostuizen, JB, Rossouw, G, et al, J Thorac Cardiovasc Surg 1993; 105:394.<br> &#916; Data from McGuiness, G, Beacher, JR, Harkin, TJ, et al, Chest 1994; 105:1155.<br> &#9674; Data from Hirshberg, B, Biran, I, Glazer, M, Kramer, M, Chest 1997; 112:440.</div><div id=\"graphicVersion\">Graphic 66122 Version 1.0</div></div></div>"},"66123":{"type":"graphic_figure","displayName":"Cross section of the lumbar spine","title":"Cross section of the lumbar spine","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Cross section of the lumbar spine</div><div class=\"cntnt\"><img style=\"width:510px; height:426px;\" src=\"images/NEURO/66123_Cross_sect_lumbar_spine_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66123 Version 4.0</div></div></div>"},"66125":{"type":"graphic_picture","displayName":"PCMZL solitary tumor on lower leg","title":"Primary cutaneous marginal zone lymphoma with solitary tumor on lower leg associated with Borrelia burgdorferi infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous marginal zone lymphoma with solitary tumor on lower leg associated with Borrelia burgdorferi infection</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/HEME/66125_PCMZL_solitary_tumor_PR.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66125 Version 1.0</div></div></div>"},"66126":{"type":"graphic_figure","displayName":"Posterior tibial artery puncture site","title":"Posterior tibial artery puncture site","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior tibial artery puncture site</div><div class=\"cntnt\"><img style=\"width:346px; height:500px;\" src=\"images/EM/66126_PosttibiaartpuncsitePR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The site for arterial puncture of the posterior tibial artery is shown.</div><div class=\"graphic_reference\">Reproduced with permission from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66126 Version 6.0</div></div></div>"},"66128":{"type":"graphic_table","displayName":"Nonoccupational HIV exposure labs","title":"Recommended laboratory evaluation for nonoccupational post-exposure prophylaxis (nPEP) of HIV infection*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended laboratory evaluation for nonoccupational post-exposure prophylaxis (nPEP) of HIV infection*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Baseline</td> <td class=\"subtitle1\">4 to 6 weeks after exposure</td> <td class=\"subtitle1\">3 months after exposure</td> <td class=\"subtitle1\">6 months after exposure</td> </tr> <tr> <td>HIV&nbsp;serologic testing<sup>&#182;</sup></td> <td>E, S<sup>&#916;</sup></td> <td>E</td> <td>E</td> <td>E<sup><span style=\"font-size: 13px;\">&#9674;</span></sup></td> </tr> <tr> <td>Complete blood count with differential<sup>&#167;</sup></td> <td>E</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <p>Serum liver enzymes (ALT, AST)</p> </td> <td>E</td> <td>E</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Blood urea nitrogen/creatinine</td> <td>E</td> <td>E</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Sexually transmitted diseases screen (gonorrhea, chlamydia, syphilis)<sup>&#165;</sup></td> <td>E, S</td> <td>E<sup>&#135;</sup></td> <td>&nbsp;</td> <td>E<sup>&#135;</sup></td> </tr> <tr> <td> <p>Hepatitis B serology (HBsAg, anti-HBs, anti-HBc)</p> </td> <td>E, S</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>E<sup>&#134;</sup></td> </tr> <tr> <td>Hepatitis C serology</td> <td>E, S<sup>**</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>E</td> </tr> <tr> <td>Pregnancy test (for women of reproductive age)</td> <td>E</td> <td>E (if sexual exposure)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>HIV viral load<sup>&#182;</sup><sup>&#182;</sup></td> <td>S (only if HIV-infected)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>HIV resistance testing<sup>&#182;</sup><sup>&#182;</sup></td> <td>S&nbsp;(only if HIV-infected)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; AST: aspartate aminotransferase; HBV: hepatitis B virus; HCV: hepatitis&nbsp;C virus; E: exposed patient; S: source; HBsAg: hepatitis B surface antigen.<br />* This table is designed to monitor asymptomatic patients receiving tenofovir disoproxil fumarate-emtricitabine as the nucleoside combination with a third agent (eg, an integrase inhibitor or a boosted protease inhibitor). Additional testing (eg, for pregnancy, sexually transmitted diseases, hepatitis) should be performed if clinically indicated.<br />¶ A lab-based fourth-generation HIV antigen-antibody assay is the preferred test.<br />Δ HIV&nbsp;serologic testing is indicated for sources of unknown serostatus.<br />◊ Only if patient became acutely infected with HCV.<br />§ If zidovudine-lamivudine is used as the nucleoside combination, a complete blood count should be performed while the patient is receiving nonoccupational post-exposure prophylaxis (after approximately two weeks).&nbsp;<br />¥ For patients with a sexual exposure. Refer to the topic review in UpToDate that discusses screening of sexually transmitted infections.<br />‡ Syphilis testing should be performed four to six weeks and six months after a sexual exposure. Chlamydia and gonorrhea testing should be performed four to six weeks after a sexual exposure for those who were not treated empirically at baseline and for those who are symptomatic.&nbsp;&nbsp;<br />† For patients who were not immune at baseline and were exposed to a source who is HBsAg-positive or whose HBsAg status is unknown. Refer to the UpToDate topic that discusses nonoccupational exposures to HBV for a discussion of HBV post-exposure prophylaxis.<br />** If the source tests positive for HCV, additional monitoring of the exposed patient may be required. Refer to the UpToDate topic review that discusses the diagnosis of acute HCV in adults. <br />¶¶&nbsp;For the exposed patient, virologic testing should<STRONG> only</STRONG> be performed if symptoms of acute HIV infection develop or if the patient is found to be HIV-infected on&nbsp;serologic testing.</div><div class=\"graphic_reference\">Adapted from: United States Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. http://stacks.cdc.gov/view/cdc/38856 (Accessed on April 20, 2016).</div><div id=\"graphicVersion\">Graphic 66128 Version 5.0</div></div></div>"},"66129":{"type":"graphic_algorithm","displayName":"Assessment of pain in older adults with severe cogn impairment","title":"Assessment of pain in older adults with severe cognitive impairment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Assessment of pain in older adults with severe cognitive impairment</div><div class=\"cntnt\"><img style=\"width:376px; height:497px;\" src=\"images/ONC/66129_Pain_old_adlt_svr_cogn_impr.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Weiner, D, Herr, K, Rudy, T, eds. Persistent Pain in Older Adults: An Interdisciplinary Guide for Treatment, 2002; p. 34. Copyright ©2002 Debra Weiner, MD.</div><div id=\"graphicVersion\">Graphic 66129 Version 3.0</div></div></div>"},"66130":{"type":"graphic_figure","displayName":"RANK ligand and osteo form","title":"RANKL and osteoclast formation","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">RANKL and osteoclast formation</div><div class=\"cntnt\"><img style=\"width:491px; height:468px;\" src=\"images/ONC/66130_Rank-ligand-and-osteo-form-new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">RANKL (Receptor Activator of Nuclear Factor &#954;B Ligand)&#160;is a potent inducer of osteoclast formation. Osteotropic factors, 1,25-(OH)2 vitamin D, parathyroid hormone (PTH), prostaglandin E-2 (PGE2) and interleukin-11 (IL-11), induce osteoclast formation by upregulating expression of RANKL on the surface of marrow stromal cells and immature osteoblasts. RANKL then binds its receptor RANK on the surface of osteoclast precursors and signals through the NF&#954;B and JNK (Jun N-terminal kinase)&#160;pathways to induce osteoclastogenesis and promote osteoclast survival. In addition to RANK, a decoy receptor, osteoprotegerin (OPG/OCIF), inhibits RANKL binding to RANK. RANKL can also occur in a soluble form produced by T-cells in inflammatory states. The ratio of RANKL to OP cG determines the level of osteoclastogenesis.</div><div class=\"graphic_reference\">Modified from&#160;Roodman GD. Mechanisms of bone metastases. N Engl J Med 2004; 350:1655.</div><div id=\"graphicVersion\">Graphic 66130 Version 5.0</div></div></div>"},"66131":{"type":"graphic_table","displayName":"Epidemiology hip pain children","title":"Epidemiology of common causes of hip pain in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiology of common causes of hip pain in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Typical age</td> <td class=\"subtitle1\">M:F ratio</td> <td class=\"subtitle1\">Other</td> </tr> <tr> <td>Septic arthritis</td> <td>Any, peak 0 to 6 years</td> <td>1.2 to 2:1</td> <td>&nbsp;</td> </tr> <tr> <td>Transient synovitis</td> <td>3 to 8 years, mean 6 years</td> <td>2:1</td> <td>Fall/winter</td> </tr> <tr> <td>Legg-Calv&#233;-Perthes disease</td> <td>3 to 12 years, peak 5 to 7 years</td> <td>4:1</td> <td>Rare in blacks</td> </tr> <tr> <td rowspan=\"3\">Slipped capital femoral epiphysis</td> <td>Early adolescence</td> <td rowspan=\"3\">1.5:1</td> <td>Obese children</td> </tr> <tr> <td>Mean 12 years, girls</td> <td>Endocrinopathy in 8%</td> </tr> <tr> <td>Mean 13.5 years, boys</td> <td>Blacks &#62; whites, Hispanics</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">M; male; F: female.</div><div id=\"graphicVersion\">Graphic 66131 Version 6.0</div></div></div>"},"66132":{"type":"graphic_diagnosticimage","displayName":"Osteomyelitis radiograph MRI","title":"Osteomyelitis in a 9-year-old girl with knee pain and fever","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis in a 9-year-old girl with knee pain and fever</div><div class=\"cntnt\"><img style=\"width:468px; height:529px;\" src=\"images/PEDS/66132_Osteomyelitis_radiograph_MR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Plain radiographs of the knee are unremarkable.<br />(B) T1 weighted magnetic resonance imaging (MRI) demonstrates marked decrease in signal intensity in the medial metaphysis and epiphysis of the distal femur. There is some involvement of the soft tissue.<br />(C) These findings are more pronounced in a T1 weighted MRI with gadolinium.</div><div class=\"graphic_reference\">Courtesy of Marvin B Harper, MD.</div><div id=\"graphicVersion\">Graphic 66132 Version 3.0</div></div></div>"},"66133":{"type":"graphic_table","displayName":"Types of proarrhythmia due to antiarrhythmic drugs","title":"Types of proarrhythmia during treatment with antiarrhythmic drugs (AADs) for atrial fibrillation or atrial flutter according to the Vaughan Williams Classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of proarrhythmia during treatment with antiarrhythmic drugs (AADs) for atrial fibrillation or atrial&nbsp;flutter according to the Vaughan Williams Classification</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ventricular proarrhythmia</td> </tr> <tr> <td>&#8226;&nbsp; Torsade de pointes (Vaughan Williams class IA and type III drugs)</td> </tr> <tr> <td>&#8226;&nbsp; Sustained monomorphic ventricular tachycardia (usually class IC drugs)</td> </tr> <tr> <td>&#8226;&nbsp; Sustained polymorphic ventricular tachycardia/ventricular fibrillation without long QT interval (class IA, IC, and III drugs)</td> </tr> <tr> <td class=\"subtitle1_single\">Atrial proarrhythmia</td> </tr> <tr> <td>&#8226;&nbsp; Provocation of recurrence (probably class IA, IC, and III drugs)</td> </tr> <tr> <td>&#8226;&nbsp; Conversion of atrial fibrillation (AF) to atrial flutter (usually class IC drugs) with 1:1 conduction</td> </tr> <tr> <td>&#8226;&nbsp; Increase of defibrillation threshold (a potential problem with class IC drugs)</td> </tr> <tr> <td class=\"subtitle1_single\">Abnormalities of conduction or impulse formation</td> </tr> <tr> <td>&#8226;&nbsp; Accelerate ventricular rate during AF (class IA and type IC drugs)</td> </tr> <tr> <td>&#8226;&nbsp; Accelerate conduction over accessory pathway (digoxin, type IV drugs)</td> </tr> <tr> <td>&#8226;&nbsp; Sinus node dysfunction, atrioventricular block (almost all drugs)</td> </tr> <tr> <td class=\"subtitle1_single\">Vaughan Williams classification of AADs used for the treatment of atrial fibrillation or flutter</td> </tr> <tr> <td><strong>Class IA</strong> - Disopyramide, procainamide, quinidine</td> </tr> <tr> <td><strong>Class IC</strong> - Flecainide, propafenone</td> </tr> <tr> <td><strong>Class III</strong> - Amiodarone, dofetilide, ibutilide, sotalol</td> </tr> <tr> <td><strong>Class IV</strong> - Nondihydropyridine calcium channel blockers (diltiazem and verapamil)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.</div><div id=\"graphicVersion\">Graphic 66133 Version 4.0</div></div></div>"},"66134":{"type":"graphic_picture","displayName":"Toxic epidermal necrolysis (TEN)","title":"Toxic epidermal necrolysis (TEN)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toxic epidermal necrolysis (TEN)</div><div class=\"cntnt\"><img style=\"width:385px; height:252px;\" src=\"images/ALLRG/66134_Toxic_epidermal_necrolysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Usually caused by drugs, TEN demonstrates widespread erythema and confluent vesiculation, leading to sloughing of the skin. Affected patients are at risk for hypernatremic dehydration and sepsis.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 66134 Version 6.0</div></div></div>"},"66135":{"type":"graphic_figure","displayName":"Dose rates cervical ca","title":"Brachytherapy reference points","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brachytherapy reference points</div><div class=\"cntnt\"><img style=\"width:381px; height:434px;\" src=\"images/OBGYN/66135_Dose_rates_cervical_ca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tandem and ovoid cervical brachytherapy illustration of point A.</div><div id=\"graphicVersion\">Graphic 66135 Version 1.0</div></div></div>"},"66136":{"type":"graphic_table","displayName":"CHOP chemotherapy NHL","title":"CHOP chemotherapy for non-Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CHOP chemotherapy for non-Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"3\"><strong>CHOP-21</strong> chemotherapy consists of four agents: <strong>C</strong>yclophosphamide (Cytoxan), Doxorubicin (Adriamycin, <strong>H</strong>ydroxydaunomycin), Vincristine (<strong>O</strong>ncovin), and <strong>P</strong>rednisone. One complete course is given every 21 days. Full treatment usually consists of six to eight such courses.</td> </tr> <tr> <td class=\"subtitle2\">Drug</td> <td class=\"subtitle2\">Dose and route<sup>[1,2]</sup></td> <td class=\"subtitle2\">Given on day(s)</td> </tr> <tr> <td>Cyclophosphamide</td> <td>750 mg/m<sup>2</sup> IV</td> <td>Day 1</td> </tr> <tr> <td>Doxorubicin</td> <td>50 mg/m<sup>2</sup> IV</td> <td>Day 1</td> </tr> <tr> <td>Vincristine</td> <td>1.4 mg/m<sup>2</sup> IV (maximum 2 mg)</td> <td>Day 1</td> </tr> <tr> <td>Prednisone</td> <td>100 mg per day orally</td> <td>Days 1 through 5</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br> <ol> <li>McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin&#174;) combination chemotherapy in malignant lymphoma. Cancer 1976; 38:1484. </li> <li>Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002. </li> </ol></div><div id=\"graphicVersion\">Graphic 66136 Version 6.0</div></div></div>"},"66139":{"type":"graphic_diagnosticimage","displayName":"Angiogram RCVS","title":"Cerebral angiography of a patient with reversible cerebral vasoconstriction syndrome","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Cerebral angiography of a patient with reversible cerebral vasoconstriction syndrome</div><div class=\"cntnt\"><img style=\"width:724px; height:405px;\" src=\"images/NEURO/66139_Anggrm_RCVS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the multiple areas of stenosis (arrows) and dilatation in multiple vessels (arrowheads) of the M2 branch of the middle cerebral artery (A) and their resolution after one month (B).</div><div class=\"graphic_reference\">Reproduced with permission from: Hajj-Ali RA, Furlan A, Abou-Chebel A, Calabrese LH. Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup. Arthritis Rheum 2002; 47:662. Copyright &copy; 2002 John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 66139 Version 4.0</div></div></div>"},"66140":{"type":"graphic_picture","displayName":"RA hand 2","title":"Swelling of the metacarpophalangeal joints of the right hand in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Swelling of the metacarpophalangeal joints of the right hand in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:360px; height:211px;\" src=\"images/RHEUM/66140_RA_hand_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swelling of the MCP joints, moderate MCP flexion, and swan neck deformities are evident in this patient with rheumatoid arthritis.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal.</div><div class=\"graphic_reference\">Courtesy of Patrick J Venables, MD.</div><div id=\"graphicVersion\">Graphic 66140 Version 3.0</div></div></div>"},"66141":{"type":"graphic_picture","displayName":"Endoscopic image of a transampullary uncovered metal stent","title":"Endoscopic image of a transampullary uncovered metal stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic image of a transampullary uncovered metal stent</div><div class=\"cntnt\"><img style=\"width:324px; height:331px;\" src=\"images/GAST/66141_Endo_transamp_metal_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic post-deployment image of an uncovered metal stent.</div><div class=\"graphic_reference\">Courtesy of Douglas G. Adler, MD, FACG, FASGE.</div><div id=\"graphicVersion\">Graphic 66141 Version 1.0</div></div></div>"},"66146":{"type":"graphic_figure","displayName":"Prostaglandin synthesis","title":"Prostaglandin and thromboxane synthesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prostaglandin and thromboxane synthesis</div><div class=\"cntnt\"><img style=\"width:422px; height:327px;\" src=\"images/RHEUM/66146_Prostaglandin_synth_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of prostaglangin synthesis pathways with enzymes that catalyze specific reactions. Of note, platelets only express cyclooxygenase (COX)-1. Refer to UpToDate topics on nonsteroidal antiinflammatory drugs (NSAIDs), antiplatelet drugs,&nbsp;COX inhibitors, and specific disease states for further details.</div><div class=\"graphic_footnotes\">PG: prostaglandin; Tx: thromboxane.</div><div id=\"graphicVersion\">Graphic 66146 Version 8.0</div></div></div>"},"66147":{"type":"graphic_table","displayName":"Antibiotics for suspected shigellosis in developing settings","title":"Antibiotics for suspected shigellosis in developing settings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotics for suspected shigellosis in developing settings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Typical pediatric dose</td> <td class=\"subtitle1\">Comment(s)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Preferred agents</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin</td> <td>Oral</td> <td>30 mg/kg/day (divided twice daily) for 3 days</td> <td>Multi-dose therapy is preferred.</td> </tr> <tr> <td class=\"indent1\">Azithromycin</td> <td>Oral</td> <td> <p>15 mg/kg initial dose (day 1)</p> <p>10 mg/kg/day (daily, day 2-5)</p> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Alternative agents</td> </tr> <tr> <td class=\"indent1\">Ceftriaxone</td> <td>IM/IV</td> <td>50-100 mg/kg/day (divided four times daily) for 2-5 days</td> <td rowspan=\"2\">Ceftriaxone is the preferred empiric therapy for severe infections and infections refractory to other therapies.</td> </tr> <tr> <td class=\"indent1\">Pivmecillinam</td> <td>PO</td> <td>80 mg/kg/day (divided four times daily) for 5 days</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Resistance to amoxicillin, trimethoprim-sulfamethoxazole, and chloramphenicol (original first-line therapies) is too widespread to justify their empiric use for invasive diarrhea in developing countries.</div><div class=\"graphic_reference\">Modified from: World Health Organization. Guidelines for the control of shigellosis, incuding epidemics due to Shigella dysenteriae 1. World Health Organization, Geneva 2005.</div><div id=\"graphicVersion\">Graphic 66147 Version 2.0</div></div></div>"},"66148":{"type":"graphic_picture","displayName":"Bedbug versus bat bug","title":"Bedbug versus bat bug","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Bedbug versus bat bug</div><div class=\"cntnt\"><img style=\"width:470px; height:546px;\" src=\"images/DERM/66148_Bedbug_vs_batbug.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral hairs behind the head are shorter in the human bedbug (A) than in the bat bug (B). Hairs shorter than the diameter of the eye are present in the bedbug. Hairs longer than the diameter of the eye are found in the bat bug.</div><div id=\"graphicVersion\">Graphic 66148 Version 2.0</div></div></div>"},"66149":{"type":"graphic_table","displayName":"Survival MDS by IPSS and age","title":"Median survival (in years) in myelodysplastic syndrome according to International Prognostic Scoring System (IPSS) and age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Median survival (in years) in myelodysplastic syndrome according to International Prognostic Scoring System (IPSS) and age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">IPSS risk group</td> <td class=\"subtitle1\">Age &#8804;60</td> <td class=\"subtitle1\">Age &#62;60</td> <td class=\"subtitle1\">Age &#62;70</td> </tr> <tr> <td>Low</td> <td class=\"centered\">11.8</td> <td class=\"centered\">4.8</td> <td class=\"centered\">3.9</td> </tr> <tr> <td>Intermediate-1</td> <td class=\"centered\">5.2</td> <td class=\"centered\">2.7</td> <td class=\"centered\">2.4</td> </tr> <tr> <td>Intermediate-2</td> <td class=\"centered\">1.8</td> <td class=\"centered\">1.1</td> <td class=\"centered\">1.2</td> </tr> <tr> <td>High</td> <td class=\"centered\">0.3</td> <td class=\"centered\">0.5</td> <td class=\"centered\">0.4</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079.</div><div id=\"graphicVersion\">Graphic 66149 Version 4.0</div></div></div>"},"66150":{"type":"graphic_figure","displayName":"Stellate cell activation","title":"Phenotypic features of hepatic stellate cell activation during liver injury and resolution","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Phenotypic features of hepatic stellate cell activation during liver injury and resolution</div><div class=\"cntnt\"><img style=\"width:466px; height:408px;\" src=\"images/GAST/66150_Stellate_cell_activation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following liver injury, hepatic stellate cells undergo &quot;activation,&quot; which connotes a transition from quiescent vitamin A-rich cells into proliferative, fibrogenic and contractile myofibroblasts. The major phenotypic changes after activation include proliferation, contractility, fibrogenesis, matrix degradation, chemotaxis, retinoid loss, and white blood cell chemoattraction. Key mediators underlying these effects are shown. The fate of activated stellate cells during resolution of liver injury is uncertain but may include reversion to a quiescent phenotype and/or selective clearance by apoptosis.</div><div class=\"graphic_reference\">Courtesy of Scott L Friedman, MD.</div><div id=\"graphicVersion\">Graphic 66150 Version 1.0</div></div></div>"},"66152":{"type":"graphic_table","displayName":"Travel vaccines – immunocompromised","title":"Immunization of immunocompromised adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunization of immunocompromised adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">HIV infection, CD4 cells &#8805;200/mm<sup>3</sup></td> <td class=\"subtitle1\">Severe immunosuppression (HIV/AIDS) CD4 cells &#60;200/mm<sup>3</sup></td> <td class=\"subtitle1\">Severe immunosuppression (not HIV-related)</td> <td class=\"subtitle1\">Asplenia</td> <td class=\"subtitle1\">Renal failure</td> <td class=\"subtitle1\">Chronic liver disease, diabetes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Live vaccines</td> </tr> <tr> <td class=\"indent1\">Bacillus Calmette-Gu&#233;rin (BCG)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Cholera</td> <td class=\"centered\">ND*</td> <td class=\"centered\">ND*</td> <td class=\"centered\">ND*</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Influenza, live attenuated (LAIV)<sup>&#182;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">P</td> <td class=\"centered\">P</td> </tr> <tr> <td class=\"indent1\">Measles-mumps-rubella (MMR)</td> <td class=\"centered\">R<sup>&#916;</sup></td> <td class=\"centered\">X<sup>&#916;</sup></td> <td class=\"centered\">X<sup>&#916;</sup></td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Typhoid, Ty21a</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Varicella (adults)<sup>&#9674;</sup></td> <td class=\"centered\">C<sup>&#9674;</sup></td> <td class=\"centered\">X<sup>&#9674;</sup></td> <td class=\"centered\">X<sup>&#9674;</sup></td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Yellow fever<sup>&#167;</sup></td> <td class=\"centered\">P<sup>&#167;</sup></td> <td class=\"centered\">X<sup>&#167;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">U</td> <td class=\"centered\">OC<sup>&#165;</sup></td> <td class=\"centered\">OC<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zoster</td> <td class=\"centered\">OC<sup>&#135;</sup></td> <td class=\"centered\">X<sup>&#135;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Inactivated vaccines</td> </tr> <tr> <td class=\"indent1\">Tdap, DTaP</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus influenzae</em> type b (Hib)</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">OC<sup>&#134;</sup></td> <td class=\"centered\">R**</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Hepatitis A<sup>&#182;&#182;</sup></td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U (diabetes), R (liver disease)</td> </tr> <tr> <td class=\"indent1\">Hepatitis B<sup>&#916;&#916;</sup></td> <td class=\"centered\">R<sup>&#9674;&#9674;</sup></td> <td class=\"centered\">R<sup>&#9674;&#9674;</sup></td> <td class=\"centered\">U<sup>&#9674;&#9674;</sup></td> <td class=\"centered\">U<sup>&#9674;&#9674;</sup></td> <td class=\"centered\">R<sup>&#9674;&#9674;</sup></td> <td class=\"centered\">R<sup>&#9674;&#9674;,</sup><sup>&#167;&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Human papillomavirus</td> <td class=\"centered\">U<sup>&#165;&#165;</sup></td> <td class=\"centered\">U<sup>&#165;&#165;</sup></td> <td class=\"centered\">U<sup>&#165;&#165;</sup></td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Influenza (inactivated)</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> </tr> <tr> <td class=\"indent1\">Japanese encephalitis<sup>&#135;&#135;</sup></td> <td class=\"centered\">ND</td> <td class=\"centered\">ND</td> <td class=\"centered\">ND</td> <td class=\"centered\">ND</td> <td class=\"centered\">ND</td> <td class=\"centered\">ND</td> </tr> <tr> <td class=\"indent1\">Meningococcal conjugate</td> <td class=\"centered\">R<sup>&#134;&#134;</sup></td> <td class=\"centered\">R<sup>&#134;&#134;</sup></td> <td class=\"centered\">U</td> <td class=\"centered\">R<sup>&#134;&#134;</sup></td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Meningococcal group B</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">R</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> </tr> <tr> <td class=\"indent1\">PCV13 followed by PPSV23***</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">OC<sup>&#182;&#182;&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Polio (IPV)</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Rabies</td> <td class=\"centered\">U</td> <td class=\"centered\">OC<sup>&#916;&#916;&#916;</sup></td> <td class=\"centered\">OC<sup>&#916;&#916;&#916;</sup></td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Td or Tdap</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> <tr> <td class=\"indent1\">Typhoid, Vi</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> <td class=\"centered\">U</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">X: contraindicated (per the Advisory Committee on Immunization Practices [ACIP]); U: use as indicated for normal hosts; R: recommended for all in this patient category; P: precaution (per ACIP); OC: other considerations; C: consider; ND: no data; PCV13: 13-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine.<br />* No safety or efficacy data exist regarding use of the current formulation of CVD 103-HgR vaccine in HIV-positive adults or people with severe immunosuppression. Limited data from an older formulation of the CVD 103-HgR suggest no association between the vaccine and serious or systemic adverse events, and slightly lower immunogenicity of the vaccine in HIV-positive versus HIV-negative adults.<br />¶ The United States Centers for Disease Control and Prevention (CDC) did not recommend use of LAIV in the 2016 to 2017 season due to questions about LAIV effectiveness. Readers should consult the most recent guideline for recommendations in subsequent years.<br />Δ MMR vaccination is recommended for all HIV-infected patients aged ≥12 months with (for patients aged &lt;6 years) CD4 percentage ≥15 percent&nbsp;or (for patients aged ≥6 years) CD4 percentage ≥15 percent&nbsp;and CD4 counts ≥200/mm<SUP>3</SUP> for ≥6 months if they are without evidence of measles immunity. Immune globulin may be administered for short-term protection of those facing high risk of measles and for whom MMR vaccine is contraindicated. Additional guidance is available at <A href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm\" target=_blank>www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm</A>.<br /><FONT class=lozenge>◊</FONT> Varicella vaccine should not be administered to people who have cellular immunodeficiencies, but people with impaired humoral immunity (including congenital or acquired hypoglobulinemia or dysglobulinemia) may be vaccinated. HIV-positive adults with CD4 counts ≥200 cells/mm<SUP>3</SUP> should be considered to receive 2 doses of vaccine spaced at 3-month intervals. VariZIG (varicella-zoster–specific immune globulin) is recommended for those exposed to varicella or herpes zoster if they do not have evidence of varicella immunity and have contraindications to vaccination.<br />§&nbsp;Refer to&nbsp;details in CDC Health Information for International Travel 2018: Chapter 3, Yellow Fever (available at <A href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/yellow-fever\">https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/yellow-fever</A>). Yellow fever (YF) vaccination is a precaution for asymptomatic HIV-infected people with CD4 cell counts of 200 to 499/mm<SUP>3</SUP>. YF vaccination is not a precaution for people with asymptomatic HIV infection and CD4 cell counts ≥500/mm<SUP>3</SUP>. YF vaccine is also considered contraindicated by ACIP for symptomatic HIV patients without AIDS and with CD4 counts &lt;200/mm<SUP>3</SUP>.<br />¥ No data suggest increased risk of serious adverse events after use of YF vaccine in people with these conditions; however, varying degrees of immune deficit might be present, and providers should carefully weigh vaccine risks and benefits before deciding to vaccinate people with these conditions.<br />‡ Also contraindicated by ACIP for symptomatic HIV patients without AIDS and with CD4 counts &lt;200/mm<SUP>3</SUP>. No recommendation for asymptomatic HIV patients without AIDS and with CD4 counts ≥200/mm<SUP>3</SUP>.<br />† Recipients of a hematopoietic stem cell transplant should be vaccinated with a 3-dose regimen 6 to 12 months after a successful transplant, regardless of vaccination history; at least 4 weeks should separate doses.<br />** Only recommended for asplenic adults who have not previously received Hib vaccine.<br />¶¶ Routinely indicated for all men who have sex with men, people with multiple sexual partners, hemophiliacs, patients with chronic hepatitis, injection drug users, and others.<br />ΔΔ Hepatitis B vaccination is indicated for people at risk for infection by sexual exposure, including sex partners of hepatitis B surface antigen (HBsAg)-positive people, sexually active people who are not in a long-term mutually monogamous relationship, people seeking evaluation or treatment for a sexually transmitted disease, men who have sex with men, people at risk for infection by percutaneous or mucosal exposure to blood, current or recent injection-drug users, household contacts of HBsAg-positive people, residents and staff of facilities for developmentally disabled people, health care and public safety workers with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids, people with end-stage renal disease, international travelers to regions with high or intermediate levels (HBsAg prevalence &gt;2 percent) of endemic HBV infection (refer to&nbsp;Map 3-04, available at <A href=\"https://www.cdc.gov/travel-static/yellowbook/2018/map_3-04.pdf\">https://www.cdc.gov/travel-static/yellowbook/2018/map_3-04.pdf</A>), people with chronic liver disease, and people with HIV infection.<br /><FONT class=double_lozenge>◊◊</FONT> Adult patients receiving hemodialysis or with other immunocompromising conditions should receive 1 dose of 40 mcg/mL Recombivax HB administered on a 3-dose schedule at 0, 1, and 6 months or 2 doses of 20 mcg/mL (Engerix-B) administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months. Test for antibodies to hepatitis B virus surface antigen serum after vaccination and revaccinate if initial antibody response is absent or suboptimal (&lt;10 mIU/mL). HIV-infected nonresponders may react to a subsequent vaccine course if CD4 cell counts rise to 500/mm<SUP>3</SUP> after institution of highly active antiretroviral therapy.&nbsp;<br />§§ People with diabetes who are younger than 60 years as soon as feasible after diagnosis; people with diabetes who are age 60 years or older at the discretion of the treating clinician based on the likelihood of acquiring HBV infection, including the risk posed by an increased need for assisted blood glucose monitoring in long-term care facilities, the likelihood of experiencing chronic sequelae if infected with HBV, and the likelihood of immune response to vaccination; all people with chronic liver disease not caused by hepatitis B. At present, routine testing of antibody response after vaccination in people with diabetes or chronic liver disease is not recommended.<br />¥¥ HPV vaccine should be administered as indicated for males and females but is additionally recommended for all in this patient category for men 22 through 26 years of age (otherwise male indication is through age 21 years). Female indication in each category is through 26 years of age.<br />‡‡ No safety or efficacy data exist regarding the use of Ixiaro in immunocompromised people. In general, inactivated vaccines can be administered safely to people with altered immunocompetence, using the usual doses and schedules, but the effectiveness might be suboptimal. The inactivated, Vero cell–derived Japanese encephalitis vaccine, Ixiaro, is the only Japanese encephalitis vaccine available in the United States; other types of Japanese encephalitis vaccines, including live vaccines, are available internationally but are not included here.<br />†† Two doses ≥2 months apart recommended for patients with HIV infection if they are aged ≥2 years. If younger than 7 years old at previous dose, a patient should receive an additional dose of Menactra or Menveo 3 years after the primary series. Boosters should be repeated every 5 years thereafter. If aged ≥7 years at previous dose, a patient should receive an additional dose of Menactra or Menveo 5 years after the primary series. Boosters should be repeated every 5 years thereafter.<br />*** Previously unimmunized asplenic, HIV-infected, with chronic renal disease or nephrotic syndrome, or immunocompromised adults aged ≥5 years should receive 1 dose of PCV13 followed by 1 dose of PPSV23 ≥8 weeks later. People with these conditions previously immunized with PPSV23 should follow catch-up guidelines per ACIP.<br />¶¶¶ This is an indication for PPSV23 only (as opposed to both PCV13 and PPSV23).<br />ΔΔΔ For postexposure prophylaxis, both vaccine (5 doses at day 0, 3, 7, 14, 28) and immune globulin should be given to immunocompromised people, regardless of previous vaccination status.</div><div class=\"graphic_reference\">Reproduced from: The Centers for Disease Control and Prevention and Brunette GW (Ed). CDC Health Information for International Travel 2018. Oxford University Press, New York, 2017.</div><div id=\"graphicVersion\">Graphic 66152 Version 12.0</div></div></div>"},"66153":{"type":"graphic_figure","displayName":"Ischemic events with asymptomatic bruits","title":"Cerebral ischemia events with asymptomatic carotid artery bruits","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Cerebral ischemia events with asymptomatic carotid artery bruits</div><div class=\"cntnt\"><img style=\"width:467px; height:265px;\" src=\"images/NEURO/66153_Ischemic_events_with_asx_br.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of ischemic events in 500 patients with asymptomatic carotid artery bruits according to the severity of carotid artery stenosis on initial Doppler ultrasonography. Patients with ≥75 percent stenosis were at significantly increased risk (P &lt;0.0001).</div><div class=\"graphic_reference\">Data from Chambers BR, Norris JW. Outcome in patients with asymptomatic neck bruits. N Engl J Med 1986; 315:860.</div><div id=\"graphicVersion\">Graphic 66153 Version 3.0</div></div></div>"},"66154":{"type":"graphic_figure","displayName":"Hist RT-associated STS","title":"Histology of radiation-associated soft tissue sarcomas (n = 123)","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Histology of radiation-associated soft tissue sarcomas (n = 123)</div><div class=\"cntnt\"><img style=\"width:498px; height:384px;\" src=\"images/ONC/66154_Hist_radinduced_sarcs.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MFH: malignant fibrous histiocytoma; MPNT: malignant peripheral nerve tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: Cha C, Antonescu CR, Quan ML, et al. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004; 239:903. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66154 Version 10.0</div></div></div>"},"66155":{"type":"graphic_picture","displayName":"Circumcision skin bridges","title":"Circumcision skin bridges","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circumcision skin bridges</div><div class=\"cntnt\"><img style=\"width:360px; height:329px;\" src=\"images/PEDS/66155_Circumcision_skin_bridges.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin bridges (dense adhesions) after circumcision.</div><div class=\"graphic_reference\">Courtesy of Laurence S Baskin, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 66155 Version 3.0</div></div></div>"},"66156":{"type":"graphic_figure","displayName":"Female perirectal perivesical sp2","title":"Palpating for tumor extension in the female perirectal and perivesical spaces during radical hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Palpating for tumor extension in the female perirectal and perivesical spaces during radical hysterectomy</div><div class=\"cntnt\"><img style=\"width:466px; height:435px;\" src=\"images/OBGYN/66156_Perirectal_perivesical_sp2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Placing an index finger in the perivesical space and the middle finger in the perirectal space allows the tissue in between (parametrium) to be palpated to assess for tumor extension.</div><div class=\"graphic_footnotes\">BL: bladder; VVS: vesicovaginal space; VA: vagina; RVS: rectovaginal space; RE: rectum; RRS: retrorectal space.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 66156 Version 2.0</div></div></div>"},"66157":{"type":"graphic_diagnosticimage","displayName":"Radionuclide imaging of Chagas cardiomyopathy","title":"Radionuclide imaging of Chagas cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Radionuclide imaging of Chagas cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:456px; height:408px;\" src=\"images/CARD/66157_Myocardial_SESTAMIBI_Tc99M.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images of a 63-year-old man presenting with syncope due to episodes of sustained ventricular tachycardia with Chagas cardiomyopathy and normal echocardiogram. This figure shows <sup>99m</sup>Tc sestamibi myocardial perfusion SPECT images for assessment of myocardial viability and <sup>123</sup>I MIBG myocardial SPECT (lower rows) for assessment of cardiac sympathetic innervation. There is a large defect in <sup>123</sup>I MIBG uptake involving the inferior and apical walls with corresponding normal <sup>99m</sup>Tc sestamibi uptake, consistent with viable but denervated myocardium.</div><div class=\"graphic_footnotes\">SPECT: single-photon emission computed tomography. </div><div id=\"graphicVersion\">Graphic 66157 Version 4.0</div></div></div>"},"66158":{"type":"graphic_figure","displayName":"Pelvic bones and female organs","title":"Pelvic bones and female organs","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Pelvic bones and female organs</div><div class=\"cntnt\"><img style=\"width:492px; height:381px;\" src=\"images/EM/66158_Pelvicviscera.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic drawing demonstrating the close relationship of the pelvic viscera (bladder, vagina, urethra, and rectum) to bony structures of the pelvis.</div><div class=\"graphic_reference\">Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66158 Version 11.0</div></div></div>"},"66159":{"type":"graphic_picture","displayName":"Angioedema and hives face","title":"Angioedema and hives face","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angioedema and hives face</div><div class=\"cntnt\"><img style=\"width:314px; height:200px;\" src=\"images/ALLRG/66159_Angioedema_and_hives_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Facial angioedema and urticaria (forehead).</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd&nbsp;ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66159 Version 2.0</div></div></div>"},"66160":{"type":"graphic_table","displayName":"Delayed gastric emptying in DM","title":"Putative mechanisms of delayed gastric emptying in diabetes mellitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Putative mechanisms of delayed gastric emptying in diabetes mellitus</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Altered gastric electrical activity (\"tachygastria\")</td>\n</tr>\n<tr>\n<td>Decreased fundus tone</td>\n</tr>\n<tr>\n<td>Decreased antral contraction amplitude and frequency (in fasting and fed state)</td>\n</tr>\n<tr>\n<td>Impaired antroduodenal coordination (in fasting and fed state)</td>\n</tr>\n<tr>\n<td>Increased postprandial frequency of isolated pyloric pressure waves</td>\n</tr>\n<tr>\n<td>Decreased duodenal contraction amplitude and frequency (in fasting and fed state)</td>\n</tr>\n<tr>\n<td>Small intestinal dysmotility (in fasting state)</td>\n</tr>\n<tr>\n<td>Altered visceral perception</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">6.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=17797&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Del_gastric_emptying_diabet.htm</title></head></div><div id=\"graphicVersion\">Graphic 66160 Version 2.0</div></div></div>"},"66161":{"type":"graphic_diagnosticimage","displayName":"Esophageal stricture Ba swallow","title":"Proximal esophageal stricture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal esophageal stricture</div><div class=\"cntnt\"><img style=\"width:255px; height:365px;\" src=\"images/GAST/66161_Esophageal_stricture_Ba_swa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium swallow shows proximal esophageal stricture (arrow) due to reflux esophagitis.</div><div class=\"graphic_reference\">Courtesy of Peter J Kahrilas, MD.</div><div id=\"graphicVersion\">Graphic 66161 Version 2.0</div></div></div>"},"66162":{"type":"graphic_figure","displayName":"Location Bartholin gland","title":"Location of the Bartholin glands and ducts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Location of the Bartholin glands and ducts</div><div class=\"cntnt\"><img style=\"width:278px; height:316px;\" src=\"images/OBGYN/66162_Location_Bartholin_gland.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each Bartholin gland is approximately one-half centimeter (cm) in size and drains into a duct 2.5 cm long. The ducts emerge onto the vestibule, one at each side of the vaginal orifice, in the groove (superficial perineal pouch) between the hymenal ring and the labia minora.</div><div id=\"graphicVersion\">Graphic 66162 Version 1.0</div></div></div>"},"66164":{"type":"graphic_table","displayName":"Therapeutic exercise","title":"Types of therapeutic exercise","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of therapeutic exercise</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of exercise</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"sublist_other_start\" colspan=\"2\"><strong>Flexibility exercises</strong></td> </tr> <tr> <td class=\"indent1\">Static stretching</td> <td>Target muscle is stretched and held for 30 seconds or longer</td> </tr> <tr> <td class=\"indent1\">Progressive velocity flexibility program</td> <td>Stretches muscles at higher velocities over time</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist_other_start\" colspan=\"2\"><strong>Strengthening exercises</strong></td> </tr> <tr> <td class=\"indent1\">Isometric</td> <td>Muscle contracts without changing length</td> </tr> <tr> <td class=\"indent1\">Isotonic</td> <td>Muscle contracts against fixed resistance throughout its arc of motion</td> </tr> <tr> <td class=\"indent1\">Isokinetic</td> <td>The speed of muscle contraction is constant</td> </tr> <tr> <td class=\"indent1\">Concentric</td> <td>Contract or shorten muscles during exercise (eg, flexion phase of biceps curl)</td> </tr> <tr> <td class=\"indent1\">Eccentric</td> <td>Controlled lengthening of the muscle against resistance (eg, extension phase of biceps curl)</td> </tr> <tr> <td class=\"indent1\">Closed kinetic chain</td> <td>Distal extremity is fixed (eg, squat)</td> </tr> <tr> <td class=\"indent1\">Open kinetic chain</td> <td>Distal extremity is not fixed (eg, straight leg raise in supine)</td> </tr> <tr> <td class=\"indent1\">Functional</td> <td>Strengthen muscles in their position of normal use or function; generally replicate movements or patterns of movements used in sports activity</td> </tr> <tr class=\"divider_top\"> <td><strong>Endurance exercises</strong></td> <td>High-repetition, low-load</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist_other_start\" colspan=\"2\"><strong>Power exercises</strong></td> </tr> <tr> <td class=\"indent1\">Plyometric activities (eg, bouncing, box jumps, rebounders, and explosive/ballistic exercise)</td> <td>Use the stretch-shortening cycle to get a greater force of contraction</td> </tr> <tr class=\"divider_top\"> <td><strong>Agility drills</strong></td> <td>Figure-eight running, zigzag running, shuttle running, carioca, retro running, cross-over cutting</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Anderson SJ. Principles of rehabilitation. In: Care of the Young Athlete, Sullivan JA, Anderson SJ (Eds). American Academy of Orthopedic Surgeons: American Academy of Pediatrics, Rosemont, IL 2000. p.267.</div><div id=\"graphicVersion\">Graphic 66164 Version 4.0</div></div></div>"},"66165":{"type":"graphic_table","displayName":"BAL fluid in smokers","title":"Expected values of BAL fluid constituents in healthy smokers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected values of BAL fluid constituents in healthy smokers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Mean &#177; SEM</td> <td class=\"subtitle1\">5th percentile*</td> <td class=\"subtitle1\">95th percentile<sup>&#182;</sup></td> </tr> <tr> <td>Percent recovery of lavagate</td> <td>59.2 &#177; 1.4</td> <td>35.9</td> <td>74.9</td> </tr> <tr> <td>Total cells, 10<sup>6&#916;</sup></td> <td>59.9 &#177; 7.3</td> <td>10.5</td> <td>176</td> </tr> <tr> <td>Total cells/ml, 10<sup>4&#916;</sup></td> <td>41.8 &#177; 4.5</td> <td>8.1</td> <td>117.1</td> </tr> <tr> <td>Macrophages, percent<sup>&#916;</sup></td> <td>92.5 &#177; 1</td> <td>79.5</td> <td>99</td> </tr> <tr> <td>Macrophages/mL, 10<sup>4&#916;</sup></td> <td>39 &#177; 4.3</td> <td>7</td> <td>108.4</td> </tr> <tr> <td>Lymphocytes, percent<sup>&#916;</sup></td> <td>5.2 &#177; 0.9</td> <td>1</td> <td>18.6</td> </tr> <tr> <td>Lymphocytes/mL, 10<sup>4&#916;</sup></td> <td>1.74 &#177; 0.28</td> <td>0.1</td> <td>7.1</td> </tr> <tr> <td>Neutrophils, percent<sup>&#916;</sup></td> <td>1.6 &#177; 0.2</td> <td>0</td> <td>7</td> </tr> <tr> <td>Neutrophils/mL, 10<sup>4&#916;</sup></td> <td>0.82 &#177; 0.18</td> <td>0</td> <td>3.5</td> </tr> <tr> <td>Eosinophils, percent<sup>&#916;</sup></td> <td>0.56 &#177; 0.13&nbsp;</td> <td>0</td> <td>3</td> </tr> <tr> <td>Eosinophils/mL, 10<sup>4&#916;</sup></td> <td>0.28 &#177; 0.09</td> <td>0</td> <td>2.5</td> </tr> <tr> <td>T cells, percent<sup>&#9674;</sup></td> <td>69.2 &#177; 4.32</td> <td>15</td> <td>95.5</td> </tr> <tr> <td>T-helper cells, percent<sup>&#9674;</sup></td> <td>32.21 &#177; 2.71</td> <td>9</td> <td>65</td> </tr> <tr> <td>T-suppressor cells, percent<sup>&#9674;</sup></td> <td>29.2 &#177; 3</td> <td>5</td> <td>58</td> </tr> <tr> <td>Helper/suppressor ratio<sup>&#9674;</sup></td> <td>1.64 &#177; 0.29</td> <td>0.3</td> <td>6.1</td> </tr> <tr> <td>B cells, percent<sup>&#9674;</sup></td> <td>6.54 &#177; 1.54</td> <td>0</td> <td>28.1</td> </tr> <tr> <td>IgG, mcg/mL<sup>&#167;</sup></td> <td>10.22 &#177; 0.9</td> <td>2.5</td> <td>22.2</td> </tr> <tr> <td>IgA, mcg/mL<sup>&#167;</sup></td> <td>5.94 &#177; 0.53</td> <td>1.06</td> <td>15.4</td> </tr> <tr> <td>IgM, mcg/mL<sup>&#167;</sup></td> <td>0.227 &#177; 0.05</td> <td>0.01</td> <td>1</td> </tr> <tr> <td>Albumin, mcg/mL<sup>&#167;</sup></td> <td>42.92 &#177; 2.73</td> <td>14</td> <td>91.1</td> </tr> <tr> <td>Total protein, mcg/mL<sup>&#167;</sup></td> <td>95.39 &#177; 5.24</td> <td>37.8</td> <td>182.7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage.<br />* 5th percentile of the study population.<br />¶ 95th percentile of the study population.<br />Δ n = 64.<br /><FONT class=lozenge>◊</FONT> n = 29.<br />§ n = 62.</div><div class=\"graphic_reference\">Data from: BAL Cooperative Group. Am Rev Respir Dis 1990; 141:S169 (BAL Cooperative Group, 1990 #261).</div><div id=\"graphicVersion\">Graphic 66165 Version 3.0</div></div></div>"},"66166":{"type":"graphic_diagnosticimage","displayName":"Sequestration CT I","title":"Intralobar sequestration left lower lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intralobar sequestration left lower lobe</div><div class=\"cntnt\"><img style=\"width:396px; height:290px;\" src=\"images/PULM/66166_Sequestration_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan displays the multicystic nature of the sequestration.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66166 Version 3.0</div></div></div>"},"66167":{"type":"graphic_figure","displayName":"Neer classification of proximal humerus fractures","title":"Neer classification of proximal humerus fractures","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Neer classification of proximal humerus fractures</div><div class=\"cntnt\"><img style=\"width:492px; height:731px;\" src=\"images/EM/66167_Neer_class_prox_humerus_fxs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The main subgroups of Neer classification of proximal humerus fractures. The rarer articular surface fractures (head-splitting or impression fractures) are not depicted here.</div><div class=\"graphic_reference\">Reproduced with permission from: Robinson CM. Proximal humerus fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66167 Version 2.0</div></div></div>"},"66169":{"type":"graphic_table","displayName":"Spotted fever group rickettsiae","title":"Spotted fever group rickettsiae","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spotted fever group rickettsiae</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Vectors</td> <td class=\"subtitle1\">Geographic distribution</td> <td class=\"subtitle1\">Severity of symptoms</td> </tr> <tr> <td rowspan=\"3\">Rocky mountain spotted fever</td> <td rowspan=\"3\">R. rickettsii</td> <td> <p>Dermacentor andersoni</p> <p>&nbsp;</p> </td> <td>United States</td> <td rowspan=\"3\">Human - severe to mild</td> </tr> <tr> <td>D. variabilis</td> <td>Southern Canada</td> </tr> <tr> <td> <p>Rhipicephalus sanguineous ticks</p> <p>&nbsp;</p> <p>Ambylomma ticks</p> </td> <td> <p>Mexico</p> <p>Central America</p> <p>Brazil</p> </td> </tr> <tr> <td>Rickettsialpox</td> <td>R. akari</td> <td>Allodermanyssus sanguineous (mouse mites)</td> <td> <p>North America</p> <p>Korea</p> <p>Balkans</p> </td> <td>Mild</td> </tr> <tr> <td rowspan=\"2\">Mediterranean spotted fever</td> <td rowspan=\"2\">R. conorii</td> <td>R. sanguineous</td> <td>North Africa</td> <td rowspan=\"2\">Mild to severe</td> </tr> <tr> <td>Haemaphysalis ticks</td> <td> <p>Kenya</p> <p>Israel</p> <p>Southern Europe</p> <p>Pakistan</p> </td> </tr> <tr> <td>Queensland tick typhus</td> <td>R. australis</td> <td>Ixodes ticks</td> <td>Eastern Australia</td> <td>Mild to moderate</td> </tr> <tr> <td>Flinders Island spotted fever</td> <td>R. honei</td> <td>Ticks of several genera</td> <td> <p>Australia</p> <p>Southeast Asia</p> <p>Northwestern North America</p> <p>Thailand</p> </td> <td>Mild to moderate</td> </tr> <tr> <td>African tick bite fever</td> <td>R. africae</td> <td>Amblyomma ticks</td> <td> <p>Sub-Saharan Africa</p> <p>Caribbean</p> </td> <td>Mild</td> </tr> <tr> <td>Siberian tick typhus</td> <td>R. sibirica, R. sibirica mongolotimonae</td> <td>Dermacentor ticks</td> <td> <p>China</p> <p>Russia</p> <p>Southern and Eastern Europe</p> </td> <td>Mild to moderate</td> </tr> <tr> <td>Japanese spotted fever</td> <td>R. japonica</td> <td> <p>Dermacentor</p> <p>Haemaphysalis</p> <p>Ixodes ticks</p> </td> <td>Southwest Japan</td> <td>Mild to severe</td> </tr> <tr> <td>Flea rickettsiosis</td> <td>R. felis</td> <td>Cat fleas</td> <td> <p>Europe</p> <p>North America</p> <p>South America</p> <p>Africa</p> <p>Asia</p> </td> <td>Mild</td> </tr> <tr> <td>Lymphangitis-associated rickettsiosis</td> <td>R. sibirica mongolotimonae</td> <td>Hyalomma ticks</td> <td> <p>China</p> <p>Sub-Saharan Africa</p> <p>France</p> </td> <td>Mild to moderate</td> </tr> <tr> <td>Tick-borne lymphadenopathy</td> <td>R. slovaca</td> <td>Dermacentor ticks</td> <td>Southern and eastern Europe</td> <td>Mild</td> </tr> <tr> <td>R. parkeri infection</td> <td>R. parkeri</td> <td>Amblyomma ticks</td> <td>United States</td> <td>-</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66169 Version 2.0</div></div></div>"},"66173":{"type":"graphic_picture","displayName":"Squamous debris","title":"Old tympanostomy tube with squamous debris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Old tympanostomy tube with squamous debris</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/66173_Squamousdebris.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extrusion of most tubes is initiated by the continual shedding of squamous debris from the epithelium of the tympanic membrane. As debris accumulates under the outer flange of the tube, the pressure causes the flange to lift up from the surface of the membrane, as depicted above.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 93, Pages 924-9, Copyright © 1994 by the AAP.</div><div id=\"graphicVersion\">Graphic 66173 Version 13.0</div></div></div>"},"66174":{"type":"graphic_picture","displayName":"Trapezius muscle palpation","title":"Upper trapezius muscle palpation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper trapezius muscle palpation</div><div class=\"cntnt\"><img style=\"width:395px; height:368px;\" src=\"images/PC/66174_Trapezius_muscle_palpation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper portion of the trapezius muscle originates from the seven cervical spinous processes and the distal aspect of the acromial process. Palpate the superior trapezius muscle halfway between the acromion and spinous processes. Local muscular tenderness can result from trauma, but the majority of cases are due to reactive cervical muscular strain.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 66174 Version 2.0</div></div></div>"},"66175":{"type":"graphic_figure","displayName":"Thyroid hormone structure","title":"Structures of the thyroid hormones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structures of the thyroid hormones</div><div class=\"cntnt\"><img style=\"width:340px; height:376px;\" src=\"images/ENDO/66175_Thyroid_hormone_structure.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66175 Version 1.0</div></div></div>"},"66177":{"type":"graphic_diagnosticimage","displayName":"Pelvic congestion syndrome 11b","title":"Left ovarian venogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ovarian venogram</div><div class=\"cntnt\"><img style=\"width:241px; height:474px;\" src=\"images/OBGYN/66177_Pelvic_congestion_syndrom2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ovarian venogram shows occlusion of the left ovarian vein following coil embolization (arrows). The patient's symptoms improved significantly after embolization.</div><div id=\"graphicVersion\">Graphic 66177 Version 2.0</div></div></div>"},"66178":{"type":"graphic_picture","displayName":"Umbilical artery aneurysm","title":"Umbilical artery aneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Umbilical artery aneurysm</div><div class=\"cntnt\"><img style=\"width:382px; height:511px;\" src=\"images/OBGYN/66178_Umbilical_artery_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of the placenta shows an abnormal vascular dilatation at the base of the placenta cord insertion site (A). Dye injection studies demonstrate aneurysm of the single umbilical artery (B and C).</div><div class=\"graphic_reference\">Reproduced from: Sepulveda W, Corral E, Kottmann C, et al. Umbilical cord aneurysm: prenatal identification in three fetuses with trisomy 18. Ultrasound Obstet Gynecol 2003; 21:292. Copyright &copy; 2003. Reproduced with permission from: John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 66178 Version 3.0</div></div></div>"},"66179":{"type":"graphic_picture","displayName":"Bullous pemphigoid oral mucosa","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/66179_Bullous_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions on the oral mucosa in this patient with bullous pemphigoid.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66179 Version 4.0</div></div></div>"},"66180":{"type":"graphic_picture","displayName":"Giant keratoacanthoma on nose","title":"Giant keratoacanthoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Giant keratoacanthoma</div><div class=\"cntnt\"><img style=\"width:504px; height:286px;\" src=\"images/DERM/66180_Giant_keratoacanthoma_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large crateriform nodule is present on the nose.</div><div id=\"graphicVersion\">Graphic 66180 Version 1.0</div></div></div>"},"66182":{"type":"graphic_picture","displayName":"Aerial yellow jacket nest","title":"Aerial yellow jacket nest","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Aerial yellow jacket nest</div><div class=\"cntnt\"><img style=\"width:504px; height:344px;\" src=\"images/ALLRG/66182_Aerial_yellowjacket_nest.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 66182 Version 2.0</div></div></div>"},"66183":{"type":"graphic_diagnosticimage","displayName":"Avulsion fracture fifth metatarsal tuberosity","title":"Avulsion fracture of the fifth metatarsal tuberosity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Avulsion fracture of the fifth metatarsal tuberosity</div><div class=\"cntnt\"><img style=\"width:293px; height:540px;\" src=\"images/EM/66183_Avulsion_fx_tuberosity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fracture of the fifth metatarsal tuberosity (black arrow)&nbsp;is seen on this plain radiograph. Although this view&nbsp;suggests the fracture fragment is displaced, additional views are needed to make this determination definitively.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 66183 Version 4.0</div></div></div>"},"66184":{"type":"graphic_table","displayName":"Autopsy findings in SIDS","title":"Typical morphologic findings in a SIDS autopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical morphologic findings in a SIDS autopsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">External examination</td> </tr> <tr> <td>Well-developed, well-nourished baby</td> </tr> <tr> <td>Frothy blood-tinged fluid around the nose (50 percent)</td> </tr> <tr> <td>Cyanosis of the lips and nail beds</td> </tr> <tr> <td>Hypostatic staining anteriorly suggesting face down position</td> </tr> <tr> <td class=\"subtitle1_single\">Internal examination</td> </tr> <tr> <td>Pulmonary congestion</td> </tr> <tr> <td>Pulmonary edema </td> </tr> <tr> <td>Thymic petechiae (up to 80 percent)</td> </tr> <tr> <td>Persistent hepatic erythropoiesis </td> </tr> <tr> <td>\"Subacute\" inflammation of the upper respiratory tract (up to 60 percent)</td> </tr> <tr> <td>Focal fibrinoid necrosis of the larynx</td> </tr> <tr> <td>Full expansion of the lungs</td> </tr> <tr> <td>Liquid blood in the heart</td> </tr> <tr> <td>Normal prominent lymphoid tissue</td> </tr> <tr> <td>Empty urinary bladder (50 percent)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Percentages refer to frequency of this finding in infants undergoing autopsy with a final diagnosis of SIDS. </div><div class=\"graphic_reference\">Data from Berry PJ. Pathological findings in SIDS. J Clin Pathol 1992; 45:11.</div><div id=\"graphicVersion\">Graphic 66184 Version 2.0</div></div></div>"},"66185":{"type":"graphic_table","displayName":"Major causes of occupational asthma and rhinitis","title":"Major causes of occupational asthma and rhinitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of occupational asthma and rhinitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Occupation at risk</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Low molecular weight chemicals</td> </tr> <tr> <td class=\"indent1\">Isocyanates (eg, toluene diisocyanate, diphenylmethane diisocyanate, hexamethylene diisocyanate, naphthalene diisocyanate)</td> <td>Polyurethane workers, roofers, insulators, painters</td> </tr> <tr> <td class=\"indent1\">Anhydrides (eg, trimellitic anhydride, phthalic anhydride)</td> <td>Manufacturers of paint, plastics, epoxy resins</td> </tr> <tr> <td class=\"indent1\">Metals (eg, chromic acid, potassium dichromate, nickel sulfate, vanadium, platinum salts)</td> <td>Platers, welders, metal and chemical workers</td> </tr> <tr> <td class=\"indent1\">Drugs (eg, beta-lactam agents, opiates, other)</td> <td>Pharmaceutical workers, farm workers, health professionals</td> </tr> <tr> <td class=\"indent1\">Wood dust (eg, Western red cedar, maple, oak, exotic woods)</td> <td>Carpenters, woodworkers</td> </tr> <tr> <td class=\"indent1\">Dyes and bleaches (eg, anthraquinone, carmine, henna extract, persulfate, reactive dyes)</td> <td>Fabric and fur dyers, hairdressers</td> </tr> <tr> <td class=\"indent1\">Amines</td> <td>Chemists, cleaners, plastic manufacturers</td> </tr> <tr> <td class=\"indent1\">Glues and resins (eg, acrylates, epoxy)</td> <td>Plastic manufacturers</td> </tr> <tr> <td class=\"indent1\">Miscellaneous (eg, formaldehyde, glutaraldehyde, ethylene oxide, pyrethrin, polyvinyl chloride vapor)</td> <td>Laboratory workers, textile workers, paint sprayers, health professionals</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">High molecular weight organic materials</td> </tr> <tr> <td class=\"indent1\">Animal proteins (eg, domestic and laboratory animals, fish and seafood)</td> <td>Farmers, veterinarians, poultry processors, fish and seafood processors</td> </tr> <tr> <td class=\"indent1\">Flours and cereals</td> <td>Bakers, food processors, dock workers</td> </tr> <tr> <td class=\"indent1\">Enzymes (eg, pancreatic extracts, papain, trypsin, <em>Bacillus subtilis</em>, bromelain, pectinase, amylase, lipase)</td> <td>Bakers, food processors, pharmaceutical workers, plastic workers, detergent manufacturers</td> </tr> <tr> <td class=\"indent1\">Plant proteins (eg, wheat, grain dust, coffee beans, tobacco dust, cotton, tea, latex, psyllium, various flours)</td> <td>Bakers, farmers, food and plant processors, health professionals, textile workers</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66185 Version 5.0</div></div></div>"},"66186":{"type":"graphic_diagnosticimage","displayName":"SCLC normal CT","title":"CT negative PET positive Paraneoplastic disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT negative PET positive Paraneoplastic disease</div><div class=\"cntnt\"><img style=\"width:432px; height:292px;\" src=\"images/PULM/66186_SCLC_normal_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 71-year-old man presented with a polyneuropathy thought secondary to a paraneoplastic syndrome as he had a high P/Q type calcium channel antibody present in serum. CT showing a normal sized hilar node.</div><div class=\"graphic_footnotes\">CT: computed tomography; PET: positron emission tomography.</div><div id=\"graphicVersion\">Graphic 66186 Version 3.0</div></div></div>"},"66188":{"type":"graphic_picture","displayName":"Filiform wart","title":"Filiform wart","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Filiform wart</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/66188_Filiform_wart.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A solitary papule with finger-like, keratotic projections is present lateral to the eye.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66188 Version 4.0</div></div></div>"},"66189":{"type":"graphic_figure","displayName":"Posterior tibiofibular ligament and inferior transverse ligament","title":"Posterior tibiofibular ligament and inferior transverse ligament","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior tibiofibular ligament and inferior transverse ligament</div><div class=\"cntnt\"><img style=\"width:302px; height:512px;\" src=\"images/EM/66189_Post_tib_lig_inf_trans_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior view of the key ligamentous attachments between the distal tibia and fibula. The posterior tibiofibular ligament (PTiFL) and the inferior transverse ligament (ITL) attach the posterolateral tibila tubercle to the posterior aspect of the fibula.</div><div id=\"graphicVersion\">Graphic 66189 Version 3.0</div></div></div>"},"66190":{"type":"graphic_picture","displayName":"Entamoeba in stool","title":"<EM innerHtml>Entamoeba </EM>in stool","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM innerHtml>Entamoeba </EM>in stool</div><div class=\"cntnt\"><img style=\"width:359px; height:238px;\" src=\"images/ID/66190_Entamoebahistolyticainst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wet mount of stool (x1000) showing a cyst, which could be <EM>Entamoeba histolytica</EM>,&nbsp;<EM innerHtml>Entamoeba dispar</EM><EM>,</EM>&nbsp;or<EM> Entamoeba moshkovskii</EM>; these are indistinguishable by morphology. However, <EM>E. dispar </EM>and <EM>E. moshkovskii </EM>are nonpathogenic and do not cause symptomatic disease.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 66190 Version 6.0</div></div></div>"},"66195":{"type":"graphic_diagnosticimage","displayName":"Prostatic enlargement","title":"Urinary retention due to prostatic enlargement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urinary retention due to prostatic enlargement</div><div class=\"cntnt\"><img style=\"width:276px; height:301px;\" src=\"images/NEPH/66195_Prostatic_enlargement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse sonogram of the bladder showing a markedly enlarged prostate gland (cursors).</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 66195 Version 2.0</div></div></div>"},"66196":{"type":"graphic_diagnosticimage","displayName":"Adenomyosis 6b","title":"Sagittal spin-echo T2-weighted MR image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sagittal spin-echo T2-weighted MR image</div><div class=\"cntnt\"><img style=\"width:357px; height:365px;\" src=\"images/OBGYN/66196_Adenomyosis_6b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal spin-echo T2-weighted MR image obtained three months after embolization shows normal junctional zone thickness (arrow). The patient's symptoms improved significantly after uterine fibroid embolization. Follow-up MR of the pelvis one year later showed no changes from 3-month follow-up study and no evidence of recurrence.</div><div id=\"graphicVersion\">Graphic 66196 Version 3.0</div></div></div>"},"66197":{"type":"graphic_figure","displayName":"Captopril lowers cardiovascular mortality post-MI","title":"Captopril lowers cardiovascular mortality post-MI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Captopril lowers cardiovascular mortality post-MI</div><div class=\"cntnt\"><img style=\"width:402px; height:270px;\" src=\"images/CARD/66197_ACEI_for_LV_dysfunction_pos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Life table for death from cardiovascular disease in 2231 patients in the SAVE trial with left ventricular dysfunction but without overt heart failure randomized to captopril or placebo 3 to 16 days after an acute myocardial infarction. Captopril significantly lowered the cardiovascular mortality.</div><div class=\"graphic_reference\">Data from Pfeffer MA, Braunwald E, Moye LA, et al. N Engl J Med 1992, 327:669.</div><div id=\"graphicVersion\">Graphic 66197 Version 3.0</div></div></div>"},"66198":{"type":"graphic_figure","displayName":"CLL survival beta 2 microglob","title":"Survival of patients with chronic lymphocytic leukemia stratified by beta-2 microglobulin levels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival of patients with chronic lymphocytic leukemia stratified by beta-2 microglobulin levels</div><div class=\"cntnt\"><img style=\"width:431px; height:328px;\" src=\"images/HEME/66198_CLL_survival_beta_2_microgl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph illustrates overall survival (Kaplan-Meier method) in 153 patients with chronic lymphocytic leukemia, stratified according to their serum levels of beta-2 microglobulin. The numbers to the right of each graph refer to the beta-2 microglobulin concentration in milligrams per liter.</div><div class=\"graphic_reference\">Data from Fayad, L, et al. Blood 2001; 97:256.</div><div id=\"graphicVersion\">Graphic 66198 Version 1.0</div></div></div>"},"66199":{"type":"graphic_table","displayName":"Dextromethorphan-DXM street names","title":"Common street names for dextromethorphan","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common street names for dextromethorphan</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Triple C (C-C-C)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Candy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Dex</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>DM</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Drex</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Red Devils</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Robo</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Rojo</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Skittles</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tussin</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Velvet</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Vitamin D</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 66199 Version 2.0</div></div></div>"},"66200":{"type":"graphic_picture","displayName":"Scapular strength T PI","title":"Scapular strengthening exercise - \"T\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scapular strengthening exercise - \"T\"</div><div class=\"cntnt\"><img style=\"width:345px; height:487px;\" src=\"images/PI/66200_Scapular_strength_T_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Using the same body position, squeeze your shoulder blades down and backward towards the spine while moving the arms to form a \"T.\"<br />(B) Raise the arms straight out to each side, parallel to the floor. This can be done with the thumbs up or down. Hold for a second or two, then return the arms to the starting position; repeat 10 to 15 times.</div><div id=\"graphicVersion\">Graphic 66200 Version 4.0</div></div></div>"},"66203":{"type":"graphic_picture","displayName":"Urticarial vasculitis II","title":"Urticarial vasculitis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Urticarial vasculitis</div><div class=\"cntnt\"><img style=\"width:468px; height:307px;\" src=\"images/ALLRG/66203_UV_lesions_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular patch with elevated borders.</div><div id=\"graphicVersion\">Graphic 66203 Version 2.0</div></div></div>"},"66205":{"type":"graphic_figure","displayName":"Aspiration subtalar joint","title":"Aspiration from subtalar joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspiration from subtalar joint</div><div class=\"cntnt\"><img style=\"width:411px; height:239px;\" src=\"images/RHEUM/66205_Aspiration_subtalar_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unilateral ankle effusions can be crystal-induced &quot;cluster attacks&quot; in which several anatomically adjacent joints are involved. These attacks can sometimes be made to yield fluid by aspirating the subtalar joint, one finger breadth below the prominence of the lateral malleolus.</div><div id=\"graphicVersion\">Graphic 66205 Version 1.0</div></div></div>"},"66206":{"type":"graphic_waveform","displayName":"Prolonged QT","title":"Prolonged QT interval due to hypocalcemia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prolonged QT interval due to hypocalcemia</div><div class=\"cntnt\"><img style=\"width:421px; height:99px;\" src=\"images/CARD/66206_Prolonged_QT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The QT interval in this case is quite prolonged (0.50 sec) at a heart rate of 55 beats/min. The rate corrected QT (QTc) interval can be calculated from: QT interval ÷ sqrt (RR interval). The RR interval is 1.05 sec leading to a QTc of 0.48 sec which is longer than the normal value of ≤0.44 sec. A long QT interval with a &quot;stretched out&quot; ST segment and normal T wave is most consistent with hypocalcemia. In contrast, hypercalcemia shortens the QT, hyponatremia usually has no effect on the ECG, and hypokalemia prolongs repolarization with flattened or broad T waves and prominent U waves.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 66206 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"66207":{"type":"graphic_figure","displayName":"Critical view of safety in laparoscopic cholecystectomy","title":"Critical view of safety in laparoscopic cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Critical view of safety in laparoscopic cholecystectomy</div><div class=\"cntnt\"><img style=\"width:473px; height:388px;\" src=\"images/SURG/66207_Laparoscopic critical view of safety.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The critical view of safety is a &quot;window&quot; crossed by two structures: the cystic duct and artery. This is achieved by exposing the base of the liver bed and dissecting Calot's triangle free of all tissue except for the cystic duct and artery. The two structures emanating from the gallbladder (cystic duct and cystic artery) and the interface with the liver at the base of the gallbladder fossa should be definitively identified. The critical view of safety should be achieved prior to clipping or dividing any tubular structures in a laparoscopic cholecystectomy. Difficulty with identification of the critical view should lead the surgeon to consider performing cholangiography or converting the laparoscopic cholecystectomy into an open procedure.</div><div id=\"graphicVersion\">Graphic 66207 Version 3.0</div></div></div>"},"66208":{"type":"graphic_picture","displayName":"Normal endoscopic view of open eustachian tube","title":"Normal endoscopic view of open eustachian tube","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Normal endoscopic view of open eustachian tube</div><div class=\"cntnt\"><img style=\"width:480px; height:324px;\" src=\"images/PC/66208_Normal_endo_ET_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal left eustachian tube in the open position. Dilated valve (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Poe DS, Gopen Q. Eustachian Tube Dysfunction. In Wackym PA: Ballenger's Textbook of Otolaryngology. Toronto: BC Decker, 2008. Copyright &#169; 2008 PMPH-USA.</div><div id=\"graphicVersion\">Graphic 66208 Version 2.0</div></div></div>"},"66210":{"type":"graphic_diagnosticimage","displayName":"CT cystogram bladder rupture extraperitoneal","title":"CT cystogram of extraperitoneal bladder rupture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT cystogram of extraperitoneal bladder rupture</div><div class=\"cntnt\"><img style=\"width:432px; height:348px;\" src=\"images/EM/66210_Bladder_rupture_EP_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This CT cystogram shows an extraperitoneal bladder rupture. Contrast is seen directly adjacent to the bladder (arrow).</div><div class=\"graphic_reference\">Courtesy of Michael S Runyon, MD, FAAEM.</div><div id=\"graphicVersion\">Graphic 66210 Version 2.0</div></div></div>"},"66212":{"type":"graphic_figure","displayName":"Gender and aortic waveform","title":"Gender related differences in the central aortic pressure waveform","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Gender related differences in the central aortic pressure waveform</div><div class=\"cntnt\"><img style=\"width:505px; height:333px;\" src=\"images/CARD/66212_Gender_and_aortic_waveform.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After the fourth decade, women have an initial inflection on the upstroke of the aortic pressure waveform (P1) with a prominent secondary late systolic peak (P2) (type A pulse waveform). In contrast, men have a dominant initial pressure peak (P1) with an inflection (P2) on the downstroke. As a result women have a higher augmentation index, ie, difference between early and late pressure peaks divided by the pulse pressure, which is an index of pulsatile afterload. Women also have a lower subendocardial viability index, ie, the ratio of diastolic to systolic time integral, reflecting a reduction in subendocardial blood flow, largely due to a higher heart rate and shorter diastolic period.</div><div class=\"graphic_footnotes\">TTI: tension time index; DPTI: diastolic pressure time index.</div><div class=\"graphic_reference\">Data from: Hayward CS, Kelly RP. J Am Coll Cardiol 1997; 30:1863.</div><div id=\"graphicVersion\">Graphic 66212 Version 2.0</div></div></div>"},"66213":{"type":"graphic_table","displayName":"Initiation ADHD drugs","title":"Criteria for initiation of pharmacotherapy in children with ADHD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for initiation of pharmacotherapy in children with ADHD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Diagnostic assessment is complete and confirms diagnosis of ADHD</td> </tr> <tr> <td>Child is age six years or older*</td> </tr> <tr> <td>Parents accept medication as a contribution to management</td> </tr> <tr> <td>School will cooperate in administration and monitoring<sup>&#182;</sup></td> </tr> <tr> <td>No previous sensitivity to the chosen medication</td> </tr> <tr> <td>Child has normal heart rate and blood pressure</td> </tr> <tr> <td>Child is seizure free<sup>&#916;</sup></td> </tr> <tr> <td>Child does not have Tourette syndrome<sup>&#916;</sup></td> </tr> <tr> <td>Child does not have pervasive developmental delay<sup>&#916;</sup></td> </tr> <tr> <td>Child does not have significant anxiety</td> </tr> <tr> <td>Substance abuse among household members is not a concern (for children who will be treated with immediate-release stimulants)<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADHD: attention deficit hyperactivity disorder.<br />* Children younger than six years should be managed by or in consultation with a specialist since the effects of stimulants on preschool children are unpredictable.<br />¶ It is not safe to permit the child or adolescent to take his or her own medication to school.<br />Δ Children with these conditions should be managed by, or in consultation with, a specialist.<br /><FONT class=lozenge>◊</FONT> Atomoxetine, osmotic release methylphenidate, or the methylphenidate patch are alternatives to immediate-release stimulant preparations for children who live in households where substance abuse is a concern.</div><div class=\"graphic_reference\">Adapted from: Hill T, Taylor E. An auditable protocol for treating attention deficit/hyperactivity disorder. Arch Dis Child 2001; 84:404.</div><div id=\"graphicVersion\">Graphic 66213 Version 7.0</div></div></div>"},"66214":{"type":"graphic_figure","displayName":"Stepping response","title":"Infantile stepping response","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infantile stepping response</div><div class=\"cntnt\"><img style=\"width:446px; height:561px;\" src=\"images/PEDS/66214_Stepping_response.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The stepping response can be obtained in infants greater than 32 weeks conceptional age. It is elicited by holding the infant in a vertical position with his or her feet in contact with a flat surface. This initiates a slow alternate stepping action of flexion and extension of the legs.</div><div id=\"graphicVersion\">Graphic 66214 Version 3.0</div></div></div>"},"66215":{"type":"graphic_table","displayName":"Types of post-acute care facilities","title":"Capabilities of types of post-acute care hospital facilities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Capabilities of types of post-acute care hospital facilities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp; </td> <td class=\"subtitle1\" rowspan=\"2\">Acute care hospitals </td> <td class=\"subtitle1\" rowspan=\"2\">IRFs and LTACs </td> <td class=\"subtitle1\" colspan=\"2\">Medicare-certified facilities (SNFs, TCUs, subacute) </td> <td class=\"subtitle1\" rowspan=\"2\">Medicaid-certified extended care facilities (ECFs)</td> </tr> <tr> <td class=\"subtitle2\">Hospital-based (TCU) </td> <td class=\"subtitle2\">Community-based subacute and SNF </td> </tr> <tr> <td rowspan=\"2\"><strong>Response to resuscitation*</strong> </td> <td class=\"sublist1_start\">Rapid </td> <td class=\"sublist1_start\">Rapid </td> <td class=\"sublist1_start\">Rapid </td> <td class=\"sublist1_start\">Slow </td> <td class=\"sublist1_start\">Slow </td> </tr> <tr> <td class=\"sublist1\">Equipment and trained staff </td> <td class=\"sublist1\">Equipment and trained staff </td> <td class=\"sublist1\">Hospital level </td> <td class=\"sublist1\">Limited equipment and trained staff, \"911\" </td> <td class=\"sublist1\">Limited equipment and trained staff, \"911\" </td> </tr> <tr> <td rowspan=\"2\"><strong>Access to complex diagnostic/therapeutic modalities</strong> </td> <td class=\"sublist1_start\">High </td> <td class=\"sublist1_start\">Moderate </td> <td class=\"sublist1_start\">High </td> <td class=\"sublist1_start\">Low </td> <td class=\"sublist1_start\">Low </td> </tr> <tr> <td class=\"sublist1\">Laboratory, imaging, IR </td> <td class=\"sublist1\">Radiograph, ultrasound, laboratory on site </td> <td class=\"sublist1\">Hospital level </td> <td class=\"sublist1\">Off-site radiograph and laboratory </td> <td class=\"sublist1\">Off-site radiograph and laboratory </td> </tr> <tr> <td rowspan=\"2\"><strong>Availability of subspecialty consultants</strong> </td> <td class=\"sublist1_start\">High </td> <td class=\"sublist1_start\">Moderate </td> <td class=\"sublist1_start\">High </td> <td class=\"sublist1_start\">Low </td> <td class=\"sublist1_start\">Low </td> </tr> <tr> <td class=\"sublist1\">Full-range, subspecialties </td> <td class=\"sublist1\">Psych, Pain, Ortho, Neuro, PM&#38;R </td> <td class=\"sublist1\">Hospital level </td> <td class=\"sublist1\">Psych, Hospice, Ophthalmology, Dental, Podiatry </td> <td class=\"sublist1\">Psych, Hospice, Ophthalmology, Dental, Podiatry </td> </tr> <tr> <td rowspan=\"2\"><strong>Intensity of RN services</strong> </td> <td class=\"sublist1_start\">High </td> <td class=\"sublist1_start\">Moderate </td> <td class=\"sublist1_start\">Moderate-low </td> <td class=\"sublist1_start\">Moderate-low </td> <td class=\"sublist1_start\">Low </td> </tr> <tr> <td class=\"sublist1\"> <p>12 hours/</p> <p>patient/day (ICU)</p> </td> <td class=\"sublist1\"> <p>Five to six&nbsp;hours/</p> <p>patient/day</p> </td> <td class=\"sublist1\"> <p>Three to four&nbsp;hours/</p> <p>patient/day</p> </td> <td class=\"sublist1\"> <p>Two to four&nbsp;hours/</p> <p>patient/day</p> </td> <td class=\"sublist1\"> <p>0.5 to 2&nbsp;hours/</p> <p>patient/day</p> </td> </tr> <tr> <td rowspan=\"2\"><strong>Intensity of MD services</strong> </td> <td class=\"sublist1_start\">High </td> <td class=\"sublist1_start\">High </td> <td class=\"sublist1_start\">High </td> <td class=\"sublist1_start\">Moderate </td> <td class=\"sublist1_start\">Low </td> </tr> <tr> <td class=\"sublist1\">24-hour, on-site MD </td> <td class=\"sublist1\">24-hour, on-site MD </td> <td class=\"sublist1\">24-hour, on-site MD </td> <td class=\"sublist1\">Two to three times per week, rarely daily </td> <td class=\"sublist1\">Once per month, rarely daily </td> </tr> <tr> <td rowspan=\"2\"><strong>Intensity of rehabilitation services</strong> </td> <td class=\"sublist1_start\">High </td> <td class=\"sublist1_start\">High </td> <td class=\"sublist1_start\">Moderate </td> <td class=\"sublist1_start\">Moderate </td> <td class=\"sublist1_start\">Low </td> </tr> <tr> <td class=\"sublist1\">All modalities </td> <td class=\"sublist1\">All modalities </td> <td class=\"sublist1\">Most modalities </td> <td class=\"sublist1\">PT, OT, speech, rarely PM&#38;R, low complexity </td> <td class=\"sublist1\">PT, OT, speech, maintenance </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IRF: inpatient rehabilitation facility; LTAC: long-term acute care hospital; SNF: skilled nursing facility; TCU: transitional care unit; ECF: extended care facility; IR: interventional radiology; PM&amp;R: physical medicine and rehabilitation; ICU: intensive care unit; RN: registered nurse; MD: doctor of medicine; PT: physical therapy; OT: occupational therapy.<br />* Response to resuscitation can be interpreted as a proxy for the facility's ability to cope with clinically unstable patients.</div><div id=\"graphicVersion\">Graphic 66215 Version 3.0</div></div></div>"},"66223":{"type":"graphic_figure","displayName":"Secretin test for gastrinoma","title":"Secretin test for gastrinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Secretin test for gastrinoma</div><div class=\"cntnt\"><img style=\"width:418px; height:280px;\" src=\"images/ENDO/66223_Secretin_test_for_gastrinom.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked hypersecretion of gastrin occurs after the administration of secretin in a patient with a gastrinoma (Zollinger-Ellison syndrome) compared to the lack of response in normal subjects.</div><div id=\"graphicVersion\">Graphic 66223 Version 2.0</div></div></div>"},"66227":{"type":"graphic_picture","displayName":"Diploid-triploid mosaicism","title":"Diploid-triploid mosaicism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diploid-triploid mosaicism</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/PEDS/66227_Diploid-triploid-mosaicism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diploid-triploid mosaicism. Note the skin syndactylies.</div><div class=\"graphic_reference\">Courtesy of John Tolmie, MD.</div><div id=\"graphicVersion\">Graphic 66227 Version 1.0</div></div></div>"},"66228":{"type":"graphic_table","displayName":"Major PRRs: Cell-associated","title":"Major pattern recognition receptors (PRRs): Cell-associated*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major pattern recognition receptors (PRRs): Cell-associated*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">PRR</td> <td class=\"subtitle1\">Recognize</td> <td class=\"subtitle1\">Functions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Plasma membrane-bound</td> </tr> <tr> <td class=\"indent1\">TLRs 1, 2, 4, 5, 6</td> <td>Variety of microbial PAMPs</td> <td>Cytokine release, activation of immune cells</td> </tr> <tr> <td class=\"indent1\">Macrophage scavenger receptor</td> <td>Gram-negative and gram-positive bacteria</td> <td>Cytokine release, activation of immune cells</td> </tr> <tr> <td class=\"indent1\">Macrophage mannose receptor</td> <td>Microbial mannan</td> <td>Opsonization of bacteria, fungi</td> </tr> <tr> <td class=\"indent1\">Dectin-1</td> <td>Fungal beta-glucan</td> <td>Opsonization of bacteria, fungi</td> </tr> <tr> <td class=\"indent1\">Formyl peptide receptor</td> <td>Bacterial membrane N-formylmethionine</td> <td>Opsonization and microbial lysis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Intracellular (cytoplasmic or endolysosomal)</td> </tr> <tr> <td class=\"indent1\">TLRs 3, 7, 8, 9, 10</td> <td>Variety of microbial PAMPs</td> <td>Cytokine release, activation of immune cells</td> </tr> <tr> <td class=\"indent1\">NLRs (NOD1 and 2)</td> <td>Bacterial cell wall peptidoglycan, MDP</td> <td>Cytokine release, immune cell activation</td> </tr> <tr> <td class=\"indent1\">RLRs (RIG-1)</td> <td>Viral dsRNA</td> <td>Clearance of RNA and DNA viruses</td> </tr> <tr> <td class=\"indent1\">MDA5</td> <td>Viral dsRNA</td> <td>Clearance of RNA viruses</td> </tr> <tr> <td class=\"indent1\">LGP2</td> <td>Viral RNA</td> <td>Clearance of RNA viruses </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Additional plasma membrane receptors that typically do not react directly with microbes but play an important role in innate host defense are the complement receptors that bind activated (cleaved) C3 (C3b and C3bi), which mediate opsonization, and the macrophage receptor for phosphatidyl serine, which aids recovery from inflammation by removing apoptotic cells. Complement receptor 3 (CR3) can bind beta-glucan in the fungal cell wall at a site distinct from its complement-binding site, but the biologic significance of this binding is not proven.</div><div class=\"graphic_footnotes\">* This table includes&nbsp;major examples but is not exhaustive.<br />PRR: pattern recognition receptor; TLRs: toll-like receptors; PAMPs: pathogen-associated molecular patterns; NLRs: NOD-like receptors; NOD: nucleotide-binding oligomerization domain; MDP: muramyl dipeptide; RLRs: RIG-1-like receptors; RIG-1: retinoic acid-inducible gene 1; dsRNA: double-stranded RNA; MDA5: melanoma differentiation-associated gene 5; LGP2: laboratory of genetics and physiology 2.</div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced from: Liu AH, Zasloff MA, Johnston RB Jr. Innate immunity. In: Middleton's Allergy: Principles and Practice, 7th ed, Adkinson NF Jr, Busse WW, Bochner BS, et al (Eds), Elsevier 2008. Illustration used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 66228 Version 7.0</div></div></div>"},"66229":{"type":"graphic_table","displayName":"Elicited signs of catatonia","title":"Elicited signs of catatonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Elicited signs of catatonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Description and examples</td> </tr> <tr> <td>Ambitendency</td> <td>The patient appears \"stuck\" in an indecisive, hesitant movement when the examiner verbally contradicts his or her own nonverbal signal. As an example, the examiner offers his hand as if to shake hands while stating, \"Do not shake my hand.\"</td> </tr> <tr> <td>Waxy flexibility</td> <td>The rigid patient's initial resistance to the examiner's manipulations is gradually overcome, allowing re-positioning (as in bending a candle).</td> </tr> <tr> <td>Automatic obedience</td> <td>The patient moves with the examiner's light pressure into a new position despite instructions to the contrary. The new position may then be maintained despite instructions to the contrary. Test bilaterally as this sign may result from contralateral brain lesions.</td> </tr> <tr> <td>Negativism</td> <td>The patient resists the examiner's manipulations with strength equal to that applied (rigidity); social negativism may include sleeping under the bed, turning away when addressed, refusing to open the eyes, and closing the mouth when offered food or liquids.</td> </tr> <tr> <td>Stimulus-bound behavior</td> <td>The patient's behavior is tied to certain stimuli. As an example, the examiner states, \"When I touch my nose, you touch your chest,\" and the patient touches his nose in a mirrored behavior despite understanding the instruction.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br> <ol> <li>Fink M, Taylor MA. The catatonia syndrome: Forgotten but not gone. Arch Gen Psychiatry 2009; 66:1173. </li> <li>American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000. </li> <li>Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:129. </li> <li>Greenhalgh J, Knight C, Hind D, et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 2005; 9:1. </li> </ol></div><div id=\"graphicVersion\">Graphic 66229 Version 2.0</div></div></div>"},"66230":{"type":"graphic_figure","displayName":"Trails test","title":"Trails test (B version)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trails test (B version)</div><div class=\"cntnt\"><img style=\"width:419px; height:524px;\" src=\"images/NEURO/66230_Trailstest.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trail-making tests assess visual attention.<br />In the \"A version\" of the test, the subject connects 25 consecutive targets - each numbered (1, 2, 3, etc).<br />In the \"B version\" of the test, shown here, the subject alternates between numbers and letters (1, A, 2, B, 3, C, etc).<br />The test is scored in speed and accuracy.</div><div class=\"graphic_reference\">Reproduced with permission from: Schiffer RB, Lajara-Nanson WA. Neuropsychiatric examination. In: Neuropsychiatry, 2nd ed, Schiffer RB, Rao SM, Fogel BS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66230 Version 8.0</div></div></div>"},"66231":{"type":"graphic_diagnosticimage","displayName":"Sesamoid under fifth metatarsophalangeal joint - Lateral","title":"Small sesamoid underlying the fifth metatarsophalangeal joint (arrow)","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Small sesamoid underlying the fifth metatarsophalangeal joint (arrow)</div><div class=\"cntnt\"><img style=\"width:491px; height:315px;\" src=\"images/EM/66231_Sesamoid_under_5th_mcp_late.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 66231 Version 3.0</div></div></div>"},"66232":{"type":"graphic_table","displayName":"Differential dx of lipodystrophic disorders","title":"Differential diagnosis of lipodystrophic disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of lipodystrophic disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>SHORT syndrome - short stature, hyperextensibility of joints and/or hernia (inguinal), ocular depression, Reiger anomaly (ocular and dental), teething delay</td> </tr> <tr> <td>Leprechaunism</td> </tr> <tr> <td>Widemann-Rautenstrauch syndrome (neonatal progeroid syndrome)</td> </tr> <tr> <td>Severe weight loss due to anorexia nervosa, starvation, malnutrition, uncontrolled diabetes, hyperthyroidism, adrenal insufficiency, cancer cachexia, severe chronic infections</td> </tr> <tr> <td>Multiple symmetric lipomatosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66232 Version 2.0</div></div></div>"},"66233":{"type":"graphic_picture","displayName":"Mumps orchitis","title":"Mumps orchitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mumps orchitis</div><div class=\"cntnt\"><img style=\"width:279px; height:432px;\" src=\"images/PC/66233_Mumps_orchitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epididymo-orchitis is the most common complication of mumps infection in the adult male. It is frequently characterized by the abrupt onset of fever from 39 to 41&#186;C and severe testicular pain, accompanied by swelling and erythema of the scrotum.</div><div class=\"graphic_reference\">Reproduced with permission from Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 66233 Version 1.0</div></div></div>"},"66236":{"type":"graphic_table","displayName":"No interaction theophylline","title":"Drugs that have been documented NOT to interact with theophylline or NOT to have clinically important interactions with theophylline","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that have been documented NOT to interact with theophylline or NOT to have clinically important interactions with theophylline</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td>Albuterol, systemic and inhaled</td></tr>\n\t\t\t\t\t\t<tr><td>Amoxicillin</td></tr>\n\t\t\t\t\t\t<tr><td>Ampicillin,\nwith or without sulbactam</td></tr>\n\t\t\t\t\t\t<tr><td>Atenolol</td></tr>\n\t\t\t\t\t\t<tr><td>Azithromycin</td></tr>\n\t\t\t\t\t\t<tr><td>Caffeine, dietary\ningestion</td></tr>\n\t\t\t\t\t\t<tr><td>Cefaclor</td></tr>\n\t\t\t\t\t\t<tr><td>Co-trimoxazole (trimethoprim and sulfamethoxazole)</td></tr>\n\t\t\t\t\t\t<tr><td>Diltiazem</td></tr>\n\t\t\t\t\t\t<tr><td>Dirithromycin</td></tr>\n\t\t\t\t\t\t<tr><td>Enflurane</td></tr>\n\t\t\t\t\t\t<tr><td>Famotidine</td></tr>\n\t\t\t\t\t\t<tr><td>Felodipine</td></tr>\n\t\t\t\t\t\t<tr><td>Fluoxetine</td></tr>\n\t\t\t\t\t\t<tr><td>Finasteride</td></tr>\n\t\t\t\t\t\t<tr><td>Hydrocortisone</td></tr>\n\t\t\t\t\t\t<tr><td>Isoflurane</td></tr>\n\t\t\t\t\t\t<tr><td>Isoniazid</td></tr>\n\t\t\t\t\t\t<tr><td>Isradipine</td></tr>\n\t\t\t\t\t\t<tr><td>Influenza vaccine</td></tr>\n\t\t\t\t\t\t<tr><td>Ketoconazole</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\">Lomefloxacin</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td>Mebendazole</td></tr>\n\t\t\t\t\t\t<tr><td>Medroxyprogesterone</td></tr>\n\t\t\t\t\t\t<tr><td>Methylprednisolone</td></tr>\n\t\t\t\t\t\t<tr><td>Metronidazole</td></tr>\n\t\t\t\t\t\t<tr><td>Metoprolol</td></tr>\n\t\t\t\t\t\t<tr><td>Nadolol</td></tr>\n\t\t\t\t\t\t<tr><td>Nifedipine</td></tr>\n\t\t\t\t\t\t<tr><td>Nizatidine</td></tr>\n\t\t\t\t\t\t<tr><td>Norfloxacin</td></tr>\n\t\t\t\t\t\t<tr><td>Ofloxacin</td></tr>\n\t\t\t\t\t\t<tr><td>Omeprazole</td></tr>\n\t\t\t\t\t\t<tr><td>Paroxetine</td></tr>\n\t\t\t\t\t\t<tr><td>Prednisone, prednisolone</td></tr>\n\t\t\t\t\t\t<tr><td>Ranitidine</td></tr>\n\t\t\t\t\t\t<tr><td>Rifabutin</td></tr>\n\t\t\t\t\t\t<tr><td>Roxithryomycin</td></tr>\n\t\t\t\t\t\t<tr><td>Sertraline</td></tr>\n\t\t\t\t\t\t<tr><td>Sorbitol (purgative doses do not\ninhibit theophylline absorption)</td></tr>\n\t\t\t\t\t\t<tr><td>Sucralfate</td></tr>\n\t\t\t\t\t\t<tr><td>Terbutaline, systemic</td></tr>\n\t\t\t\t\t\t<tr><td>Terfenadine</td></tr>\n\t\t\t\t\t\t<tr><td>Tetracycline</td></tr>\n\t\t\t\t\t\t<tr><td>Tocainide</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n    \n    \n    \n    \n    \n    \n\n    \n\n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n\n    \n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Redrawn from Hendeles, L, Jenkins, J, Temple, R, Pharmacotherapy 1995; 15:409.</div><div id=\"graphicVersion\">Graphic 66236 Version 1.0</div></div></div>"},"66239":{"type":"graphic_diagnosticimage","displayName":"TTTS1","title":"TTTS1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TTTS1</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/OBGYN/66239_TTTS1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stuck donor twin at 21 weeks of gestation. Arrow denotes the donor twin against the left upper quadrant of the uterine cavity. Note that the calipers indicate a maximum vertical amniotic pocket of only 1 cm. The cord can be seen with color Doppler adjacent to the abdomen of the donor twin.</div><div class=\"graphic_reference\">Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.</div><div id=\"graphicVersion\">Graphic 66239 Version 2.0</div></div></div>"},"66241":{"type":"graphic_algorithm","displayName":"Evaluation of 46 XY infant with undervirilization","title":"Algorithm for evaluation of an infant with ambiguous genitalia and a 46,XY karyotype (SRY positive)*","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of an infant with ambiguous genitalia and a 46,XY karyotype (SRY positive)*</div><div class=\"cntnt\"><img style=\"width:638px; height:568px;\" src=\"images/PEDS/66241_Diagnosis_XY_undervirilizat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If the cause of the disorder of sex development (DSD) remains unclear after the biochemical workup outlined above, we suggest further evaluation with a high-coverage chromosomal microarray analysis (CMA; also known as array-based comparative genomic hybridization, aCGH). If the results are not informative, whole genome sequencing or whole exome sequencing can be considered.</div><div class=\"graphic_footnotes\">SRY: sex-determining region on the Y chromosome; 17-OH-pregnenolone: 17-hydroxypregnenolone; SF-1: steroidogenic factor 1; DAX-1: dose-sensitive sex-reversal locus on the X chromosome (also known as NROB1); 17-&alpha;-hydroxylase: 17-alpha hydroxylase (CYP17A1); StAR: steroid acute regulatory protein; p450scc: P450 side chain cleavage; ACTH: adrenocorticotropic hormone (corticotropin); 3-&beta;-HSD: 3-beta-hydroxysteroid dehydrogenase; AMH: anti-M&uuml;llerian hormone (also known as M&uuml;llerian inhibiting substance); hCG: human chorionic gonadotropin; AIS: androgen insensitivity syndrome; T: testosterone; DHT: dihydrotestosterone; 5-&alpha;-reductase: 5-alpha reductase type 2; 17-lyase deficiency: also known as isolated 17,20 lyase deficiency; LH: luteinizing hormone.<br />* If SRY is negative in an infant with a 46,XY karyotype, this indicates SRY deletion or mutation.<br />&para; In infants with 3-&beta;-HSD deficiency, 17-OH progesterone may be either normal or elevated (because the 3-&beta;-HSD type 1 gene is intact in these patients).<br />&Delta; P450 oxidoreductase deficiency causes genital ambiguity in either 46,XX or 46,XY individuals, usually with glucocorticoid deficiency. Affected individuals tend to have elevated 17-hydroxyprogesterone (which may be mild) and 17-hydroxypregnenolone, and low levels of DHEA and androstenedione. There may be associated craniofacial and orthopedic anomalies (Antley-Bixler syndrome).<br /><span class=\"lozenge\">&loz;</span> To distinguish among these disorders, measure cortisol, progesterone, pregnenolone, 17-alpha hydroxyprogesterone, 17-alpha hydroxypregnenolone, dehydroepiandrosterone (DHEA), and androstenedione, before and after stimulation with ACTH. Measurement of these precursors will identify adrenal insufficiency and will help to identify the level of the steroidogenic block. In most of these disorders (except 17-alpha hydroxylase deficiency), all steroidogenic precursors are low.<br />&sect; A normal response to hCG stimulation is defined as a doubling of testosterone by day three, and quadrupling by day six.</div><div id=\"graphicVersion\">Graphic 66241 Version 7.0</div></div></div>"},"66242":{"type":"graphic_picture","displayName":"Histology of nephrophthisis","title":"Histologic aspect of nephronophthisis","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Histologic aspect of nephronophthisis</div><div class=\"cntnt\"><img style=\"width:500px; height:355px;\" src=\"images/PEDS/66242_Hist_nephroph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic cross section of kidney showing various tubular changes including tubular collapse and thickened tubular basement membranes. Note the laminated and wrinkled appearance of some tubular basement membrane segments as well as the abrupt attenuation of others in the same tubule (light microscopy; magnification x360).</div><div class=\"graphic_reference\">Courtesy of Marie-Claire Gubler, MD.</div><div id=\"graphicVersion\">Graphic 66242 Version 4.0</div></div></div>"},"66243":{"type":"graphic_waveform","displayName":"Intermediate case 13","title":"Intermediate case 13","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Intermediate case 13</div><div class=\"cntnt\"><img style=\"width:540px; height:331px;\" src=\"images/CARD/66243_Intermediate_case_13.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66243 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"66244":{"type":"graphic_table","displayName":"DSM IV criteria for dementia","title":"DSM-IV criteria for dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV criteria for dementia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>1. Memory impairment</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   2. At least one of the following:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Aphasia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Apraxia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Agnosia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Disturbance in executive functioning\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>3. The disturbance in 1 and 2 significantly interferes with work, social activities, or relationships</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>4. Disturbance does not occur exclusively during delirium</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Additional criteria for dementia type:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Dementia of the Alzheimer type:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Gradual onset and continuing cognitive decline\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Not caused by identifiable medical, psychiatric, or neurologic condition\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Vascular dementia:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Focal neurological signs or laboratory evidence of cerebrovascular condition\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Dementia due to other medical conditions:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Evidence from history, physical exam, or laboratory findings of a specific medical condition causing cognitive deficits (HIV disease, head trauma, Parkinson disease, Huntington's chorea, Pick's disease, Creutzfeld-Jacob)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from American Psychiatric Association Diagnostic and Statistical Manual, 4th ed, APA Press, Washington DC, 1994.</div><div id=\"graphicVersion\">Graphic 66244 Version 1.0</div></div></div>"},"66248":{"type":"graphic_waveform","displayName":"EEG frontal sharp waves","title":"Left frontal sharp wave in a patient with left frontal lobe epilepsy","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Left frontal sharp wave in a patient with left frontal lobe epilepsy</div><div class=\"cntnt\"><img style=\"width:490px; height:347px;\" src=\"images/NEURO/66248_EEG_front_sharp_waves_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal sharp waves are frequently seen to some degree on both sides, especially when the maximum is frontopolar as here (&quot;bifrontal&quot;). The referential montage (right side) confirms the maximum at Fp1 followed by F7.</div><div id=\"graphicVersion\">Graphic 66248 Version 4.0</div></div></div>"},"66249":{"type":"graphic_picture","displayName":"Herpes zoster rash 2 PI","title":"Shingles (herpes zoster)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shingles (herpes zoster)</div><div class=\"cntnt\"><img style=\"width:350px; height:360px;\" src=\"images/PI/66249_Herpes_zoster_rash_2_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Vaibhav Parekh, MD, MBA.</div><div id=\"graphicVersion\">Graphic 66249 Version 2.0</div></div></div>"},"66250":{"type":"graphic_table","displayName":"Distribution of GSD","title":"Frequency of most common causes of glycogen storage disease among 1438 patients from the United States and Europe","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of most common causes of glycogen storage disease among 1438 patients from the United States and Europe</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Enzyme</td> <td class=\"subtitle1\">Percent of total</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Liver glycogenoses</td> </tr> <tr> <td class=\"indent1\">Type I</td> <td>Glucose-6-phosphatase system</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Type III</td> <td>Glycogen debrancher</td> <td>24</td> </tr> <tr> <td class=\"indent1\">Type VI and IX</td> <td>Liver phosphorylase and phosphorylase b kinase</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Type IV</td> <td>Glycogen branching enzyme</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Muscle glycogenoses</td> </tr> <tr> <td class=\"indent1\">Type II</td> <td>Acid maltase</td> <td>15</td> </tr> <tr> <td class=\"indent1\">Type V</td> <td>Muscle phosphorylase</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Type VII</td> <td>Phosphofructokinase</td> <td>&#60;1</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Chen YT. Glycogen storage diseases. In: The Metabolic&nbsp;and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), 8th ed, McGraw-Hill, New York, 2001, p.1530.</div><div id=\"graphicVersion\">Graphic 66250 Version 4.0</div></div></div>"},"66251":{"type":"graphic_diagnosticimage","displayName":"Acetabular fracture of posterior column","title":"Radiograph of acetabular posterior column fracture","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Radiograph of acetabular posterior column fracture</div><div class=\"cntnt\"><img style=\"width:457px; height:473px;\" src=\"images/EM/66251_Acetabular_fx_post_col.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) On the anteroposterior view, the displacement of the ilioischial line (arrow) is apparent while the iliopectineal line is seen to be intact (black arrowheads). As typical, the ilioischial line (arrow) is displaced relative to the radiographic U (white arrowhead). <br />(B) The obturator oblique view confirms the anterior column to be intact (arrowheads) and demonstrates the fracture of the ischial ramus (arrow). <br />(C) The iliac oblique view shows the disruption of the greater sciatic notch and the displacement of the posterior column (arrow). <br />(D) The computed tomography section shows a fracture line typical of a posterior column fracture.</div><div class=\"graphic_reference\">Originally published in: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Reproduced with permission. Copyright © Berton R. Moed, MD.</div><div id=\"graphicVersion\">Graphic 66251 Version 2.0</div></div></div>"},"66252":{"type":"graphic_picture","displayName":"Pigmented seborrheic keratoses face","title":"Multiple small pigmented seborrheic keratoses of the face (dermatosis papulosa nigra)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Multiple small pigmented seborrheic keratoses of the face (dermatosis papulosa nigra)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/66252_Photoaging_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66252 Version 3.0</div></div></div>"},"66254":{"type":"graphic_picture","displayName":"Colonic polyps Endosc","title":"Colonic polyps","html":"<div class=\"graphic normal\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Colonic polyps</div><div class=\"cntnt\"><img style=\"width:477px; height:218px;\" src=\"images/GAST/66254_Colonic_polyps_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Over 95 percent of colonic polyps are hyperplastic or adenomatous. Although these two types have some distinctive features on gross appearance, they cannot be reliably distinguished endoscopically. Left panel: a typical small sessile hyperplastic polyp that is less than 5 mm in size. Right panel: a typical pedunculated adenomatous polyp.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 66254 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal sigmoid colon</div><div class=\"cntnt\"><img style=\"width:216px; height:216px;\" src=\"images/GAST/55563_Normal_sigmoid_colon_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 55563 Version 1.0</div></div></div>"},"66255":{"type":"graphic_table","displayName":"Rate iron deficiency anemia","title":"Prevalence of iron deficiency and iron deficiency anemia in the National Health and Nutrition Examination Survey (NHANES III), 1988-1994","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of iron deficiency and iron deficiency anemia in the National Health and Nutrition Examination Survey (NHANES III), 1988-1994</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Sex and age, years\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Iron deficiency, percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Iron deficiency anemia, percent\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">\r\n  \r\n   Both sexes\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   1-2\r\n  \r\n   </td>\r\n  \r\n   <td>9</td>\r\n  \r\n   <td>3*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   3-5\r\n  \r\n   </td>\r\n  \r\n   <td>3</td>\r\n  \r\n   <td>&#60;1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   6-11\r\n  \r\n   </td>\r\n  \r\n   <td>2</td>\r\n  \r\n   <td>&#60;1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">\r\n  \r\n   Females\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   12-15\r\n  \r\n   </td>\r\n  \r\n   <td>9</td>\r\n  \r\n   <td>2*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   16-19\r\n  \r\n   </td>\r\n  \r\n   <td>11*</td>\r\n  \r\n   <td>3*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   20-49\r\n  \r\n   </td>\r\n  \r\n   <td>11</td>\r\n  \r\n   <td>5*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   50-69\r\n  \r\n   </td>\r\n  \r\n   <td>5</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8805;70\r\n  \r\n   </td>\r\n  \r\n   <td>7*</td>\r\n  \r\n   <td>2*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">\r\n  \r\n   Males\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   12-15\r\n  \r\n   </td>\r\n  \r\n   <td>1</td>\r\n  \r\n   <td>&#60;1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   16-19\r\n  \r\n   </td>\r\n  \r\n   <td>&#60;1</td>\r\n  \r\n   <td>&#60;1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   20-49\r\n  \r\n   </td>\r\n  \r\n   <td>&#60;1</td>\r\n  \r\n   <td>&#60;1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   50-69\r\n  \r\n   </td>\r\n  \r\n   <td>2</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8805;70\r\n  \r\n   </td>\r\n  \r\n   <td>4</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">* Prevalence in nonblacks is 1 percent lower than in all races.</div><div class=\"graphic_reference\">Adapted from Looker, AC, Dallman, PR, Carroll, MD, et al, JAMA 1997; 277:973.</div><div id=\"graphicVersion\">Graphic 66255 Version 1.0</div></div></div>"},"66256":{"type":"graphic_figure","displayName":"IVUS angiography comparison","title":"Comparison between angiography and intracoronary ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comparison between angiography and intracoronary ultrasound</div><div class=\"cntnt\"><img style=\"width:327px; height:204px;\" src=\"images/CARD/66256_IVUS_angiography_comparison.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Luminal irregularity is often not adequately appreciated on angiography, but can be well visualized on a cross-sectional image obtained with intracoronary ultrasound. Panel A: A concentric stenosis will appear similar in orthogonal angiographic views, ie, right (RAO) and left anterior oblique (LAO). Panel B: In comparison, an eccentric lesion will appear markedly different in the two angiographic views. Panel C: A complex lesion with marked luminal irregularity cannot be appreciated in any angiographic view and requires intracoronary ultrasound to be delineated.</div><div class=\"graphic_reference\">Courtesy of Neil Weissman, MD.</div><div id=\"graphicVersion\">Graphic 66256 Version 1.0</div></div></div>"},"66257":{"type":"graphic_picture","displayName":"Patient tamponade of nosebleed","title":"Patient tamponade of nosebleed","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient tamponade of nosebleed</div><div class=\"cntnt\"><img style=\"width:270px; height:360px;\" src=\"images/EM/66257_Patient_tamponade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">While the provider assembles necessary materials, the patient can perform tamponade. The patient wears a protective gown. He bends at the waist to minimize swallowing of blood and the risk of aspiration, and grasps his nasal alae in firm approximation. The patient should be encouraged not to check for active bleeding, but rather to hold constant pressure for at least five to ten minutes.</div><div class=\"graphic_reference\">Courtesy of Harrison Alter, MD.</div><div id=\"graphicVersion\">Graphic 66257 Version 5.0</div></div></div>"},"66260":{"type":"graphic_picture","displayName":"Triatomine bugs","title":"Visual aid for the identification of triatomine bugs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Visual aid for the identification of triatomine bugs</div><div class=\"cntnt\"><img style=\"width:428px; height:728px;\" src=\"images/ID/66260_Triatomine_bugs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult triatomine bugs are typically 0.75 to 1.25 inches in length.<br />(A) <em>Rhodnius prolixus</em> adult with eggs, commonly found in Central America and northern South America.<br />(B) <em>Triatoma protacta</em> adult, commonly found in California and Arizona.<br />(C) <em>Triatoma dimidiata</em> adult, commonly found in Central America and northern South America.<br />(D) <em>Triatoma gerstaeckeri</em> adult, commonly found in Texas.<br />(E) <em>Triatoma sanguisuga</em> adult, commonly found in the southeastern United States and Texas.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. Available online at: <a href=\"http://www.cdc.gov/chagas/resources/visual_triatomine_aid.pdf\" target=\"_blank\">http://www.cdc.gov/chagas/resources/visual_triatomine_aid.pdf</a>.</div><div id=\"graphicVersion\">Graphic 66260 Version 3.0</div></div></div>"},"66261":{"type":"graphic_picture","displayName":"Pediatric hemodialysis split catheter","title":"Pediatric hemodialysis split catheter","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pediatric hemodialysis split catheter</div><div class=\"cntnt\"><img style=\"width:504px; height:343px;\" src=\"images/PEDS/66261_Catheter_hemodial_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An example of a pediatric hemodialysis split catheter that consists of two catheters&nbsp;joined proximally but separated distally.</div><div class=\"graphic_reference\">Photo courtesy of Medcomp. Reproduced with permission. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 66261 Version 2.0</div></div></div>"},"66264":{"type":"graphic_figure","displayName":"Dialysate flow and solute clearance in PD","title":"Dialysate flow and solute clearance in peritoneal dialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dialysate flow and solute clearance in peritoneal dialysis</div><div class=\"cntnt\"><img style=\"width:337px; height:239px;\" src=\"images/NEPH/66264_Role_of_dialysate_flow_in_P.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between dialysate flow rate and clearance of different solutes in peritoneal dialysis. Clearance of small solutes rises with dialysate flow since the delivery of new dialysate containing none of the solute maintains a favorable concentration gradient for continued diffusion. Dialysate flow is less important for larger solutes such as inulin since clearance is too slow for a limiting concentration gradient to be reached.</div><div class=\"graphic_reference\">Data from Popovich RP, Moncrief JW, Nolph KD, et al. Continuous ambulatory peritoneal dialysis. Ann Intern Med 1978; 88:449.</div><div id=\"graphicVersion\">Graphic 66264 Version 3.0</div></div></div>"},"66266":{"type":"graphic_diagnosticimage","displayName":"CF atelectasis2","title":"Right sided atelectasis in a newborn with cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right sided atelectasis in a newborn with cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:432px; height:389px;\" src=\"images/PEDS/66266_CF_atelectasis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follow up radiographs one day later. The condition has progressed to complete right-sided atelectasis, with mediastinal shift toward the right.</div><div class=\"graphic_reference\">Courtesy of Jonathan D Finder, MD.</div><div id=\"graphicVersion\">Graphic 66266 Version 3.0</div></div></div>"},"66267":{"type":"graphic_picture","displayName":"Bullous pemphigoid pathology","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:432px; height:312px;\" src=\"images/PC/66267_Bullous_pemphigoid_path.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This hematoxylin and eosin stain of a skin&nbsp;tissue biopsy specimen from the edge of an established lesion of bullous pemphigoid demonstrates a subepidermal blister with an edematous papillary dermis as its base. The roof of the blister consists of the intact epidermis, including the stratum basalis. Eosinophil-rich inflammatory cells, fibrin, and tissue fluid fill the blister.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright ©1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66267 Version 4.0</div></div></div>"},"66268":{"type":"graphic_picture","displayName":"Prurigo nodularis 2","title":"Prurigo nodularis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prurigo nodularis</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/66268_Prurigonodularis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple nodules, some of which excoriated, on the lower limb of a patient with nodular prurigo.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66268 Version 4.0</div></div></div>"},"66269":{"type":"graphic_picture","displayName":"Midpalmar space abscess","title":"Midpalmar space abscess","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Midpalmar space abscess</div><div class=\"cntnt\"><img style=\"width:548px; height:355px;\" src=\"images/SURG/66269_Midpalmar_space_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A midpalmar space abscess is characterized by loss of the normal palmar concavity as shown in the photograph. The long and ring fingers assume a partially flexed posture, and there is pain on passive extension of these fingers.</div><div id=\"graphicVersion\">Graphic 66269 Version 3.0</div></div></div>"},"66270":{"type":"graphic_diagnosticimage","displayName":"Tracheal foreign body","title":"Foreign body in the trachea","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Foreign body in the trachea</div><div class=\"cntnt\"><img style=\"width:511px; height:390px;\" src=\"images/PULM/66270_Tracheal_foreign_body_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The frontal radiograph demonstrates an apparent intratracheal foreign body, which proved to be the projection of a necklace over the tracheal gas column.</div><div id=\"graphicVersion\">Graphic 66270 Version 2.0</div></div></div>"},"66271":{"type":"graphic_picture","displayName":"Mesoscissioning procedure 2","title":"Mesoscissioning procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mesoscissioning procedure</div><div class=\"cntnt\"><img style=\"width:396px; height:339px;\" src=\"images/EM/66271_Mesoscissioning_procedure_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrical resistance from the skin (electrodes with pads) feeds back to the mesoscission device and determines the depth of nail boring.</div><div class=\"graphic_reference\">Reproduced with permission from: Path Scientific. Available at: www.pathscientific.com (Accessed on May 6, 2009).</div><div id=\"graphicVersion\">Graphic 66271 Version 1.0</div></div></div>"},"66274":{"type":"graphic_table","displayName":"Values history","title":"The values history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The values history</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Section 1</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Written legal documents</td>\n\n\n    </tr>\n\n    <tr>\n      <td class=\"indent1 sublist1\">Living will</td>\n    </tr>\n    <tr>\n      <td class=\"indent1 sublist1\">Durable power of\nattorney</td>\n    </tr>\n    <tr>\n      <td class=\"indent1 sublist1\">Organ donations</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"1\">Wishes concerning specific medical\nprocedures</td>\n\n\n    </tr>\n\n    <tr>\n      <td class=\"indent1 sublist1\">Organ donation</td>\n    </tr>\n    <tr>\n      <td class=\"indent1 sublist1\">Kidney dialysis </td>\n    </tr>\n    <tr>\n      <td class=\"indent1 sublist1\"> Cardiopulmonary resuscitation</td>\n    </tr>\n    <tr>\n      <td class=\"indent1 sublist1\">Respirators</td>\n    </tr>\n    <tr>\n      <td class=\"indent1 sublist1\">Artificial nutrition </td>\n    </tr>\n    <tr>\n      <td class=\"indent1 sublist1\">Artificial hydration </td>\n    </tr>\n    <tr>\n      <td class=\"indent1 sublist1\">General comments</td>\n    </tr>\n    <tr>\n\n      <td class=\"subtitle1_single\">Section 2</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Overall attitude toward health</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Perception of the role of physician\nand other health caregivers</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Thoughts about independence and\ncontrol</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Personal relationships</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Overall attitude toward life</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Attitude toward illness, dying and death</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Religious background and beliefs</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Living environment</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Attitude concerning finances</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Wishes concerning funeral</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Lambert, P, Gibson, J, Nathanson, P, Law, Medicine and Health Care 1990; 18:202.</div><div id=\"graphicVersion\">Graphic 66274 Version 1.0</div></div></div>"},"66275":{"type":"graphic_diagnosticimage","displayName":"Malignant pleural eff II CT","title":"Malignant pleural effusions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant pleural effusions</div><div class=\"cntnt\"><img style=\"width:362px; height:349px;\" src=\"images/PULM/66275_Malignant_pleural_eff_II_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral malignant pleural effusions in patient with metastatic carcinoma of the breast. The right breast is surgically absent. CT scan shows bilateral posterior pleural effusions and passive atelectasis of the right lower lobe with marked enhancement after intravenous contrast material injection.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66275 Version 4.0</div></div></div>"},"66276":{"type":"graphic_picture","displayName":"Small pulmonary artery","title":"Pulmonary hypertension histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary hypertension histology</div><div class=\"cntnt\"><img style=\"width:374px; height:239px;\" src=\"images/PULM/66276_Small_pulmonary_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of a small pulmonary artery demonstrating medial hypertrophy and intimal proliferation.</div><div class=\"graphic_reference\">Courtesy of Colleen L Bailey, MD and Lewis J Rubin, MD.</div><div id=\"graphicVersion\">Graphic 66276 Version 2.0</div></div></div>"},"66277":{"type":"graphic_table","displayName":"Cytokines and fibroblasts","title":"Effect of cytokines on fibroblast collagen metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effect of cytokines on fibroblast collagen metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n<tr>\n<td class=\"subtitle1\">Fibroblast response</td>\n<td class=\"subtitle1\">Mediators</td>\n</tr>\n<tr>\n<td>Increased fibroblast chemotaxis </td>\n<td>TGF-beta, IL-4, TNF-alpha and beta, PDGF, IFN gamma, ET-1</td>\n</tr>\n<tr>\n<td>Increased fibroblast proliferation </td>\n<td>IL-1 alpha and beta, bFGF, aFGF, PDGF, IL-6, EGF, TGF-beta (via PDGF), ET-1, IL-17</td>\n</tr>\n<tr>\n<td>Increased collagen synthesis </td>\n<td>TGF-&#946;, IL-1 alpha and beta, IL-4, IGF</td>\n</tr>\n<tr>\n<td>Decreased collagen synthesis</td>\n<td>bFGF, IFN gamma and alpha, relaxin, EGF, TNF-alpha</td>\n</tr>\n<tr>\n<td>Increased collagenase synthesis </td>\n<td>IL-1 alpha and beta, bFGF, TNF-alpha and beta</td>\n</tr>\n<tr>\n<td>Decreased collagen synthesis</td>\n<td>TGF-beta</td>\n</tr>\n<tr>\n<td>Increased TIMP synthesis </td>\n<td>IL-1 alpha and beta, TGF-beta</td>\n</tr>\n<tr>\n<td>Decreased TIMP synthesis </td>\n<td>IL-6</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">EGF: Epidermal growth factor; ET: Endothelin; FGF: Fibroblast growth factor; IFN: Interferon; IL: Interleukin; PDGF: Platelet-derived growth factor; TGF: Transforming growth factor; TIMP: Tissue inhibitor of metalloproteinase; TNF: Tumor necrosis factor.</div><div id=\"graphicVersion\">Graphic 66277 Version 3.0</div></div></div>"},"66278":{"type":"graphic_picture","displayName":"Single lumen catheter","title":"Single lumen catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single lumen catheter</div><div class=\"cntnt\"><img style=\"width:432px; height:285px;\" src=\"images/SURG/66278_Single_lumen_catheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Hologic.</div><div id=\"graphicVersion\">Graphic 66278 Version 2.0</div></div></div>"},"66280":{"type":"graphic_figure","displayName":"Muscles of the lateral abdominal wall","title":"Muscles of the lateral abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Muscles of the lateral abdominal wall</div><div class=\"cntnt\"><img style=\"width:532px; height:702px;\" src=\"images/SURG/66280_Abdominal-wall-musculature-lateral.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66280 Version 3.0</div></div></div>"},"66281":{"type":"graphic_diagnosticimage","displayName":"FAST subxiphoid normal","title":"FAST: Subxiphoid normal view","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Subxiphoid normal view</div><div class=\"cntnt\"><img style=\"width:504px; height:408px;\" src=\"images/EM/66281_FAST_subxiphoid_normal_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows a normal heart as seen using a subxiphoid view as part of the FAST examination.</div><div class=\"graphic_footnotes\">FAST: Focused Assessment with Sonography for Trauma; LA: left atrium; LV: left ventricle; RA: right atrium; RV: right ventricle.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 66281 Version 3.0</div></div></div>"},"66282":{"type":"graphic_figure","displayName":"Types of hepatic resection","title":"Types of hepatic resection","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Types of hepatic resection</div><div class=\"cntnt\"><img style=\"width:541px; height:677px;\" src=\"images/SURG/66282_Types-of-hepatic-resection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The types of hepatic resection are based on the anatomic nomenclature. \"Wedge resection\" refers to any nonanatomic liver resection exclusive of biopsy. \"Sectorectomy\" refers to any one of the following: right anterior sectorectomy, right posterior sectorectomy, left medial sectorectomy, and left lateral sectorectomy.</div><div id=\"graphicVersion\">Graphic 66282 Version 1.0</div></div></div>"},"66283":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber echo vegetations mitral valve","title":"Apical 4 chamber echocardiogram showing vegetations on the mitral valve in patient with endocarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical 4 chamber echocardiogram showing vegetations on the mitral valve in patient with endocarditis</div><div class=\"cntnt\"><img style=\"width:364px; height:277px;\" src=\"images/CARD/66283_Apical_4_chamber_vegetation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four chamber views from the transthoracic echocardiography show bulky vegetations on the mitral valve (arrows). These images have been captured digitally and are displayed in quadrant screen format. In spite of insensitivity for smaller vegetations, precordial imaging is often effective for the purpose of imaging vegetations.</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle; LA: left atrium; RA: right atrium; TV: tricuspid valve.</div><div id=\"graphicVersion\">Graphic 66283 Version 4.0</div></div></div>"},"66284":{"type":"graphic_picture","displayName":"Miliary lesions bartonellos","title":"Miliary lesions (eruptive-phase bartonellosis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Miliary lesions (eruptive-phase bartonellosis)</div><div class=\"cntnt\"><img style=\"width:504px; height:359px;\" src=\"images/ID/66284_Miliary_lesions_bartonellos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left foot of a 16-year-old patient from Peru showing numerous fine papular lesions.</div><div class=\"graphic_reference\">Reproduced with permission from Maguina C, Garcia PJ, Gotuzzo E, et al. Bartonellosis (Carrion's disease) in the modern era. Clin Infect Dis 2001; 33:772. Copyright ©2001 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 66284 Version 3.0</div></div></div>"},"66287":{"type":"graphic_picture","displayName":"Chickenpox rash PI","title":"Chickenpox rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chickenpox rash</div><div class=\"cntnt\"><img style=\"width:382px; height:252px;\" src=\"images/PI/66287_Chickenpox_rash_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chickenpox is an infection that causes itchy, red bumps to form on your skin. It is caused by a virus called varicella-zoster virus.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 66287 Version 4.0</div></div></div>"},"66288":{"type":"graphic_table","displayName":"Nutrition labs IBD","title":"Suggested laboratory tests for monitoring nutrition in patients with inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested laboratory tests for monitoring nutrition in patients with inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Ulcerative colitis</td> <td class=\"subtitle1\">Crohn disease or indeterminate colitis</td> <td class=\"subtitle1\">Conditional testing*</td> </tr> <tr> <td><strong>Complete blood count</strong></td> <td class=\"centered\">x</td> <td class=\"centered\">x</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Albumin</strong></td> <td class=\"centered\">x</td> <td class=\"centered\">x</td> <td>&nbsp;</td> </tr> <tr> <td><strong>25-OH vitamin D</strong></td> <td class=\"centered\">x</td> <td class=\"centered\">x</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Vitamin B12</strong></td> <td>&nbsp;</td> <td class=\"centered\">x</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Folate</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">x</td> </tr> <tr> <td><strong>Calcium</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">x</td> </tr> <tr> <td><strong>Phosphorus</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">x</td> </tr> <tr> <td><strong>Magnesium</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">x</td> </tr> <tr> <td><strong>Vitamin A</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">x</td> </tr> <tr> <td><strong>Vitamin E</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">x</td> </tr> <tr> <td><strong>Prothrombin time</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">x</td> </tr> <tr> <td><strong>Zinc</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">x</td> </tr> <tr> <td><strong>DXA scanning<sup>&#182;</sup></strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">x</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The above tests and frequencies reflect the author's practice, and may vary among providers. We perform these tests at least every 12 to 24 months in patients with quiescent disease, and more frequently in patients with active disease or known deficiency, or in growing children.</div><div class=\"graphic_footnotes\">DXA: dual energy x-ray absorptiometry; 25-OH vitamin D: 25-hydroxy vitamin D.<br />* These tests are performed in the case of malnutrition, malabsorption, symptoms of deficiency, or specific risk factors (eg, total parenteral or enteral nutrition).<br />¶ DXA scanning is recommended in adults with risk factors for bone disease, including prolonged cortiocosteroid use or low trauma fracture (See topic review on Metabolic bone disease in inflammatory bowel disease). There are no generally accepted standards for frequency of DXA scanning in children with IBD.</div><div class=\"graphic_reference\">Courtesy of: Jonathan E Teitelbaum, MD.</div><div id=\"graphicVersion\">Graphic 66288 Version 3.0</div></div></div>"},"66289":{"type":"graphic_picture","displayName":"Porokeratosis histopathology","title":"Histopathology of porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathology of porokeratosis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/66289_Porokeratosis_histopath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A column of porokeratotic cells consistent with a cornoid lamella is present within the dermis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66289 Version 5.0</div></div></div>"},"66293":{"type":"graphic_figure","displayName":"Pheresis yield PEG rHuMGDF","title":"PEG-rHuMGDF increased the yield of platelet apheresis","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">PEG-rHuMGDF increased the yield of platelet apheresis</div><div class=\"cntnt\"><img style=\"width:509px; height:385px;\" src=\"images/HEME/66293_Pheresis_yield_PEG_rHuMGDF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A single dose of PEG-rHuMGDF was given to routine platelet apheresis donors on Day 1. There was a dose-dependent increase in the platelet count and platelet yield when apheresis was performed 15 days later.</div><div class=\"graphic_reference\">Reproduced with permission from: Kuter, DJ, Goodnough, LT, Romo, J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001; 98:1339. Copyright &#169; 2001 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 66293 Version 1.0</div></div></div>"},"66296":{"type":"graphic_diagnosticimage","displayName":"Leukocytoclastic vasculitis II","title":"Leukocytoclastic vasculitis histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukocytoclastic vasculitis histology</div><div class=\"cntnt\"><img style=\"width:360px; height:246px;\" src=\"images/RHEUM/66296_Leukocytoclastic_vasculit2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy from a patient with leukocytoclastic vasculitis showing striking mural fibrin deposition in a postcapillary venule and a concomitant angiocentric mixed neutrophilic and lymphocytic infiltrate. This pattern can be seen in a variety of disorders including hypersensitivity vasculitis, systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, Sjögren's syndrome, Behçet's syndrome, and relapsing polychondritis.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 66296 Version 7.0</div></div></div>"},"66299":{"type":"graphic_figure","displayName":"Supraorbital and supratrochlear nerve block","title":"Supraorbital and supratrochlear nerve block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Supraorbital and supratrochlear nerve block</div><div class=\"cntnt\"><img style=\"width:419px; height:589px;\" src=\"images/EM/66299_Supraorbsupratrochnerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This block anesthetizes the forehead and anterior&nbsp;third of the scalp. To perform, locate the supraorbital nerve foramen in the medial aspect of the supraorbital ridge as shown in A. After cleansing, insert a small needle (25 or 27 gauge) to a depth of 0.5 to 1 cm just medial and directed towards the foramen as shown in B. Inject 1 to 3 mL of local anesthetic. In older children, adolescents, and adults who report paresthesias, withdraw the needle until paresthesias resolve prior to injection of anesthetic. Allow 5 to 10 minutes for complete anesthesia to occur.</div><div class=\"graphic_reference\">Reproduced with permission from: Cimpello LB, Deutsch RJ, Dixon C, et al. Illustrated techniques of pediatric emergency procedures. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66299 Version 10.0</div></div></div>"},"66301":{"type":"graphic_algorithm","displayName":"Pathogenesis of miliary TB","title":"Pathogenesis of tuberculosis and miliary tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of tuberculosis and miliary tuberculosis</div><div class=\"cntnt\"><img style=\"width:454px; height:432px;\" src=\"images/ID/66301_Pathogenesis_of_miliary_TB.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TB: tuberculosis.</div><div class=\"graphic_reference\">Courtesy of Nesli Basgoz, MD.</div><div id=\"graphicVersion\">Graphic 66301 Version 3.0</div></div></div>"},"66305":{"type":"graphic_table","displayName":"Outcome of twin pregnancy","title":"Fetal and infant death rates in twin gestations (both fetuses alive at 20 weeks of gestation, n=150,386)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fetal and infant death rates in twin gestations (both fetuses alive at 20 weeks of gestation, n=150,386)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Outcome</td>\n<td class=\"subtitle1\">Percent</td>\n</tr>\n<tr>\n<td>Two surviving infants</td>\n<td>93.7</td>\n</tr>\n<tr>\n<td>One infant death, one surviving infant</td>\n<td>2.3</td>\n</tr>\n<tr>\n<td>Two infant deaths</td>\n<td>1.5</td>\n</tr>\n<tr>\n<td>One fetal death, one surviving infant</td>\n<td>1.1</td>\n</tr>\n<tr>\n<td>Two fetal deaths</td>\n<td>1.1</td>\n</tr>\n<tr>\n<td>One fetal death, one infant death</td>\n<td>0.4</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=43886&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Outcome_of_twin_pregnancy.htm</title></head></div><div class=\"graphic_reference\">Based upon the Matched Multiple Birth File from the US National Center for Health Statistics. Adapted from Johnson CD, Zhang J. Obstet Gynecol 2002; 99:698.</div><div id=\"graphicVersion\">Graphic 66305 Version 3.0</div></div></div>"},"66306":{"type":"graphic_table","displayName":"Differential diagnosis of NK-LGL","title":"Differential diagnosis of T cell large granular lymphocyte leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of T cell large granular lymphocyte leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">CD56+ proliferative diseases</td> </tr> <tr> <td class=\"sublist1_start\">LGL proliferation of NK-cell phenotype</td> </tr> <tr> <td class=\"sublist1\">- Chronic NK lymphocytosis</td> </tr> <tr> <td class=\"sublist1\">- Aggressive NK cell&nbsp;leukemia</td> </tr> <tr> <td>Extranodal NK/T-cell lymphoma nasal type</td> </tr> <tr> <td>Gamma delta hepatosplenic lymphoma</td> </tr> <tr> <td>Posttransplant T-cell lymphoproliferative disorders</td> </tr> <tr> <td>S-100+ T-cell lymphoproliferative disorders</td> </tr> <tr> <td>Plasmacytoid dendritic cell neoplasms</td> </tr> <tr> <td class=\"subtitle1_single\">Reactive LGL proliferation</td> </tr> <tr> <td>Solid tumors</td> </tr> <tr> <td>Connective tissue diseases</td> </tr> <tr> <td>Hemophagocytosis syndrome</td> </tr> <tr> <td>Idiopathic thrombocytopenic purpura</td> </tr> <tr> <td>Non-Hodgkin's lymphoma</td> </tr> <tr> <td>Viral infections</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Cancer Control: Journal of the Moffitt Cancer Center. Lamy T, Loughran TP Jr. Large granular lymphocyte leukemia. Cancer Control 1998; 5:25.<br />Additional data from:<br /><ol>&#xD;&#xA;    <li>Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 66306 Version 5.0</div></div></div>"},"66308":{"type":"graphic_picture","displayName":"Calciphylaxis retiform purpura","title":"Calciphylaxis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Calciphylaxis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/66308_Calciphyl_retiform_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retiform purpura and tissue necrosis are present in this patient with calciphylaxis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66308 Version 3.0</div></div></div>"},"66310":{"type":"graphic_table","displayName":"Common radiographic views by fracture location","title":"Common radiographic views for identifying fractures by location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common radiographic views for identifying fractures by location</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Anatomic region</td> <td class=\"subtitle1\">Plain radiograph fracture views</td> </tr> <tr> <td>Wrist</td> <td> <p>AP, lateral</p> <p>Oblique: fracture suspected but AP and lateral negative*</p> Scaphoid: scaphoid fracture suspected</td> </tr> <tr> <td>Elbow</td> <td>AP, lateral, oblique</td> </tr> <tr> <td>Shoulder</td> <td>AP, scapular Y, axillary</td> </tr> <tr> <td>Knee</td> <td> <p>AP, lateral, oblique<sup>&#182;</sup> (internal or external rotated)</p> Sunrise (axial, tangential): patellar injury</td> </tr> <tr> <td>Foot</td> <td> <p>AP, lateral</p> Oblique: if fracture seen on AP or lateral</td> </tr> <tr> <td>Tibia, femur, forearm</td> <td>AP, lateral</td> </tr> <tr> <td>Ankle</td> <td>AP, lateral, and mortise<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AP: anterior-posterior.<br />* Provides view of the scaphoid-trapezoid-trapezium articulation.<br />&para; Provides a different projection of the femoral condyles and tibial tuberosities as well as a cleaner view of the medial and lateral margins of the patella.<br />&Delta; Mortise view requires 10 to 20 degrees of internal rotation and allows the tibia and fibula to be viewed without superimposition.</div><div id=\"graphicVersion\">Graphic 66310 Version 5.0</div></div></div>"},"66311":{"type":"graphic_figure","displayName":"ICS and bone mineral density","title":"Change in bone mineral density in adults with asthma taking inhaled glucocorticoids","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Change in bone mineral density in adults with asthma taking inhaled glucocorticoids</div><div class=\"cntnt\"><img style=\"width:543px; height:399px;\" src=\"images/ENDO/66311_Inhaled_steroids_and_BMD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For both the total hip and the trochanter, the rate of decline in bone density was 0.00044 g/cm<SUP>2</SUP> per year for each additional daily puff of inhaled glucocorticoid (p = 0.01 and&nbsp;p = 0.005, respectively). The solid line in each panel represents the mean yearly change in bone density. The dashed lines indicate the 95 percent confidence interval for the mean.</div><div class=\"graphic_reference\">Data from Isreal E, Banerjee TR, Fitzmaurice GM, et al. N Engl J Med 2001; 345:941.</div><div id=\"graphicVersion\">Graphic 66311 Version 3.0</div></div></div>"},"66316":{"type":"graphic_diagnosticimage","displayName":"Cartilage calcification US","title":"Ultrasonographic appearance of cartilage calcification (chondrocalcinosis) of the wrist","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ultrasonographic appearance of cartilage calcification (chondrocalcinosis) of the wrist</div><div class=\"cntnt\"><img style=\"width:504px; height:324px;\" src=\"images/RHEUM/66316_Cartilagenous_calcification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This long axis sonogram of the wrist of a 72-year-old woman with cartilage calcification (chondrocalcinosis) shows both hypoechoic and hyperechoic areas in the triangular fibrocartilage complex. Areas of hyperechogenicity (arrows) are likely to represent calcium pyrophosphate dihydrate (CPP) crystal deposits.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 66316 Version 4.0</div></div></div>"},"66318":{"type":"graphic_table","displayName":"Other conditions of the acromioclavicular joint","title":"Other conditions of the acromioclavicular joint","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Other conditions of the acromioclavicular joint</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Synovial cyst or ganglion</td> </tr> <tr> <td>Septic arthritis (eg, staph, tuberculosis)</td> </tr> <tr> <td>Crystal arthropathy (gout, pseudogout)</td> </tr> <tr> <td>Inflammatory arthritis (rheumatoid arthritis, Crohns enteropathic arthritis)</td> </tr> <tr> <td>Synovial disorders (chondromatosis)</td> </tr> <tr> <td>Distal clavicular and acromial tumors</td> </tr> <tr> <td>Os acromiale syndrome</td> </tr> <tr> <td>Intra-articular fractures of the distal clavicle or acromion</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66318 Version 4.0</div></div></div>"},"66320":{"type":"graphic_table","displayName":"Screening von Hippel Lind","title":"Criteria for screening for von Hippel Lindau disease*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for screening for von Hippel Lindau disease*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Any blood relative of an individual diagnosed with VHL disease by gene analysis</td> </tr> <tr> <td>Individuals with a VHL associated lesion<sup>&#182;</sup> and a family history of VHL associated-lesions</td> </tr> <tr> <td>Individuals with two or more VHL-associated lesions<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1_start\">Individuals with any of the following:</td> </tr> <tr> <td class=\"sublist1\">Hemangioblastoma (HB) diagnosed at age &#60;30 years</td> </tr> <tr> <td class=\"sublist1\">&#62;2 CNS hemangioblastomas (diagnosed at any age)</td> </tr> <tr> <td class=\"sublist1\">Clear cell renal carcinoma (RCC) diagnosed at age &#60;40 years</td> </tr> <tr> <td class=\"sublist1\">Bilateral and/or multiple RCC</td> </tr> <tr> <td class=\"sublist1\">Pheochromocytoma (PHEO) diagnosed at age &#60;40 years</td> </tr> <tr> <td class=\"sublist1\">Bilateral and/or multiple PHEO</td> </tr> <tr> <td class=\"sublist1\">Personal and family history of pheochromocytoma</td> </tr> <tr> <td class=\"sublist1\">&#62;1 Pancreatic serous cystadenoma</td> </tr> <tr> <td class=\"sublist1\">&#62;1 Pancreatic neuroendocrine tumor</td> </tr> <tr> <td class=\"sublist1\">Multiple pancreatic cysts + any VHL associated lesion</td> </tr> <tr> <td class=\"sublist1\">Middle ear endolymphatic sac tumor (unilateral or bilateral)</td> </tr> <tr> <td class=\"sublist1\">Epididymal papillary cystadenoma (unilateral or bilateral)</td> </tr> <tr> <td class=\"sublist1\">Bilateral epididymal cysts</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* As used by the Massachusetts General Hospital Center for Cancer Risk Analysis and the VHL Clinic.<br />¶ VHL associated-lesions include any of the following: Hemangioblastoma, clear cell renal carcinoma, pheochromocytoma, middle ear endolymphatic sac tumor, epididymal papillary cystadenoma, pancreatic serous cystadenomas (but not mucinous cystadenoma), pancreatic neuroendocrine tumor. (Note: Simple cysts of the kidneys, pancreas or liver are not considered VHL-associated lesions).</div><div id=\"graphicVersion\">Graphic 66320 Version 2.0</div></div></div>"},"66322":{"type":"graphic_picture","displayName":"Labaret stud","title":"Labaret stud","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Labaret stud</div><div class=\"cntnt\"><img style=\"width:340px; height:300px;\" src=\"images/PEDS/66322_Labaret_stud.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of R Michelle Schmidt, MD and Myrna L Armstrong, EdD, RN, FAAN.</div><div id=\"graphicVersion\">Graphic 66322 Version 1.0</div></div></div>"},"66323":{"type":"graphic_figure","displayName":"Penile length in newborns","title":"Penile length in newborns","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Penile&nbsp;length in newborns</div><div class=\"cntnt\"><img style=\"width:505px; height:384px;\" src=\"images/PEDS/66323_Penilelength.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stretched penile length of 63 normal premature and full-term male infants (•). The mean length at full-term is 35 mm (3.5 cm), with the 2-standard deviation range from 28 to 42 mm (2.8 to 4.2 cm). The solid line approximates the mean values, and the broken lines the 2-standard deviation values. Superimposed are data for two small-for-gestational-age infants (Δ), seven large-for-gestational-age infants (closed triangles), and four twins (closed boxes), all of which are in the normal range.&nbsp;&nbsp; </div><div class=\"graphic_reference\">Reproduced with permission from: Feldman KW, Smith DW. Fetal phallic growth and penile standards for newborn male infants. J Pediatr 1975; 86:395. Copyright © 1975 Elsevier.</div><div id=\"graphicVersion\">Graphic 66323 Version 6.0</div></div></div>"},"66325":{"type":"graphic_picture","displayName":"Pinhole occluder","title":"Pinhole occluder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pinhole occluder</div><div class=\"cntnt\"><img style=\"width:432px; height:345px;\" src=\"images/PC/66325_Pinhole_occluder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pinhole occluder is a simple way to focus light, as in a pinhole camera, temporarily removing the effects of refractive errors such as myopia in order to assess visual acuity.</div><div id=\"graphicVersion\">Graphic 66325 Version 2.0</div></div></div>"},"66330":{"type":"graphic_picture","displayName":"Normal bone","title":"Micrograph showing normal bone histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph showing normal bone histology</div><div class=\"cntnt\"><img style=\"width:382px; height:269px;\" src=\"images/NEPH/66330_Normalboneedit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic appearance of normal bone.<br />(Left panel) Goldner Masson trichrome stain shows mineralized lamellar bone in blue and adjacent nonmineralized osteoid in red-brown. Osteoid usually comprises less than 25% of bone surfaces. The cellular area between the osseous structures is the marrow space.<br />(Right panel) Villanueva-stained section viewed under polarized light following time-spaced tetracycline labeling. Osteoid appears orange, mineralized bone is green, and tetracycline markers appear as luminescent yellow-green bands within bone and beneath osteoid (arrow). The distinct dual bands represent active mineralized bone formation.</div><div class=\"graphic_reference\">Courtesy of L Darryl Quarles, MD.</div><div id=\"graphicVersion\">Graphic 66330 Version 6.0</div></div></div>"},"66332":{"type":"graphic_picture","displayName":"Stockinette types","title":"Stockinette in different sizes","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Stockinette in different sizes</div><div class=\"cntnt\"><img style=\"width:468px; height:355px;\" src=\"images/EM/66332_Stockinette_types.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Stephen Titus, MD.</div><div id=\"graphicVersion\">Graphic 66332 Version 1.0</div></div></div>"},"66333":{"type":"graphic_table","displayName":"Symptoms and signs of anaphylaxis","title":"Symptoms and signs of anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs of anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Skin</td> </tr> <tr> <td class=\"indent1\">Feeling of warmth, flushing (erythema), itching, urticaria, angioedema, and \"hair standing on end\" (pilor erection)</td> </tr> <tr> <td class=\"subtitle1_single\">Oral</td> </tr> <tr> <td class=\"indent1\">Itching or tingling of lips, tongue, or palate</td> </tr> <tr> <td class=\"indent1\">Edema of lips, tongue, uvula, metallic taste</td> </tr> <tr> <td class=\"subtitle1_single\">Respiratory</td> </tr> <tr> <td class=\"indent1\">Nose - Itching, congestion, rhinorrhea, and sneezing</td> </tr> <tr> <td class=\"indent1\">Laryngeal - Itching and \"tightness\" in the throat, dysphonia, hoarseness, stridor</td> </tr> <tr> <td class=\"indent1\">Lower airways - Shortness of breath (dyspnea), chest tightness, cough, wheezing, and cyanosis</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Nausea, abdominal pain, vomiting, diarrhea, and dysphagia (difficulty swallowing)</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Feeling of faintness or dizziness; syncope, altered mental status, chest pain, palpitations, tachycardia, bradycardia or other dysrhythmia, hypotension, tunnel vision, difficulty hearing, urinary or fecal incontinence, and cardiac arrest</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Anxiety, apprehension, sense of impending doom, seizures, headache and confusion; young children may have sudden behavioral changes (cling, cry, become irritable, cease to play)</td> </tr> <tr> <td class=\"subtitle1_single\">Ocular</td> </tr> <tr> <td class=\"indent1\">Periorbital itching, erythema and edema, tearing, and conjunctival erythema</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Uterine cramps in women and girls</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Simons FER. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 66333 Version 15.0</div></div></div>"},"66334":{"type":"graphic_diagnosticimage","displayName":"Substernal goiter scan II","title":"Substernal goiter: Radioiodine scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Substernal goiter: Radioiodine scan</div><div class=\"cntnt\"><img style=\"width:346px; height:328px;\" src=\"images/ENDO/66334_Substernal_goiter_Scan_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">123-Iodine scan showing a cervical and large hyperfunctioning substernal goiter. The enlarged cervical thyroid is indicated by the circle; SSN indicates the suprasternal notch.</div><div class=\"graphic_reference\">Courtesy of Douglas S Ross, MD.</div><div id=\"graphicVersion\">Graphic 66334 Version 4.0</div></div></div>"},"66335":{"type":"graphic_table","displayName":"HAV post exp treatment PI","title":"Recommendations for preventive treatment after exposure to hepatitis A","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for preventive treatment after exposure to hepatitis A</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Group or person</td> <td class=\"subtitle1\">Needs preventive treatment?</td> </tr> <tr class=\"divider_bottom\"> <td>Anyone who lives with an infected person</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>People who have occasional contact with an infected person</td> <td> <p>Depends on likelihood of exposure</p> Consult with a healthcare provider to determine if treatment recommended</td> </tr> <tr class=\"divider_bottom\"> <td>Staff and children at a daycare</td> <td> <p><strong>If there are ANY children in diapers</strong> at the day care center: Yes, all children/staff should be treated if one child/staff member or two or more households* are infected</p> <strong>If there are NO children in diapers</strong> at the day care center: Yes, but only children/staff in the class with the infected person(s) should be treated</td> </tr> <tr class=\"divider_bottom\"> <td>Families of children who attend a daycare where there is an infected person</td> <td><strong>If the child who attends day care wears diapers:</strong> Yes, the family members should be treated if <strong>three or more</strong> households* are infected</td> </tr> <tr class=\"divider_bottom\"> <td>Sexual partners of an infected person</td> <td>Yes, if the person had sex within one month of the infection</td> </tr> <tr class=\"divider_bottom\"> <td>People who have shared IV drugs with an infected person</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>All food handlers who work with an infected person</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>People who ate at restaurant once when an infected person was working</td> <td> <p>Yes, <strong>if:</strong></p> <p>1) The infected person had diarrhea and handled food <strong>and</strong></p> 2) Patrons can be identified and treated &#8804;2 weeks after exposure</td> </tr> <tr class=\"divider_bottom\"> <td>People who <strong>regularly</strong> dined at a restaurant when an infected person was working</td> <td> <p>Depends on likelihood of exposure</p> Consult a healthcare provider to determine if treatment recommended</td> </tr> <tr> <td>Co-workers or classmates of an infected person</td> <td>No, if a <strong>single</strong> person is infected (suggesting that the source of the infection is likely to be outside of school or work)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Household is defined as anyone who lives in the house.</div><div id=\"graphicVersion\">Graphic 66335 Version 3.0</div></div></div>"},"66336":{"type":"graphic_figure","displayName":"Cervical agenesis A","title":"Cervical agenesis with the presence of a vagina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical agenesis with the presence of a vagina</div><div class=\"cntnt\"><img style=\"width:406px; height:333px;\" src=\"images/OBGYN/66336_CervicalagenesisA.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66336 Version 12.0</div></div></div>"},"66337":{"type":"graphic_table","displayName":"BCR breakpoints in leukemia","title":"Phenotypes and frequencies of leukemias in the presence of various BCR breakpoint sites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phenotypes and frequencies of leukemias in the presence of various BCR breakpoint sites</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Leukemia</td>\n\n      <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Breakpoints</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">M-BCR</td>\n\n      <td class=\"subtitle2\">m-BCR</td>\n\n      <td class=\"subtitle2\">&#181;-BCR</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">CML</td>\n\n      <td>P: classic</td>\n\n      <td>P: classic</td>\n\n      <td>P: CNL1; CML2</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>f: &#62;90 percent</td>\n      <td>f: &#60;9 percent</td>\n      <td>f: +1 percent</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">AML</td>\n\n      <td>P: AML</td>\n\n      <td>P: M4/M5a AML</td>\n\n      <td>P: AML</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>f: majority of 1 percent</td>\n      <td>f: rare</td>\n      <td>f: very rare</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Adult ALL</td>\n\n      <td>P: classic</td>\n\n      <td>P: classic</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>f: 10 percent</td>\n      <td>f: 20 percent</td>\n      <td>-</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Childhood ALL</td>\n\n      <td>P: hyperleukocytic</td>\n\n      <td>P: classic</td>\n\n      <td>-<br />\n      </td>\n\n    </tr>\n\n    <tr>\n      \n      <td>f: 0.75 percent</td>\n      <td>f: 4.25 percent</td>\n      <td>-</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">P: leukemia phenotype; f: frequency, expressed in percentage of total number of patients diagnosed with specific neoplasm; 1: predominantly; 2: occasional; -: absent.</div><div id=\"graphicVersion\">Graphic 66337 Version 2.0</div></div></div>"},"66339":{"type":"graphic_figure","displayName":"Development of the adreno-genital primordium","title":"Development of the adreno-genital primordium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Development of the adreno-genital primordium</div><div class=\"cntnt\"><img style=\"width:446px; height:479px;\" src=\"images/SURG/66339_Embryology.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66339 Version 2.0</div></div></div>"},"66340":{"type":"graphic_figure","displayName":"Enuresis alarm","title":"Enuresis alarm","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Enuresis alarm</div><div class=\"cntnt\"><img style=\"width:503px; height:686px;\" src=\"images/PEDS/66340_Enuresisalarm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enuresis alarms are activated when a sensor, placed in the undergarments or on a bed pad, detects moisture. The arousal device is usually an auditory alarm and/or a vibrating belt or pager.</div><div id=\"graphicVersion\">Graphic 66340 Version 4.0</div></div></div>"},"66341":{"type":"graphic_picture","displayName":"Ulceration in amebic colitis","title":"Ulceration in amebic colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulceration in amebic colitis</div><div class=\"cntnt\"><img style=\"width:423px; height:580px;\" src=\"images/ID/66341_Ulceration_amebic_colitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Gross pathology of amebic colitis showing multiple ulcer formation.<br> (B) Classic flask-shaped ulcer of amebiasis. Mucosal ulceration with widespread submucosal invasion shown.</div><div class=\"graphic_reference\">Reproduced from: the Centers for Disease Control and Prevention and Drs. Mae Melvin and E West.</div><div id=\"graphicVersion\">Graphic 66341 Version 2.0</div></div></div>"},"66342":{"type":"graphic_figure","displayName":"Types of frontonasal dysplasia","title":"Types of frontonasal dysplasia due to mutations in cartilage-specific homeoproteins","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Types of frontonasal dysplasia due to mutations in cartilage-specific homeoproteins</div><div class=\"cntnt\"><img style=\"width:566px; height:416px;\" src=\"images/ALLRG/66342_Types_frontonasal_dysplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\"><EM>ALX</EM>: aristaless-like homeobox; FND: frontonasal dysplasia.</div><div class=\"graphic_reference\">Reproduced from: Uz E, Alanay Y, Aktas D, et al. Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: Expanding the spectrum of autosomal-recessive ALX-related frontonasal dysplasia. Am J Hum Genet 2010; 86:789. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 66342 Version 3.0</div></div></div>"},"66343":{"type":"graphic_figure","displayName":"Airway resistance child","title":"Comparison of airway resistance in a pediatric versus adult airway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comparison of airway resistance in a pediatric versus adult airway</div><div class=\"cntnt\"><img style=\"width:346px; height:729px;\" src=\"images/EM/66343_Airwayresistancechild.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effects of airway narrowing. Resistance to gas flow is inversely proportional to the fourth power of the radius of the airway lumen, meaning that small decreases in luminal diameter result in large increases in airway resistance. Because infants and children have smaller airways than adults at comparable levels, the same amount of airway narrowing (eg, 1 mm) results in a disproportionate increase in resistance for these patients. This problem is compounded by the fact that the immature respiratory musculature of a pediatric patient is less efficient and therefore more prone to fatigue than that of an adult.</div><div class=\"graphic_reference\">Reproduced with permission from: King, C, Rappaport, LD. Emergent Endotracheal Intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King, C, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66343 Version 10.0</div></div></div>"},"66344":{"type":"graphic_table","displayName":"Energy spent with activity","title":"Leisure activity energy expenditure in metabolic equivalents (METs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Leisure activity energy expenditure in metabolic equivalents (METs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Activity</td> <td class=\"subtitle1\">Mean</td> <td class=\"subtitle1\">Range</td> </tr> <tr> <td>Archery</td> <td>3.9</td> <td>3 to 4</td> </tr> <tr> <td>Backpacking</td> <td>--</td> <td>5 to 11</td> </tr> <tr> <td>Badminton</td> <td>5.8</td> <td>4 to 9+</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Basketball</td> </tr> <tr> <td class=\"sublist1\">Gameplay</td> <td class=\"sublist_other\">8.3</td> <td class=\"sublist_other\">7 to 12+</td> </tr> <tr> <td class=\"sublist1\">Nongame</td> <td class=\"sublist_other\">--</td> <td class=\"sublist_other\">3 to 9</td> </tr> <tr> <td>Billiards</td> <td>2.5</td> <td>--</td> </tr> <tr> <td>Bowling</td> <td>--</td> <td>2 to 4</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Boxing</td> </tr> <tr> <td class=\"sublist1\">In-ring</td> <td class=\"sublist_other\">13.3</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td class=\"sublist1\">Sparring</td> <td class=\"sublist_other\">8.3</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td>Canoeing, rowing, kayaking</td> <td>--</td> <td>3 to 8</td> </tr> <tr> <td>Conditioning exercise</td> <td>--</td> <td>3 to 8+</td> </tr> <tr> <td>Climbing hills</td> <td>7.2</td> <td>5 to 10+</td> </tr> <tr> <td>Cricket</td> <td>5.2</td> <td>4.6 to 7.4</td> </tr> <tr> <td>Croquet</td> <td>3.5</td> <td>--</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Cycling</td> </tr> <tr> <td class=\"sublist1\">Pleasure or to work</td> <td class=\"sublist_other\">--</td> <td class=\"sublist_other\">3 to 8+</td> </tr> <tr> <td class=\"sublist1\">10 miles per hour</td> <td class=\"sublist_other\">7.0</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td>Dancing (social, square, tap)</td> <td>--</td> <td>3.7 to 7.4</td> </tr> <tr> <td>Dancing (aerobic)</td> <td>--</td> <td>6 to 9</td> </tr> <tr> <td>Fencing</td> <td>--</td> <td>6 to 10+</td> </tr> <tr> <td>Field hockey</td> <td>8.0</td> <td>--</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Fishing</td> </tr> <tr> <td class=\"sublist1\">From bank</td> <td class=\"sublist_other\">3.7</td> <td class=\"sublist_other\">2 to 4</td> </tr> <tr> <td class=\"sublist1\">Wading in stream</td> <td class=\"sublist_other\">--</td> <td class=\"sublist_other\">5 to 6</td> </tr> <tr> <td>Football (touch)</td> <td>7.9</td> <td>6 to 10</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Golf</td> </tr> <tr> <td class=\"sublist1\">Power cart</td> <td class=\"sublist_other\">--</td> <td class=\"sublist_other\">2 to 3</td> </tr> <tr> <td class=\"sublist1\">Walking (carrying bag or pulling cart)</td> <td class=\"sublist_other\">5.1</td> <td class=\"sublist_other\">4 to 7</td> </tr> <tr> <td>Handball</td> <td>--</td> <td>8 to 12+</td> </tr> <tr> <td>Hiking (cross country)</td> <td>--</td> <td>3 to 7</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Horseback riding</td> </tr> <tr> <td class=\"sublist1\">Galloping</td> <td class=\"sublist1\">8.2</td> <td class=\"sublist1\">--</td> </tr> <tr> <td class=\"sublist1\">Trotting</td> <td class=\"sublist1\">6.6</td> <td class=\"sublist1\">--</td> </tr> <tr> <td class=\"sublist1\">Walking</td> <td class=\"sublist1\">2.4</td> <td class=\"sublist1\">--</td> </tr> <tr> <td>Horseshoe pitching</td> <td>--</td> <td>2 to 3</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Hunting (bow or gun)</td> </tr> <tr> <td class=\"sublist1\">Small game (walking, carrying light load)</td> <td class=\"sublist_other\">--</td> <td class=\"sublist_other\">3 to 7</td> </tr> <tr> <td class=\"sublist1\">Big game (dragging carcass, walking)</td> <td class=\"sublist_other\">--</td> <td class=\"sublist_other\">3 to 14</td> </tr> <tr> <td>Judo</td> <td>13.5</td> <td>--</td> </tr> <tr> <td>Mountain climbing</td> <td>--</td> <td>5-to 10+</td> </tr> <tr> <td>Music playing</td> <td>--</td> <td>2 to 3</td> </tr> <tr> <td>Paddleball, raquetball</td> <td>9</td> <td>8 to 12</td> </tr> <tr> <td class=\"sublist1_start\">Rope jumping</td> <td class=\"sublist_other_start\">11</td> <td class=\"sublist_other_start\">--</td> </tr> <tr> <td class=\"sublist1\">60 to 80 skips/minute</td> <td class=\"sublist_other\">9</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td class=\"sublist1\">120 to 140 skips/minute</td> <td class=\"sublist_other\">--</td> <td class=\"sublist_other\">11 to 12</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Running</td> <td class=\"sublist_other_start\">--</td> </tr> <tr> <td class=\"sublist1\">12 minutes/mile</td> <td class=\"sublist_other\">8.7</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td class=\"sublist1\">11 minutes/mile</td> <td class=\"sublist_other\">9.4</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td class=\"sublist1\">10 minutes/mile </td> <td class=\"sublist_other\">10.2</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td class=\"sublist1\">9 minutes/mile</td> <td class=\"sublist_other\">11.2</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td class=\"sublist1\">8 minutes/mile</td> <td class=\"sublist_other\">12.5</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td class=\"sublist1\">7 minutes/mile</td> <td class=\"sublist_other\">14.1</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td class=\"sublist1\">6 minutes/mile</td> <td class=\"sublist_other\">16.3</td> <td class=\"sublist_other\">--</td> </tr> <tr> <td>Sailing</td> <td>--</td> <td>2 to 5</td> </tr> <tr> <td>Scuba diving</td> <td>--</td> <td>5 to 10</td> </tr> <tr> <td>Shuffleboard</td> <td>--</td> <td>2 to 3</td> </tr> <tr> <td>Skating, ice and roller</td> <td>--</td> <td>5 to 8</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Skiing, snow</td> </tr> <tr> <td class=\"sublist1\">Downhill</td> <td class=\"sublist_other\">--</td> <td class=\"sublist_other\">5-to 8</td> </tr> <tr> <td class=\"sublist1\">Cross-country</td> <td class=\"sublist_other\">--</td> <td class=\"sublist_other\">6 to 12+</td> </tr> <tr> <td>Skiing, water</td> <td>--</td> <td>5 to 7</td> </tr> <tr> <td>Sledding, tobogganing</td> <td>--</td> <td>4 to 8</td> </tr> <tr> <td>Snowshoeing</td> <td>9.9</td> <td>7 to 14</td> </tr> <tr> <td>Squash</td> <td>--</td> <td>8 to 12+</td> </tr> <tr> <td>Soccer</td> <td>--</td> <td>5 to 12+</td> </tr> <tr> <td>Stairclimbing</td> <td>--</td> <td>4 to 8</td> </tr> <tr> <td>Swimming</td> <td>--</td> <td>4 to 8+</td> </tr> <tr> <td>Table tennis</td> <td>4.1</td> <td>3 to 5</td> </tr> <tr> <td>Tennis</td> <td>6.5</td> <td>4 to 9+</td> </tr> <tr> <td>Volleyball</td> <td>--</td> <td>3 to 6</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: American College of Sports Medicine. Guidelines for Exercise Testing and Prescription, 3rd ed, Lea and Febiger, Philadelphia 1986, p.20.</div><div id=\"graphicVersion\">Graphic 66344 Version 6.0</div></div></div>"},"66345":{"type":"graphic_diagnosticimage","displayName":"Tech factors add imaging","title":"Technical factors leading to additional imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Technical factors leading to additional imaging</div><div class=\"cntnt\"><img style=\"width:286px; height:578px;\" src=\"images/PC/66345_Technical_factors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On a standard CC view performed during routine screening mammogram, the nipple (arrows) can appear as a nodule (Panel A) if not properly positioned leading to additional work up. When the CC view of the same breast is repeated with the nipple in profile (Panel B), it becomes clear that there is no lesion. Similarly, deodorant may appear as very faint radiodensities. This is usually seen in the axillary portion of the breast on the MLO view, mimicking microcalcifications (Panel C). A repeat MLO view (Panel D) after washing the axilla shows normal appearance.</div><div class=\"graphic_footnotes\">CC: craniocaudal; MLO: mediolateral oblique.</div><div id=\"graphicVersion\">Graphic 66345 Version 2.0</div></div></div>"},"66348":{"type":"graphic_table","displayName":"Classification of pulmonary hypertension","title":"Clinical classification of pulmonary hypertension (NICE, 2013)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical classification of pulmonary hypertension (NICE, 2013)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Pulmonary arterial hypertension (PAH)</td> </tr> <tr> <td class=\"indent1\">1.1. Idiopathic PAH </td> </tr> <tr> <td class=\"sublist2_start\">1.2. Heritable </td> </tr> <tr> <td class=\"sublist2\">1.2.1. BMPR2 </td> </tr> <tr> <td class=\"sublist2\">1.2.2. ALK1, endoglin, SMAD9, CAV1, KCNK3</td> </tr> <tr> <td class=\"sublist2\">1.2.3. Unknown </td> </tr> <tr> <td class=\"indent1\">1.3. Drug- and toxin-induced </td> </tr> <tr> <td class=\"sublist2_start\">1.4. Associated with </td> </tr> <tr> <td class=\"sublist2\">1.4.1. Connective tissue diseases </td> </tr> <tr> <td class=\"sublist2\">1.4.2. HIV infection </td> </tr> <tr> <td class=\"sublist2\">1.4.3. Portal hypertension </td> </tr> <tr> <td class=\"sublist2\">1.4.4. Congenital heart diseases </td> </tr> <tr> <td class=\"sublist2\">1.4.5. Schistosomiasis </td> </tr> <tr> <td class=\"sublist2\"></td> </tr> <tr> <td class=\"indent1\">1&#8242;. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)&nbsp;</td> </tr> <tr> <td>&nbsp;&nbsp;&nbsp;&nbsp; 1&#8242;&#8242;. Persistent pulmonary hypertension of the newborn (PPHN)</td> </tr> <tr> <td>2. Pulmonary hypertension owing to left heart disease</td> </tr> <tr> <td class=\"indent1\">2.1. Left ventricular systolic dysfunction </td> </tr> <tr> <td class=\"indent1\">2.2. Left ventricular diastolic dysfunction </td> </tr> <tr> <td class=\"indent1\">2.3. Valvular disease </td> </tr> <tr> <td class=\"indent1\">2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies&nbsp;</td> </tr> <tr> <td>3. Pulmonary hypertension owing to lung diseases and/or hypoxia</td> </tr> <tr> <td class=\"indent1\">3.1. Chronic obstructive pulmonary disease </td> </tr> <tr> <td class=\"indent1\">3.2. Interstitial lung disease </td> </tr> <tr> <td class=\"indent1\">3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern </td> </tr> <tr> <td class=\"indent1\">3.4. Sleep-disordered breathing </td> </tr> <tr> <td class=\"indent1\">3.5. Alveolar hypoventilation disorders </td> </tr> <tr> <td class=\"indent1\">3.6. Chronic exposure to high altitude </td> </tr> <tr> <td class=\"indent1\">3.7. Developmental abnormalities </td> </tr> <tr> <td>4. Chronic thromboembolic pulmonary hypertension (CTEPH)</td> </tr> <tr> <td>5. Pulmonary hypertension with unclear multifactorial mechanisms</td> </tr> <tr> <td class=\"indent1\">5.1. Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy </td> </tr> <tr> <td class=\"indent1\">5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis </td> </tr> <tr> <td class=\"indent1\">5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders </td> </tr> <tr> <td class=\"indent1\">5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental pulmonary hypertension&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALK1: activin receptor-like kinase type 1; SMAD9: mothers against decapentaplegic 9; CAV1: caveolin1; KKCNK3: potassium channel super family K member-3; BMPR2: bone morphogenetic protein receptor type 2; HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Original figure modified for this publication.&nbsp;Simonneau, G,&nbsp;Gatzoulis, M, Adiata, I,&nbsp;et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol 2013; 62:S34. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 66348 Version 4.0</div></div></div>"},"66349":{"type":"graphic_figure","displayName":"Plasma NEP asx LV dysfunction","title":"Plasma norepinephrine predicts outcome in patients with asymptomatic left ventricular dysfunction","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Plasma norepinephrine predicts outcome in patients with asymptomatic left ventricular dysfunction</div><div class=\"cntnt\"><img style=\"width:499px; height:223px;\" src=\"images/CARD/66349_Plasma_NEP_asx_LV_dysfuncti.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the SOLVD trial of patients with asymptomatic left ventricular dysfunction, mostly following myocardial infarction, plasma norepinephrine concentrations (PNe) above the median were associated with significant increases in cardiovascular mortality (left panel, p = 0.003) and all-cause mortality or hospitalization for heart failure (right panel, p &lt;0.001).</div><div class=\"graphic_reference\">Data from Benedict CR, Shelton B, Johnstone DE, et al. Circulation 1996; 94:690.</div><div id=\"graphicVersion\">Graphic 66349 Version 2.0</div></div></div>"},"66351":{"type":"graphic_diagnosticimage","displayName":"Ultrasound ureterocele","title":"Ureterocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ureterocele</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/OBGYN/66351_Ultrasound_ureterocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 66351 Version 2.0</div></div></div>"},"66352":{"type":"graphic_figure","displayName":"Prognosis RCC by UISS stage","title":"Prognosis of renal cell cancer stratified by University of California Los Angeles Integrated Staging System (UISS) stage","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Prognosis of renal cell cancer stratified by University of California Los Angeles Integrated Staging System (UISS) stage</div><div class=\"cntnt\"><img style=\"width:465px; height:300px;\" src=\"images/ONC/66352_Prognosis_RCC_by_UISS_stage.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival curves indicating the different postnephrectomy outcome for patients with renal cell cancer stratified by UISS categories. These categories incorporate TNM classification as well as performance status, and tumor histologic grade. Black triangles mark the point in each group where ten patients remain at risk.</div><div class=\"graphic_reference\">Data from Zisman, et al. J Clin Oncol 2001; 19:1654.</div><div id=\"graphicVersion\">Graphic 66352 Version 2.0</div></div></div>"},"66353":{"type":"graphic_picture","displayName":"Bone marrow aplastic anemia","title":"Bone marrow of a child with aplastic anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow of a child with aplastic anemia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/66353_Bone_marrow_aplastic_anemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Min Xu, MD, PhD.</div><div id=\"graphicVersion\">Graphic 66353 Version 1.0</div></div></div>"},"66355":{"type":"graphic_table","displayName":"Signs adrenal insufficiency","title":"Clinical manifestations of adrenal insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of adrenal insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Glucocorticoid deficiency</td> </tr> <tr> <td>Gastrointestinal symptoms (nausea, vomiting)</td> </tr> <tr> <td>Fatigue, weakness</td> </tr> <tr> <td>Failure to thrive</td> </tr> <tr> <td>Morning headache</td> </tr> <tr> <td>Fasting hypoglycemia</td> </tr> <tr> <td>Increased insulin sensitivity</td> </tr> <tr> <td>Decreased gastric acidity</td> </tr> <tr> <td>Decreased free water clearance</td> </tr> <tr> <td class=\"subtitle1_single\">Mineralocorticoid deficiency</td> </tr> <tr> <td>Hypotension, dizziness</td> </tr> <tr> <td>Muscle weakness</td> </tr> <tr> <td>Fatigue</td> </tr> <tr> <td>Gastrointestinal symptoms (nausea, vomiting, anorexia)</td> </tr> <tr> <td>Salt-craving</td> </tr> <tr> <td>Weight loss</td> </tr> <tr> <td>Dehydration</td> </tr> <tr> <td>Hyponatremia, hyperkalemia, metabolic acidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Adrenal androgen deficiency in females</td> </tr> <tr> <td>Decreased pubic and axillary hair development in pubertal patients</td> </tr> <tr> <td>Decreased libido in older patients</td> </tr> <tr> <td class=\"subtitle1_single\">Increased melanocortin from POMC cleavage products</td> </tr> <tr> <td>Hyperpigmentation of skin, mucosa, palmar creases, axillae, gingival borders</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">POMC: pro-opiomelanocortin (the precursor molecule for ACTH, melanocortin, and β-endorphin).</div><div class=\"graphic_reference\">Courtesy of Patricia Donohoue, MD.</div><div id=\"graphicVersion\">Graphic 66355 Version 8.0</div></div></div>"},"66356":{"type":"graphic_figure","displayName":"Classification of iatrogenic bile duct injury","title":"Classification of iatrogenic bile duct injury","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Classification of iatrogenic bile duct injury</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/GAST/66356_Classification_biliary_inju.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Strasberg classification:<br> Type A - Injury to the  cystic duct or from minor hepatic ducts draining the liver bed.<br> Type B - Occlusion of biliary tree, commonly aberrant right hepatic duct(s)<br> Type C - Transection without ligation of aberrant right hepatic duct(s)<br> Type D - Lateral injury to a major bile duct.<br> Type E (1-5) - Injury to the main hepatic duct; classified according to level of injury (ie, below). <br> - E1 (Bismuth type 1) - Injury more than 2 cm from confluence<br> - E2 (Bismuth type 2) - Injury less than 2 cm from confluence<br> - E3 (Bismuth type 3) - Injury at the confluence; confluence intact<br> - E4 (Bismuth type 4) - Destruction of the biliary confluence<br> - E5 (Bismuth type 5) - Injury to aberrant right hepatic duct</div><div class=\"graphic_reference\">Strasberg, SM, Hertl, M, Soper, NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg 1995; 180:101.<br> Bismuth, H, Lazorthes, F. Les traumatismes operatoires de la voie biliare principale. Paris, France: Masson, 1981.<br> Chartrand-Lefebvre, C, Dufresne, M-P, Lafortune, M, et al. Iatrogenic injury to the bile duct: A working classification for radiologists. Radiology 1994; 193:523.</div><div id=\"graphicVersion\">Graphic 66356 Version 5.0</div></div></div>"},"66357":{"type":"graphic_algorithm","displayName":"Exacerbation COPD outpatient","title":"Outpatient management of exacerbations of COPD","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Outpatient management of exacerbations of COPD</div><div class=\"cntnt\"><img style=\"width:612px; height:504px;\" src=\"images/ID/66357_AECOPD_abx_outpatient.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease.<br />* <EM>Pseudomonas</EM> risk factors: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Advanced COPD</LI>&#xD;&#xA;<LI>Previous isolation of <EM>Pseudomonas</EM> from sputum</LI>&#xD;&#xA;<LI>Concomitant bronchiectasis</LI>&#xD;&#xA;<LI>Frequent administration of antibiotics</LI>&#xD;&#xA;<LI>Frequent hospital admissions</LI>&#xD;&#xA;<LI>Systemic glucocorticoid use</LI></UL></div><div class=\"graphic_reference\">Adapted with permission from: Sethi S, Murphy TF. Acute exacerbations of chronic bronchitis: New developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy. Infect Dis Clin N Am 2004; 18:861. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2004 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 66357 Version 8.0</div></div></div>"},"66362":{"type":"graphic_figure","displayName":"Jones metroplasty E","title":"Jones metroplasty E","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Jones metroplasty E</div><div class=\"cntnt\"><img style=\"width:503px; height:339px;\" src=\"images/OBGYN/66362_Jones_metroplasty_E.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(E) Using the lightest possible suture, the third layer approximates the superficial myometrium and serosa. The rough edges should be imbricated as much as possible to prevent adhesions along the suture line.</div><div id=\"graphicVersion\">Graphic 66362 Version 1.0</div></div></div>"},"66363":{"type":"graphic_picture","displayName":"Uterosacral ligm plication","title":"Uterosacral ligament plication during laparoscopic hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterosacral ligament plication during laparoscopic hysterectomy</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/OBGYN/66363_Uterosacral_ligm_plication.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Thomas Lyons, MD.</div><div id=\"graphicVersion\">Graphic 66363 Version 3.0</div></div></div>"},"66364":{"type":"graphic_waveform","displayName":"Advanced case 5 with answer","title":"Accelerated idioventricular rhythm","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Accelerated idioventricular rhythm</div><div class=\"cntnt\"><img style=\"width:540px; height:142px;\" src=\"images/CARD/66364_Advanced_case_5_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus rhythm interrupted by an accelerated idioventricular rhythm (AIVR). The first beat (N) is a normally conducted sinus beat; the very wide beats are ventricular beats (V); and the beats marked F are fusion beats due to &quot;collision&quot; of a sinus beat and a ventricular beat. Note how the P waves become dissociated from the QRS complexes during the idioventricular rhythm. AIVR is usually seen with underlying heart disease and represents a &quot;slow&quot; type of ventricular tachycardia that does not generally warrant specific therapy. AIVR may be a marker of reperfusion during acute myocardial infarction, occurring spontaneously or after reperfusion therapy. The slow ventricular rate distinguishes this arrhythmia from nonsustained ventricular tachycardia in which the ventricular rate is above 100 beats/min.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 66364 Version 2.0</div></div></div>"},"66366":{"type":"graphic_figure","displayName":"Classification of endometriosis","title":"Examples of the classification of endometriosis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Examples of the classification of endometriosis</div><div class=\"cntnt\"><img style=\"width:540px; height:409px;\" src=\"images/ENDO/66366_Classification_of_endometriosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Original figure modified for this publication. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67:817. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 66366 Version 2.0</div></div></div>"},"66367":{"type":"graphic_figure","displayName":"Pregnancy rate singleton","title":"Cumulative singleton rate","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Cumulative singleton rate</div><div class=\"cntnt\"><img style=\"width:480px; height:318px;\" src=\"images/ENDO/66367_Pregnancy_rate_singleton.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative pregnancy rate resulting in singleton live birth of a consecutive series of 240 normogonadotrophic anovulatory infertile women undergoing classical ovulation induction (clomiphene citrate as first therapy, followed by FSH as second-line therapy if required), calculated by the Kaplan-Meier method, with 95 percent confidence interval.</div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone.</div><div class=\"graphic_reference\">Eijkemans, MJ, Imani, B, Mulders, AG, et al. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod 2003; 18:2357.</div><div id=\"graphicVersion\">Graphic 66367 Version 2.0</div></div></div>"},"66371":{"type":"graphic_picture","displayName":"Ulcer after gastric bypass","title":"Marginal ulcer after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Marginal ulcer after gastric bypass</div><div class=\"cntnt\"><img style=\"width:360px; height:282px;\" src=\"images/GAST/66371_Ulcer_after_gastric_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large marginal ulcer after gastric bypass.</div><div class=\"graphic_reference\">Courtesy of Christopher S Huang, MD.</div><div id=\"graphicVersion\">Graphic 66371 Version 3.0</div></div></div>"},"66373":{"type":"graphic_figure","displayName":"ST resolution vs TIMI flow","title":"Improvement in TIMI flow grade is associated with ST segment resolution","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Improvement in TIMI flow grade is associated with ST segment resolution</div><div class=\"cntnt\"><img style=\"width:568px; height:341px;\" src=\"images/CARD/66373_ST_resolution_vs_TIMI_flow.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The reperfusion regimens used in the TIMI-14 substudy were tissue plasminogen activator (tPA) and combinations of abciximab plus reduced-dose tPA, whereas the fibrinolytic agent used in the HIT-4 study was streptokinase. In both studies there is a direct relationship between the degree of ST segment resolution and the TIMI flow grade achieved (p &lt;0.001 for the correlation between ST resolution and TIMI 3 flow; p &lt;0.001 for correlation between ST resolution and infarct-related artery patency, ie, TIMI 2 + 3 flow).</div><div class=\"graphic_reference\">Data from de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38:1283.</div><div id=\"graphicVersion\">Graphic 66373 Version 2.0</div></div></div>"},"66374":{"type":"graphic_picture","displayName":"Nail psoriasis oil drop","title":"Oil drop sign and distal onycholysis in psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oil drop sign and distal onycholysis in psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/66374_Nailpsoriasisoildrop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Discoloration of the nail plate and distal onycholysis (separation of the nail plate from the nail bed) are present in this patient with psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66374 Version 5.0</div></div></div>"},"66375":{"type":"graphic_table","displayName":"Leukocyte-adhesion deficiency syndromes","title":"Leukocyte-adhesion deficiency syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Leukocyte-adhesion deficiency syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp; </td> <td class=\"subtitle1\">LAD I </td> <td class=\"subtitle1\">LAD II </td> <td class=\"subtitle1\">LAD III </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Clinical manifestation </td> </tr> <tr> <td class=\"indent1\">Recurrent severe infections </td> <td>+++</td> <td>+</td> <td>+++</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"4\">Neutrophilia </td> </tr> <tr> <td class=\"sublist2\">basal </td> <td class=\"sublist_other\">+ </td> <td class=\"sublist_other\">+++ </td> <td class=\"sublist_other\">++ </td> </tr> <tr> <td class=\"sublist2\">with infection </td> <td class=\"sublist_other\">+++ </td> <td class=\"sublist_other\">+++ </td> <td class=\"sublist_other\">+++ </td> </tr> <tr> <td class=\"indent1\">Periodontitis </td> <td>++</td> <td>++</td> <td>?</td> </tr> <tr> <td class=\"indent1\">Skin infection </td> <td>++</td> <td>+</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Delayed separation of the umbilical cord </td> <td>+++</td> <td>-</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Developmental abnormalities </td> <td>-</td> <td>+++</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Bleeding tendency </td> <td>-</td> <td>-</td> <td>+++</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Laboratory findings </td> </tr> <tr> <td class=\"indent1\">CD18 expression </td> <td>&#8595; &#8595; &#8595; or absent</td> <td>NL</td> <td>NL</td> </tr> <tr> <td class=\"indent1\">SLeX expression </td> <td>NL</td> <td>Absent</td> <td>NL</td> </tr> <tr> <td class=\"indent1\">Neutrophil motility </td> <td>&#8595; &#8595; &#8595;</td> <td>&#8595; &#8595;</td> <td>&#8595; &#8595;</td> </tr> <tr> <td class=\"indent1\">Neutrophil rolling </td> <td>NL</td> <td>&#8595; &#8595; &#8595;</td> <td>NL</td> </tr> <tr> <td class=\"indent1\">Neutrophil adherence </td> <td>&#8595; &#8595; &#8595;</td> <td>&#8595;</td> <td>&#8595; &#8595; &#8595;</td> </tr> <tr> <td class=\"indent1\">Opsonophagocytic activity </td> <td>&#8595;</td> <td>NL</td> <td>NL</td> </tr> <tr> <td class=\"indent1\">T and B cell function </td> <td>&#8595;</td> <td>NL</td> <td>?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LAD: leukocyte-adhesion deficiency; CD18: common beta-2 subunit of the beta-2 leukocyte integrins; SLeX: sialyl Lewis X; NL: normal.<br /></div><div id=\"graphicVersion\">Graphic 66375 Version 4.0</div></div></div>"},"66376":{"type":"graphic_figure","displayName":"Endotracheal tube insertion","title":"Insertion of the endotracheal tube","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Insertion of the endotracheal tube</div><div class=\"cntnt\"><img style=\"width:461px; height:608px;\" src=\"images/EM/66376_ETTinsertion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insertion of the endotracheal tube. A) The tube is rotated somewhat laterally and inserted from the right of midline so that the vocal cords can be kept in view at all times. B) With the stylet in place and after molding into a hockey stick configuration, the tube is inserted into the trachea, and the laryngoscope blade is removed from the mouth. C) The stylet is removed and the tube held securely in place.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66376 Version 10.0</div></div></div>"},"66377":{"type":"graphic_table","displayName":"Percutaneous transtracheal ventilation complications","title":"Potential complications of needle cricothyroidotomy and percutaneous transtracheal ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential complications of needle cricothyroidotomy and percutaneous transtracheal ventilation</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Category\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Complication\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Unsuccessful catheter placement <strong>OR</strong> Successful catheter placement with subsequent obstruction, kinking, or dislodgement\r\n  \r\n   </td>\r\n  \r\n   <td>Inability to ventilate</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Subcutaneous emphysema</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"4\">\r\n  \r\n   Barotrauma\r\n  \r\n   </td>\r\n  \r\n   <td>Subcutaneous emphysema</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pneumomediastinum</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pneumothorax</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pneumatocele of the larynx</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"5\">\r\n  \r\n   Damage to adjacent structures\r\n  \r\n   </td>\r\n  \r\n   <td>Posterior tracheal laceration or perforation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Esophageal perforation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mediastinitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Vocal cord injury</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Laryngeal injury and/or laryngospasm</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Excessive bleeding</td>\r\n  \r\n   <td>Hematoma (cutaneous and/or airway) with extrinsic or intrinsic airway narrowing</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   Infection\r\n  \r\n   </td>\r\n  \r\n   <td>Cellulitis and abscess (cutaneous and/or prevertebral)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tracheitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Osteomyelitis of the cervical spine</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 66377 Version 3.0</div></div></div>"},"66378":{"type":"graphic_table","displayName":"Differentiation of Uhl anomaly from ARVC","title":"Differentiation of Uhl anomaly from arrhythmogenic right ventricular cardiomyopathy (ARVC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiation of Uhl anomaly from arrhythmogenic right ventricular cardiomyopathy (ARVC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Uhl anomaly</td> <td class=\"subtitle1\">ARVC</td> </tr> <tr> <td>Family history</td> <td>No</td> <td>Yes (some patients)</td> </tr> <tr> <td>Gender, ratio M:F</td> <td>1.3:1</td> <td>2.9:1</td> </tr> <tr> <td>Age at presentation</td> <td>Infancy + childhood</td> <td>Adolescence + older</td> </tr> <tr> <td>Usual mode of presentation</td> <td>Heart failure</td> <td>Arrhythmia, syncope, or sudden death</td> </tr> <tr> <td>Exercise-induced deaths</td> <td>Rare</td> <td>Uncommon</td> </tr> <tr> <td>Pathology</td> <td>Areas of complete absence of myocardium of parietal wall of RV: endocardial and epicardial layers are directly opposed</td> <td>Localized patchy replacement of the parietal wall of RV by fibrous and fatty tissue</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ARVC: Arrhythmogenic right ventricular cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 66378 Version 4.0</div></div></div>"},"66379":{"type":"graphic_picture","displayName":"B dermatitidis wet mount","title":"<EM>Blastomyces dermatitidis</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Blastomyces dermatitidis</EM></div><div class=\"cntnt\"><img style=\"width:394px; height:252px;\" src=\"images/ID/66379_B_dermatitidis_wet_mount.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wet mount from a patient infected with <EM>Blastomyces dermatitidis</EM> shows multinucleate yeast cells with thick refractile cell walls.</div><div class=\"graphic_reference\">Courtesy of Stanley W Chapman, MD.</div><div id=\"graphicVersion\">Graphic 66379 Version 3.0</div></div></div>"},"66383":{"type":"graphic_table","displayName":"Developmental milestones: 0 through 12 months","title":"Developmental milestones: 0 through 12 months","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Developmental milestones: 0 through 12 months</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"12\" width=\"7.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"12\">Approximate chronologic age</td> </tr> <tr> <td class=\"subtitle2\">1 month</td> <td class=\"subtitle2\">2 months</td> <td class=\"subtitle2\">3 months</td> <td class=\"subtitle2\">4 months</td> <td class=\"subtitle2\">5 months</td> <td class=\"subtitle2\">6 months</td> <td class=\"subtitle2\">7 months</td> <td class=\"subtitle2\">8 months</td> <td class=\"subtitle2\">9 months</td> <td class=\"subtitle2\">10 months</td> <td class=\"subtitle2\">11 months</td> <td class=\"subtitle2\">12 months</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gross motor</strong></td> <td> <ul> <li>Turns head in supine </li> <li>Chin up in prone </li> </ul> </td> <td> <ul> <li>Chest up in prone </li> <li>Tries to steady head briefly when held </li> </ul> </td> <td> <ul> <li>Props on forearms in prone </li> <li>Rolls to side </li> </ul> </td> <td> <ul> <li>Sits with trunk support </li> <li>No head lag when pulled to sit </li> <li>Props on wrists </li> <li>Rolls front to back </li> </ul> </td> <td> <ul> <li>Sits with pelvic support </li> <li>Rolls back to front </li> <li>Parachute sits with arms supporting trunk (anterior protection) </li> </ul> </td> <td> <ul> <li>Sits momentarily propped on hands </li> <li>Pivots in prone (on belly) </li> <li>Bears weight on one hand in prone </li> </ul> </td> <td> <ul> <li>Bounces when held </li> <li>Sits without support (steady) </li> <li>Puts arms out to sides for balance (lateral protection) </li> </ul> </td> <td> <ul> <li>Gets into sitting </li> <li>Commando crawls </li> <li>Pulls to sitting/kneeling </li> </ul> </td> <td> <ul> <li>\"Stands\" on feet and hands </li> <li>Begins creeping </li> <li>Pulls to stand </li> <li>Crawls with all four limbs straightened (bear walks) </li> </ul> </td> <td> <ul> <li>Creeps well </li> <li>Cruises around furniture with two hands </li> <li>Stands, one hand held </li> <li>Walks, two hands held </li> </ul> </td> <td> <ul> <li>Walks, one hand held </li> <li>Pivots in sitting </li> <li>Cruises furniture holding on with one hand </li> <li>Stands for a few seconds </li> </ul> </td> <td> <ul> <li>Stands well with arms high and legs splayed (posterior protection) </li> <li>Independent steps </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fine motor/writing</strong></td> <td> <ul> <li>Hands fisted near face </li> </ul> </td> <td> <ul> <li>Hands unfisted 50% </li> <li>Retains rattle if placed in hand </li> <li>Holds hands together </li> </ul> </td> <td> <ul> <li>Hands unfisted 50% </li> <li>Inspects fingers </li> <li>Bats at objects </li> </ul> </td> <td> <ul> <li>Clutches at clothes </li> <li>Reaches persistently </li> <li>Plays with rattle </li> <li>Holds hands predominately open </li> </ul> </td> <td> <ul> <li>Grasps cube using whole hand (palmar grasp) </li> <li>Transfers objects: Hand-mouth-hand </li> <li>Holds hands together </li> <li>Reaches/grasps dangling ring </li> </ul> </td> <td> <ul> <li>Transfers hand-hand </li> <li>Rakes pellet </li> <li>Takes second cube, holds on to one </li> <li>Reaches with one hand </li> </ul> </td> <td> <ul> <li>Grasps using side of hand (radial-palmar grasp) </li> </ul> </td> <td> <ul> <li>Bangs spoon after a demo </li> <li>Grasps with all four fingers and side of thumb (scissor grasp) </li> <li>Takes cube out of cup </li> <li>Pulls large peg out </li> </ul> </td> <td> <ul> <li>Grasps with two finger and thumb below (radial-digital) </li> <li>Bangs two cubes together </li> </ul> </td> <td> <ul> <li>Clumsy release of cube </li> <li>Grasps pellet with side of index finger and thumb (inferior pincer grasp) </li> <li>Isolates index finger and pokes </li> </ul> </td> <td> <ul> <li>Throws objects </li> <li>Stirs with spoon </li> </ul> </td> <td> <ul> <li>Scribbles after demo </li> <li>Fine pincer grasp of pellet </li> <li>Holds crayon </li> <li>Attempts tower of two cubes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Self-help</strong></td> <td> <ul> <li>Sucks well </li> </ul> </td> <td> <ul> <li>Opens mouth at sight of breast or bottle </li> </ul> </td> <td> <ul> <li>Brings hands to mouth </li> </ul> </td> <td> <ul> <li>Briefly holds onto breast or bottle </li> </ul> </td> <td> <ul> <li>Gums/mouths pureed food </li> </ul> </td> <td> <ul> <li>Feeds self crackers </li> <li>Places hands on bottle </li> </ul> </td> <td> <ul> <li>Refuses excess food </li> </ul> </td> <td> <ul> <li>Holds own bottle </li> <li>Finger feeds Cheerios or string beans </li> </ul> </td> <td> <ul> <li>Bites, chews cookie </li> </ul> </td> <td> <ul> <li>Drinks (not sucks) from cup held for him/her </li> </ul> </td> <td> <ul> <li>Cooperates in dressing </li> </ul> </td> <td> <ul> <li>Cooperates in dressing </li> <li>Finger feeds part of meal </li> <li>Takes hat off </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cognitive/academic</strong></td> <td> <ul> <li>Gazes at black-white objects </li> <li>Follows face </li> </ul> </td> <td> <ul> <li>Follows large highly contrasting objects </li> <li>Recognizes mother </li> </ul> </td> <td> <ul> <li>Reaches for parent's face </li> <li>Follows objects moved in circle (in supine) </li> <li>Regards toys </li> </ul> </td> <td> <ul> <li>Mouths objects </li> <li>Stares longer at novel faces than familiar ones </li> <li>Shakes rattle </li> <li>Reaches for ring/rattle </li> </ul> </td> <td> <ul> <li>Turns head to look for dropped spoon </li> <li>Regards pellet or small cracker </li> </ul> </td> <td> <ul> <li>Touches reflection and vocalizes </li> <li>Removes cloth on face </li> <li>Bangs and shakes toys </li> </ul> </td> <td> <ul> <li>Explores different aspects of a toy </li> <li>Observes cube in each hand </li> <li>Finds partially hidden object </li> </ul> </td> <td> <ul> <li>Seeks object after it falls silently to the floor </li> </ul> </td> <td> <ul> <li>Inspects parts of a bell </li> <li>Rings bell after demo </li> <li>Pulls string to obtain an attached toy out of reach </li> </ul> </td> <td> <ul> <li>Uncovers toy under cloth </li> <li>Pokes at pellet in bottle </li> <li>Tries to put cube in cup, but may not be able to let go </li> </ul> </td> <td> <ul> <li>Finds toy under cup </li> <li>Looks at pictures in book </li> </ul> </td> <td> <ul> <li>Rattles spoon in cup </li> <li>Lifts box lid to find toy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Social/emotional</strong></td> <td> <ul> <li>Discriminates mother's voice </li> <li>Cries out of distress </li> </ul> </td> <td> <ul> <li>Reciprocal smiling: Responds to adult voice and smiles </li> </ul> </td> <td> <ul> <li>Expression of disgust (eg, sour taste, loud sound) </li> <li>Visually follows person who is moving across a room </li> </ul> </td> <td> <ul> <li>Smiles spontaneously at pleasurable sight/sound </li> <li>Stops crying at parent's voice </li> <li>To and fro alternating vocalizations </li> </ul> </td> <td> <ul> <li>Recognizes caregiver visually </li> <li>Forms attachment: Relationship to caregiver </li> </ul> </td> <td> <ul> <li>Stranger anxiety: Recognizes familiar versus unfamiliar people </li> </ul> </td> <td> <ul> <li>Looks from object to parent and back when wanting help (eg, with a wind-up toy) </li> </ul> </td> <td> <ul> <li>Lets parents know when happy versus upset </li> <li>Engages in gaze monitoring: Adult looks away and child follows adult glance with own eyes </li> </ul> </td> <td> <ul> <li>Uses sounds to get attention </li> <li>Separation anxiety </li> <li>Follows a point \"Oh look at...\" </li> <li>Recognizes familiar people visually </li> </ul> </td> <td> <ul> <li>Experiences fear </li> <li>Looks preferentially when name is called </li> </ul> </td> <td> <ul> <li>Gives objects to adult for action after demonstration (lets adult know he/she needs help) </li> </ul> </td> <td> <ul> <li>Shows objects to parent to share interest </li> <li>Points in order to get desired object (proto-imperative pointing) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Receptive language</strong></td> <td> <ul> <li>Startles to loud noise </li> </ul> </td> <td> <ul> <li>Alerts to voice/sound </li> </ul> </td> <td> <ul> <li>Regards speaker </li> </ul> </td> <td> <ul> <li>Orients head in direction of a voice </li> <li>Stops crying to soothing voice </li> </ul> </td> <td> <ul> <li>Begins to respond to name </li> </ul> </td> <td> <ul> <li>Stops momentarily to \"no\" </li> <li>Gestures for \"up\" </li> </ul> </td> <td> <ul> <li>Looks toward familiar object when named </li> <li>Attends to music </li> </ul> </td> <td> <ul> <li>Responds to \"come here\" </li> <li>Looks for family members when asked (eg, \"Where's Mama?\", etc) </li> </ul> </td> <td> <ul> <li>Enjoys gesture games </li> <li>Orients to name well </li> <li>Turns head upward and diagonally to view source of sound </li> </ul> </td> <td> <ul> <li>Enjoys peek-a-boo </li> <li>Waves \"bye-bye\" back </li> </ul> </td> <td> <ul> <li>Stops activity when told \"no\" </li> <li>Bounces to music </li> </ul> </td> <td> <ul> <li>Follows one-step command with gesture </li> <li>Recognizes names of two objects, looks when named </li> </ul> </td> </tr> <tr> <td><strong>Expressive language</strong></td> <td> <ul> <li>Makes sounds other than crying </li> </ul> </td> <td> <ul> <li>Coos </li> <li>Social smile (six weeks) </li> <li>Vowel-like noises </li> </ul> </td> <td> <ul> <li>Chuckles </li> <li>Vocalizes when talked to </li> </ul> </td> <td> <ul> <li>Laughs out loud </li> <li>Vocalizes when alone </li> </ul> </td> <td> <ul> <li>Says \"Ah-goo\" </li> <li>Razz, squeal </li> <li>Expresses anger with sounds other than crying </li> </ul> </td> <td> <ul> <li>Reduplicate babble with consonants </li> <li>Listens then vocalizes when adult stops </li> <li>Smiles/vocalizes to mirror </li> </ul> </td> <td> <ul> <li>Increasing variety of syllables </li> </ul> </td> <td> <ul> <li>Says \"Mama\" (nonspecific) </li> <li>Nonreduplicate babble </li> <li>Imitates sounds </li> </ul> </td> <td> <ul> <li>Says \"Mama\" (nonspecific) </li> <li>Nonreduplicate babble </li> <li>Imitates sounds </li> </ul> </td> <td> <ul> <li>Says \"Dada\" (specific) </li> <li>Waves \"bye-bye\" </li> </ul> </td> <td> <ul> <li>Says first word </li> <li>Vocalizes to songs </li> </ul> </td> <td> <ul> <li>Points in order to get desired object (proto-imperative pointing) </li> <li>Uses several gestures with vocalizing (eg, waving, reaching, etc) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">&copy; 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS: Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.</div><div id=\"graphicVersion\">Graphic 66383 Version 10.0</div></div></div>"},"66384":{"type":"graphic_picture","displayName":"Acanthosis nigricans - axilla","title":"Acanthosis nigricans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acanthosis nigricans</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/66384_Acanthosis_nigricans_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented velvety plaques are present in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66384 Version 3.0</div></div></div>"},"66385":{"type":"graphic_table","displayName":"Menzies method","title":"Menzies method","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Menzies method</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Criteria</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td rowspan=\"2\"> <p><strong>Negative features</strong></p> <p>Neither can be present in melanoma</p> </td> <td>Symmetrical pigmentation pattern</td> <td>Symmetric pigment pattern across all axes.</td> </tr> <tr> <td>Presence of only a single color</td> <td>Presence of only 1 color: <ol> <li>Tan </li> <li>Dark brown </li> <li>Black </li> <li>Gray </li> <li>Blue </li> <li>Red </li> </ol> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"9\"> <p><strong>Positive features</strong></p> <p>At least one feature has to be present to consider the diagnosis of melanoma</p> </td> <td>Multiple (5-6) colors</td> <td>Presence of 5 or 6 of the above colors.</td> </tr> <tr> <td>Blue-white veil</td> <td>Irregular and confluent blue pigmentation with an overlying white \"ground glass\" film, not associated with red-blue lacunae.</td> </tr> <tr> <td>Multiple brown dots</td> <td>Aggregations of dark brown dots, usually within the body of the lesion.</td> </tr> <tr> <td>Multiple blue/gray dots</td> <td>Diffuse, partly aggregated dots, \"pepper-like\" in appearance.</td> </tr> <tr> <td>Peripheral black dots or globules</td> <td>Black dots or globules at or near the edge of the lesion.</td> </tr> <tr> <td>Broadened network</td> <td>Pigment network with areas of thick grids.</td> </tr> <tr> <td>Pseudopods</td> <td>Finger-like projections with small knobs at their tips, which are directly connected to the tumor body or the pigment network.</td> </tr> <tr> <td>Radial streaming</td> <td>Radial and asymmetric linear extensions at the edge of the lesion.</td> </tr> <tr> <td>Scar-like depigmentation</td> <td>White, irregular area of depigmentation.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">21</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=92125&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Menzies SW, Ingvar C, Crotty KA, McCarthy WH. Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. Arch Dermatol 1996; 132:1178. </LI>&#xD;&#xA;<LI>Menzies SW, Ingvar C, McCarthy WH. A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma. Melanoma Res 1996; 6:55. </LI></OL>Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 66385 Version 5.0</div></div></div>"},"66386":{"type":"graphic_table","displayName":"Diagnosis autonomic neuropathy","title":"Techniques for the diagnosis of diabetic autonomic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Techniques for the diagnosis of diabetic autonomic neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cardiovascular autonomic testing</td> </tr> <tr> <td class=\"indent1\">Tests of predominantly parasympathetic function</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Heart rate variability to deep breathing (ie, supine position with the subject breathing at a fixed rate of five breaths per minute during a six-minute period): Analyzed by the heart rate variability and the expiratory to inspiratory ratio </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Heart rate response to standing (the 30:15 ratio) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Heart rate response to Valsalva maneuver (the Valsalva ratio) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Tests of predominantly sympathetic adrenergic function</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>The beat-to-beat blood pressure response to a Valsalva maneuver (drop in phase 2, the phase 4 overshoot) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>The systolic and diastolic blood pressure change in response to tilt table testing or active standing </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Tests of sympathetic cholinergic function</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Quantitative sudomotor axon reflex testing (QSART) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Thermoregulatory sweat testing (TST) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Sympathetic skin response (SSR) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Direct assessment of cardiac autonomic integrity by scintigraphic imaging</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal autonomic testing</td> </tr> <tr> <td class=\"indent1\">Gastric emptying scintigraphy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Isotope-based breath test</td> </tr> <tr> <td class=\"subtitle1_single\">Urologic autonomic function testing</td> </tr> <tr> <td class=\"indent1\">Post-void residual</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Urodynamic studies</td> </tr> <tr> <td class=\"subtitle1_single\">Pupillary autonomic function testing</td> </tr> <tr> <td class=\"indent1\">Pupillometry</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66386 Version 4.0</div></div></div>"},"66387":{"type":"graphic_algorithm","displayName":"Dx esophageal chest pain","title":"Approach to the patient with unexplained chest pain","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Approach to the patient with unexplained chest pain</div><div class=\"cntnt\"><img style=\"width:672px; height:422px;\" src=\"images/GAST/66387_Dx_esophageal_chest_pain.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease; DES: diffuse esophageal spasm; LES: lower esophageal sphincter.<br />* Combined impedance-pH monitoring, if available.</div><div id=\"graphicVersion\">Graphic 66387 Version 2.0</div></div></div>"},"66388":{"type":"graphic_diagnosticimage","displayName":"Lymphoma bone MRI","title":"Lymphoma of bone on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoma of bone on MRI</div><div class=\"cntnt\"><img style=\"width:292px; height:350px;\" src=\"images/HEME/66388_Lymphoma_bone_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging (MRI)&nbsp;of the tibial bones following Gadolinium contrast shows abnormal signal intensity in the proximal right tibia, involving the entire intramedullary space (arrow). There is no involvement of the other tibia. Biopsy showed transformed follicular non-Hodgkin lymphoma.</div><div class=\"graphic_reference\">Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.</div><div id=\"graphicVersion\">Graphic 66388 Version 3.0</div></div></div>"},"66390":{"type":"graphic_table","displayName":"Allergen avoidance trials","title":"Controlled trials of allergen avoidance that have achieved prolonged decrease in mite allergen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Controlled trials of allergen avoidance that have achieved prolonged decrease in mite allergen</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Authors</td> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Avoidance</td> <td class=\"subtitle1\">Active/controls </td> <td class=\"subtitle1\">Decrease in mite</td> <td class=\"subtitle1\">Primary outcome(s)</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Murray AB, Ferguson AC.</p> Pediatrics 1983; 71:418.</td> <td>One year</td> <td>Physical barriers</td> <td>10/10</td> <td>++</td> <td>BHR*</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Carswell et al.</p> Clin Exp Allergy 1996; 26:386.</td> <td>Six months</td> <td>Physical barriers + Acarosan</td> <td>24/25</td> <td>+</td> <td> <p>Peak flow<sup>&#182;</sup></p> BHR<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Ehnert B, et al.</p> J Allergy Clin Immunol 1992; 90:135.</td> <td>One year</td> <td>Physical barriers + tannic acid</td> <td>8/16</td> <td>++</td> <td>BHR*</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Walshaw MJ, Evans CC.</p> Q J Med 1986; 58:199.</td> <td>One year</td> <td>Physical barriers</td> <td>22/20</td> <td>++</td> <td>PEFR/BHR*</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Halken et al.</p> J Allergy Clin Immunol 1997; 99:S320.</td> <td>One year</td> <td>Physical barriers</td> <td>28/24</td> <td>++</td> <td> <p>PEFR*</p> BHR<sup>&#916;</sup></td> </tr> <tr> <td> <p>Htut T, et al.</p> J Allergy Clin Immunol 2001; 107:55.</td> <td>One year</td> <td>Dry heat and steam cleaning</td> <td>20/10</td> <td>++</td> <td>BHR<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BHR: bronchial hyperreactivity; PEFR: peak expiratory flow rate.<br /><STRONG>Improvement:</STRONG><br />* Highly significant.<br />¶&nbsp;Improved, but not significant.<br />Δ Significant.</div><div id=\"graphicVersion\">Graphic 66390 Version 4.0</div></div></div>"},"66393":{"type":"graphic_figure","displayName":"Allergic child","title":"Allergic child","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Allergic child</div><div class=\"cntnt\"><img style=\"width:524px; height:332px;\" src=\"images/RHEUM/66393_Allergicchild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of a four-year-old allergic child with \"allergic shiners,\" mouth breathing, and \"adenoid facies.\" The features of adenoid facies include a long, narrow face; narrow, upturned nose; short upper lip; exposed upper incisors; receded lower jaw; and forward head posture. </div><div id=\"graphicVersion\">Graphic 66393 Version 4.0</div></div></div>"},"66395":{"type":"graphic_table","displayName":"Case studies of FUO II","title":"Case studies of fever of unknown origin: prevalent diagnoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Case studies of fever of unknown origin: prevalent diagnoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Diagnosis</td> <td class=\"subtitle1\" colspan=\"6\">Case study</td> </tr> <tr> <td class=\"subtitle2\"> <p>Alt</p> <p>1913 to 1930</p> <p>n = 23</p> </td> <td class=\"subtitle2\"> <p>Petersdorf</p> <p>1952 to 1959</p> <p>n = 93</p> </td> <td class=\"subtitle2\"> <p>de Kleijn</p> <p>1992 to 1994</p> <p>n = 117</p> </td> <td class=\"subtitle2\"> <p>Vanderschueren</p> <p>1990 to 1999</p> <p>n = 192</p> </td> <td class=\"subtitle2\"> <p>Miller</p> <p>1989 to 1993</p> <p>n = 72</p> </td> <td class=\"subtitle2\"> <p>Knockaert</p> <p>1980 to 1989</p> <p>n = 41</p> </td> </tr> <tr> <td>Location</td> <td>Boston, United States</td> <td>Seattle, United States</td> <td>Netherlands</td> <td>Belgium</td> <td>London, United Kingdom</td> <td>Belgium</td> </tr> <tr> <td>Rheumatic fever</td> <td>2</td> <td>6</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Abdominal abscess</td> <td>1</td> <td>4</td> <td>4</td> <td>5</td> <td>0</td> <td>5</td> </tr> <tr> <td>Endocarditis</td> <td>0</td> <td>5</td> <td>4</td> <td>11</td> <td>0</td> <td>2</td> </tr> <tr> <td>Syphilis</td> <td>1</td> <td>1</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Mycobacterial</td> <td>6</td> <td>12</td> <td>3</td> <td>8</td> <td>57</td> <td>15</td> </tr> <tr> <td>Lymphoma</td> <td>2</td> <td>8</td> <td>11</td> <td>14</td> <td>7</td> <td>5</td> </tr> <tr> <td>Solid tumor</td> <td>3</td> <td>10</td> <td>7</td> <td>7</td> <td>1</td> <td>7</td> </tr> <tr> <td>Sarcoid</td> <td>0</td> <td>2</td> <td>2</td> <td>10</td> <td>0</td> <td>2</td> </tr> <tr> <td>Lupus</td> <td>0</td> <td>5</td> <td>2</td> <td>8</td> <td>0</td> <td>0</td> </tr> <tr> <td>Rheumatoid arthritis</td> <td>0</td> <td>0</td> <td>2</td> <td>2</td> <td>0</td> <td>5</td> </tr> <tr> <td>Giant cell arteritis</td> <td>0</td> <td>2</td> <td>4</td> <td>11</td> <td>0</td> <td>19</td> </tr> <tr> <td>Drug fever</td> <td>0</td> <td>1</td> <td>3</td> <td>4</td> <td>0</td> <td>7</td> </tr> <tr> <td>Factitious fever</td> <td>0</td> <td>3</td> <td>2</td> <td>1</td> <td>3</td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Numbers represent number of cases.</div><div class=\"graphic_reference\">Alt H, et al. JAMA 1930; 94:1457. Petersdorf RG. Arch Intern Med 1992; 152:21. de Kleijn EM, et al. Medicine (Baltimore) 1997; 76:392. Vanderschueren S, et al. Arch Intern Med 2003; 163:1033. Miller RF, et al. Int J STD AIDS 1996; 7:170. Knockaert DC, et al. Clin Infect Dis 1994; 18:601.</div><div id=\"graphicVersion\">Graphic 66395 Version 5.0</div></div></div>"},"66396":{"type":"graphic_table","displayName":"Smallpox vaccine complications","title":"Complications of smallpox vaccination after 14.2 million doses in the 1968 United States National Surveillance Study","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of smallpox vaccination after 14.2 million doses in the 1968 United States National Surveillance Study</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Primary (N = 5.6 million)</td>\n\n      <td class=\"subtitle1\">Secondary (N = 8.6 million)</td>\n\n      <td class=\"subtitle1\">Contacts</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Total complications</td>\n\n      <td>418 (6 deaths)</td>\n\n      <td>40 (2 deaths)</td>\n\n      <td>114 (1 death)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Postvaccine encephalitis</td>\n\n      <td>16 (4 deaths)</td>\n\n      <td>0</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Progressive vaccinia (vaccinia necrosum)</td>\n\n      <td>5 (2 deaths)</td>\n\n      <td>6 (2 deaths)</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Eczema vaccinatum </td>\n\n      <td>58</td>\n\n      <td>8</td>\n\n      <td>60 (1 death)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Generalized vaccinia</td>\n\n      <td>131</td>\n\n      <td>10</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Accidental inoculation</td>\n\n      <td>142</td>\n\n      <td>7</td>\n\n      <td>44</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Other</td>\n\n      <td>66</td>\n\n      <td>9</td>\n\n      <td>8</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from Lane JM, Ruben FL, Neff JM, Millar JD. N Engl J Med 1969; 281:1201.</div><div id=\"graphicVersion\">Graphic 66396 Version 2.0</div></div></div>"},"66398":{"type":"graphic_table","displayName":"Survival by T and N stg","title":"Survival of paranasal sinus cancer according to tumor site and T and N stage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival of paranasal sinus cancer according to tumor site and T and N stage</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Tumor site\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\" colspan=\"2\">\r\n \r\n Maxillary sinus<sup>[1]</sup>\r\n \r\n </td>\r\n\r\n <td class=\"subtitle1\" colspan=\"2\">\r\n \r\n Maxillary sinus<sup>[2]</sup>\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\" colspan=\"2\">\r\n \r\n Ethmoid sinus<sup>[1]</sup>\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2\">\r\n \r\n Characteristic\r\n \r\n </td>\r\n \r\n <td class=\"subtitle2\">\r\n \r\n N (n = 399)\r\n \r\n </td>\r\n \r\n <td class=\"subtitle2\">\r\n \r\n 5-year OS\r\n \r\n </td>\r\n\r\n <td class=\"subtitle2\">\r\n \r\n N (n = 650)\r\n \r\n </td>\r\n \r\n <td class=\"subtitle2\">\r\n \r\n 5-year OS\r\n \r\n </td>\r\n \r\n <td class=\"subtitle2\">\r\n \r\n N (n = 704)\r\n \r\n </td>\r\n \r\n <td class=\"subtitle2\">\r\n \r\n 5-year OS\r\n \r\n </td>\r\n \r\n\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle3_left\" colspan=\"7\">\r\n \r\n AJCC-UICC 2002 classification\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n T1\r\n \r\n </td>\r\n \r\n <td>0</td>\r\n \r\n <td>NE</td>\r\n\r\n <td>80</td>\r\n \r\n <td>51.6</td>\r\n \r\n <td>27</td>\r\n \r\n <td>53.2</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n T2\r\n \r\n </td>\r\n \r\n <td>156</td>\r\n \r\n <td>61.7</td>\r\n\r\n <td>63</td>\r\n \r\n <td>41.8</td>\r\n \r\n <td>46</td>\r\n \r\n <td>60.3</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n T3\r\n \r\n </td>\r\n \r\n <td>37</td>\r\n \r\n <td>50.5</td>\r\n\r\n <td>169</td>\r\n \r\n <td>39.8</td>\r\n \r\n <td>85</td>\r\n \r\n <td>48.2</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n T4a/b\r\n \r\n </td>\r\n \r\n <td>206</td>\r\n \r\n <td>35.9</td>\r\n\r\n <td>335</td>\r\n \r\n <td>28.9</td>\r\n \r\n <td>147</td>\r\n \r\n <td>35.4</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n Not assigned\r\n \r\n </td>\r\n \r\n <td>&nbsp;</td>\r\n \r\n <td>&nbsp;</td>\r\n\r\n <td>3</td>\r\n \r\n <td>NE</td>\r\n \r\n <td>&nbsp;</td>\r\n \r\n <td>&nbsp;</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle3_left\" colspan=\"7\">\r\n \r\n Nodal status\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n N0\r\n \r\n </td>\r\n \r\n <td>366</td>\r\n \r\n <td>50.6</td>\r\n\r\n <td>323</td>\r\n \r\n <td>40.1</td>\r\n \r\n <td>300</td>\r\n \r\n <td>45.3</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n N+\r\n \r\n </td>\r\n \r\n <td>33</td>\r\n \r\n <td>16.8</td>\r\n\r\n <td>&nbsp;</td>\r\n \r\n <td>&nbsp;</td>\r\n \r\n <td>5</td>\r\n \r\n <td>0</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n N1\r\n \r\n </td>\r\n \r\n <td>23</td>\r\n \r\n <td>NE</td>\r\n\r\n <td>16</td>\r\n \r\n <td>35.7</td>\r\n \r\n <td>3</td>\r\n \r\n <td>NE</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n N2\r\n \r\n </td>\r\n \r\n <td>9</td>\r\n \r\n <td>NE</td>\r\n\r\n <td>31</td>\r\n \r\n <td>0</td>\r\n \r\n <td>2</td>\r\n \r\n <td>NE</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n N3\r\n \r\n </td>\r\n \r\n <td>1</td>\r\n \r\n <td>NE</td>\r\n\r\n <td>1</td>\r\n \r\n <td>NE</td>\r\n \r\n <td>0</td>\r\n \r\n <td>NE</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent2\">\r\n \r\n Not assigned\r\n \r\n </td>\r\n \r\n <td>&nbsp;</td>\r\n \r\n <td>&nbsp;</td>\r\n\r\n <td>279</td>\r\n \r\n <td>NE</td>\r\n \r\n <td>&nbsp;</td>\r\n \r\n <td>&nbsp;</td>\r\n \r\n </tr>\r\n </table></div><div class=\"graphic_footnotes\">N: number of patients; NE: not estimated; OS: overall survival; PNS: paranasal sinuses (including maxillary, ethmoid, sphenoid, and frontal sinuses; esthesioneuroblastoma excluded).</div><div class=\"graphic_reference\">Data from:<br>1. Cantu, G, et al. Arch Otolaryngol Head Neck Surg 2008; 134:170.<br>2. Bhattacharyya, N. J Oral Maxillofac Surg 2003; 61:1016.</div><div id=\"graphicVersion\">Graphic 66398 Version 1.0</div></div></div>"},"66400":{"type":"graphic_picture","displayName":"Rickets bow-legs 2","title":"Bow-legs in rickets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bow-legs in rickets</div><div class=\"cntnt\"><img style=\"width:252px; height:207px;\" src=\"images/PEDS/66400_Rickets_bow-legs_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral, symmetric bowing of the femurs and tibias.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 66400 Version 1.0</div></div></div>"},"66401":{"type":"graphic_algorithm","displayName":"Diagnostic approach to acute respiratory distress in children","title":"Diagnostic approach to acute respiratory distress in children","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to acute respiratory distress in children</div><div class=\"cntnt\"><img style=\"width:619px; height:805px;\" src=\"images/EM/66401_Acute_resp_distress.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BS: breath sounds; CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 66401 Version 5.0</div></div></div>"},"66402":{"type":"graphic_figure","displayName":"Distal clavicle fracture type III","title":"Distal clavicle fracture type III","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal clavicle fracture type III</div><div class=\"cntnt\"><img style=\"width:418px; height:383px;\" src=\"images/EM/66402_Clav_fx_dist_type3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts a type III distal clavicle fracture, involving only the articular surface of the acromioclavicular joint. No ligamentous disruption or displacement occurs. These fractures present as late degenerative changes of the joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Rockwood CA Jr, Green DP, Bucholz RW, Heckman JD (Eds). Rockwood and Green's Fractures in Adults, 4th ed, Lippincott-Raven, Philadelphia 1996. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66402 Version 4.0</div></div></div>"},"66403":{"type":"graphic_diagnosticimage","displayName":"Cystic thyroid nodule US","title":"Complex cystic thyroid nodule: Appearance on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complex cystic thyroid nodule: Appearance on ultrasound</div><div class=\"cntnt\"><img style=\"width:228px; height:210px;\" src=\"images/ENDO/66403_Cystic_thyroid_nodule_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound picture of a complex cystic thyroid nodule showing a degenerating adenoma (arrow) in the wall of the cyst.</div><div class=\"graphic_reference\">Courtesy Douglas Ross, MD.</div><div id=\"graphicVersion\">Graphic 66403 Version 3.0</div></div></div>"},"66404":{"type":"graphic_table","displayName":"Marrow asp bx indications","title":"Indications for bone marrow aspiration and biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for bone marrow aspiration and biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Unexplained anemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Macrocytic anemia (to distinguish megaloblastic from normoblastic&nbsp; maturation)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Unexplained leukopenia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unexplained thrombocytopenia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pancytopenia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Presence of blasts on peripheral smear (investigation for possible leukemia)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Presence of teardrop red cells on peripheral smear (possible myelofibrosis)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Presence of hairy cells on peripheral smear (possible hairy cell leukemia)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Suspected multiple myeloma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Staging of non-Hodgkin's lymphoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unexplained splenomegaly (possible lymphoma)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Suspected storage disease (eg, Gaucher disease, Niemann-Pick)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fever of unknown origin</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Suspected chromosomal disorders in neonates (requiring rapid confirmation)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Confirmation of normal marrow in potential allogeneic donor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Work-up of amyloidosis (to detect clonal plasma cell disorder)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 66404 Version 1.0</div></div></div>"},"66405":{"type":"graphic_table","displayName":"Gamblers anonymous survey","title":"Gamblers Anonymous 20 question survey","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gamblers Anonymous 20 question survey</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>1. Did you ever lose time from work due to gambling?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. Has gambling ever made your home life unhappy?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3. Did gambling ever affect your reputation?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4. Have you ever felt remorse after gambling?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5. Did you ever gamble to get money with which to pay debts or otherwise solve financial difficulties?</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>6. Did gambling cause a decrease in your ambition or efficiency?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>7. After losing, did you feel you must return as soon as possible and win back your losses?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>8. After a win, did you have a strong urge to return and win more?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>9. Did you often gamble until your lasts dollar was gone?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>10. Did you ever borrow to finance your gambling?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>11. Have you ever sold anything to finance your gambling?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>12. Were you reluctant to use gambling money for normal expenditures?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>13. Did gambling make you careless of yourself or your family?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>14. Have you ever gambled longer than you planned?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>15. Have you ever gambled to escape worry and trouble?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>16. Have you ever committed or considered committing an illegal act to finance gambling?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>17. Has gambling caused you to have difficulty in sleeping?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>18. Have arguments, disappointment, or frustrations caused you to gamble?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>19. Have you had an urge to celebrate any good fortune with a few hours of gambling?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>20. Have you ever considered self-destruction as a result of your gambling?</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Seven or more positive responses suggest pathologic gambling.</div><div class=\"graphic_reference\">Data from Gamblers Anonymous International Service Office, Los Angeles, CA.</div><div id=\"graphicVersion\">Graphic 66405 Version 1.0</div></div></div>"},"66406":{"type":"graphic_figure","displayName":"Muscle fiber type VO2 in HF","title":"Changes in muscle fiber type in HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Changes in muscle fiber type in HF</div><div class=\"cntnt\"><img style=\"width:297px; height:414px;\" src=\"images/CARD/66406_Muscle_fiber_type_VO2_in_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scatter plots show a significant direct correlation (p</div><div class=\"graphic_reference\">Data from: Mancini, DM, Coyle, E, Coggan, A, et al. Circulation 1989; 80:1338.</div><div id=\"graphicVersion\">Graphic 66406 Version 1.0</div></div></div>"},"66408":{"type":"graphic_diagnosticimage","displayName":"Pneumatic dilation fluoroscopy - balloon inflation","title":"Pneumatic dilation for the treatment of achalasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumatic dilation for the treatment of achalasia</div><div class=\"cntnt\"><img style=\"width:302px; height:559px;\" src=\"images/GAST/66408_Pneumatic_dilation_fluoro_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Arrows indicate the &quot;waist&quot; of the balloon as it is being insufflated with air and pre-injected with water-soluble contrast.<br> (B) Obliteration of the waist with the balloon fully inflated.</div><div class=\"graphic_reference\">Courtesy of Linda Nguyen, MD.</div><div id=\"graphicVersion\">Graphic 66408 Version 5.0</div></div></div>"},"66409":{"type":"graphic_picture","displayName":"Hemihyperplasia in a patient with Beckwith-Wiedemann syndrome","title":"Hemihyperplasia in a patient with Beckwith-Wiedemann syndrome","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Hemihyperplasia in a patient with Beckwith-Wiedemann syndrome</div><div class=\"cntnt\"><img style=\"width:514px; height:327px;\" src=\"images/ALLRG/66409_Hemihyperplasia_BW_syndr.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66409 Version 1.0</div></div></div>"},"66410":{"type":"graphic_picture","displayName":"Acne scars","title":"Acne scars","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acne scars</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/66410_Acne_scars.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pitted scars due to acne vulgaris are present on the cheek and mandible.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66410 Version 3.0</div></div></div>"},"66411":{"type":"graphic_waveform","displayName":"EEG generalized periodic discharges","title":"Generalized periodic discharges (GPDs)","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Generalized periodic discharges (GPDs)</div><div class=\"cntnt\"><img style=\"width:544px; height:357px;\" src=\"images/NEURO/66411_GPEDS.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol 2005; 22:79. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66411 Version 12.0</div></div></div>"},"66412":{"type":"graphic_figure","displayName":"Repair of 4th degree laceration","title":"Repair of a fourth-degree obstetric laceration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of a fourth-degree obstetric laceration</div><div class=\"cntnt\"><img style=\"width:400px; height:588px;\" src=\"images/OBGYN/66412_Repair_4th_laceration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A. 4th degree laceration B. The torn anal mucosa is repaired using a running stitch, but interrupted stitches are also acceptable. C. The internal anal sphincter should be properly identified and repaired as a separate layer. D. The external sphincter is then identified and repaired. The repair consists of either end-to-end or overlapping plication of the disrupted external anal sphincter and capsule using interrupted or figure-of-eight sutures.</div><div id=\"graphicVersion\">Graphic 66412 Version 2.0</div></div></div>"},"66413":{"type":"graphic_figure","displayName":"Digestive organ development","title":"Development of the digestive organs","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Development of the digestive organs</div><div class=\"cntnt\"><img style=\"width:556px; height:757px;\" src=\"images/PEDS/66413_Digest_organ_devel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Origin of the accessory organs of digestion.<br> (A-B) The accessory organs of digestion (liver, gallbladder, and pancreas) first emerge as buds of the foregut tube in the space provided by the ventral mesentery.<br> (C-E) As the organs enlarge and move, the foregut mesentery goes with them and persists in the same way that the dorsal mesentery does.</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler TW. Langman's Medical Embryology, 10th Edition. Baltimore: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66413 Version 3.0</div></div></div>"},"66414":{"type":"graphic_table","displayName":"Enhanced elimination drugs and toxins","title":"Intoxications in which enhanced elimination techniques may be used","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intoxications in which enhanced elimination techniques may be used</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Ion Trapping</td></tr>\n\t\t\t\t\t\t<tr><td>Aspirin</td></tr>\n\t\t\t\t\t\t<tr><td>Phenobarbital</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Multi-dose Charcoal</td></tr>\n\t\t\t\t\t\t<tr><td>Phenobarbital</td></tr>\n\t\t\t\t\t\t<tr><td>Dapsone</td></tr>\n\t\t\t\t\t\t<tr><td>Aspirin</td></tr>\n\t\t\t\t\t\t<tr><td>Quinine/quinidine</td></tr>\n\t\t\t\t\t\t<tr><td>Theophylline</td></tr>\n\t\t\t\t\t\t<tr><td>Carbamazepine</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Hemodialysis</td></tr>\n\t\t\t\t\t\t<tr><td>Ethylene glycol</td></tr>\n\t\t\t\t\t\t<tr><td>Methanol</td></tr>\n\t\t\t\t\t\t<tr><td>Isopropyl alcohol</td></tr>\n\t\t\t\t\t\t<tr><td>Ethanol</td></tr>\n\t\t\t\t\t\t<tr><td>Aspirin</td></tr>\n\t\t\t\t\t\t<tr><td>Theophylline</td></tr>\n\t\t\t\t\t\t<tr><td>Phenobarbital</td></tr>\n\t\t\t\t\t\t<tr><td>Lithium</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Hemoperfusion</td></tr>\n\t\t\t\t\t\t<tr><td>Theophylline</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Chelation</td></tr>\n\t\t\t\t\t\t<tr><td>Iron</td></tr>\n\t\t\t\t\t\t<tr><td>Mercury</td></tr>\n\t\t\t\t\t\t<tr><td>Lead</td></tr>\n\t\t\t\t\t\t<tr><td>Arsenic</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 66414 Version 2.0</div></div></div>"},"66415":{"type":"graphic_table","displayName":"Poisoning home survey","title":"Poisoning prevention home survey","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Poisoning prevention home survey</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Area</td> <td class=\"subtitle1\">Preventive approaches</td> </tr> <tr> <td rowspan=\"5\">Kitchen</td> <td>Store detergents, oven cleaners, and drain cleaners on higher shelves.</td> </tr> <tr> <td>Store safe items in cabinets and drawers that are within the child's reach.</td> </tr> <tr> <td>Install child-guard latches on cabinet doors and drawers that contain dangerous items.</td> </tr> <tr> <td>Avoid storage of chemicals in the refrigerator.</td> </tr> <tr> <td>Do not use insecticides, traps, or baits in locations to which children have access.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Bathroom</td> <td>Store medications out of sight and out of reach, preferably in a locked cabinet, box, or closet.</td> </tr> <tr> <td>Store perfumes, colognes, cosmetics, and hair care products out of sight and out of reach (eg, on upper shelves or in locked containers).</td> </tr> <tr> <td>Do not use insecticides, traps, or baits in locations to which children have access.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Bedrooms</td> <td>Store medications and contraceptives out of sight and out of reach, preferably in a locked cabinet, box, or closet.</td> </tr> <tr> <td>Store perfumes, colognes, cosmetics, and hair care products out of sight and out of reach (eg, on upper shelves or in locked containers).</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Living and dining rooms</td> <td>Remove toxic plants or keep them out of reach.</td> </tr> <tr> <td>Keep tobacco products, lighters, and matches out of sight and out of reach. This includes electronic cigarettes and nicotine refill cartridges.</td> </tr> <tr> <td>Keep alcohol in a locked cabinet; dispose of partially consumed drinks.</td> </tr> <tr class=\"divider_top\"> <td>Laundry</td> <td>Keep cleaning supplies out of reach.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Garage/basement</td> <td>Store paints, solvents, insecticides, herbicides, and chemicals for use in hobbies in locked cabinets; always store these materials in the original containers.</td> </tr> <tr> <td>Do not use insecticides, traps, or baits in locations to which children have access.</td> </tr> <tr> <td>Install a carbon monoxide detector.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Outdoor areas</td> <td>Identify toxic plants, berries, and bulbs.</td> </tr> <tr> <td>Do not leave unplanted bulbs in areas to which children have access.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Miscellaneous</td> <td>Check and secure (with tape) battery compartments on household products.</td> </tr> <tr> <td>Store batteries out of the reach and sight of children.</td> </tr> <tr> <td>Do not allow children to play with batteries.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Committee on Injury and Poison Prevention, American Academy of Pediatrics. Injury prevention in and around the home. In: Injury Prevention and Control for Children and Youth. American Academy of Pediatrics, Elk Grove Village, IL 1997. p.47. </LI>&#xD;&#xA;<LI>Litovitz T, Whitaker N, Clark L. Preventing battery ingestions: An analysis of 8648 cases. Pediatrics 2010; 125:1178. </LI></OL></div><div id=\"graphicVersion\">Graphic 66415 Version 5.0</div></div></div>"},"66416":{"type":"graphic_diagnosticimage","displayName":"Coats disease","title":"Coats disease","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Coats disease</div><div class=\"cntnt\"><img style=\"width:488px; height:596px;\" src=\"images/PEDS/66416_Retinal_detachment_Coats.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The retinal photograph depicts bullous retinal detachment in the left eye of a 1-year-old child with Coats disease simulating retinoblastoma. The magnetic resonance images confirm the diagnosis of retinal detachment and exclude retinoblastoma because of the absence of an intraocular mass.</div><div class=\"graphic_reference\">Courtesy of Richard A Saunders, MD.</div><div id=\"graphicVersion\">Graphic 66416 Version 4.0</div></div></div>"},"66417":{"type":"graphic_figure","displayName":"Course of type 1 diabetes","title":"Time course of type 1 diabetes mellitus","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Time course of type 1 diabetes mellitus</div><div class=\"cntnt\"><img style=\"width:507px; height:290px;\" src=\"images/ENDO/66417_CourseofIDDM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time course of the development of type 1 diabetes. Genetic markers are present from birth, immune markers first appear at the time of the environmental triggering events, and sensitive metabolic markers of deficient insulin secretion begin to appear soon after the onset of beta cell dysfunction. However, clinically evident type 1 diabetes does not occur until there has been a much greater loss of functioning beta cell mass.</div><div id=\"graphicVersion\">Graphic 66417 Version 3.0</div></div></div>"},"66419":{"type":"graphic_figure","displayName":"Iron deficiency testing","title":"Testing for iron deficiency","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Testing for iron deficiency</div><div class=\"cntnt\"><img style=\"width:457px; height:399px;\" src=\"images/HEME/66419_Iron_deficiency_testing.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Receiver operating characteristic (ROC) curves showing the sensitivity and specificity of various tests for the diagnosis of iron deficiency [ferritin, red cell protoporphyrin, transferrin saturation, mean red cell volume (MCV), and red cell volume distribution width (RDW)]. Note that, at any given level of sensitivity or specificity, serum ferritin outperforms all the other tests shown.</div><div class=\"graphic_reference\">Data from from Guyatt GH, et al, J Gen Intern Med. 1992; 7:145.</div><div id=\"graphicVersion\">Graphic 66419 Version 2.0</div></div></div>"},"66420":{"type":"graphic_figure","displayName":"Attenuation of PET emission","title":"Nonuniform photon attenuation and tissue electron density","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonuniform photon attenuation and tissue electron density</div><div class=\"cntnt\"><img style=\"width:322px; height:214px;\" src=\"images/PULM/66420_Attenuation_of_PET_emission.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cartoon depicting the thorax containing tissues of varying electron densities. The emitted photons must therefore traverse some regions with a potential to decrease the activity detected by the gamma camera.</div><div id=\"graphicVersion\">Graphic 66420 Version 2.0</div></div></div>"},"66421":{"type":"graphic_diagnosticimage","displayName":"M-mode cardiomyopathy II","title":"M-mode echocardiogram of cardiomyopathy compared with normal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of cardiomyopathy compared&nbsp;with normal</div><div class=\"cntnt\"><img style=\"width:447px; height:332px;\" src=\"images/CARD/66421_MmodecardiomyopathyII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal M-modes of the minor axis of the left ventricle are taken along the line (Mp) superimposed on the anatomical diagram in panel A. Panel B is from a normal patient and panel C is from a patient with cardiomyopathy. The minor axis dimension of the normal left ventricle (LV) at the end of systole (LVESd) is 5.2 cm compared&nbsp;with 6.3 cm in the patient with cardiomyopathy; the LV end diastolic dimensions (LVEDd) are 3.4 and 5.3 cm, respectively. The fractional shortening of the normal heart (LVEDd - LVESd / LVEDd) is 35 percent) is compared&nbsp;with 16 percent for that of the heart with cardiomyopathy. Panels D and E are M-mode echocardiograms obtained from a level nearer to the LV base, and the beam is passed through the mitral valve. In the normal heart (panel D), the mitral valve (MV) opens widely, very near to the septum (S); in the cardiomyopathic heart, MV opening is reduced, due to a low stroke volume, and it is separated from the septum by nearly 2 cm; this separation is called E point mitral-septal separation, or EPSS.</div><div class=\"graphic_footnotes\">RV: right ventricle; IVS: interventricular septum; PM: papillary muscle; PML: posterior mitral valve leafet; AML: anterior mitral valve leaflet; Ao: aorta; LVW: left ventricular posterior wall.</div><div id=\"graphicVersion\">Graphic 66421 Version 5.0</div></div></div>"},"66422":{"type":"graphic_picture","displayName":"Mediastinal seminoma I Low","title":"Mediastinal seminoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal seminoma</div><div class=\"cntnt\"><img style=\"width:360px; height:230px;\" src=\"images/PULM/66422_Mediastinal_seminoma_I_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph shows discohesive cells with abundant cytoplasm, vesicular nuclei, and prominent nucleoli surrounded by numerous lymphocytes (hematoxylin and eosin, magnification 50x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 66422 Version 2.0</div></div></div>"},"66423":{"type":"graphic_picture","displayName":"Balance walk","title":"Balance exercises: Balance walk","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balance exercises: Balance walk</div><div class=\"cntnt\"><img style=\"width:374px; height:306px;\" src=\"images/PC/66423_Balance_walk_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Good balance helps you walk safely and avoid tripping and falling over objects in your way.   <OL>  <LI>Raise arms to sides, shoulder height. </LI>  <LI>Choose a spot ahead of you and focus on it to keep you steady as you walk. </LI>  <LI>Walk in a straight line with one foot in front of the other. </LI>  <LI>As you walk, lift your back leg. Pause for one second before stepping forward. </LI>  <LI>Repeat for 20 steps, alternating legs. </LI></OL>As you progress, try looking from side to side as you walk, but skip this step if you have inner ear problems.</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 66423 Version 3.0</div></div></div>"},"66425":{"type":"graphic_algorithm","displayName":"Emergency department approach to chest pain","title":"Emergency department approach to chest pain","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Emergency department approach to chest pain</div><div class=\"cntnt\"><img style=\"width:601px; height:794px;\" src=\"images/EM/66425_Chest_pain_ED_appr_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACS: acute coronary syndrome; ASA: aspirin; CXR: chest x-ray; ECG: electrocardiogram; HF: heart failure; PCI: percutaneous coronary intervention.</div><div id=\"graphicVersion\">Graphic 66425 Version 3.0</div></div></div>"},"66427":{"type":"graphic_figure","displayName":"FALDH catalytic pathway","title":"FALDH catalytic pathway","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">FALDH catalytic pathway</div><div class=\"cntnt\"><img style=\"width:522px; height:480px;\" src=\"images/NEURO/66427_FALDH_catalytic_pathway_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FALDH catalyzes the oxidation of long-chain fatty aldehydes (here, octadecanal) to the corresponding carboxylic acid.</div><div class=\"graphic_footnotes\">FALDH: fatty aldehyde dehydrogenase.</div><div class=\"graphic_reference\">Reproduced with permission from: Willemsen, MA, Van Der, Graaf M, Van Der, Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004; 25:649. Copyright &#169; 2004 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 66427 Version 3.0</div></div></div>"},"66428":{"type":"graphic_table","displayName":"Disorders with lentigines","title":"Disorders associated with multiple lentigines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders associated with multiple lentigines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Genetics</td> <td class=\"subtitle1\">Features of lentigines</td> <td class=\"subtitle1\">Other manifestations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Generalized</td> </tr> <tr> <td class=\"indent1\">LEOPARD (multiple lentigines) syndrome</td> <td> <p>AD</p> <p><em>PTPN11</em> (nonreceptor protein tyrosine phosphatase)</p> </td> <td> <p>Onset in infancy/early childhood</p> <p>Generalized</p> <p>Spare oral mucosa</p> <p>Also caf&#233;-noir and caf&#233;-au-lait macules</p> </td> <td> <p>Electrocardiogram changes</p> <p>Ocular hypertelorism</p> <p>Pulmonary stenosis, hypertrophic obstructive cardiomyopathy</p> <p>Abnormal genitalia</p> <p>Retardation of growth or mental retardation</p> <p>Deafness</p> <p>Also triangular facies, skeletal abnormalities</p> </td> </tr> <tr> <td class=\"indent1\">Carney complex (NAME/LAMB syndrome)</td> <td> <p>AD</p> <p><em>PRKAR1A</em> (type 1-alpha regulatory subunit of protein kinase A)</p> </td> <td> <p>Onset in early childhood, but the full distribution is not seen until puberty</p> <p>Generalized</p> <p>May involve eyelids, conjunctiva, vermilion border of lips, genitals</p> <p>Usually spare oral mucosa</p> </td> <td> <p>Atrial myxomas</p> <p>Mucocutaneous myxomas (often on eyelids, ears, nipples)</p> <p>Blue nevi (epithelioid variant)</p> <p>Pigmented nodular adrenocortical disease</p> <p>Pituitary, thyroid, and testicular (calcifying Sertoli cell) tumors</p> <p>Myxoid mammary fibroadenomas</p> <p>Psammomatous melanotic schwannomas</p> </td> </tr> <tr> <td class=\"indent1\">Arterial dissection</td> <td>AD versus AR</td> <td> <p>Onset in childhood</p> <p>Generalized</p> </td> <td>Dissection of aortic, internal carotid, and vertebral arteries</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Localized</td> </tr> <tr> <td class=\"indent1\">Peutz-Jeghers syndrome</td> <td> <p>AD</p> <p><em>STK11</em> (serine/threonine protein kinase 11)</p> </td> <td> <p>Onset in infancy/early childhood</p> <p>Perioral (may fade), oral mucosa (persist), hands, feet</p> <p>Longitudinal melanonychia</p> </td> <td> <p>Multiple hamartomatous gastrointestinal polyps (intussusception may occur)</p> <p>Increased incidence of gastrointestinal, ovarian, cervical (adenoma malignum), pancreatic, and breast cancers</p> </td> </tr> <tr> <td class=\"indent1\">Laugier-Hunziker syndrome</td> <td> <p>AD</p> <p>?</p> </td> <td> <p>As in Peutz-Jeghers</p> <p>Also genital melanosis</p> </td> <td> <p>None</p> <p>May see similar lesions in patients receiving zidovudine (AZT)</p> </td> </tr> <tr> <td class=\"indent1\">Cowden disease</td> <td> <p>AD</p> <p><em>PTEN</em> (phosphatase and tensin homolog)</p> </td> <td> <p>Onset in childhood to young adulthood</p> <p>Periorificial and acral lentigines (occasionally seen)</p> <p>Caf&#233;-au-lait macules</p> </td> <td> <p>Facial trichilemmomas</p> <p>Oral mucosal cobblestoning</p> <p>Acral keratoses</p> <p>Lipomas, sclerotic fibromas</p> <p>Macrocephaly, adenoid facies, mental retardation</p> <p>Thyroid adenomas/carcinoma</p> <p>Breast fibroadenomas/carcinoma</p> <p>Gastrointestinal hamartomas/carcinoma</p> <p>Uterine fibroids/carcinoma</p> </td> </tr> <tr> <td class=\"indent1\">Bannayan-Riley-Ruvalcaba syndrome</td> <td> <p>AD</p> <p><em>PTEN</em> (phosphatase and tensin homolog)</p> </td> <td> <p>Genital melanosis</p> <p>Caf&#233;-au-lait macules</p> </td> <td> <p>Capillary and/or venous malformations</p> <p>Lipomas</p> <p>Facial trichilemmomas</p> <p>Acanthosis nigricans</p> <p>Macrocephaly, mental retardation</p> <p>Gastrointestinal hamartomas</p> <p>Thyroid tumors</p> </td> </tr> <tr> <td class=\"indent1\">Centrofacial lentiginosis</td> <td> <p>AD</p> <p>?</p> </td> <td> <p>Onset in infancy; increase in number in childhood</p> <p>Butterfly distribution on nose and cheeks &#62; forehead, eyelids, upper lip</p> </td> <td> <p>Neuropsychiatric disorders</p> <p>Osseous anomalies</p> </td> </tr> <tr> <td class=\"indent1\">Inherited patterned lentiginosis</td> <td> <p>AD</p> <p>African Americans with light brown skin</p> </td> <td> <p>Central face, lips &#62; buttocks, elbows, hands, feet</p> <p>Usually spare oral mucosa</p> </td> <td>None</td> </tr> <tr> <td class=\"indent1\">Partial unilateral lentiginosis</td> <td>--</td> <td> <p>Onset in childhood, with wavefront extension over time</p> <p>Segmental distribution (no background hyperpigmentation)</p> <p>Often have caf&#233;-au-lait macules in same area</p> <p>Can have ocular lesions</p> </td> <td> <p>May be associated with segmental neurofibromatosis</p> <p>A few reports of associated mental retardation and seizures</p> </td> </tr> <tr> <td class=\"indent1\">Xeroderma pigmentosum</td> <td> <p>AR</p> <p>XP-A through G and variant (abnormal nucleotide excision repair)</p> </td> <td>Favor (but not limited to) sun-exposed sites (represent solar lentigines)</td> <td> <p>Photosensitivity</p> <p>Markedly increased incidence of basal and squamous cell carcinomas and melanoma</p> <p>Also increased incidence of internal malignancies</p> <p>CNS degeneration in a subset of patients</p> </td> </tr> <tr> <td class=\"indent1\">Neurofibromatosis type 1</td> <td> <p>AD</p> <p><em>NFI</em> (neurofibromin)</p> </td> <td> <p>\"Freckling\" (actually represents lentigines) favors flexural sites (neck, axillae, groin), but may be generalized</p> <p>&#8805;6 caf&#233;-au-lait macules (in 80 to 90% of patients)</p> </td> <td> <p>Cutaneous neurofibromas</p> <p>Lisch nodules (iris hamartomas)</p> <p>Optic glioma</p> <p>Distinct bone lesions (eg, sphenoid dysplasia)</p> <p>Macrocephaly</p> <p>Learning disabilities</p> </td> </tr> <tr> <td class=\"indent1\">Legius (neurofibromatosis type 1-like) syndrome</td> <td> <p>AD</p> <p><em>SPRED1</em> (Sprouty-related EVH1 domain containing protein 1)</p> </td> <td> <p>Intertriginous \"freckling\" (actually lentigines) in&nbsp;approximately half of patients</p> <p>&#8805;6 caf&#233;-au-lait macules in &#62;80% of patients</p> </td> <td> <p><strong>Lacks</strong> neurofibromas, Lisch nodules, optic gliomas, and typical osseous lesions of neurofibromatosis type 1</p> <p>Macrocephaly and learning disabilities are common</p> <p>Occasionally lipomas, hypopigmented macules, and vascular anomalies</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LEOPARD: lentigines, electrocardiogram abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural&nbsp;deafness; AD: autosomal dominant; NAME: nevi, atrial myxoma, ephelides; LAMB: lentigines, atrial myxoma, blue nevi;&nbsp;AR: autosomal recessive; CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 66428 Version 6.0</div></div></div>"},"66430":{"type":"graphic_picture","displayName":"Postop sled exstrophy","title":"The use of a sled for traction and immobilization after bladder exstrophy repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The use of a sled for traction and immobilization after bladder exstrophy repair</div><div class=\"cntnt\"><img style=\"width:331px; height:357px;\" src=\"images/PEDS/66430_Postop_sled_exstrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 66430 Version 4.0</div></div></div>"},"66431":{"type":"graphic_figure","displayName":"Red reflex interpretation","title":"Red reflex interpretation","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Red reflex interpretation</div><div class=\"cntnt\"><img style=\"width:614px; height:751px;\" src=\"images/PEDS/66431_Red_reflex_interpretation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red reflex examination.</div><div class=\"graphic_footnotes\">* Welch Allyn Ophthalmoscope #11720.</div><div class=\"graphic_reference\">Reproduced with permission from: Alfred G. Smith, MD. As printed in: Red Reflex Examination in Neonates, Infants, and Children. Pediatrics 2008; 122:1401-1404.</div><div id=\"graphicVersion\">Graphic 66431 Version 2.0</div></div></div>"},"66432":{"type":"graphic_picture","displayName":"Central line fem needle","title":"Aspiration of the common femoral vein in preparation for placement of a central venous catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspiration of the common femoral vein in preparation for placement of a central venous catheter</div><div class=\"cntnt\"><img style=\"width:432px; height:273px;\" src=\"images/EM/66432_Central_line_fem_needle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The common femoral vein lies superficial and medial to the femoral artery. When accessing the vein, orient the needle with the bevel up and introduce it angled 20 to 30 degrees to the skin. Insert the needle 1 to 2 cm inferior to the inguinal ligament and just medial to the femoral artery. The vessel is normally reached within 2 to 4 cm but may be deeper in obese or edematous patients.</div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 66432 Version 2.0</div></div></div>"},"66433":{"type":"graphic_table","displayName":"ASCO DXA in breast ca","title":"ASCO Guidelines for monitoring with DXA scans in women in breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ASCO Guidelines for monitoring with DXA scans in women in breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1_single\">Monitoring indicated for:</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Women over age 65 years</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Women ages 60 to 64 years with the one or more of the following:</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Family history of osteoporosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Low body weight less than 70 kg</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Prior non-traumatic fracture</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Other risk factors such as sedentary, smoking</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Postmenopausal women on AI</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Premenopausal women who develop treatment-related premature menopause</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">ASCO: American Society of Clinical Oncology; AI: aromatase inhibitor.</div><div class=\"graphic_reference\">Reproduced with permission from: Pant, S, Shapiro, CL. Aromatase inhibitor-associated bone loss. Drugs 2008; 68:2591. Copyright &#169;2008 Adis Data Information BV.</div><div id=\"graphicVersion\">Graphic 66433 Version 1.0</div></div></div>"},"66435":{"type":"graphic_diagnosticimage","displayName":"Leptomeningeal lymphoma","title":"Leptomeningeal involvement by non-Hodgkin's lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leptomeningeal involvement by non-Hodgkin's lymphoma</div><div class=\"cntnt\"><img style=\"width:390px; height:503px;\" src=\"images/HEME/66435_Leptomeningeal_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This axial T1 gadolinium-enhanced magnetic resonance imaging shows multifocal leptomeningeal enhancement (red arrows), consistent with lymphomatous involvement.</div><div id=\"graphicVersion\">Graphic 66435 Version 3.0</div></div></div>"},"66436":{"type":"graphic_diagnosticimage","displayName":"Mesothelioma MRI I","title":"Mesothelioma on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mesothelioma on MRI</div><div class=\"cntnt\"><img style=\"width:360px; height:286px;\" src=\"images/PULM/66436_Mesothelioma_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal T1-weighted image shows a multilobular mass in the right paravertebral sulcus (arrow) extending into the minor fissure and along the diaphragm.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66436 Version 3.0</div></div></div>"},"66438":{"type":"graphic_picture","displayName":"Acute Raynaud phenomenon","title":"Raynaud phenomenon","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Raynaud phenomenon</div><div class=\"cntnt\"><img style=\"width:548px; height:299px;\" src=\"images/RHEUM/66438_Acute_Raynaud_phenom_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows sharply demarcated pallor in several fingers resulting from the closure of digital arteries.<br />Panel B shows digital cyanosis of the fingertips resulting from vasoconstriction in the thermoregulatory vessel in the skin.</div><div class=\"graphic_reference\">Courtesy of Fredrick M Wigley, MD.</div><div id=\"graphicVersion\">Graphic 66438 Version 6.0</div></div></div>"},"66439":{"type":"graphic_picture","displayName":"Hemangioma and angiokeratoma","title":"Dermoscopy of hemangioma and angiokeratoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of hemangioma and angiokeratoma</div><div class=\"cntnt\"><img style=\"width:318px; height:546px;\" src=\"images/DERM/66439_Hemangioma_angiokeratoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Red lacunae seen in a hemangioma.<br />(B) Red, blue, and black lacunae seen in an angiokeratoma.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 66439 Version 4.0</div></div></div>"},"66440":{"type":"graphic_picture","displayName":"Brugia timori smear","title":"<EM>Brugia timori </EM>smear","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\"><EM>Brugia timori </EM>smear</div><div class=\"cntnt\"><img style=\"width:543px; height:231px;\" src=\"images/ID/66440_Brugia_timori_smear_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Microfilariae of <em>B. timori</em> in a thick blood smear from a patient from Indonesia, stained with Giemsa and captured at 500x oil magnification. The organism has a sheath (yellow arrow) and two nuclei in its tail (red arrows).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Filariasis. Available at: <A href=\"http://www.cdc.gov/dpdx/lymphaticFilariasis\">http://www.cdc.gov/dpdx/lymphaticFilariasis</A>.</div><div id=\"graphicVersion\">Graphic 66440 Version 5.0</div></div></div>"},"66441":{"type":"graphic_diagnosticimage","displayName":"Ankle mortise","title":"Normal mortise view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal mortise view</div><div class=\"cntnt\"><img style=\"width:275px; height:516px;\" src=\"images/EM/66441_Ankle_mortise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mortise view enables assessment for fractures and spacing of the entire joint surface, including that between the fibula and talus. The distance between the talus and either the fibula or tibia should be equal throughout the joint.</div><div class=\"graphic_reference\">Courtesy of Patrice Eiff, MD.</div><div id=\"graphicVersion\">Graphic 66441 Version 2.0</div></div></div>"},"66444":{"type":"graphic_table","displayName":"Rx EC IE (R to PCN, gent, and vanc) ","title":"Suggested regimens for therapy of native or prosthetic valve endocarditis due to enterococcal strains resistant to penicillin, aminoglycosides, and vancomycin*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested regimens for therapy of native or prosthetic valve endocarditis due to enterococcal strains resistant to penicillin, aminoglycosides, and vancomycin*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)</td> <td class=\"subtitle1\">European Society of Cardiology (ESC)</td> </tr> <tr> <td class=\"subtitle2\">Adult dose</td> <td class=\"subtitle2\">Pediatric dose</td> <td class=\"subtitle2\">Adult dose</td> </tr> <tr> <td class=\"indent1\"> <p>Linezolid<sup>&#182;</sup> 600 mg IV or orally every 12 hours for &#62;6 weeks</p> <p><strong>or</strong></p> <p>Daptomycin<sup>&#916;</sup> 10 to 12 mg/kg IV every 24 hours for &#62;6 weeks</p> <p><strong>or</strong></p> <p>Alternative regimens (ie, daptomycin plus ampicillin, or ceftaroline) may be reasonable in patients with persistent bacteremia or strains with daptomycin MIC at high end of susceptible range</p> </td> <td class=\"indent1\"> <p>Consultation with a pediatric infectious disease specialist is recommended</p> </td> <td class=\"indent1\"> <p>Daptomycin 10 mg/kg per 24 hours IV once per day for &#8805;8 weeks</p> <p><strong>plus</strong></p> <p>Ampicillin 12 g per 24 hours (or 200 mg/kg per 24 hours) IV in six divided doses for &#8805;8 weeks</p> <p><strong>OR</strong></p> <p>Linezolid<sup>&#182;</sup> 1200 mg per 24 hours IV or orally in two divided doses for &#8805;8 weeks</p> <p><strong>OR</strong></p> <p>Quinupristin-dalfopristin<sup>&#9674;</sup> 22.5 mg/kg per 24 hours IV in three divided doses for &#8805;8 weeks</p> <p><strong>OR</strong></p> <p>Combinations of antibiotics according to in vitro susceptibility<sup>&#167;</sup> (eg, daptomycin plus ertapenem or ceftaroline)</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class=\"graphic_footnotes\">IV: intravenously; MIC: minimum inhibitory concentration; HLAR: high-level aminoglycoside resistance.<br />* Patients with endocarditis caused by these strains, most commonly <EM>Enterococcus faecium</EM>, should be treated in consultation with an infectious disease specialist; cardiac valve replacement may be necessary for bacteriologic cure; cure with antimicrobial therapy alone may be &lt;50 percent.<br />¶ Linezolid use may be associated with potentially severe bone marrow suppression, neuropathy, and drug interactions. Monitor hematologic toxicity.<br />Δ Daptomycin is usually used in combination with either ampicillin (12 g/day in four or six divided doses) or ceftaroline (600 mg IV every 8 or 12 hours).<br />◊&nbsp;Only effective against <EM>Enterococcus faecium</EM> and can cause severe myalgias, which may require discontinuation of therapy.<br />§&nbsp;An alternative regimen for isolates with high-level resistance to gentamicin (MIC &gt;500 mcg/mL) that do not have HLAR to streptomycin consists of streptomycin (15 mg/kg per 24 hours IV in two divided doses) in combination with beta-lactam or vancomycin.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</LI>&#xD;&#xA;<LI>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</LI>&#xD;&#xA;<LI>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</LI></OL></div><div id=\"graphicVersion\">Graphic 66444 Version 6.0</div></div></div>"},"66445":{"type":"graphic_table","displayName":"Hemodynamics kidney pregnancy","title":"Hemodynamic and renal changes during normal pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamic and renal changes during normal pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Systemic hemodynamics</td>\n</tr>\n<tr>\n<td> Increase in cardiac output</td>\n</tr>\n<tr>\n<td> Fall in vascular resistance and blood pressure</td>\n</tr>\n<tr>\n<td> Blood volume expansion</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Renal function and electrolyte balance</td>\n</tr>\n<tr>\n<td> Increase in glomerular filtration rate</td>\n</tr>\n<tr>\n<td> Chronic respiratory alkalosis</td>\n</tr>\n<tr>\n<td> Hyponatremia due to resetting of osmostat</td>\n</tr>\n<tr>\n<td> Increased ADH metabolism and polyuria in selected women</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 66445 Version 1.0</div></div></div>"},"66446":{"type":"graphic_table","displayName":"Presentation JSS","title":"Presenting signs and symptoms in children with systemic sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presenting signs and symptoms in children with systemic sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Signs and symptoms</td> <td class=\"subtitle1\">Percent of patients (n = 164 patients)*</td> </tr> <tr> <td>Skin tightening</td> <td class=\"centered\">84</td> </tr> <tr> <td>Raynaud's phenomenon</td> <td class=\"centered\">72</td> </tr> <tr> <td>Arthralgia</td> <td class=\"centered\">32</td> </tr> <tr> <td>Muscle weakness and pain</td> <td class=\"centered\">17</td> </tr> <tr> <td>Subcutaneous calcification</td> <td class=\"centered\">10</td> </tr> <tr> <td>Dysphagia</td> <td class=\"centered\">16</td> </tr> <tr> <td>Dyspnea</td> <td class=\"centered\">14</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Percentage calculated only on those series in which detailed information were provided.</div><div class=\"graphic_reference\">Cumulative series from references Martini G, et al. Arthritis Rheum 2003; Burge SM, et al. JR Soc Med 1984; Larregue M, et al. Ann Dermatol Venereol 1983; Suarez-Almazor ME, et al. Arthritis Rheum 1985.</div><div id=\"graphicVersion\">Graphic 66446 Version 3.0</div></div></div>"},"66449":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture","title":"Calcaneus fracture in a toddler","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture in a toddler</div><div class=\"cntnt\"><img style=\"width:478px; height:275px;\" src=\"images/EM/66449_Calcaneusfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fracture of the calcaneus in a toddler was not seen on the initial x-ray (A) but was visible on subsequent x-rays (B).</div><div class=\"graphic_reference\">Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66449 Version 11.0</div></div></div>"},"66450":{"type":"graphic_waveform","displayName":"Advanced case 15 with answer","title":"Isorhythmic AV dissociation","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Isorhythmic AV dissociation</div><div class=\"cntnt\"><img style=\"width:531px; height:99px;\" src=\"images/CARD/66450_Advanced_case_15_with_answe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rhythm strip showing sinus rhythm with isorhythmic atrioventricular dissociation. The sinus P waves and QRS complex have a similar rate, but the P waves are not conducted as ventricular depolarization is initiated by a junctional focus. Note that the P waves appear to move into, fuse with (beats 2 and 3), and then move out of (beats 4 through 7) the QRS complex.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 66450 Version 2.0</div></div></div>"},"66451":{"type":"graphic_table","displayName":"Katz index of independence in activities of daily living","title":"Katz index of independence in activities of daily living","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Katz index of independence in activities of daily living</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Activities </td> <td class=\"subtitle1\">Independence </td> <td class=\"subtitle1\">Dependence </td> </tr> <tr> <td class=\"subtitle3\">Points (1 or 0) </td> <td class=\"subtitle3\"> <p>Points (1)</p> <p><em>NO</em> supervision, direction, or personal assistance</p> </td> <td class=\"subtitle3\"> <p>Points (0)</p> <p><em>WITH</em> supervision, direction, personal assistance, or total care</p> </td> </tr> <tr> <td class=\"indent1\">Bathing </td> <td rowspan=\"2\"><strong>(1 point)</strong> Bathes self completely or needs help in bathing only a single part of the body, such as the back, genital area, or disabled extremity. </td> <td rowspan=\"2\"><strong>(0 points)</strong> Needs help with bathing more than one part of the body, getting in or out of the tub or shower. Requires total bathing. </td> </tr> <tr> <td class=\"sublist2\">POINTS:_____ </td> </tr> <tr> <td class=\"indent1\">Dressing </td> <td rowspan=\"2\"><strong>(1 point)</strong> Gets clothes from closets and drawers and puts on clothes and outer garments complete with fasteners. May have help tying shoes. </td> <td rowspan=\"2\"><strong>(0 points)</strong> Needs help with dressing self or needs to be completely dressed. </td> </tr> <tr> <td class=\"sublist2\">POINTS:_____ </td> </tr> <tr> <td class=\"indent1\">Toileting </td> <td rowspan=\"2\"><strong>(1 point)</strong> Goes to toilet, gets on and off, arranges clothes, cleans genital area without help. </td> <td rowspan=\"2\"><strong>(0 points)</strong> Needs help transferring to the toilet and&nbsp;cleaning self or uses bedpan or commode. </td> </tr> <tr> <td class=\"sublist2\">POINTS:_____ </td> </tr> <tr> <td class=\"indent1\">Transferring </td> <td rowspan=\"2\"><strong>(1 point)</strong> Moves in and out of bed or chair unassisted. Mechanical transferring aides are acceptable. </td> <td rowspan=\"2\"><strong>(0 points)</strong> Needs help in moving from bed to chair or requires a complete transfer. </td> </tr> <tr> <td class=\"sublist2\">POINTS:_____ </td> </tr> <tr> <td class=\"indent1\">Continence </td> <td rowspan=\"2\"><strong>(1 point)</strong> Exercises complete self-control over urination and defecation. </td> <td rowspan=\"2\"><strong>(0 points)</strong> Is partially or totally incontinent of bowel or bladder. </td> </tr> <tr> <td class=\"sublist2\">POINTS:_____ </td> </tr> <tr> <td class=\"indent1\">Feeding </td> <td rowspan=\"2\"><strong>(1 point)</strong> Gets food from plate into mouth without help. Preparation of food may be done by another person. </td> <td rowspan=\"2\"><strong>(0 points)</strong> Needs partial or total help with feeding or requires parenteral feeding. </td> </tr> <tr> <td class=\"sublist2\">POINTS:_____ </td> </tr> <tr> <td colspan=\"4\"><strong>Total points:</strong>_____ </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>6 points:</STRONG> High (patient independent).<br /><STRONG>0 points:</STRONG> Low (patient very dependent).</div><div class=\"graphic_reference\">Reproduced with permission from: Katz S, Down TD, Cash HR, Grotz RC. Progress in the development of the index of ADL. Gerontologist 1970, 10:20. Copyright © 1970 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 66451 Version 11.0</div></div></div>"},"66453":{"type":"graphic_table","displayName":"Lung preservation procurement","title":"Donor management during procurement for lung transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Donor management during procurement for lung transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Ventilation</strong></td> <td> <p>Tidal volume:&nbsp;6 to 10 mL/kg</p> <p>FiO<sub>2</sub>: 50 percent</p> <p>PEEP: 5 to 10 cm H<sub>2</sub>O</p> </td> </tr> <tr> <td><strong>Anticoagulation (once lungs and heart exposed)</strong></td> <td>Heparin 250 to 300 units per kg, intravenously</td> </tr> <tr> <td><strong>Prostaglandin pretreatment</strong></td> <td>Prostaglandin E1 (PGE1, Alprostadil) 500 mcg via main pulmonary artery</td> </tr> <tr> <td><strong>Flush solution</strong></td> <td>Low potassium dextran (Perfadex)</td> </tr> <tr> <td><strong>Temperature</strong></td> <td>4 to 8&#176;C</td> </tr> <tr> <td><strong>Antegrade flush</strong></td> <td> <p>Infuse 50 to 75 mL/kg of flush solution into main pulmonary artery.</p> <p>Hang preservation solution 30 cm above level of donor and let flush by gravity. Do not use pressurized bags.</p> </td> </tr> <tr> <td><strong>Cardioplegia solution (only when heart is used for transplantation)</strong></td> <td>Infuse retrograde from aorta</td> </tr> <tr> <td><strong>Topical cooling</strong></td> <td>Iced saline slush added to pleural and pericardial spaces</td> </tr> <tr> <td><strong>Retrograde flush, after removal of heart</strong></td> <td>Infuse 250 mL of flush solution into each pulmonary vein orifice and vent at pulmonary artery opening</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66453 Version 3.0</div></div></div>"},"66454":{"type":"graphic_figure","displayName":"Outcome CRI VE VCO2","title":"Outcome in patients with heart failure is related to VE/VCO2 and the chronotropic index","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Outcome in patients with heart failure is related to VE/VCO2 and the chronotropic index</div><div class=\"cntnt\"><img style=\"width:457px; height:323px;\" src=\"images/CARD/66454_OutcomeCRIVEVCO2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 470 patients with heart failure, Kaplan-Meier plot shows that survival is reduced when VE/V<SUB>CO2</SUB> is increased to ≥44.7 (33 versus 10 percent for value &lt;44.7) and the chronotropic index (CRI), which correlates with the peak heart rate during exercise, is reduced to ≤0.51 (27 versus 11 percent for CRI &gt;0.51). The combination of VE/V<SUB>CO2</SUB> and CRI was associated with the highest risk of death.</div><div class=\"graphic_reference\">Data from Robbins M, Francis G, Pashkow FJ, et al, Circulation 1999; 100:2411.</div><div id=\"graphicVersion\">Graphic 66454 Version 2.0</div></div></div>"},"66455":{"type":"graphic_diagnosticimage","displayName":"Tuberculous pleurisy","title":"Primary tuberculosis in pregnant woman","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary tuberculosis in pregnant woman</div><div class=\"cntnt\"><img style=\"width:324px; height:313px;\" src=\"images/PULM/66455_Tuberculous_pleurisy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large right sided pleural effusion with typical meniscoid arc and with extension into the major fissure.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66455 Version 2.0</div></div></div>"},"66456":{"type":"graphic_table","displayName":"Progesterone supplementation to prevent preterm birth","title":"Recommendations for progesterone supplementation to prevent preterm birth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for progesterone supplementation to prevent preterm birth</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Progesterone supplementation indicated?</td> <td class=\"subtitle1\">Management</td> </tr> <tr class=\"divider_bottom\"> <td>Singleton pregnancy, prior spontaneous singleton preterm birth, normal cervical length</td> <td>Yes</td> <td> <p>Hydroxyprogesterone caproate 250 mg intramuscularly weekly beginning between 16 and 20 weeks of gestation and continuing through 36 weeks of gestation or until delivery and monitor cervical length. Natural progesterone administered vaginally is a reasonable alternative.</p> Short (&#60;25 mm) cervix &#8594; consider performing cerclage</td> </tr> <tr class=\"divider_bottom\"> <td>Singleton pregnancy, prior spontaneous twin preterm birth, normal cervical length</td> <td>Possibly</td> <td> <p>Hydroxyprogesterone caproate 250 mg intramuscularly weekly beginning between 16 and 20 weeks of gestation and continuing through 36 weeks of gestation or until delivery and monitor cervical length. Natural progesterone administered vaginally is a reasonable alternative.</p> Short (&#60;25 mm) cervix &#8594; consider performing cerclage</td> </tr> <tr class=\"divider_bottom\"> <td>Singleton pregnancy, no prior spontaneous preterm birth, short cervix (&#8804;20 mm)</td> <td>Yes</td> <td> <p>Progesterone suppository 90 to 200 mg vaginally each night from time of diagnosis through 36 weeks of gestation.</p> <p>A vaginal suppository can be prepared by a compounding pharmacy utilizing a commercially available standardized kit.</p> Other options include a 100 mg micronized progesterone vaginal tablet or an 8 percent vaginal gel containing 90 mg micronized progesterone per dose. Both preparations are commercially available in US, but not approved for prevention of preterm birth in cervical shortening.</td> </tr> <tr class=\"divider_bottom\"> <td>Multiple pregnancy (twins or triplets) without prior preterm birth, normal cervical length</td> <td>No</td> <td>No progesterone, no cerclage</td> </tr> <tr class=\"divider_bottom\"> <td>Twins, prior preterm birth</td> <td>Possibly</td> <td>Hydroxyprogesterone caproate 250 mg intramuscularly weekly beginning between 16 and 20 weeks of gestation and continuing through 36 weeks of gestation or until delivery. Natural progesterone administered vaginally is a reasonable alternative.</td> </tr> <tr class=\"divider_bottom\"> <td>Twins, short cervix</td> <td>Possibly</td> <td>Vaginal progesterone, no cerclage</td> </tr> <tr class=\"divider_bottom\"> <td>Preterm premature rupture of membranes</td> <td>No</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>Positive fetal fibronectin test</td> <td>No</td> <td>&ndash;</td> </tr> <tr> <td>Undelivered after an episode of preterm labor</td> <td>No</td> <td>&ndash;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66456 Version 12.0</div></div></div>"},"66457":{"type":"graphic_picture","displayName":"Conjunctival suffusion in staphylococcal toxic shock syndrome","title":"Conjunctival suffusion in staphylococcal toxic shock syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Conjunctival suffusion in staphylococcal toxic shock syndrome</div><div class=\"cntnt\"><img style=\"width:376px; height:252px;\" src=\"images/ID/66457_Conjunctival_suffusion_in_T.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conjunctival suffusion in a patient with staphylococcal toxic shock syndrome (TSS).</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 66457 Version 5.0</div></div></div>"},"66458":{"type":"graphic_figure","displayName":"BNP and survival in HF","title":"Brain natriuretic peptide level predicts outcome in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain natriuretic peptide level predicts outcome in heart failure</div><div class=\"cntnt\"><img style=\"width:371px; height:271px;\" src=\"images/CARD/66458_BNP_and_survival_in_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival curves in patients with heart failure show that survival is significantly lower among those with a brain natriuretic peptide (BNP) level &gt;73 pg/ml compared with patients with a level &lt;73 pg/ml.</div><div class=\"graphic_reference\">Data from: Tsutamoto T, Wada A, Maeda K, et al. Circulation 1997; 96:509.</div><div id=\"graphicVersion\">Graphic 66458 Version 3.0</div></div></div>"},"66460":{"type":"graphic_picture","displayName":"Bucket test  to find subjective visual vertical","title":"Hemispheric dome and bucket method of subjective visual vertical testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemispheric dome and bucket method of subjective visual vertical testing</div><div class=\"cntnt\"><img style=\"width:442px; height:186px;\" src=\"images/NEURO/66460_Bucket_test_tilt_of_SVV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bucket method for determining monocular and binocular visual vertical: patients sit upright looking into a translucent plastic bucket so that the bucket rims prevent any gravitational orientation clues. On the bottom inside the bucket there is a dark, straight, diametric line. On the bottom outside there is a perpendicular that originates from the center of a quadrant divided into degrees with the zero line corresponding to the true vertical. For measurement, the examiner rotates the bucket clockwise or counterclockwise to an end position and then slowly rotates it back toward the zero degree position. Patients indicate the position where they estimate the inside bottom line to be truly vertical by signaling stop. The examiner reads off the degrees on the outside scale. A total of 10 repetitions&nbsp;are performed. An eye patch&nbsp;is used for monocular testing.</div><div class=\"graphic_reference\">Reproduced with permission from: Zwergal A, Rettinger N, Frenzel C, et al. A bucket of static vestibular function. Neurology 2009; 72:1689. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66460 Version 14.0</div></div></div>"},"66462":{"type":"graphic_picture","displayName":"EGFR inhibitor paronychia","title":"EGFR inhibitor paronychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">EGFR inhibitor paronychia</div><div class=\"cntnt\"><img style=\"width:425px; height:319px;\" src=\"images/PC/66462_EGFR_inhibitor_paronychia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paronychia of the great toe secondary to cetuximab therapy.</div><div class=\"graphic_reference\">Courtesy of Aimee S Payne, MD, PhD.</div><div id=\"graphicVersion\">Graphic 66462 Version 1.0</div></div></div>"},"66463":{"type":"graphic_figure","displayName":"Resection of omentum from transverse colon","title":"Resection of omentum from transverse colon","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Resection of omentum from transverse colon</div><div class=\"cntnt\"><img style=\"width:515px; height:476px;\" src=\"images/SURG/66463_Resection-of-omentum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The omentum is resected from the colon in a relatively avascular plane using electrocautery. If a cancer in the transverse colon involves the omentum, it is resected en bloc with the colectomy.</div><div id=\"graphicVersion\">Graphic 66463 Version 1.0</div></div></div>"},"66465":{"type":"graphic_picture","displayName":"Acute diffuse myocarditis Light","title":"Acute diffuse myocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute diffuse myocarditis</div><div class=\"cntnt\"><img style=\"width:360px; height:227px;\" src=\"images/CARD/66465_Acute_diffuse_myocarditis_L.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endomyocardial biopsy of the right ventricle showing acute diffuse myocarditis. There is prominent myofiber necrosis and loss in association with a high-grade mononuclear infiltrates.</div><div class=\"graphic_reference\">Courtesy of Walter Abelmann, MD.</div><div id=\"graphicVersion\">Graphic 66465 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal endomyocardial byopsy</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/CARD/80914_Normal_myocardium_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopy from a normal endomyocardial biopsy.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 80914 Version 1.0</div></div></div>"},"66466":{"type":"graphic_figure","displayName":"Cellular/mitochondrial distribution of steps in heme synthesis","title":"Cellular and mitochondrial distribution of heme synthesis enzymatic steps in the erythroblast","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Cellular and mitochondrial distribution of heme synthesis&nbsp;enzymatic steps&nbsp;in the erythroblast</div><div class=\"cntnt\"><img style=\"width:548px; height:392px;\" src=\"images/HEME/66466_Pathway_hemoglobin_syn_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate for details of conditions caused by specific enzyme deficiencies.</div><div class=\"graphic_footnotes\">ALAS2: 5-aminolevulinate synthase; PLP: pyridoxal 5'-phosphate; FECH: ferrochelatase; Tf: transferrin.</div><div class=\"graphic_reference\">Modified from: Bottomley, SS. Iron overload in sideroblastic and other non- thalassemic anemias. In: Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Barton, JC, Edwards, CQ (Eds), Cambridge University Press, Cambridge UK 2000. p.422.</div><div id=\"graphicVersion\">Graphic 66466 Version 8.0</div></div></div>"},"66467":{"type":"graphic_table","displayName":"A practical guide for using CBT to treat somatization","title":"A practical guide for treating somatization with cognitive-behavioral therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A practical guide for treating somatization with cognitive-behavioral therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Principles and tasks</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td>Explore beliefs</td> <td>Ask patients what they believe is causing their symptoms.</td> </tr> <tr> <td>Define goals</td> <td>Define goals, eg, take responsibility for one's health or improved functioning.</td> </tr> <tr> <td>Behavioral analysis</td> <td>Analyze behavior to determine antecedents and consequences (ABC: antecedent, behavior, consequence). Ask about thoughts, behaviors, emotions, and situations that precede, accompany, and follow the symptoms.</td> </tr> <tr> <td>Diary</td> <td>The patient should use a diary to record symptoms, rate their severity, describe the situation during which a symptom occurred, describe how they felt at the time, and what they were thinking at the time. These entries are reviewed during treatment sessions.</td> </tr> <tr> <td>Family</td> <td>The spouse or parents should be invited to attend one or more treatment sessions so they understand the treatment approach. Family members should be directed to stop their responses and accommodations to symptoms that are performed out of concern but which ultimately serve to reinforce the illness.</td> </tr> <tr> <td>Behavior first</td> <td>The focus of treatment is changing cognitions and behaviors. It is easier to first change behaviors, especially for those patients who are less psychiatrically minded or more resistant to psychiatric explanations of their illness.</td> </tr> <tr> <td>Reduce maladaptive behavior</td> <td>Behavioral change starts with reducing avoidance behavior and other maladaptive behavioral responses to symptoms. This can reduce the frequency and intensity of symptoms, reduce disability, and help facilitate cognitive changes. In addition, clinicians and patients need to decide which adaptive behaviors to increase. These should be clearly specified, realistically attainable, and of value to the patient.</td> </tr> <tr> <td>Incremental change</td> <td>Behavioral change is approached in a gradual way, with graded increases in desired activities. The difference between current behavior and the desired goals is assessed, and then broken down into manageable steps.</td> </tr> <tr> <td>Practice</td> <td>The clinician should warn the patient that each increase in previously avoided behavior could cause a transient increase in symptoms. The desired behavior is practiced daily until it is mastered, and then the next goal is undertaken.</td> </tr> <tr> <td>Relaxation</td> <td>Teach relaxation techniques to increase the ability to bear with symptoms, reduce stress, and develop pleasant bodily sensations.</td> </tr> <tr> <td>Social skills</td> <td>Provide social skills training.</td> </tr> <tr> <td>Regulate emotions</td> <td>Teach patients how to regulate their emotions.</td> </tr> <tr> <td>Cognitive change</td> <td>Cognitive change begins with identifying the patient's thoughts and beliefs about bodily sensations and physical symptoms. The clinician then asks the patient to consider alternative explanations and interpretations of symptoms. Patients record their thoughts about symptoms and practice challenging them by producing and recording more benign explanations.</td> </tr> <tr> <td>Psychoeducation</td> <td>Provide psychoeducation about somatization.</td> </tr> <tr> <td>Realistic health concept</td> <td>Help the patient develop a realistic health concept. Challenge faulty assumptions, such as the idea that one must be in perfect health in order to function, or that any bodily sensation is pathologic.</td> </tr> <tr> <td>Restructure cognitions</td> <td>Aim to restructure cognitions to accept the role of psychiatric factors in somatization.</td> </tr> <tr> <td>Demonstrate role of psychiatric factors</td> <td>Conduct exercises to demonstrate the role of psychiatric factors in health. Biofeedback experiments can help patients understand how their somatic preoccupation perpetuates their symptoms and disability. As an example, if the patient focuses on a normal bodily sensation such as the heartbeat, this will reveal an increase in its apparent intensity. The value of distraction as a method of symptom control can then be demonstrated. These experiments provide personal evidence the patient can use in reconsidering&nbsp;a general medical condition&nbsp;as the explanation of their symptoms.</td> </tr> <tr> <td>Well-being</td> <td>Address problems affecting well-being, such as difficulties in relationships and at work, cognitive misattributions, and emotional state.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br> <ol> <li>Bornschein S, Forstl H, Zilker T. Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives. J Intern Med 2001; 250:309. </li> <li>Sharpe M, Peveler R, Mayou R. The psychological treatment of patients with functional symptoms: a practical guide. J Psychosom Res 1992; 36:515. </li> </ol></div><div id=\"graphicVersion\">Graphic 66467 Version 7.0</div></div></div>"},"66468":{"type":"graphic_picture","displayName":"Asbestosis lung gross","title":"Whole lung section of freeze-dried lung from a person who died of asbestosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Whole lung section of freeze-dried lung from a person who died of asbestosis</div><div class=\"cntnt\"><img style=\"width:243px; height:434px;\" src=\"images/PULM/66468_Asbestosis_lung_gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the peripheral honeycombing, which is most severe in the lower zones.</div><div class=\"graphic_reference\">Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org.</div><div id=\"graphicVersion\">Graphic 66468 Version 1.0</div></div></div>"},"66470":{"type":"graphic_diagnosticimage","displayName":"LUL atelectasis CT","title":"CT scan of left upper lobe atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of left upper lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:360px; height:226px;\" src=\"images/PULM/66470_LUL_atelectasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The atelectatic left upper lobe (arrow) is in close apposition to the anterior chest wall and the mediastinum. Occlusion of the left upper lobe bronchus is visible (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66470 Version 3.0</div></div></div>"},"66471":{"type":"graphic_table","displayName":"Mechanical vent in BP fistula","title":"Guidelines for ventilator management in the patient with barotrauma and bronchopleural fistula","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for ventilator management in the patient with barotrauma and bronchopleural fistula</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"sublist1_start\">Reduce both mean airway pressure and the number of\npositive-pressure breaths, using the lowest number of mechanical\nbreaths that permits acceptable alveolar ventilation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Wean patient completely if possible&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Partial ventilatory support (eg, low-rate SIMV or pressure support) is preferable to total ventilatory support (eg, assist/control, high-rate SIMV, or pressure control ventilation)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Avoid or correct respiratory alkalosis (to minimize minute ventilation)</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Consider use of permissive hypercapnia (reducing minute ventilation and allowing arterial PCO2 to rise)</td>\n    </tr>\n    <tr>\n\n      <td>Limit effective (returned) tidal volume to 5 to 8 mL/kg</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Minimize inspiratory time, and hence mean airway pressure:</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Keep inspiration-to-expiration ratio low (eg, 0.33) </td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Use high inspiratory flow rate (eg, 70 to 100 L/min) </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Avoid inflation hold (end-inspiratory pause) and inverse-ratio ventilation </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Use low-compressible-volume (non-disposable) ventilator circuit</td>\n    </tr>\n    <tr>\n\n      <td>Minimize PEEP (both dialed-in and auto-PEEP)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use least amount of chest tube suction that maintains lung inflation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>If spontaneous movement exacerbates leak, keep patient\nheavily sedated (in unusual circumstances muscle relaxation may also be\nnecessary)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Explore position differences, and avoid patient positions that increase the leak</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Treat bronchospasm and other causes of expiratory airflow obstruction</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Consider specific or unconventional measures (eg, independent\nlung ventilation, high-frequency jet ventilation, PEEP to chest tubes,\netc) only if the air leak per se is clinically felt to be worsening the\npatient's condition (eg, intractable hypotension or arrhythmias in\nassociation with respiratory acidosis)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Treat underlying cause of respiratory failure, maintaining\nnutritional and other support, with goal of discontinuing mechanical\nventilation as soon as possible</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=66406&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Mechanical_vent_in_BP_fistu.htm</title></head></div><div id=\"graphicVersion\">Graphic 66471 Version 2.0</div></div></div>"},"66472":{"type":"graphic_waveform","displayName":"Old anterior MI tutorial","title":"Chronic anterior wall myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Chronic anterior wall myocardial infarction</div><div class=\"cntnt\"><img style=\"width:533px; height:166px;\" src=\"images/CARD/66472_Old_anterior_MI_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chronic anterior wall infarction is diagnosed by the presence of initial deep and broad Q waves in any of the precordial leads; in this case they are present in leads V1 to V4.</div><div id=\"graphicVersion\">Graphic 66472 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"66473":{"type":"graphic_diagnosticimage","displayName":"Abdominal aortic aneurysm on ultrasound","title":"Abdominal aortic aneurysm on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abdominal aortic aneurysm on ultrasound</div><div class=\"cntnt\"><img style=\"width:367px; height:264px;\" src=\"images/CARD/66473_Aortic_aneurysm_Echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Routine sonographic evaluation of an abdominal aortic aneurysm involves measuring the anteroposterior, longitudinal, and transverse dimensions of the aorta. In this instance, the diameters in the transverse dimensions (5.75 and 5.43 cm) are much greater than normal (typically around 2 cm or less). Thrombus or echodense calcifications (arrow) in or adjacent to the aortic wall may also be visualized.</div><div class=\"graphic_reference\">Courtesy of Emile R Mohler III, MD.</div><div id=\"graphicVersion\">Graphic 66473 Version 3.0</div></div></div>"},"66474":{"type":"graphic_figure","displayName":"Ceftriaxone drug concentrations","title":"Ceftriaxone CSF concentrations in serum and CSF of infants and children ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ceftriaxone CSF concentrations in serum and CSF of infants and children </div><div class=\"cntnt\"><img style=\"width:448px; height:308px;\" src=\"images/ID/66474_Ceftriaxone_CSF_concentrati.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean concentrations of ceftriaxone in serum and cerebrospinal fluid after&nbsp;intravenous infusion of 50 mg/kg in infants and children.</div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid.</div><div id=\"graphicVersion\">Graphic 66474 Version 4.0</div></div></div>"},"66476":{"type":"graphic_picture","displayName":"Rhizopus hyphae lung tissue","title":"<EM>Rhizopus arrhizus</EM> hyphae in lung tissue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Rhizopus arrhizus</EM> hyphae in lung tissue</div><div class=\"cntnt\"><img style=\"width:432px; height:267px;\" src=\"images/ID/66476_Rhizopus_hyphae_lung_tissue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyphae in lung tissue,&nbsp;hematoxylin and eosin stain.</div><div class=\"graphic_reference\">Courtesy of www.doctorfungus.org. Copyright ©2007.</div><div id=\"graphicVersion\">Graphic 66476 Version 2.0</div></div></div>"},"66477":{"type":"graphic_table","displayName":"Significant interactions involving triazoles","title":"Examples of common azole antifungal pharmacokinetic drug interactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of common azole antifungal pharmacokinetic drug interactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Common types of azole drug interactions</td> <td class=\"subtitle1\">Examples (see important note below)</td> <td class=\"subtitle1\">Approach to management</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Inhibition of metabolism of coadministered drug by azole leading to <strong>increased</strong> <strong>serum concentrations of coadministered drug</strong></p> <ul> <li>Combined use of fluconazole, posaconazole, voriconazole, or itraconazole with medicines that are highly dependent upon CYP3A metabolism for clearance and have a narrow therapeutic index can result in toxicity of coadministered drug(s). </li> <li>Combined use of fluconazole with medicines that are highly dependent upon CYP2C metabolism for clearance and have a narrow therapeutic index can result in toxicity of coadministered drug(s). </li> </ul> </td> <td> <ul> <li>Apixaban, conivaptan, cyclosporine, dronedarone, everolimus, lovastatin, methadone, rivaroxaban, simvastatin, sirolimus, tacrolimus, and vincristine are examples of medicines that are dependent upon CYP3A for clearance; interaction of these drugs&nbsp;with azoles can result in elevated serum concentrations leading to toxic levels. </li> <li>Warfarin is an example of a medicine that is dependent upon CYP2C for clearance, and interaction of warfarin&nbsp;with&nbsp;fluconazole can result in elevated INR and an increased&nbsp;risk of pathologic bleeding. </li> </ul> </td> <td> <ul> <li>When appropriate non-interacting alternatives are readily available, consider modifying treatment to avoid combined use of CYP3A substrate with fluconazole, posaconazole, voriconazole, or itraconazole. <ul class=\"decimal_heading\"> <li>Example: Substitute a non-interacting statin (eg, fluvastatin, rosuvastatin) for an interacting statin (lovastatin, simvastatin). </li> </ul> </li> <li>In patients receiving immunosuppressants, monitor immunosuppressant concentrations and signs of toxicity. Substantial, including preemptive, dose reduction of immunosuppressant may be needed. Some combinations are considered contraindicated; refer to appropriate topic reviews for detail. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Induction of azole metabolism leading to <strong>decreased azole serum concentrations</strong></p> <ul> <li>Combined use of voriconazole, posaconazole, isavuconazole, or itraconazole with medicines that are potent inducers of CYP metabolism can result in subtherapeutic azole serum concentrations and therapeutic failure of antifungal treatment. </li> </ul> </td> <td> <ul> <li>Rifampin (rifampicin), enzyme-inducing antiepileptic drugs (eg, carbamazepine, phenobarbital, phenytoin), dexamethasone, and St. John's wort are examples of drugs that induce metabolism of azoles.* </li> <li>Although ritonavir is a CYP3A inhibitor, it acts as an inducer of voriconazole metabolism and can result in decreased voriconazole concentrations. </li> </ul> </td> <td> <ul> <li>Combined use of strong inducers of CYP with voriconazole, posaconazole, isavuconazole, or itraconazole should generally be avoided. Some combinations are considered contraindicated; others may be managed by therapeutic drug monitoring and dose adjustment. </li> <li>Combined use with fluconazole may warrant an increase in fluconazole dose.<sup>&#182;</sup> </li> <li>Enzyme induction can require up to two weeks to achieve maximum effect and persists for up to two weeks after discontinuation of the interacting medication. However, clinically significant effects can occur within hours to days of starting a CYP inducer. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>Inhibition of azole metabolism leading to <strong>increased azole serum concentrations</strong></p> <ul> <li>Combined use of voriconazole with medicines that are potent inhibitors of CYP2C may result in elevated concentrations of voriconazole and potential toxicity. </li> <li>Combined use of itraconazole or isavuconazole with medicines that are potent inhibitors of CYP3A may result in elevated serum concentrations of these azoles and potential toxicity. </li> </ul> </td> <td> <ul> <li>Fluconazole, fluvoxamine, and gemfibrozil are examples of drugs that inhibit CYP2C metabolism of voriconazole; toxicity might include central nervous system adverse effects. </li> <li>Clarithromycin, cobicistat, conivaptan, and ritonavir are examples of drugs that inhibit CYP3A* metabolism of isavuconazole and itraconazole; toxicity might include altered QTc interval. </li> </ul> </td> <td> <ul> <li>Combined use of voriconazole with strong CYP2C inhibitors should be undertaken with caution. </li> <li>Combined use of strong inhibitors of CYP3A with itraconazole or isavuconazole should be avoided. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI><STRONG>Important note:</STRONG> The interactions listed in this table illustrate some of the common types of azole antifungal drug interactions; this is <STRONG>not</STRONG> a complete list and many (over 1000) other&nbsp;azole drug interactions can occur.&nbsp;</LI>&#xD;&#xA;<LI>Azole antifungals are subject to pharmacokinetic interactions with drugs that are substrates of, inhibit, or induce CYP3A or 2C&nbsp;drug metabolism and P-glycoprotein efflux transporters. Some interactions can lead to undetectable serum concentrations and failure of azole antifungal therapy or dangerously toxic levels of other drugs, such as immunosuppressive agents used in solid organ and hematopoietic cell transplant recipients, anticoagulants, and chemotherapeutic agents.</LI>&#xD;&#xA;<LI>Patients receiving azole antifungals should have their medication regimen analyzed carefully for drug interactions particularly when initiating and adjusting therapy; this may be done by use of the Lexi-Interact program included within UpToDate.</LI></UL></div><div class=\"graphic_footnotes\">CYP: cytochrome P450 metabolism; INR: international normalized ratio.<br />* A list of strong and moderate CYP3A inducers and inhibitors is provided in a separate table within UpToDate.<br />¶ Drugs that are inducers of CYP3A metabolism are also inducers of CYP2C; CYP2C metabolism&nbsp;plays a minor role in the clearance of fluconazole.</div><div id=\"graphicVersion\">Graphic 66477 Version 10.0</div></div></div>"},"66479":{"type":"graphic_table","displayName":"Liver diseases and HPS","title":"Liver diseases associated with the hepatopulmonary syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Liver diseases associated with the hepatopulmonary syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Cryptogenic cirrhosis</td> </tr> <tr> <td>Postnecrotic cirrhosis</td> </tr> <tr> <td>Alcoholic cirrhosis</td> </tr> <tr> <td>Autoimmune cirrhosis</td> </tr> <tr> <td>Primary biliary cholangitis</td> </tr> <tr> <td>Chronic active hepatitis</td> </tr> <tr> <td>Primary sclerosing cholangitis</td> </tr> <tr> <td>Alpha-1 antitrypsin deficiency (associated with Z and M-malton alleles)</td> </tr> <tr> <td>Wilson's disease</td> </tr> <tr> <td>Sarcoidosis<sup>[1]</sup></td> </tr> <tr> <td>Hemochromatosis</td> </tr> <tr> <td>Biliary atresia</td> </tr> <tr> <td>Non-cirrhotic portal hypertension</td> </tr> <tr> <td>Tyrosinemia</td> </tr> <tr> <td>Gaucher disease</td> </tr> <tr> <td>Schistosomiasis</td> </tr> <tr> <td>Nodular regenerative hyperplasia of the liver</td> </tr> <tr> <td>Hepatic allograft rejection</td> </tr> <tr> <td>Langerhans-cell histiocytosis</td> </tr> <tr> <td>Hepatic graft-versus-host disease following hematopoietic stem cell transplantation</td> </tr> <tr> <td>Short telomere syndrome&nbsp;</td> </tr> <tr> <td>Budd Chiari Syndrome</td> </tr> <tr> <td>Chronic granulomatous hepatitis</td> </tr> <tr> <td>Some acute liver diseases</td> </tr> <tr> <td>Congenital vascular disease (eg, cavopulmonary shunt, Abernethy malformation)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Patel AN, Patel K, Mador MJ. Hepatopulmonary syndrome and liver sarcoidosis: a tale of two diseases. South Med J 2009; 102:844.</LI></OL>Adapted from: Krowka MJ. Clinical management of hepatopulmonary syndrome. Semin Liver Dis 1993; 13:414.</div><div id=\"graphicVersion\">Graphic 66479 Version 5.0</div></div></div>"},"66480":{"type":"graphic_figure","displayName":"Normal LV Ao pressure","title":"Normal left ventricular and aortic pressures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal left ventricular and aortic pressures</div><div class=\"cntnt\"><img style=\"width:343px; height:277px;\" src=\"images/CARD/66480_Normal_LV_Ao_pressure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal cardiac hemodynamics during cardiac catheterization wth a hi-fidelity catheter. One can see the relationships between the simultaneous ECG and pressure tracings from the aortic root (Ao) and left ventricle (LV).</div><div class=\"graphic_reference\">Reproduced with permission from Kern MJ (ed). Cardiac Catheterization Handbook, 2nd ed, Mosby-Year Book, St. Louis, 1995.</div><div id=\"graphicVersion\">Graphic 66480 Version 1.0</div></div></div>"},"66481":{"type":"graphic_picture","displayName":"Erythema multiforme extrem PI","title":"Erythema multiforme spots","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme spots</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/PI/66481_Erythema_multiforme_extr_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema multiforme causes many red spots to appear on the body. The spots often have a dark center surrounded by pale red rings, like a target or bull's-eye.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66481 Version 6.0</div></div></div>"},"66482":{"type":"graphic_picture","displayName":"Molluscum conjunctivitis","title":"Molluscum contagiosum on the eyelid with conjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum on the eyelid with conjunctivitis</div><div class=\"cntnt\"><img style=\"width:400px; height:287px;\" src=\"images/DERM/66482_Molluscum_conjunctivitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Molluscum contagiosum. Examination also revealed unilateral conjunctivitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed, Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66482 Version 2.0</div></div></div>"},"66483":{"type":"graphic_diagnosticimage","displayName":"SIP free air supine xray","title":"Supine radiograph demonstrating pneumoperitoneum in an infant with spontaneous intestinal perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Supine radiograph demonstrating pneumoperitoneum in an infant with spontaneous intestinal perforation</div><div class=\"cntnt\"><img style=\"width:326px; height:432px;\" src=\"images/PEDS/66483_SIP_free_air_supine_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mary Brandt, MD.</div><div id=\"graphicVersion\">Graphic 66483 Version 3.0</div></div></div>"},"66484":{"type":"graphic_picture","displayName":"Skin abscess from epidermal inclusion cyst","title":"Epidermal inclusion cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidermal inclusion cyst</div><div class=\"cntnt\"><img style=\"width:396px; height:306px;\" src=\"images/PC/66484_Epidermal_inclusion_cyst_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">It is common for epidermal inclusion cysts of the breast to become infected, requiring incision and drainage.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 66484 Version 4.0</div></div></div>"},"66485":{"type":"graphic_picture","displayName":"Injection Dupuytrens","title":"Local injection for Dupuytren's contracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Local injection for Dupuytren's contracture</div><div class=\"cntnt\"><img style=\"width:359px; height:283px;\" src=\"images/RHEUM/66485_Injection_Dupuytrens.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hand is placed in the palm up position. Ethyl chloride is sprayed on the skin for anesthesia. A 5/8 inch, 25-gauge needle is inserted vertically adjacent to the nodular thickening in the midline over the flexor tendon, to a depth of 1/4 to 3/8 inch. 1/2 mL lidocaine and 1/4 mL triamcinolone acetonide (40 mg/mL) are injected.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 66485 Version 3.0</div></div></div>"},"66486":{"type":"graphic_figure","displayName":"LVH and sudden death","title":"LVH increases the risk of sudden death","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LVH increases the risk of sudden death</div><div class=\"cntnt\"><img style=\"width:341px; height:234px;\" src=\"images/CARD/66486_LVH_and_sudden_death.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The incidence of sudden death is related to the presence and extent of left ventricular hypertrophy (LVH). In both men and women, the presence of left ventricular hypertropy (LVH), defined as &gt;143 g/m in men and &gt;102 g/m in women, increases the incidence of sudden death.</div><div class=\"graphic_reference\">Data from Haider, AW, Larson, MG, Benjamin, EJ, et al. J Am Coll Cardiol 1998; 32:1454.</div><div id=\"graphicVersion\">Graphic 66486 Version 1.0</div></div></div>"},"66488":{"type":"graphic_algorithm","displayName":"Approach to managing CPAP problems","title":"Multidisciplinary approach to managing CPAP-related problems","html":"<div class=\"graphic\"><div style=\"width: 654px\" class=\"figure\"><div class=\"ttl\">Multidisciplinary approach to managing CPAP-related problems</div><div class=\"cntnt\"><img style=\"width:634px; height:493px;\" src=\"images/SLEEP/66488_Apprch_mngng_CPAP_prob_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CPAP: continuous positive airway pressure; OSA: obstructive sleep apnea; UA: upper airway.</div><div class=\"graphic_reference\">Original figure modified for this publication. Engleman HM, Wild MR. Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS). Sleep Med Rev 2003; 7:81. Copyright © 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 66488 Version 4.0</div></div></div>"},"66489":{"type":"graphic_waveform","displayName":"ECG APB noncompensatory pause","title":"Electrocardiogram (ECG) strips showing an atrial premature beat (APB) followed by a noncompensatory pause","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) strips showing an atrial premature beat (APB) followed by a noncompensatory pause</div><div class=\"cntnt\"><img style=\"width:448px; height:349px;\" src=\"images/CARD/66489_APB_noncompensatory_pause.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneous electrocardiographic recording from surface leads V1, II, and V5 shows an atrial premature beat (P') which is conducted with aberration. The P wave is different from that of the sinus beat and the PR interval is longer, due to delayed conduction in the atrioventricular node. A noncompensatory pause is present, ie, the interval measured from the sinus beat before and after the atrial premature beat is less than two sinus RR intervals.</div><div id=\"graphicVersion\">Graphic 66489 Version 3.0</div></div></div>"},"66491":{"type":"graphic_waveform","displayName":"Basic case 3 with answer","title":"Atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:531px; height:90px;\" src=\"images/CARD/66491_Basic_case_3_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lead V1 showing coarse atrial fibrillation with moderate ventricular response. The two characteristic findings in AF are present: the very rapid atrial fibrillatory waves (f waves) which are variable in appearance; and the irregularly irregular ventricular response as the R-R interval between beats is unpredictable. Coarse atrial fibrillation may appear similar to atrial flutter. However, the variable height and duration of the f waves differentiate them from atrial flutter (F) waves which are identical in appearance and occur at a constant rate of about 250 to 350 beats/min.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 66491 Version 2.0</div></div></div>"},"66492":{"type":"graphic_diagnosticimage","displayName":"RSV in neutropenia PA","title":"Respiratory syncytial virus infection","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respiratory syncytial virus&nbsp;infection</div><div class=\"cntnt\"><img style=\"width:356px; height:276px;\" src=\"images/ID/66492_RSV_in_neutropenia_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest&nbsp;radiograph shows interstitial infiltrates in a peribronchovascular distribution in a neutropenic patient with malignant melanoma. The etiology was proven to be respiratory syncytial virus.</div><div class=\"graphic_reference\">Courtesy of Jay Fishman, MD.</div><div id=\"graphicVersion\">Graphic 66492 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"66493":{"type":"graphic_table","displayName":"Second-line TB drugs: Dosing","title":"Dosing of second-line antituberculosis drugs in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing of second-line antituberculosis drugs in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\"><span style=\"color: #000000;\">​</span>Drug</td> <td class=\"subtitle1\">Adult dose*<br /> (normal renal function)</td> <td class=\"subtitle1\">Adult dose: Patients with creatinine clearance &#60;30 mL/min or patients on intermittent hemodialysis</td> <td class=\"subtitle1\">Main and rare but serious adverse effects</td> <td class=\"subtitle1\">Pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td>Levofloxacin</td> <td>750 to 1000 mg orally or IV once daily<sup>&#182;</sup></td> <td>750 to 1000 mg orally or IV three times weekly</td> <td>GI toxicity, CNS effects, rash, dysglycemia, tendonitis, tendon rupture, QT prolongation</td> <td>Potential choice when there are no suitable alternatives</td> </tr> <tr class=\"divider_bottom\"> <td>Moxifloxacin</td> <td>400 mg orally or IV once daily (doses up to 800 mg once daily have been used)</td> <td>No change</td> <td>GI toxicity, CNS effects, rash, dysglycemia, tendonitis, tendon rupture, QT prolongation, hepatotoxicity</td> <td>Potential choice when there are no suitable alternatives</td> </tr> <tr class=\"divider_bottom\"> <td>Amikacin<sup>&#916;</sup><sup>&#9674;</sup><sup>&#167;</sup><sup>&#165;</sup></td> <td>15 mg/kg IM or IV once daily (usual maximum 1 g) adjusted according to serum concentrations</td> <td>12 to 15 mg/kg/dose IM or IV two to three times weekly<sup>&#135;</sup> adjusted according to serum concentrations</td> <td>Ototoxicity, vestibular toxicity, nephrotoxicity, electrolyte disturbances, local pain with IM injection</td> <td>Avoid</td> </tr> <tr class=\"divider_bottom\"> <td>Kanamycin<sup>&#916;</sup><sup>&#9674;</sup><sup>&#167;</sup><sup>&#165;</sup></td> <td>15 mg/kg IM or IV once daily (usual maximum 1 g) adjusted according to serum concentrations</td> <td>12 to 15 mg/kg/dose IM or IV two to three times weekly<sup>&#135;</sup> adjusted according to serum concentrations</td> <td>Ototoxicity, vestibular toxicity, nephrotoxicity, electrolyte disturbances</td> <td>Avoid</td> </tr> <tr class=\"divider_bottom\"> <td>Capreomycin<sup>&#916;</sup><sup>&#167;</sup><sup>&#165;</sup></td> <td>15 mg/kg IM or IV once daily (usual maximum 1 g) adjusted according to serum concentrations</td> <td>12 to 15 mg/kg/dose IM or IV two to three times weekly<sup>&#135;</sup> adjusted according to serum concentrations</td> <td>Ototoxicity, vestibular toxicity, nephrotoxicity, electrolyte disturbances, local pain with IM injections</td> <td>Avoid</td> </tr> <tr class=\"divider_bottom\"> <td>Streptomycin<sup>&#916;</sup><sup>&#167;</sup><sup>&#165;</sup></td> <td>15 mg/kg IM or IV once daily (usual maximum 1 g) adjusted according to serum concentrations</td> <td>12 to 15 mg/kg/dose IM or IV two to three times weekly<sup>&#135;</sup></td> <td>Ototoxicity, vestibular toxicity, nephrotoxicity, electrolyte disturbances, local pain with IM injections</td> <td>Avoid</td> </tr> <tr class=\"divider_bottom\"> <td>Ethionamide<sup>&#134;,</sup>**<sup>,</sup><sup>&#182;&#182;</sup></td> <td>15 to 20 mg/kg orally (usually 500 to 750 mg per day) as a single daily dose or two divided doses (maximum 1 g per day)</td> <td>No change; some suggest 250 to 500 mg/day</td> <td>GI toxicity (antiemetic premedication is often helpful), hepatic toxicity, metallic taste, neurotoxicity including optic neuritis (administer with pyridoxine 100 mg per day), endocrine effects including hypothyroidism (treat with thyroid replacement)</td> <td>Potential choice when there are no suitable alternatives</td> </tr> <tr class=\"divider_bottom\"> <td>Cycloserine<sup>&#134;,</sup>**<sup>,</sup><sup>&#916;&#916;</sup></td> <td>10 to 15 mg/kg orally in two divided doses (usually 250 mg twice daily, maximum 500 mg twice daily) adjusted according to serum concentrations</td> <td>250 mg orally once daily or 500 mg orally three times weekly adjusted according to serum concentrations</td> <td> <p>CNS toxicity (psychiatric symptoms, seizures usually occur at peak concentrations &#62;35 mcg/mL but may occur in the normal therapeutic range), peripheral neuropathy, dermatologic effects include serious cutaneous hypersensitivity reactions.</p> Administration of pyridoxine 50 mg (oral once per day) for every 250 mg of cycloserine may be useful in preventing or reducing neurotoxicity.</td> <td>Potential choice when there are no suitable alternatives</td> </tr> <tr class=\"divider_bottom\"> <td>Linezolid**</td> <td>600 mg orally or IV once daily</td> <td>No change (toxic metabolites may accumulate)</td> <td>Myelosuppression, GI toxicity, neuropathy (optic and peripheral); pyridoxine 50 to 100 mg per day may be useful in preventing or reducing peripheral neuropathy</td> <td>Avoid (limited data)</td> </tr> <tr class=\"divider_bottom\"> <td>Clofazimine (not commercially available in the United States)<sup>&#9674;&#9674;</sup></td> <td>100 to 200 mg orally once daily</td> <td>No change</td> <td>Red discoloration of skin, eyes, body fluids; GI toxicity, photosensitivity, others</td> <td>Avoid</td> </tr> <tr class=\"divider_bottom\"> <td>High-dose isoniazid**</td> <td>900 to 1500 mg orally, IM, or IV twice or three times weekly</td> <td>900 mg orally or IV three times weekly</td> <td>Hepatitis, peripheral neuropathy (administer with pyridoxine), hypersensitivity, others</td> <td>May be used</td> </tr> <tr class=\"divider_bottom\"> <td>Bedaquiline</td> <td>400 mg orally once daily for two weeks, followed by 200 mg three times weekly (maximum duration studied 24 weeks)</td> <td>No change for mild-moderate renal dysfunction; use with caution in severe renal disease</td> <td>QT prolongation, hepatitis, GI toxicity, others</td> <td>May be used</td> </tr> <tr class=\"divider_bottom\"> <td>Delamanid</td> <td>100 mg orally twice daily with food (maximum duration studied 26 weeks)</td> <td>No change; not recommended in severe renal disease (data lacking)</td> <td>GI toxicity, QT prolongation</td> <td>Avoid</td> </tr> <tr class=\"divider_bottom\"> <td>Para-aminosalicylic acid<sup>&#134;</sup></td> <td>8 to 12 g orally in two or three divided doses</td> <td>No change; some suggest 4 g/dose twice daily</td> <td>GI toxicity, hepatotoxicity, hypothyroidism (treat with thyroid replacement)</td> <td>Potential choice when there are no suitable alternatives</td> </tr> <tr class=\"divider_bottom\"> <td>Imipenem-cilastatin</td> <td>1000 mg IV every 12 hours. Must be given with clavulanate 125 mg orally every 8 to 12 hours (available as amoxicillin-clavulanate; see below).</td> <td>500 mg IV every 12 hours (refer to Lexicomp monograph for detail)</td> <td>GI toxicity, seizures</td> <td>Potential choice when there are no suitable alternatives</td> </tr> <tr class=\"divider_bottom\"> <td>Meropenem</td> <td>2000 mg IV every 8 to 12 hours (based on published study); 1000 mg every 12 hours may be sufficient (based on pharmacokinetic data). Must be given with clavulanate 125 mg orally every 8 to 12 hours (available as amoxicillin-clavulanate; see below).</td> <td>500 mg IV every 12 hours (refer to Lexicomp monograph for detail)</td> <td>GI toxicity, seizures</td> <td>Potential choice when there are no suitable alternatives</td> </tr> <tr class=\"divider_bottom\"> <td>Amoxicillin-clavulanate</td> <td>2000 mg amoxicillin/125 mg clavulanate orally every 8 to 12 hours</td> <td>1000 mg amoxicillin/125 mg clavulanate orally every 12 hours</td> <td>GI toxicity</td> <td>May be used</td> </tr> <tr> <td>Thioacetazone (not available in the United States)<sup>&#167;&#167;</sup></td> <td>150 mg once daily</td> <td>Renally excreted; not recommended</td> <td>GI toxicity, myelosuppression, hepatitis, peripheral neuropathy, serious cutaneous hypersensitivity reactions</td> <td>Potential choice when there are no suitable alternatives</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Antituberculous agents are used in multidrug combination regimens of varying duration, which are described in detail in a separate table (refer to the UpToDate table on regimens for treatment of drug-susceptible tuberculosis) and in the accompanying text.</div><div class=\"graphic_footnotes\">IV: intravenous; GI: gastrointestinal; CNS: central nervous system; IM: intramuscular; FDA: US Food and Drug Administration.<br />* Dose may need to be adjusted for renal impairment. Dosing of oral medications for treatment of multidrug-resistant tuberculosis (MDR-TB) or extensively drug-resistant tuberculosis (XDR-TB) should be daily, not intermittent.<br />¶ Greater efficacy has been observed with administration of 1000 mg (compared with 500 mg) for treatment of multidrug-resistant tuberculosis. For treatment of contacts to MDR-TB: 500 mg/day if ≤45.5 kg and 750 mg/day if &gt;45.5 kg.<br /><FONT class=lozenge>◊</FONT> For patients who are overweight or obese, dose is based on ideal body weight or dosing weight (a calculator is available in UpToDate). Adjust dose based on serum concentration monitoring for target trough &lt;1 mcg/mL and target peak of 56 to 64 mcg/mL for once-daily administration.<br />§ Injectable agents (ie, aminoglycosides and capreomycin) are typically given 5 days per week; injectable agents should be administered 7 days per week for patients who are severely ill. The initial duration of therapy is at least two to three months (and until culture conversion is documented). After documentation of culture conversion, three-days-per-week dosing can be used for the remaining duration of injectable use (normally through at least six months beyond culture conversion).<br />¥ For patients over 59 years of age, some favor administering a lower dose (10 mg/kg), with standard target drug levels.<br />‡ For patients with creatinine clearance between 50 and 70 mL/min, 12 to 15 mg/kg/dose IM or IV three times weekly may be a reasonable dose. For patients with creatinine clearance between 30 and 50 mL/min, 12 mg/kg/dose IM or IV twice weekly may be a reasonable dose.<br />† Administration of cycloserine, para-aminosalicylic acid, and ethionamide should be via dose escalation (drug ramping) over a two-week period. The initial dose of cycloserine should 250 mg orally once daily for 3 to 4 days, followed by 250 mg orally twice daily for 3 to 4 days, followed by 250 mg orally in the morning and 500 mg orally in the evening; the goal peak serum cycloserine level is &lt;35 mcg/mL. The initial dose of para-aminosalicylic acid is 2 g orally twice daily for 3 to 4 days, followed by 2 g orally in the morning and 4 g orally in the evening for 3 to 4 days, followed by 4 g orally twice daily. The initial dose of ethionamide is 250 mg orally daily for 3 to 4 days, followed by 250 mg orally twice daily for 3 to 4 days, followed by 250 mg orally in the morning and 500 mg orally in the evening.<br />** <FONT color=black>Patients on regimens including high-dose isoniazid, ethionamide, cycloserine, or linezolid should receive oral pyridoxine (100 mg daily) for prevention of neurotoxicity.<br />¶¶ Ethionamide can be given at bedtime or with a main meal in an attempt to reduce nausea. Clinicians experienced with using ethionamide suggest starting with 250 mg once daily and gradually increasing as tolerated. Serum concentrations may be useful in determining the appropriate dose for a given patient. Few patients tolerate 500 mg twice daily.<br />ΔΔ Clinicians experienced with using cycloserine suggest starting with 250 mg once daily and gradually increasing as tolerated. Serum concentrations often are useful in determining the appropriate dose for a given patient. Few patients tolerate 500 mg twice daily.<br />◊◊ Clofazimine is not commercially available in the United States; its use requires application to the US&nbsp;Food and Drug Administration, Division of Special Pathogen and Immunologic Drug Products (telephone <SPAN class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">301-796-1600<A title=\"Call: 301-796-1600\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: 301-796-1600\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,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\"></A></SPAN>).<br />§§&nbsp;Thioacetazone should not be administered to patients with HIV infection.</FONT></div><div class=\"graphic_reference\"><FONT color=black>References:<br /><br /></FONT>&#xD;&#xA;<OL>&#xD;&#xA;<LI><FONT color=black>Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition.</FONT></LI>&#xD;&#xA;<LI><FONT color=black>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016 Aug 10 [Epub ahead of print].</FONT></LI>&#xD;&#xA;<LI><FONT color=black>Treatment Guidelines from The Medical Letter, April 2012; Vol. 10 (116):29. <A href=\"http://www.medicalletter.org/\">www.medicalletter.org</A>.</FONT></LI>&#xD;&#xA;<LI><FONT color=black>Centers for Disease Control and Prevention. Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Recomm Rep 2003; 52:3.</FONT></LI></OL></div><div id=\"graphicVersion\">Graphic 66493 Version 13.0</div></div></div>"},"66496":{"type":"graphic_table","displayName":"Indications for ventilation","title":"Respiratory abnormalities suggestive of the need for mechanical ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Respiratory abnormalities suggestive of the need for mechanical ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Value</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Clinical assessment</td> </tr> <tr> <td class=\"indent1\">Apnea</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Stridor</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Severely depressed mental status</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Flail chest</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Inability to clear respiratory secretions (eg, excessive secretions, loss of protective reflexes, neuromuscular failure)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Trauma to mandible, larynx, trachea</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Loss of ventilatory reserve</td> </tr> <tr> <td class=\"indent1\">Respiratory rate</td> <td>&#62;35 breaths/min</td> </tr> <tr> <td class=\"indent1\">Tidal volume</td> <td>&#60;5 mL/kg</td> </tr> <tr> <td class=\"indent1\">Vital capacity</td> <td>&#60;10 mL/kg</td> </tr> <tr> <td class=\"indent1\">Negative inspiratory force</td> <td>Weaker than &ndash;25 cm H<sub>2</sub>O (2.44 kPa)</td> </tr> <tr> <td class=\"indent1\">Minute ventilation</td> <td>&#60;10 L/min</td> </tr> <tr> <td class=\"indent1\">Rise in PaCO<sub>2</sub></td> <td>&#62;10 mmHg (1.33 kPa)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Refractory hypoxemia</td> </tr> <tr> <td class=\"indent1\">Alveolar-arterial gradient (FiO<sub>2</sub> = 1)</td> <td>&#62;450</td> </tr> <tr> <td class=\"indent1\">PaO<sub>2</sub>/PAO<sub>2</sub></td> <td>&#60;0.15</td> </tr> <tr> <td class=\"indent1\">PaO<sub>2</sub> with supplemental O<sub>2</sub></td> <td>&#60;55 mmHg (7.32 kPa)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PaCO<sub>2</sub>: arterial tension of carbon dioxide; FiO<sub>2</sub>: fraction of inspired oxygen; PaO<sub>2</sub>: arterial tension of oxygen; PAO<sub>2</sub>: alveolar tension of oxygen.</div><div id=\"graphicVersion\">Graphic 66496 Version 3.0</div></div></div>"},"66498":{"type":"graphic_figure","displayName":"AF activation patterns","title":"Activation patterns in atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Activation patterns in atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:345px; height:236px;\" src=\"images/CARD/66498_AF_activation_patterns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isochronal activation maps obtained from the right atrial free wall during atrial fibrillation show four distinct patterns of myocardial activation, indicated by black arrows. Activation from a localizable site which spreads in all directions away from the site is termed focal atrial activation (upper left). Type I activation is a single broad wavefront that propagates without conduction delay (upper right). Type II activation is a single wavefront that is associated with conduction slowing or block, or with two wavefronts (lower left). Type III activation results from the presence of three or more wave fronts associated with areas of slow and blocked conduction (lower right).</div><div class=\"graphic_reference\">Reproduced with permission from Holm M, Johansson R, Brandt J, et al. Eur Heart J 1997; 18:290.</div><div id=\"graphicVersion\">Graphic 66498 Version 2.0</div></div></div>"},"66500":{"type":"graphic_table","displayName":"Intralesional steroid dose","title":"Commonly injected lesions and associated concentrations of corticosteroids for intralesional injection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly injected lesions and associated concentrations of corticosteroids for intralesional injection</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Lesion\n   </td>\n   <td  class=\"subtitle1\">\n   Triamcinolone concentration in mg/mL\n   </td>\n   </tr>\n   <tr>\n   <td>Inflamed acne cysts (face)</td>\n   <td>1 to 3</td>\n   </tr>\n   <tr>\n   <td>Inflamed acne cysts (back, chest, arms)</td>\n   <td>2 to 5</td>\n   </tr>\n   <tr>\n   <td>Psoriasis</td>\n   <td>2.5 to 5</td>\n   </tr>\n   <tr>\n   <td>Lichen simplex chronicus</td>\n   <td>5</td>\n   </tr>\n   <tr>\n   <td>Prurigo nodularis</td>\n   <td>5 to 10</td>\n   </tr>\n   <tr>\n   <td>Hypertrophic lichen planus</td>\n   <td>5 to 10</td>\n   </tr>\n   <tr>\n   <td>Hypertrophic scars</td>\n   <td>10 to 20</td>\n   </tr>\n   <tr>\n   <td>Keloids</td>\n   <td>10 to 40</td>\n   </tr>\n   <tr>\n   <td>Aphthous ulcers and oral lichen planus</td>\n   <td>2 to 5</td>\n   </tr>\n   <tr>\n   <td>Granuloma annulare</td>\n   <td>2 to 10</td>\n   </tr>\n   <tr>\n   <td>Necrobiosis lipoidica diabeticorum</td>\n   <td>2 to 10</td>\n   </tr>\n   <tr>\n   <td>Alopecia areata</td>\n   <td>5</td>\n   </tr>\n   <tr>\n   <td>Chronic cutaneous lupus erythematosis</td>\n   <td>5 to 10</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Reproduced with permission from Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 66500 Version 1.0</div></div></div>"},"66501":{"type":"graphic_figure","displayName":"Long term outcome enalapril","title":"Enalapril delays mortality in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enalapril delays mortality in heart failure</div><div class=\"cntnt\"><img style=\"width:409px; height:246px;\" src=\"images/CARD/66501_Longtermoutcomeenalapril.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis of patients entered into the CONSENSUS trial shows long-term benefit of enalapril compared&nbsp;with placebo (p = 0.008); the risk reduction, averaged over the&nbsp;10-year follow-up, was 30 percent even though the final outcomes were not different.</div><div class=\"graphic_reference\">Data from: Swedberg K, Kjekshus J, Snapinn S, for the CONSENSUS Investigators, Eur Heart J 1999; 20:136.</div><div id=\"graphicVersion\">Graphic 66501 Version 3.0</div></div></div>"},"66503":{"type":"graphic_diagnosticimage","displayName":"Anatomy of the pleural space","title":"Anatomy of the pleural space","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the pleural space</div><div class=\"cntnt\"><img style=\"width:216px; height:315px;\" src=\"images/PULM/66503_Anatomy_of_the_pleural_spac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomic relationships of the pleural space (PS) between the parietal and visceral pleurae (PP and VP, respectively), both of which are lined by a single layer of mesothelial cells (arrow).</div><div class=\"graphic_reference\">Courtesy of Kurt H Albertine, MD.</div><div id=\"graphicVersion\">Graphic 66503 Version 2.0</div></div></div>"},"66504":{"type":"graphic_figure","displayName":"Mitral inflow CW Doppler MR","title":"Continuous wave Doppler of mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuous wave Doppler of mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:375px; height:277px;\" src=\"images/CARD/66504_MitralinflowCWDopplerMR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transmitral continuous wave Doppler in severe mitral regurgitation shows an E wave dominant, restrictive inflow pattern; there is a high velocity E wave, which in this example is 1.7 m/sec. The A wave is small and the E/A ratio is therefore increased.</div><div id=\"graphicVersion\">Graphic 66504 Version 2.0</div></div></div>"},"66505":{"type":"graphic_table","displayName":"Aspiration syndromes","title":"Classification of aspiration syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of aspiration syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1\">Inoculum</td>\n\n\t\t\t<td class=\"subtitle1\">Pulmonary sequelae</td>\n\n\t\t\t<td class=\"subtitle1\">Clinical features</td>\n\n\t\t\t<td class=\"subtitle1\">Therapy</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Acid</td>\n\n\t\t\t<td>Chemical pneumonitis</td>\n\n\t\t\t<td><p>Acute dyspnea, tachpnea, tachycardia; &#177; cyanosis, bronchospasm, fever</p>\n\t\t<p>\n\t\t\tSputum: pink, frothy</p>\n\t\t<p>\n\t\t\tRadiograph: infiltrates in one or both lower lobes</p>\n\t\t<p>\n\t\t\tHypoxemia</p></td>\n\n\t\t\t<td><p>Positive pressure breathing</p>\n\t\t<p>\n\t\t\tIntravenous fluids</p>\n\t\t<p>\n\t\t\tTracheal suction</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Oropharyngeal bacteria</td>\n\n\t\t\t<td>Bacterial infection</td>\n\n\t\t\t<td><p>Usually insidious onset</p>\n\t\t<p>\n\t\t\tCough, fever, purulent sputum</p>\n\t\t<p>\n\t\t\tRadiograph: infiltrate involving dependent pulmonary segment or lobe &#177; cavitation</p></td>\n\n\t\t\t<td>Antibiotics</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Inert fluids</td>\n\n\t\t\t<td><p>Mechanical obstruction</p>\n\t\t<p>\n\t\t\tReflex airway closure</p></td>\n\n\t\t\t<td><p>Acute dyspnea, cyanosis &#177; apnea</p>\n\t\t<p>\n\t\t\tPulmonary edema</p></td>\n\n\t\t\t<td><p>Tracheal suction</p>\n\t\t<p>\n\t\t\tIntermittent positive-pressure breathing with oxygen and isoproterenol</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Particulate matter</td>\n\n\t\t\t<td>Mechanical obstruction</td>\n\n\t\t\t<td>Dependent upon level of obstruction, ranging from acute apnea and rapid death to irritative chronic cough &#177; recurrent infections</td>\n\n\t\t\t<td><p>Extraction of particulate matter</p>\n\t\t<p>\n\t\t\tAntibiotics for superimposed infection</p></td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 66505 Version 2.0</div></div></div>"},"66506":{"type":"graphic_table","displayName":"Echinococcosis serologic tests","title":"Sensitivity of serologic tests for echinococcosis at different sites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity of serologic tests for echinococcosis at different sites</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Site of lesion</td> <td class=\"subtitle1\">Sensitivity of serologic tests</td> </tr> <tr> <td rowspan=\"6\">Liver</td> <td>IgG ELISA: 80 to 90 percent</td> </tr> <tr> <td>IgE ELISA: 82 to 92 percent</td> </tr> <tr> <td>Latex agglutination: 65 to 75 percent</td> </tr> <tr> <td>Hemagglutination: 80 to 90 percent</td> </tr> <tr> <td>Immunoblot (using antigen 5 and/or a B-rich fraction): 80 to 90 percent</td> </tr> <tr> <td>Enzyme-linked immunotransfer blot: 80 percent</td> </tr> <tr> <td rowspan=\"6\">Lung</td> <td>IgG ELISA: 60 to 85 percent</td> </tr> <tr> <td>IgE ELISA: 45 to 70 percent</td> </tr> <tr> <td>Latex agglutination: 50 to 70 percent</td> </tr> <tr> <td>Hemagglutination: 50 to 70 percent</td> </tr> <tr> <td>Immunoblot (using antigen 5 and/or a B-rich fraction): 55 to 70 percent</td> </tr> <tr> <td>Enzyme-linked immunotransfer blot: 55 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ig: immunoglobulin; ELISA: enzyme-linked immunosorbent assay.</div><div id=\"graphicVersion\">Graphic 66506 Version 2.0</div></div></div>"},"66509":{"type":"graphic_waveform","displayName":"CMAP postexercise facilitation","title":"Compound muscle action potential postexercise facilitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Compound muscle action potential postexercise facilitation</div><div class=\"cntnt\"><img style=\"width:307px; height:244px;\" src=\"images/NEURO/66509_CMAPpostexercisefacilitat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exercise testing in LEMS, with the median nerve stimulated supramaximally at the wrist and the abductor pollicis brevis muscle recorded. Top: Baseline. Bottom: Immediately after 10 seconds of maximal voluntary exercise. Note marked increase in compound muscle action potential amplitude (post-exercise facilitation). Pre-exercise and post-exercise testing, looking for an increment, always is better tolerated by patients than is 50 Hz repetitive nerve stimulation.</div><div class=\"graphic_footnotes\">CMAP: compound muscle action potential; LEMS: Lambert-Eaton myasthenic syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders, 2nd ed, Butterworth-Heinemann, Boston 1998. Copyright &copy; 1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 66509 Version 4.0</div></div></div>"},"66510":{"type":"graphic_algorithm","displayName":"Pathogenesis of OHSS","title":"Pathogenesis of OHSS","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of OHSS</div><div class=\"cntnt\"><img style=\"width:484px; height:277px;\" src=\"images/ENDO/66510_Pathogenesis_of_OHSS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">OHSS: ovarian hyperstimulation syndrome; VEGF: vascular endothelial growth factor.</div><div id=\"graphicVersion\">Graphic 66510 Version 3.0</div></div></div>"},"66511":{"type":"graphic_diagnosticimage","displayName":"Chest CT differentiation syndrome","title":"Chest CT scan of alveolar hemorrhage in differentiation syndrome","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Chest CT scan of alveolar hemorrhage in differentiation syndrome</div><div class=\"cntnt\"><img style=\"width:524px; height:268px;\" src=\"images/PULM/66511_Chest_CT_differen_syn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A) and coronal (B) CT chest images from a patient with the differentiation syndrome. Bronchoalveolar lavage showed alveolar hemorrhage.</div><div class=\"graphic_reference\">Courtesy of German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 66511 Version 2.0</div></div></div>"},"66512":{"type":"graphic_picture","displayName":"Pilar cyst 2","title":"Pilar cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pilar cyst</div><div class=\"cntnt\"><img style=\"width:400px; height:332px;\" src=\"images/DERM/66512_Pilar_cyst_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66512 Version 2.0</div></div></div>"},"66513":{"type":"graphic_figure","displayName":"Vertebral flexion teardrop fracture","title":"Flexion teardrop fracture of the cervical spine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexion teardrop fracture of the cervical spine</div><div class=\"cntnt\"><img style=\"width:371px; height:441px;\" src=\"images/EM/66513_Verteb_flex_teardrop_fx.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66513 Version 4.0</div></div></div>"},"66514":{"type":"graphic_table","displayName":"GERD and Barretts","title":"Physiologic abnormalities that may contribute to gastroesophageal reflux disease (GERD) in Barrett's esophagus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic abnormalities that may contribute to gastroesophageal reflux disease (GERD) in Barrett's esophagus</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Abnormality</td>\n<td class=\"subtitle1\">Contribution to GERD</td>\n</tr>\n<tr>\n<td>Gastric acid hypersecretion with or without duodenogastric reflux</td>\n<td>Gastric contents available for reflux are highly caustic to the esophagus due to high concentrations of acid and, with duodenogastric reflux, bile</td>\n</tr>\n<tr>\n<td>Extreme hypotension of the lower esophageal sphincter</td>\n<td>Impairment in primary antireflux barrier</td>\n</tr>\n<tr>\n<td>Poor esophageal contractility</td>\n<td>Reduced ability to clear esophagus of refluxed material</td>\n</tr>\n<tr>\n<td>Diminished esophageal pain sensitivity</td>\n<td>Reduced warning of esophageal injury which can also decrease compliance with antireflux therapy</td>\n</tr>\n<tr>\n<td>Decreased salivary secretion of epidermal growth factor</td>\n<td>May delay healing of esophagus</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Spechler SJ. Barrett's esophagus. Semin Gastrointest Dis 1996; 7:51.</div><div id=\"graphicVersion\">Graphic 66514 Version 3.0</div></div></div>"},"66517":{"type":"graphic_table","displayName":"Features DMD BMD","title":"Genetic, clinical, and pathologic features of Duchenne and Becker muscular dystrophies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic, clinical, and pathologic features of Duchenne and Becker muscular dystrophies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Gene location</td> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Pathology/ CPK</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Dystrophinopathies</td> </tr> <tr> <td class=\"indent1\">Duchenne</td> <td>Xp21</td> <td>Dystrophin</td> <td>XR</td> <td> <p>Onset: 2-5 years</p> <p>Pseudohypertrophy</p> <p>Diminished IQ </p> <p>Cardiac involvement</p> <p>Rapid decline</p> <p>Death by age 20-30 years</p> </td> <td> <p>Severe dystrophic changes</p> <p>Absent dystrophin by immunohistochemistry</p> <p>Dystrophin &#60;5 percent of normal amount by Western blot</p> <p>Striking CK elevation early on</p> </td> </tr> <tr> <td class=\"indent1\">Intermediate \"outliers\"</td> <td>Xp21</td> <td>Dystrophin</td> <td>XR</td> <td>Intermediate</td> <td>Dystrophin 5-20 percent normal amount by Western blot of muscle protein</td> </tr> <tr> <td class=\"indent1\">Becker</td> <td>Xp21</td> <td>Dystrophin</td> <td>XR</td> <td> <p>Onset: variable</p> <p>More benign course</p> </td> <td> <p>Less marked changes</p> <p>Reduced dystrophin by immunohistochemistry</p> <p>Normal or abnormal size dystrophin, amount &#62;20 percent by Western blot</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CK, creatine kinase; XR, X-linked recessive.</div><div id=\"graphicVersion\">Graphic 66517 Version 3.0</div></div></div>"},"66519":{"type":"graphic_diagnosticimage","displayName":"Bronchogenic spread PA","title":"Disseminated bronchioloalveolar cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated bronchioloalveolar cell carcinoma</div><div class=\"cntnt\"><img style=\"width:360px; height:355px;\" src=\"images/PULM/66519_Bronchogenic_spread_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple ill-defined nodular tumor foci, likely resulting from bronchogenic spread.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66519 Version 3.0</div></div></div>"},"66520":{"type":"graphic_table","displayName":"Neuromuscular and chest wall conditions managed with NPPV","title":"Neuromuscular and chest wall conditions that may be managed with noninvasive alternatives to tracheostomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuromuscular and chest wall conditions that may be managed with noninvasive alternatives to tracheostomy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Myopathies</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\">Muscular dystrophies</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Dystrophinopathies - Duchenne and Becker dystrophies</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Limb-girdle, Emery-Dreifuss, facioscapulohumeral, congenital, autosomal recessive, and myotonic muscular dystrophies</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Congenital and metabolic myopathies (eg, acid maltase deficiency, alpha glucosidase deficiency)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Inflammatory myopathies (eg, polymyositis)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Diseases of myoneural junction (eg, myasthenia gravis)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Neurological disorders</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Spinal muscular atrophies</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Motor neuron diseases (eg, amyotrophic lateral sclerosis, poliomyelitis, postpoliomyelitis)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hereditary sensory motor neuropathies</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Neuropathies (eg, phrenic neuropathies, Guillain-Barr&#233; syndrome)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Multiple sclerosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Toxic tetraplegia (eg, pancuronium bromide, botulism)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Traumatic and other myelopathies (eg, spinal cord injury)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Obesity hypoventilation syndrome</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Congenital hypoventilation syndromes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Skeletal pathology</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Kyphoscoliosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Osteogenesis imperfecta</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 66520 Version 3.0</div></div></div>"},"66521":{"type":"graphic_algorithm","displayName":"Proposed GIST management algorithm","title":"Proposed algorithm for the management of localized gastrointestinal stromal cell tumors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proposed algorithm for the management of localized gastrointestinal stromal cell tumors</div><div class=\"cntnt\"><img style=\"width:336px; height:263px;\" src=\"images/ONC/66521_Proposed_GIST_mgmt_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EUS: endoscopic ultrasonography; GIST: gastrointestinal stromal cell tumor.<br> * Possible high-risk endoscopic ultrasonography features include irregular border, cystic spaces, ulceration, echogenic foci, and heterogeneity.<br> <span class=bullet>•</span> Endoscopic ultrasonography surveillance should only be considered after a thorough discussion with the patient regarding the risks and benefits.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Sepe PS, Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol 2009; 6:363. Copyright © 2009.</div><div class=\"contractual\"><br/><a href=\"http://www.nature.com/\">http://www.nature.com</a></div><div id=\"graphicVersion\">Graphic 66521 Version 2.0</div></div></div>"},"66523":{"type":"graphic_figure","displayName":"Sinus symptoms with migraine","title":"Sinus symptoms are common in patients with migraine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinus symptoms are common in patients with migraine</div><div class=\"cntnt\"><img style=\"width:436px; height:378px;\" src=\"images/NEURO/66523_Sinussymptomswithmigrain.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this observational study of patients with a history of sinus headache and no previous history of migraine, sinus pain, pressure, and congestion commonly occurred in association with typical migraine features such as pulsing head pain and sensitivity to activity, light, and sound.</div><div class=\"graphic_reference\">Reproduced with permission from: Schreiber CP, Hutchinson S, Webster CJ, et al. Prevalence of migraine in patients with a history of self-reported or physician-diagnosed \"sinus\" headache. Arch Intern Med 2004; 164:1769. Copyright &copy; 2004 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 66523 Version 18.0</div></div></div>"},"66525":{"type":"graphic_table","displayName":"CSF patterns viral meningitis","title":"Cerebrospinal fluid (CSF) patterns and diagnosis of viral meningitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cerebrospinal fluid (CSF) patterns and diagnosis of viral meningitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pathogen</td> <td class=\"subtitle1\">WBC<br /> (cells/mm3)</td> <td class=\"subtitle1\">RBC</td> <td class=\"subtitle1\">Glucose<br /> (mg/dL)</td> <td class=\"subtitle1\">Protein<br /> (mg/dL)</td> <td class=\"subtitle1\">Viral diagnosis</td> </tr> <tr class=\"divider_bottom\"> <td>Enterovirus</td> <td><span style=\"color: black;\">0-1000</span></td> <td><span style=\"color: black;\">None</span></td> <td><span style=\"color: black;\">NL/SL&#8595;</span></td> <td><span style=\"color: black;\">&#60;160</span></td> <td><span style=\"color: black;\">Cell culture: NP, rectal, CSF; PCR: CSF</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">Parechovirus</span></td> <td><span style=\"color: black;\">NL/SL&#8593;</span></td> <td><span style=\"color: black;\">None</span></td> <td><span style=\"color: black;\">NL/SL&#8595;</span></td> <td><span style=\"color: black;\">NL&nbsp;</span></td> <td><span style=\"color: black;\">Human parechovirus-specific PCR</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">Herpes simplex virus</span></td> <td><span style=\"color: black;\">~100</span></td> <td><span style=\"color: black;\">None or &#8593;</span></td> <td><span style=\"color: black;\">NL/SL&#8595;</span></td> <td><span style=\"color: black;\">~100 or higher</span></td> <td><span style=\"color: black;\">Cell culture: skin or mucosal lesion; PCR: CSF, blood</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">Epstein Barr virus</span></td> <td><span style=\"color: black;\">&#8593;</span></td> <td><span style=\"color: black;\">None</span></td> <td><span style=\"color: black;\">NL</span></td> <td><span style=\"color: black;\">&#8593;</span></td> <td> <p><span style=\"color: black;\">PCR: CSF </span></p> <span style=\"color: black;\">Serum serology</span></td> </tr> <tr class=\"divider_bottom\"> <td>Cytomegalovirus</td> <td>&#8593;</td> <td>None</td> <td>&#8595;</td> <td>&#8593;</td> <td>Cell culture and CSF PCR</td> </tr> <tr class=\"divider_bottom\"> <td>Lymphocytic choriomeningitis virus</td> <td>&#8593;</td> <td>None</td> <td>NL/SL&#8595;</td> <td>NL/SL&#8593;</td> <td>Serology, cell culture and PCR</td> </tr> <tr class=\"divider_bottom\"> <td>Influenza</td> <td>NL/SL&#8593;</td> <td>None</td> <td>NL</td> <td>NL/SL&#8593;</td> <td> <p>NP cell culture, antigen testing and PCR</p> CSF PCR</td> </tr> <tr> <td class=\"sublist1_start\">Arboviruses</td> <td class=\"sublist_other_start\">&#60;200</td> <td class=\"sublist_other_start\" rowspan=\"5\">None</td> <td class=\"sublist_other_start\" rowspan=\"5\">NL</td> <td class=\"sublist_other_start\">&#8593;</td> <td class=\"sublist_other_start\" rowspan=\"5\"> <p>Serum and CSF serology testing</p> <p>Cell culture: research laboratories</p> WEE virus: PCR: CSF</td> </tr> <tr> <td class=\"sublist1\">Eastern equine encephalitis</td> <td class=\"sublist_other\">400-4000</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Western equine encephalitis (WEE)</td> <td class=\"sublist_other\">&#8804;2000</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">West Nile virus</td> <td class=\"sublist_other\">&#60;200</td> <td class=\"sublist_other\">Up to 900</td> </tr> <tr> <td class=\"sublist1\">St. Louis encephalitis virus</td> <td class=\"sublist_other\">&#60;200</td> <td class=\"sublist_other\">~200</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NL: normal; SL: slightly; NP: nasopharyngeal aspirate; CSF: cerebrospinal fluid; PCR: polymerase chain reaction; &darr;: decrease; &uarr;: increase.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Feigin RD, Shackelford PG. Value of repeat lumbar puncture in the differential diagnosis of meningitis. N Engl J Med 1973; 289:571.</LI>&#xD;&#xA;<LI>Negrini B, Kelleher KJ, Wald ER. Cerebrospinal fluid findings in aseptic versus bacterial meningitis. Pediatrics 2000; 105:316.</LI>&#xD;&#xA;<LI>Rotbart HA. Viral meningitis. Semin Neurol 2000; 20:277. </LI>&#xD;&#xA;<LI>Sawyer MH. Enterovirus infections: diagnosis and treatment. Pediatr Infect Dis J 1999; 18:1033. </LI>&#xD;&#xA;<LI>Simko JP, Caliendo AM, Hogle K, Versalovic J. Differences in laboratory findings for cerebrospinal fluid specimens obtained from patients with meningitis or encephalitis due to herpes simplex virus (HSV) documented by detection of HSV DNA. Clin Infect Dis 2002; 35:414.</LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Gomez B, Mintegi S, Rubio MC, et al. Clinical and analytical characteristics and short-term evolution of enteroviral meningitis in young infants presenting with fever without source. Pediatr Emerg Care 2012; 28:518. </SPAN></LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">de Crom SCM, van Furth MAM, Peeters MF, et al. Characteristics of pediatric patients with enterovirus meningitis and no cerebral fluid pleocytosis. Eur J Pediatr 2012; 171:795.</SPAN></LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Sharp J, Harrison CJ, Puckett K, et al. Characteristics of Young Infants in Whom Human Parechovirus, Enterovirus or Neither Were Detected in Cerebrospinal Fluid during Sepsis Evaluations. Pediatr Infect Dis J 2013; 32:213.</SPAN></LI></OL></div><div id=\"graphicVersion\">Graphic 66525 Version 8.0</div></div></div>"},"66528":{"type":"graphic_table","displayName":"Symptoms and signs of PE","title":"Symptoms and signs of acute pulmonary embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs of acute pulmonary embolism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n      <td class=\"subtitle1\">&nbsp;</td>\n      <td class=\"subtitle1\">Frequency</td>\n    </tr>\n    <tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Symptom</td>\n\n\n      \n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Dyspnea</td>\n\n\n      <td>73 percent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Pleuritic chest pain</td>\n\n\n      <td>66 percent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Cough</td>\n\n\n      <td>37 percent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Hemoptysis</td>\n\n\n      <td>13 percent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Sign</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Tachypnea</td>\n\n\n      <td>70 percent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">Rales</td>\n\n      <td>51 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Tachycardia</td>\n\n      <td>30 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Fourth heart sound </td>\n\n      <td>24 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Accentuated pulmonic component of second heart sound</td>\n\n      <td>23 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Circulatory collapse</td>\n\n      <td>8 percent</td>\n\n    </tr>\n\n\n\n  \n  </tbody>\n</table>\n\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=69261&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Symptoms_and_signs_of_PE.htm</title></head></div><div class=\"graphic_reference\">Prepared with data from:<br /><OL>&#xD;&#xA;<LI>Stein PD, Terrin ML, Hales CA, et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest 1991; 100:598.</LI>&#xD;&#xA;<LI>Stein PD, Saltzman HA, Weg JG. Clinical characteristics of patients with acute pulmonary embolism. Am J Cardiol 1991; 68:1723.</LI></OL></div><div id=\"graphicVersion\">Graphic 66528 Version 2.0</div></div></div>"},"66529":{"type":"graphic_table","displayName":"Findings associated with time since fetal death","title":"Good predictors identified in the literature as indicators of intrauterine retention time","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Good predictors identified in the literature as indicators of intrauterine retention time</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">External fetal and cord examination</td> <td class=\"subtitle1\">Placenta and cord histological examination</td> <td class=\"subtitle1\">Histologic fetal gross features</td> </tr> <tr class=\"divider_bottom\"> <td><strong>&#8805;4 h</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Kidney: cortical tubular nuclear loss of basophilia*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>&#8805;6 h</strong></td> <td>Cord discoloration (brown or red)</td> <td class=\"divider_bottom\" rowspan=\"2\">Intravascular karyorrhexis<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Desquamation &#8805;1 cm</td> </tr> <tr class=\"divider_bottom\"> <td><strong>&#8805;12 h</strong></td> <td>Desquamation face, back, abdomen</td> <td>Cord vascular smooth muscle<sup>&#916;</sup></td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>&#8805;18 h</strong></td> <td>Desquamation &#8805;5 percent of the body</td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Desquamation 2 or more of 11 zones<sup>&#9674;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>&#8805;24 h</strong></td> <td class=\"divider_bottom\" rowspan=\"2\">Skin color brown or tan</td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td>Liver: hepatocyte, nuclear loss of basophilia</td> </tr> <tr class=\"divider_bottom\"> <td>Myocardium: inner half loss of nuclear basophilia</td> </tr> <tr class=\"divider_bottom\"> <td><strong>&#8805;36 h</strong></td> <td>&nbsp;</td> <td>Stem villous vessels luminal abnormalities (5 percent)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>&#8805;48 h</strong></td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td>Stem villous vascular lumen abnormalities</td> <td class=\"divider_bottom\" rowspan=\"2\">Myocardium: outer half maximal loss of nuclear basophilia</td> </tr> <tr class=\"divider_bottom\"> <td>Multifocally (25 percent)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>&#8805;96 h</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Bronchus: loss of epithelial nuclear basophilia</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>&#8805;1 wk</strong></td> <td class=\"divider_bottom\" rowspan=\"4\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"4\">&nbsp;</td> <td>Liver: maximal loss of nuclear basophilia</td> </tr> <tr> <td>Gastrointestinal tract: maximal loss of nuclear basophilia</td> </tr> <tr> <td>Trachea: chondrocyte loss of nuclear basophilia</td> </tr> <tr class=\"divider_bottom\"> <td>Adrenal maximal loss of nuclear basophilia</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>&#8805;2 wk</strong></td> <td class=\"divider_bottom\" rowspan=\"3\">Mummification (any)</td> <td>The stem villous vascular lumen abnormalities</td> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> </tr> <tr> <td>\"Extensively\"</td> </tr> <tr class=\"divider_bottom\"> <td>Extensive villous fibrosis</td> </tr> <tr> <td><strong>&#8805;4 wk</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Kidney: maximal loss of nuclear basophilia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">h: hours; wk: weeks.<br />* Loss of nuclear basophilia means at least 1 percent of nuclei totally pink.<br />¶ Because 36 percent of placenta lacked it when the delivery range was 24 to 36 hours, Jacques concluded that the absence of intravascular karyorrhexis cannot exclude time intervals as long as 36 hours.<br />Δ Pyknosis in the smooth muscle cells in the media of the arteries and veins (positive if &gt;1 percent), loss of cohesion with small dark pyknotic or wavy nuclei and eosinophilic cytoplasm, and presence of multi-lobed nuclei resembling neutrophils (this appearance has been termed pseudovasculitis).<br /><FONT class=lozenge>◊</FONT> Scalp, face, neck, chest, abdomen, back, arms, hands, leg, foot, and scrotum.</div><div class=\"graphic_reference\">Reproduced with permission from: Marchetti D, Belviso M, Marino M, Gaudio R. Evaluation of the placenta in a stillborn fetus to estimate the time of death. Am J Forensic Med Pathol 2007; 28:38. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66529 Version 9.0</div></div></div>"},"66530":{"type":"graphic_diagnosticimage","displayName":"Arteriovenous malformation II","title":"Pulmonary arteriovenous malformation in the right upper lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary arteriovenous malformation in the right upper lobe</div><div class=\"cntnt\"><img style=\"width:432px; height:314px;\" src=\"images/PULM/66530_Arteriovenous_malform_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT image with lung window settings shows a right upper lobe solitary pulmonary nodule with several tentacle-like extensions suspicious for an arteriovenous malformation. The enhancement of the nodule is identical to that of the central pulmonary arterial branches.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 66530 Version 3.0</div></div></div>"},"66531":{"type":"graphic_figure","displayName":"Dorsal displaced fx","title":"Dorsally displaced complete distal radius and ulnar fracture","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Dorsally displaced complete distal radius and ulnar fracture</div><div class=\"cntnt\"><img style=\"width:454px; height:299px;\" src=\"images/EM/66531_Dorsaldisplacedfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dorsal bayonet or &quot;dinner fork&quot; deformity.<br> (A) Typical distal metaphyseal fracture with dorsal bayonet showing a dorsal angulation of the distal forearm.<br> (B) Usually the periosteum is intact on the dorsal side and disrupted on the volar side.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66531 Version 15.0</div></div></div>"},"66532":{"type":"graphic_table","displayName":"Feature gestational androgenism","title":"Characteristics of the major causes of gestational hyperandrogenism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of the major causes of gestational hyperandrogenism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Luteoma </td> <td class=\"subtitle1\">Theca-lutein cyst</td> <td class=\"subtitle1\">Sertoli-Leydig tumor</td> <td class=\"subtitle1\">Krukenberg tumor</td> </tr> <tr> <td>Incidence </td> <td>?</td> <td>?</td> <td>Very rare</td> <td>Very rare</td> </tr> <tr> <td>Bilaterality</td> <td>Approximately 47%</td> <td>Approximately 96%</td> <td>Approximately 5%</td> <td>&#62;80%</td> </tr> <tr> <td>Maternal androgen excess</td> <td>Approximately 35%</td> <td>Approximately 30%</td> <td>69 to 87%</td> <td>80 to 100%</td> </tr> <tr> <td>Fetal virilization</td> <td>High if mother&nbsp;virilized</td> <td>0%</td> <td>High if mother virilized </td> <td>80 to 100%</td> </tr> <tr> <td>Malignant</td> <td>0%</td> <td>0%</td> <td>Approximately 45%</td> <td>100%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: McClamrock HD, Adashi EY. Gestational hyperandrogenism.&nbsp;Fertil Steril 1992; 57:257.</div><div id=\"graphicVersion\">Graphic 66532 Version 4.0</div></div></div>"},"66533":{"type":"graphic_picture","displayName":"TTS balloon","title":"Through-the-scope (TTS) esophageal balloon dilator","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Through-the-scope (TTS) esophageal balloon dilator</div><div class=\"cntnt\"><img style=\"width:305px; height:351px;\" src=\"images/GAST/66533_TTS_balloon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel; Primary inflation width of the TTS balloon. Right panel: Three incremental increases in balloon size.</div><div class=\"graphic_reference\">Courtesy of Boston Scientific/Microvasive.</div><div id=\"graphicVersion\">Graphic 66533 Version 2.0</div></div></div>"},"66534":{"type":"graphic_table","displayName":"Clinical features of POEMS syndrome","title":"Clinical features of POEMS syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of POEMS syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Criterion</td> <td class=\"subtitle1\">Mayo series (n = 99)</td> <td class=\"subtitle1\">Soubrier, et al. (n = 25)</td> <td class=\"subtitle1\">Nakanishi, et al. (n = 102)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Polyneuropathy</strong></td> <td>100</td> <td>100</td> <td>100</td> </tr> <tr> <td><strong>Organomegaly</strong></td> <td>50</td> <td>NA</td> <td>NA</td> </tr> <tr> <td class=\"indent1\">Hepatomegaly</td> <td>24</td> <td>68</td> <td>78</td> </tr> <tr> <td class=\"indent1\">Splenomegaly</td> <td>22</td> <td>52</td> <td>35</td> </tr> <tr> <td class=\"indent1\">Lymphadenopathy</td> <td>26</td> <td>52</td> <td>61</td> </tr> <tr class=\"divider_top\"> <td><strong>Endocrinopathy</strong></td> <td>67</td> <td>NA</td> <td>NA</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> <td>3</td> <td>36</td> <td>25</td> </tr> <tr class=\"divider_top\"> <td><strong>Monoclonal plasma cell disorder</strong></td> <td>100</td> <td>100</td> <td>75</td> </tr> <tr class=\"divider_top\"> <td><strong>Skin changes</strong></td> <td>68</td> <td>NA</td> <td>NA</td> </tr> <tr> <td class=\"indent1\">Hyperpigmentation</td> <td>46</td> <td>48</td> <td>93</td> </tr> <tr> <td class=\"indent1\">Hypertrichosis</td> <td>26</td> <td>24</td> <td>74</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table indicates the percent of patients from three major series of patients with POEMS who satisfied each of the original five components of this syndrome.</div><div class=\"graphic_footnotes\">NA: data not available.</div><div class=\"graphic_reference\">Data from: Dispenzieri, A, et al. Blood 2003; 101:2496.</div><div id=\"graphicVersion\">Graphic 66534 Version 6.0</div></div></div>"},"66537":{"type":"graphic_picture","displayName":"Hyperacute rejection IF IgM","title":"Renal allograft biopsy showing hyperacute rejection with IgM by immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal allograft biopsy showing hyperacute rejection with IgM by immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/NEPH/66537_Hyperacute_rejection_IF_IgM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy in hyperacute rejection showing the almost pathognomonic deposition of IgM around the wall of a small artery. The lumen (L) is markedly narrowed by intraluminal fibrin deposition (arrow) which comprises most of the space between the remaining lumen and the immunoglobulin positive vascular wall.</div><div class=\"graphic_footnotes\">IgM: immunoglobulin M.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 66537 Version 3.0</div></div></div>"},"66539":{"type":"graphic_table","displayName":"Causes of vertigo","title":"Causes of vertigo","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of vertigo</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Peripheral causes</td> </tr> <tr> <td class=\"indent1\">Benign paroxysmal positional vertigo</td> </tr> <tr> <td class=\"indent1\">Vestibular neuritis</td> </tr> <tr> <td class=\"indent1\">Herpes zoster oticus (Ramsay Hunt syndrome)</td> </tr> <tr> <td class=\"indent1\">Meniere disease</td> </tr> <tr> <td class=\"indent1\">Labyrinthine concussion</td> </tr> <tr> <td class=\"indent1\">Perilymphatic fistula</td> </tr> <tr> <td class=\"indent1\">Semicircular canal dehiscence syndrome</td> </tr> <tr> <td class=\"indent1\">Cogan's syndrome</td> </tr> <tr> <td class=\"indent1\">Recurrent vestibulopathy</td> </tr> <tr> <td class=\"indent1\">Acoustic neuroma</td> </tr> <tr> <td class=\"indent1\">Aminoglycoside toxicity</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Otitis media</td> </tr> <tr> <td class=\"subtitle1_single\">Central causes</td> </tr> <tr> <td class=\"indent1\">Vestibular migraine</td> </tr> <tr> <td class=\"indent1\">Brainstem ischemia</td> </tr> <tr> <td class=\"indent1\">Cerebellar infarction and hemorrhage</td> </tr> <tr> <td class=\"indent1\">Chiari malformation</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Episodic ataxia type 2</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66539 Version 8.0</div></div></div>"},"66540":{"type":"graphic_picture","displayName":"Bedbugs PI","title":"Bedbugs","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bedbugs</div><div class=\"cntnt\"><img style=\"width:504px; height:328px;\" src=\"images/PI/66540_Bedbugs_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bedbugs are reddish brown and similar in size to a dog tick. They have flat, oval bodies.</div><div class=\"graphic_reference\">Courtesy of Dirk M Elston, MD.</div><div id=\"graphicVersion\">Graphic 66540 Version 1.0</div></div></div>"},"66541":{"type":"graphic_diagnosticimage","displayName":"Open spina bifida in the first trimester","title":"Open spina bifida in the first trimester","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Open spina bifida in the first trimester</div><div class=\"cntnt\"><img style=\"width:494px; height:339px;\" src=\"images/OBGYN/66541_Open_spina_bifida_first_tri.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal view of a fetus with a crown-rump length (CRL) of 6.49 cm consistent with 12<sup>6/7</sup> weeks. The spine at the area of the arrow shows a bulge consistent with an open spina bifida. This finding was confirmed at the follow-up scan.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 66541 Version 1.0</div></div></div>"},"66543":{"type":"graphic_picture","displayName":"Cap polyposis Endosc II","title":"Cap polyposis","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Cap polyposis</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/GAST/66543_Cap_polyposis_Endosc_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopy of a polyp demonstrating a reddish lesion with adherent mucous, findings suggestive of cap polyposis. The surrounding mucosa is normal.</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 66543 Version 2.0</div></div></div>"},"66544":{"type":"graphic_figure","displayName":"GnRH vs GnRH with addback","title":"Effects of gnRH agonist alone (solid lines) versus gnRH agonist plus low-dose estrogen-progestin add-back (dotted line) on surgical staging scores as determined by pre-treatment and post- treatment laparoscopic surgery","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Effects of gnRH agonist alone (solid lines) versus gnRH agonist plus low-dose estrogen-progestin add-back (dotted line) on surgical staging scores as determined by pre-treatment and post- treatment laparoscopic surgery</div><div class=\"cntnt\"><img style=\"width:466px; height:529px;\" src=\"images/OBGYN/66544_GnRH_vs_GnRH_with_addback.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both the GnRH-agonist alone, and the GnRH agonist plus low dose estrogen-progestin add-back produced similar reductions in implant scores. RAFS- Revised American Fertility Society scoring system. ADI-additive diameter of implants score.</div><div class=\"graphic_reference\">Reproduced with permission from: Howell, R, Edmonds, D, Dowsett, M. Gonadotropin releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized clinical trial. Fertil Steril 1995; 64:474. Copyright &#169; 1995 American Society for Reproductive Medicine.</div><div id=\"graphicVersion\">Graphic 66544 Version 1.0</div></div></div>"},"66545":{"type":"graphic_figure","displayName":"Hb Constant Spring and mRNA","title":"Alpha-globin mRNA instability in hemoglobin constant spring","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Alpha-globin mRNA instability in hemoglobin constant spring</div><div class=\"cntnt\"><img style=\"width:568px; height:425px;\" src=\"images/HEME/66545_Hb_Constant_Spring_and_mRNA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As shown in the top panel of this figure, the synthesis of alpha globin mRNA and the levels of alpha-CP stabilizing proteins decline during the mid stages of erythroblast maturation. Because alpha-CP binding enhances stabilization of the Poly (A) 3' tail of mRNA by Poly (A) binding proteins, this leaves globin mRNA more susceptible to ribonuclease degradation in the late erythroblasts and circulating reticulocytes. This is illustrated in sections A and B of the lower panel for mRNA of normal alpha chains, which are stable in bone marrow precursors because of the binding of alpha-CP binding proteins (white oval with diagonal striping), and less stable in reticulocytes because of their absence. In red cell precursors in patients with the thalassemic hemoglobin Constant Spring, which contains a mutated termination codon, alpha-CP binding is blocked by ribosomal &quot;readthrough&quot; through the normally untranslated 3' Poly (A) tail region, which contains the alpha-CP binding sites (section C). This renders alpha chain (Constant Spring) mRNA unstable in early erythroblasts and very unstable in reticulocytes (section D).</div><div class=\"graphic_reference\">Reproduced with permission from: Morales, J, et al. J Biol Chem 1997; 272:6607. Copyright &#169; 1997 American Society for Biochemistry and Molecular Biology.</div><div id=\"graphicVersion\">Graphic 66545 Version 1.0</div></div></div>"},"66546":{"type":"graphic_figure","displayName":"OS imatinib AP CML","title":"Overall survival estimates for patients with chronic myeloid leukemia in accelerated phase treated with imatinib","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Overall survival estimates for patients with chronic myeloid leukemia in accelerated phase treated with imatinib</div><div class=\"cntnt\"><img style=\"width:585px; height:397px;\" src=\"images/HEME/66546_OS_imatinib_AP_CML.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Of the 119 patients in the 600-mg dose group, 24 have died, and overall survival was censored for the remaining 95; 1 of these 95 patients discontinued therapy with imatinib to undergo BMT. Of the 62 patients in the 400-mg dose group, 27 have died, and overall survival was censored for the remaining 35; 1 of these 35 patients discontinued treatment with imatinib to undergo BMT. The difference between dose groups was statistically significant (P = .014, log-rank test).</div><div class=\"graphic_reference\">This research was originally published in Blood. Talpaz, M, Silver, RT, Druker, BJ, et al. Blood 2002; 99:1928. Copyright &#169; 2002 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 66546 Version 3.0</div></div></div>"},"66548":{"type":"graphic_diagnosticimage","displayName":"Normal pleura CT","title":"Normal pleura in right posterolateral hemithorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal pleura in right posterolateral hemithorax</div><div class=\"cntnt\"><img style=\"width:323px; height:319px;\" src=\"images/PULM/66548_Normal_pleura_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On CT scan, the thin pleural complex is outlined by lung internally and extrapleural fat externally. Outside the fat are the endothoracic fascia and the intercostal muscles.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66548 Version 3.0</div></div></div>"},"66549":{"type":"graphic_table","displayName":"Usual doses oral gc asthma","title":"Usual dosages for oral glucocorticoids in asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Usual dosages for oral glucocorticoids in asthma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Oral preparations</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Methylprednisolone</td> <td>2, 4, 8, 16, and 32 mg tablets</td> <td>Short-course \"burst\" for asthma exacerbation: 32 to 48 mg per day as a single dose in the morning for 3 to 10 days; typically 32 mg daily for 5 days.</td> <td rowspan=\"4\">Short course therapy: <ul> <li>Short courses or \"bursts\" are effective for establishing control when initiating therapy, during an acute exacerbation or a period of deterioration.</li> <li>The burst should be continued until patient achieves substantial symptom improvement or resolution, which is usually associated with PEFR &#62;70 to 80 percent of predicted or personal best. This usually requires 3 to 10 days, but may require longer treatment.</li> <li>In patients receiving inhaled glucocorticoids, there is no evidence that tapering the oral dose following improvement prevents relapse.</li> </ul> Long-term control: <ul> <li>Oral glucocorticoids are used only rarely as long-term control medications, eg, in patients with very poorly controlled symptoms despite an optimal treatment regimen and environmental controls.</li> <li>The lowest effective dose is given daily in the morning, or on alternate days to minimize adrenal suppression.</li> </ul> </td> </tr> <tr> <td>Prednisolone*</td> <td>5 mg tablets; 10, 15, and 30 mg orally disintegrating tablets (ODT)</td> <td rowspan=\"2\">Short-course \"burst\" for asthma exacerbation: 40 to 60 mg per day as single dose in the morning for 3 to 10 days; typically 40 mg daily for 5 days.</td> </tr> <tr> <td>Prednisone*</td> <td>1, 2.5, 5, 10, 20, and 50 mg tablets</td> </tr> <tr> <td>Dexamethasone*</td> <td>0.5, 0.75, 1, 1.5, 2, 4, and 6 mg tablets</td> <td>Short-course \"burst\" to achieve symptom control: 6 to 9 mg per day as a single dose in the morning for 3 to 10 days; typically 6 mg daily for 5 days.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For specific recommendations about the use of oral glucocorticoids in asthma, refer to UpToDate reviews on the management of asthma exacerbations and severe asthma.</div><div class=\"graphic_footnotes\">PEFR: peak expiratory flow rate.<br />* Oral liquids are available for use by patients who are unable to swallow pills.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017. Available from: www.ginaasthma.org (accessed February 17, 2017).</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 66549 Version 5.0</div></div></div>"},"66550":{"type":"graphic_diagnosticimage","displayName":"Chondrocalcin knee x ray","title":"Chondrocalcinosis of the knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondrocalcinosis of the knee</div><div class=\"cntnt\"><img style=\"width:270px; height:427px;\" src=\"images/RHEUM/66550_Chondrocalcin_knee_x_ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior plain radiograph of the knee shows calcification of the articular cartilage (arrow) consistent with calcium pyrophosphate deposition disease (CPPD) arthropathy.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Celia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 66550 Version 2.0</div></div></div>"},"66551":{"type":"graphic_figure","displayName":"Endovascular repair of thoracic aortic aneurysm","title":"Endovascular repair of thoracic aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Endovascular repair of thoracic aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/66551_Thoracic_endograft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thoracic endovascular grafts require proximal and distal seal zones of least two centimeters.</div><div id=\"graphicVersion\">Graphic 66551 Version 4.0</div></div></div>"},"66552":{"type":"graphic_table","displayName":"Low IgG subclass levels in different populations","title":"Frequency of decreased IgG subclass concentrations in different populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of decreased IgG subclass concentrations in different populations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Sample population</td> <td class=\"subtitle1\" rowspan=\"2\">Number</td> <td class=\"subtitle1\" colspan=\"4\">Percent</td> </tr> <tr> <td class=\"subtitle2\">IgG1</td> <td class=\"subtitle2\">IgG2</td> <td class=\"subtitle2\">IgG3</td> <td class=\"subtitle2\">IgG4</td> </tr> <tr> <td>Healthy children</td> <td class=\"centered\">3854</td> <td class=\"centered\">4.9</td> <td class=\"centered\">19.4</td> <td class=\"centered\">6.3</td> <td class=\"centered\">0.8</td> </tr> <tr> <td>Healthy adults</td> <td class=\"centered\">162</td> <td class=\"centered\">8</td> <td class=\"centered\">3</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td>Adults with suspected antibody defects</td> <td class=\"centered\">1175</td> <td class=\"centered\">28</td> <td class=\"centered\">17</td> <td class=\"centered\">13</td> <td class=\"centered\">9</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=93969&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Data from different populations showing the percentage of individuals with low serum levels of specific IgG subclasses.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G.</div><div class=\"graphic_reference\">Reproduced with permission from: Meulenbroek AJ, Zeijlemaker WP. Human IgG subclasses: Useful diagnostic markers for immunocompetence, 2nd edition, CLB, Amsterdam, The Netherlands 2000. Copyright © 2000 Sanquin Blood Supply Foundation.</div><div id=\"graphicVersion\">Graphic 66552 Version 3.0</div></div></div>"},"66553":{"type":"graphic_picture","displayName":"Acid-fast staining of Nocardia","title":"Acid-fast staining of <EM>Nocardia</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acid-fast staining of <EM>Nocardia</EM></div><div class=\"cntnt\"><img style=\"width:375px; height:245px;\" src=\"images/ID/66553_Acid_fast_staining_of_Nocar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Nocardia</EM> spp, in contrast&nbsp;with <EM>Actinomyces</EM> spp, are positive by acid-fast stain. The degree of acid fastness is variable depending upon the mycolic acid content of the cell wall.</div><div class=\"graphic_reference\">Courtesy of Stanley W Chapman, MD.</div><div id=\"graphicVersion\">Graphic 66553 Version 4.0</div></div></div>"},"66556":{"type":"graphic_figure","displayName":"Pavlik harness","title":"Pavlik harness","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pavlik harness</div><div class=\"cntnt\"><img style=\"width:424px; height:542px;\" src=\"images/PEDS/66556_Pavlik_harness.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Pavlik harness is a dynamic splint that prevents hip extension and limits hip adduction, but permits hip flexion and abduction.</div><div id=\"graphicVersion\">Graphic 66556 Version 3.0</div></div></div>"},"66559":{"type":"graphic_picture","displayName":"Centruroides exilicauda","title":"Centruroides exilicauda","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Centruroides exilicauda</div><div class=\"cntnt\"><img style=\"width:396px; height:258px;\" src=\"images/EM/66559_C_exilicauda.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Banner Good Samaritan Medical Center, Department of Medical Toxicology.</div><div id=\"graphicVersion\">Graphic 66559 Version 2.0</div></div></div>"},"66560":{"type":"graphic_figure","displayName":"Cri du chat syndrome","title":"Cri du chat syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cri du chat syndrome</div><div class=\"cntnt\"><img style=\"width:344px; height:308px;\" src=\"images/HEME/66560_Cri_du_chat_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cri du chat syndrome is due to a large deletion of the terminal short arm of chromosome 5. The size of the deletion may be different in each patient, but it always encompasses chromosomal bands 5p15.2 and 5p15.3. The&nbsp;representation of chromosome 5 (on the left) indicates the deletion breakpoint that was identified in one patient. The shortened p-arm of a chromosome 5, stained by GTG (G-banding with trypsin and Giemsa)-banding, is shown on the right. For comparison, a chromosome 5 from a normal individual is placed in the middle. The boxed fragment indicates the extent of the deletion in the affected chromosome.</div><div class=\"graphic_reference\">Courtesy of Athena Cherry, Stanford Hospital and Clinics.</div><div id=\"graphicVersion\">Graphic 66560 Version 3.0</div></div></div>"},"66561":{"type":"graphic_figure","displayName":"Pravastatin heart transplant","title":"Pravastatin improves survival in cardiac transplant recipients","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Pravastatin improves survival in cardiac transplant recipients</div><div class=\"cntnt\"><img style=\"width:499px; height:381px;\" src=\"images/CARD/66561_Pravastatin_heart_transplan.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 97 heart transplant recipients randomly assigned to pravastatin or placebo, survival at one year was significantly better with pravastatin (94 versus 78 percent).</div><div class=\"graphic_reference\">Data from Kobashigawa JA, Katznelson S, Laks H, et al. N Engl J Med 1995; 333:621.</div><div id=\"graphicVersion\">Graphic 66561 Version 2.0</div></div></div>"},"66562":{"type":"graphic_figure","displayName":"Femoral nerve anatomy","title":"Femoral nerve anatomy","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Femoral nerve anatomy</div><div class=\"cntnt\"><img style=\"width:484px; height:655px;\" src=\"images/SURG/66562_Femoral_nerve_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The femoral nerve (L2 to L4) emerges at the lower border between the psoas and iliacus muscles, and passes beneath the inguinal ligament. The femoral nerve provides motor branches to&nbsp;knee extensors (quadriceps muscles) and&nbsp;sensation to the anterior thigh, femur, knee joint, and medial leg. The saphenous nerve is the extension of the femoral nerve below the knee and is purely sensory.</div><div class=\"graphic_footnotes\">n.: nerve; m.: muscle.</div><div id=\"graphicVersion\">Graphic 66562 Version 7.0</div></div></div>"},"66563":{"type":"graphic_picture","displayName":"Anhidrotic ectodermal dysplasia - teeth","title":"Anhidrotic ectodermal dysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anhidrotic ectodermal dysplasia</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/66563_Anhidrotic_ectodermal_teeth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conical &quot;peg&quot; teeth.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66563 Version 3.0</div></div></div>"},"66564":{"type":"graphic_picture","displayName":"Endoscopic image after gastric plication","title":"Endoscopic image after gastric plication","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic image after gastric plication</div><div class=\"cntnt\"><img style=\"width:442px; height:293px;\" src=\"images/SURG/66564_Endosc_img_gastr_plication.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an endoscopic image of a greater curve plication procedure.</div><div id=\"graphicVersion\">Graphic 66564 Version 1.0</div></div></div>"},"66565":{"type":"graphic_figure","displayName":"Zenith iliac branch device","title":"Zenith iliac branch device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Zenith iliac branch device</div><div class=\"cntnt\"><img style=\"width:436px; height:504px;\" src=\"images/SURG/66565_Zenith_iliac_br_device_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Permission for use granted by Cook Medical Incorporated, Bloomington, Indiana.</div><div id=\"graphicVersion\">Graphic 66565 Version 2.0</div></div></div>"},"66566":{"type":"graphic_picture","displayName":"Subconjunctival dirofilariasis","title":"Subconjunctival dirofilariasis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Subconjunctival dirofilariasis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/66566_Subconjunct_dirofilariasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A female worm of <em>D. tenuis</em> (arrow) in the conjunctiva of the left eye of a patient.</div><div class=\"graphic_reference\">Reproduced with permission from: Koneman EW, Sutton DA, Fothergill AW, et al. LWW's Organism Central. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66566 Version 1.0</div></div></div>"},"66568":{"type":"graphic_diagnosticimage","displayName":"MRI neurofibromas","title":"MRI images of a chain of neurofibromas in a patient with neurofibromatosis type 1","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">MRI images of a chain of neurofibromas in a patient with neurofibromatosis type 1</div><div class=\"cntnt\"><img style=\"width:471px; height:437px;\" src=\"images/NEURO/66568_MRIneurofibromas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) T2 image showing high signal intensity with central area of low-intensity \"target sign\" (arrows).<br />(B) T1 imaging showing fusiform tumors with signal intensity isodense to muscle (arrows).<br />(C) T1 postgadolinium showing slight, patchy enhancement of the tumor (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of James M Gilchrist, MD.</div><div id=\"graphicVersion\">Graphic 66568 Version 4.0</div></div></div>"},"66570":{"type":"graphic_figure","displayName":"Abdominal pain diary PI","title":"Pain diary","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Pain diary</div><div class=\"cntnt\"><img style=\"width:605px; height:679px;\" src=\"images/PI/66570_Abdominal_pain_diary_PI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pain diary is a way to record your child's pain over a period of one week. At the end of each day, you or the child should write down information about the day's pain. The severity is measured on a 0-to-5 scale, with 0 being no pain and 5 being the worst pain imaginable. Triggers can include foods eaten, activities, or feelings.</div><div id=\"graphicVersion\">Graphic 66570 Version 1.0</div></div></div>"},"66571":{"type":"graphic_table","displayName":"Classification of opioid agents","title":"Classification of opioid agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of opioid agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Origin</td> <td class=\"subtitle1\">Agent (Brand Name)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td rowspan=\"3\">Natural</td> <td>Codeine</td> <td>AT</td> </tr> <tr> <td>Morphine</td> <td>-</td> </tr> <tr> <td>Paregoric</td> <td>-</td> </tr> <tr> <td rowspan=\"7\">Synthetic</td> <td>Diphenoxylate (Lomotil)</td> <td>AD</td> </tr> <tr> <td>Fentanyl (Sublimaze)</td> <td>&nbsp;</td> </tr> <tr> <td>Loperamide (Imodium)</td> <td>AD</td> </tr> <tr> <td>Meperidine (Demerol)</td> <td>S,1</td> </tr> <tr> <td>Methadone (Dolophine)</td> <td>Long-acting</td> </tr> <tr> <td>Propoxyphene (Darvon)</td> <td>S</td> </tr> <tr> <td>Tramadol (Ultram)</td> <td>S</td> </tr> <tr> <td rowspan=\"14\">Semisynthetic</td> <td>Heroin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> <td>-</td> </tr> <tr> <td>Hydrocodone (Lortab)</td> <td>-</td> </tr> <tr> <td>Hydromorphone (Dilaudid)</td> <td>-</td> </tr> <tr> <td>Levorphanol (Levodromoran)</td> <td>Long-acting</td> </tr> <tr> <td>Oxycodone (Percocet)</td> <td>-</td> </tr> <tr> <td>Oxymorphone (Numorphan)</td> <td>-</td> </tr> <tr> <td>Buprenorphine (Buprenex)</td> <td>2,3</td> </tr> <tr> <td>Butorphanol (Stadol)</td> <td>2,3</td> </tr> <tr> <td>Nalburphine (Nubain)</td> <td>2,3</td> </tr> <tr> <td>Pentazocine (Talwin)</td> <td>2,3</td> </tr> <tr> <td>Nalmefene (Revex)</td> <td>-</td> </tr> <tr> <td>Naloxone (Narcane)</td> <td>-</td> </tr> <tr> <td>Naltrexone (Re Via)</td> <td>-</td> </tr> <tr> <td>Dextromethorphan</td> <td>AT</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: antidiarrheal; AT: antitussive; S: seizures; 1: use cautiously with renal compromise; 2: may cause withdrawal symptoms in opioid-dependent patients; 3: has ceiling for analgesia and respiratory depression.</div><div id=\"graphicVersion\">Graphic 66571 Version 2.0</div></div></div>"},"66572":{"type":"graphic_table","displayName":"Newborn neuromuscular disorders","title":"Neuromuscular disorders presenting in newborns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuromuscular disorders presenting in newborns</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Anterior horn cell disorders</td> </tr> <tr> <td>Acute infantile spinal muscular atrophy</td> </tr> <tr> <td>Traumatic myelopathy</td> </tr> <tr> <td>Hypoxic-ischemic myelopathy</td> </tr> <tr> <td>Arthrogryposis multiplex congenita</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital motor or sensory neuropathies</td> </tr> <tr> <td class=\"sublist1_start\">Charcot-Marie-Tooth disease</td> </tr> <tr> <td class=\"sublist1\">Congenital hypomyelinating neuropathy</td> </tr> <tr> <td class=\"sublist1\">Dejerine-Sottas disease</td> </tr> <tr> <td>Hereditary sensory and autonomic neuropathy</td> </tr> <tr> <td class=\"subtitle1_single\">Neuromuscular junction disorders</td> </tr> <tr> <td>Transient acquired neonatal myasthenia</td> </tr> <tr> <td>Congenital myasthenia</td> </tr> <tr> <td>Magnesium toxicity</td> </tr> <tr> <td>Aminoglycoside toxicity</td> </tr> <tr> <td>Infantile botulism</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital myopathies</td> </tr> <tr> <td>Nemaline myopathy</td> </tr> <tr> <td>Central core disease</td> </tr> <tr> <td>Multiminicore disease</td> </tr> <tr> <td>Centronuclear (myotubular) myopathies</td> </tr> <tr> <td>Congenital fiber type disproportion myopathy</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Muscular dystrophies</td> </tr> <tr> <td class=\"sublist1_start\">Dystrophinopathies (Duchenne and Becker muscular dystrophy)</td> </tr> <tr> <td class=\"sublist1_start\">Classic form of congenital muscular dystrophy</td> </tr> <tr> <td class=\"sublist1\">With merosin deficiency</td> </tr> <tr> <td class=\"sublist1\">Without merosin deficiency</td> </tr> <tr> <td class=\"sublist1_start\">Congenital muscular dystrophy-dystroglycanopathy with central nervous system abnormalities</td> </tr> <tr> <td class=\"sublist1\">Walker-Warburg disease</td> </tr> <tr> <td class=\"sublist1\">Muscle-eye-brain disease</td> </tr> <tr> <td class=\"sublist1\">Fukuyama disease</td> </tr> <tr> <td class=\"sublist1\">Congenital muscular dystrophy with cerebellar atrophy/hypoplasia</td> </tr> <tr> <td class=\"sublist1\">Congenital muscular dystrophy with occipital argyria</td> </tr> <tr> <td>Early infantile facioscapulohumeral dystrophy</td> </tr> <tr> <td>Congenital myotonic dystrophy</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic and multisystem diseases</td> </tr> <tr> <td class=\"sublist1_start\">Disorders of glycogen metabolism</td> </tr> <tr> <td class=\"sublist1\">Acid maltase deficiency</td> </tr> <tr> <td class=\"sublist1\">Severe neonatal phosphofructokinase deficiency</td> </tr> <tr> <td class=\"sublist1\">Severe neonatal phosphorylase deficiency</td> </tr> <tr> <td class=\"sublist1\">Debrancher deficiency</td> </tr> <tr> <td>Primary carnitine deficiency</td> </tr> <tr> <td class=\"sublist1_start\">Peroxisomal disorders</td> </tr> <tr> <td class=\"sublist1\">Neonatal adrenoleukodystrophy</td> </tr> <tr> <td class=\"sublist1\">Cerebrohepatorenal syndrome (Zellweger)</td> </tr> <tr> <td>Disorders of creatine metabolism</td> </tr> <tr> <td class=\"sublist1_start\">Mitochondrial myopathies</td> </tr> <tr> <td class=\"sublist1\">Cytochrome c oxidase deficiency</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66572 Version 4.0</div></div></div>"},"66573":{"type":"graphic_diagnosticimage","displayName":"Frykman IV radius fracture AP view","title":"Frykman IV radius fracture AP view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frykman IV radius fracture AP view</div><div class=\"cntnt\"><img style=\"width:311px; height:430px;\" src=\"images/EM/66573_Frykman_IV_AP_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This fracture occurred in a 73-year-old osteoporotic woman following a low-energy fall onto her outstretched right hand. Due to the extension of the fracture into the radiocarpal joint and the distal ulnar injury (arrow), this fracture is categorized as a Frykman IV. Most notable on this image is the displacement of the distal radial fragment (arrowhead) and the loss of radial height. Other injuries are present, most notably a scaphoid fracture (dashed arrow).</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Erik L Schroeder, MD.</div><div id=\"graphicVersion\">Graphic 66573 Version 3.0</div></div></div>"},"66575":{"type":"graphic_figure","displayName":"CCK regulation enzyme release","title":"Cholecystokinin (CCK) regulation of enzyme release","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Cholecystokinin (CCK) regulation of enzyme release</div><div class=\"cntnt\"><img style=\"width:484px; height:396px;\" src=\"images/GAST/66575_CCK_regulation_enzyme_relea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The presence of fat and protein constituents in the duodenum and proximal jejunum causes the release of CCK from gut endocrine cells. CCK acts directly and through vagal mechanisms to stimulate the release of enzymes from pancreatic acinar cells.</div><div class=\"graphic_reference\">Courtesy of Cleveland Clinic Foundation.</div><div id=\"graphicVersion\">Graphic 66575 Version 2.0</div></div></div>"},"66578":{"type":"graphic_figure","displayName":"Ferroportin hepcidin function","title":"Interactions between hepcidin and ferroportin","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Interactions between hepcidin and ferroportin</div><div class=\"cntnt\"><img style=\"width:502px; height:441px;\" src=\"images/HEME/66578_Ferroportin_hepcidin_functi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the iron export function of ferroportin in macrophages. This function (in blue, A) is regulated, in part, by the iron regulatory protein hepcidin (red circle), which binds to ferroportin (B), causing the complex to be internalized and degraded (C), preventing iron export. When hepcidin is in excess, dietary iron absorption is decreased by blocking iron export from intestinal brush border cells; iron export from macrophages is also blocked, leading to hypoferremia. When hepcidin levels are deficient, as in hereditary hemochromatosis, iron absorption proceeds without effective inhibition, leading to iron overload. Two types of ferroportin mutation are known. In one, ferroportin's iron export function is reduced, leading to accumulation of iron in macrophages and low transferrin saturation (D). In the second, hepcidin binding to ferroportin is impaired (E), leading to uncontrolled iron absorption.</div><div class=\"graphic_reference\">Redrawn after Andrews N. Ferroportin hemochromatosis - One molecule, two diseases. The Hematologist 2005; 2:1.</div><div id=\"graphicVersion\">Graphic 66578 Version 3.0</div></div></div>"},"66579":{"type":"graphic_figure","displayName":"Cross section lower leg","title":"Cross section of the lower leg demonstrating the four compartments","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cross section of the lower leg demonstrating the four compartments</div><div class=\"cntnt\"><img style=\"width:425px; height:345px;\" src=\"images/RHEUM/66579_Cross_section_lower_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows how fascia separate the lower leg into four compartments.</div><div class=\"graphic_reference\">Reproduced with permission from: Eiff MP, Hatch, RL, Calmbach W (Eds). Fracture management for Primary Care, 2nd Edition, W. B. Saunders Company, Philadelphia 2002. Copyright © 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 66579 Version 2.0</div></div></div>"},"66580":{"type":"graphic_picture","displayName":"Subacute cutaneous lupus - papular","title":"Subacute cutaneous lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subacute cutaneous lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/66580_Subcutaneouslupuspapular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous, scaly papules are present on the upper back.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66580 Version 4.0</div></div></div>"},"66581":{"type":"graphic_table","displayName":"Diagnostic criteria for rheumatic heart disease","title":"Diagnostic criteria for rheumatic heart disease based on history, cardiac auscultation, and echocardiographic findings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for rheumatic heart disease based on history, cardiac auscultation, and echocardiographic findings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Column A</td> <td class=\"subtitle1\">Column B</td> <td class=\"subtitle1\">Column C</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Category of rheumatic heart disease</strong></td> <td> <p>Presence or history of proven acute rheumatic fever</p> <p>AND/OR</p> <p>Finding on clinical cardiac auscultation (ie, presence of pathological murmur of MR, MS, AR, and/or AS)</p> <p>AND/OR</p> Echocardiographic structural and functional changes of MS without murmur (ie, silent MS)</td> <td>Echocardiographic valvular structural abnormality (ie, typical rheumatic valve morphology according to the World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease)</td> <td>Echocardiographic functional abnormality (ie, presence of significant valve regurgitation according to the World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Definite (presence of at least two of the abnormalities described in columns A, B, and C)</strong></td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Borderline (presence of abnormalities described in either column B or C)</strong></td> <td>&ndash;</td> <td>+</td> <td>+</td> </tr> <tr> <td><strong>Normal (none of the abnormalities described in columns A, B, and C)</strong></td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MR: mitral regurgitation;&nbsp;MS: mitral stenosis;&nbsp;AR: aortic regurgitation;&nbsp;AS: aortic stenosis.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>WHO Technical Report Series. Rheumatic fever and rheumatic heart disease: Report of a WHO expert panel, Geneva 29 October - 1 November 2001. Geneva: WHO; 2004.</li>&#xD;&#xA;    <li>Remenyi B, Wilson N, Steer A, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease - an evidence-based guideline. Nat Rev Cardiol 2012; 9:297.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 66581 Version 5.0</div></div></div>"},"66582":{"type":"graphic_table","displayName":"Indications for GBS intrapartum antibiotic prophylaxis","title":"Indications and nonindications for intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal (GBS) disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications and nonindications for intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal (GBS) disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Intrapartum GBS prophylaxis indicated</td> <td class=\"subtitle1\">Intrapartum GBS prophylaxis not indicated</td> </tr> <tr> <td>Previous infant with invasive GBS disease</td> <td>Colonization with GBS during a previous pregnancy (unless an indication for GBS prophylaxis is present for current pregnancy)</td> </tr> <tr> <td>GBS bacteriuria during any trimester of the current pregnancy*</td> <td>GBS bacteriuria during previous pregnancy (unless an indication for GBS prophylaxis is present for current pregnancy)</td> </tr> <tr> <td>Positive GBS vaginal-rectal screening culture in late gestation<sup>&#182;</sup> during current pregnancy*</td> <td>Negative vaginal and rectal GBS screening culture in late gestation<sup>&#182;</sup> during the current pregnancy, regardless of intrapartum risk factors</td> </tr> <tr> <td>Unknown GBS status at the onset of labor (culture not done, incomplete, or results unknown) and any of the following: <ul> <li>Delivery at &#60;37 weeks' gestation<sup>&#916;</sup> </li> <li>Amniotic membrane rupture &#8805;18 hours </li> <li>Intrapartum temperature &#8805;100.4&#176;F (&#8805;38.0&#176;C)<sup>&#9674;</sup></li> <li>Intrapartum NAAT<sup>&#167;</sup> positive for GBS </li> </ul> </td> <td>Cesarean delivery performed before onset of labor on a woman with intact amniotic membranes, regardless of GBS colonization status or gestational age</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NAAT: nucleic acid amplification tests.<br />* Intrapartum antibiotic prophylaxis is not indicated in this circumstance if a cesarean delivery is performed before onset of labor on a woman with intact amniotic membranes.<br />¶&nbsp;Optimal timing for prenatal GBS screening is at 35 to 37 weeks' gestation.<br />Δ&nbsp;Recommendations for the use of intrapartum antibiotics for prevention of early-onset GBS disease in the setting of threatened preterm delivery are discussed separately.&nbsp;<br />◊ If amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be active against GBS should replace GBS prophylaxis.<br />§&nbsp;NAAT testing for GBS is optional and might not be available in all settings. If intrapartum NAAT is negative for GBS but any other intrapartum risk factor (delivery at &lt;37 weeks' gestation, amniotic membrane rupture at ≥18 hours, or temperature ≥100.4°F [≥8.0°C]) is present, then intrapartum antibiotic prophylaxis is indicated.</div><div class=\"graphic_reference\">Reproduced from: Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease - revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.</div><div id=\"graphicVersion\">Graphic 66582 Version 5.0</div></div></div>"},"66583":{"type":"graphic_picture","displayName":"Scaphoid shift test 1","title":"Scaphoid shift test: Step 1","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Scaphoid shift test: Step 1</div><div class=\"cntnt\"><img style=\"width:480px; height:480px;\" src=\"images/EM/66583_Scaphoid_shift_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the scaphoid shift test, first have the patient position their forearm so it is angled towards you. Then grasp the patient's hand around the metacarpals from the dorsal side.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD, FAAFP, FACSM.</div><div id=\"graphicVersion\">Graphic 66583 Version 4.0</div></div></div>"},"66584":{"type":"graphic_picture","displayName":"Fungal nail infection PI","title":"Fungal nail infections","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Fungal nail infections</div><div class=\"cntnt\"><img style=\"width:584px; height:223px;\" src=\"images/PI/66584_Fungal_nail_infection_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are examples of fungal nail infections.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66584 Version 4.0</div></div></div>"},"66585":{"type":"graphic_figure","displayName":"Posterior circulation to the brain","title":"Posterior circulation to the brain","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Posterior circulation to the brain</div><div class=\"cntnt\"><img style=\"width:603px; height:496px;\" src=\"images/NEURO/66585_ICVAs_BA_PCAs.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66585 Version 3.0</div></div></div>"},"66586":{"type":"graphic_table","displayName":"Risk factors for abnormal labor progress","title":"Factors that have been associated with abnormal labor progress","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that have been associated with abnormal labor progress</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Hypocontractile uterine activity&nbsp;</td> </tr> <tr> <td>Older maternal age</td> </tr> <tr> <td>Long cervical length at midpregnancy</td> </tr> <tr> <td>Pregnancy complications</td> </tr> <tr> <td>Nonreassuring fetal heart rate pattern</td> </tr> <tr> <td>Bandl's ring&nbsp;</td> </tr> <tr> <td>Neuraxial anesthesia</td> </tr> <tr> <td>Macrosomia</td> </tr> <tr> <td>Pelvic contraction</td> </tr> <tr> <td>Non-occiput anterior position</td> </tr> <tr> <td>Nulliparity</td> </tr> <tr> <td>Short stature (less than 150 cm)</td> </tr> <tr> <td>High station at full dilatation</td> </tr> <tr> <td>Chorioamnionitis</td> </tr> <tr> <td>Postterm pregnancy</td> </tr> <tr> <td>Obesity</td> </tr> <tr> <td>Fetal anomaly resulting in cephalopelvic dystocia&nbsp;</td> </tr> <tr> <td>Uterine abnormality&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data&nbsp;from: American College of Obstetrics and Gynecology Committee on Practice Bulletins-Obstetrics. Dystocia and augmentation of labor. ACOG Practice Bulletin #49. Obstet Gynecol 2003; 102:1445.</div><div id=\"graphicVersion\">Graphic 66586 Version 5.0</div></div></div>"},"66587":{"type":"graphic_table","displayName":"TREE trials met colorectal ca","title":"TREE 1 and TREE 2 trials: comparing best response and toxicity in metastatic colorectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TREE 1 and TREE 2 trials: comparing best response and toxicity in metastatic colorectal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"28%\"></colgroup><colgroup span=\"6\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"6\">Percent of patients</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">FOLFOX6*</td> <td class=\"subtitle2\" colspan=\"2\">bFOL</td> <td class=\"subtitle2\" colspan=\"2\">CAPOX</td> </tr> <tr> <td class=\"subtitle3\">TREE 1 (n = 49)</td> <td class=\"subtitle3\">TREE 2<sup>&#182;</sup> (n = 71)</td> <td class=\"subtitle3\">TREE 1 (n = 50)</td> <td class=\"subtitle3\">TREE 2 (n = 70)</td> <td class=\"subtitle3\">TREE 1<sup>&#916;</sup> (n = 48)</td> <td class=\"subtitle3\">TREE 2<sup>&#916;</sup> (n = 72)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Response rate<sup>&#9674;</sup></td> <td>41</td> <td>52</td> <td>20</td> <td>39</td> <td>27</td> <td>46</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Time to tumor progression, months<sup>&#9674;</sup></td> <td>8.7</td> <td>9.9</td> <td>6.9</td> <td>8.3</td> <td>5.9</td> <td>10.3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Overall survival, months<sup>&#9674;</sup></td> <td>19.2</td> <td>26.1</td> <td>17.9</td> <td>20.4</td> <td>17.2</td> <td>24.6</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Grade 3 to 4 toxicity, percent</td> </tr> <tr> <td class=\"indent1\">Vomiting or nausea</td> <td>31</td> <td>7</td> <td>24</td> <td>24</td> <td>38</td> <td>21</td> </tr> <tr> <td class=\"indent1\">Diarrhea</td> <td>31</td> <td>11</td> <td>26</td> <td>26</td> <td>31</td> <td>19</td> </tr> <tr> <td class=\"indent1\">Neutropenia</td> <td>53</td> <td>49</td> <td>18</td> <td>19</td> <td>15</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Hand-foot syndrome</td> <td>8</td> <td>0</td> <td>2</td> <td>0</td> <td>19</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Sensory neurotoxicity</td> <td>18</td> <td>11</td> <td>10</td> <td>9</td> <td>21</td> <td>11</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> <td>0</td> <td>7</td> <td>0</td> <td>13</td> <td>2</td> <td>15</td> </tr> <tr> <td class=\"indent1\">Deep vein thrombosis</td> <td>6</td> <td>4</td> <td>2</td> <td>1</td> <td>0</td> <td>3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* FOLFOX6: oxaliplatin 85 mg/m<SUP>2</SUP> on day 1, leucovorin 400 mg/m<SUP>2</SUP> over two hours day 1, FU 400 mg/m<SUP>2</SUP> bolus day 1 followed by 2400 mg/m<SUP>2</SUP> over 46 hours, every 14 days; bFOL: Oxaliplatin 85 mg/m<SUP>2</SUP> days 1 and 15 plus leucovorin 20 mg/m<SUP>2</SUP> and bolus FU 500 mg/m<SUP>2</SUP> days 1, 8, and 15 every 28 days; CAPOX: Oxaliplatin 130 mg/m<SUP>2</SUP> day 1, capecitabine 1000 mg/m<SUP>2</SUP> (850 mg/m<SUP>2</SUP> for TREE 2) for 14 days every 21 days.<br />¶ TREE 2 trial added bevacizumab 5 mg/kg every other week.<br />Δ Capecitabine dose differed in TREE 1 (1000 mg/m<SUP>2</SUP> twice daily for 14 of every 21 days) and TREE 2 (850 mg/m<SUP>2</SUP> twice daily for 14 of every 21 days).<br /><FONT class=lozenge>◊</FONT> J Clin Oncol 2008; 26:3523.</div><div id=\"graphicVersion\">Graphic 66587 Version 4.0</div></div></div>"},"66588":{"type":"graphic_figure","displayName":"Dystrophin associated protein","title":"The dystrophin associated protein complex","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">The dystrophin associated protein complex</div><div class=\"cntnt\"><img style=\"width:522px; height:357px;\" src=\"images/PEDS/66588_Dystrophin_associated_prote.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dystrophin is located on the cytoplasmic face of the plasma membrane of muscle fibers. Arrows indicate the protein components mutated in various muscular dystrophies. Alterations in the dystrophin gene cause Becker and Duchenne muscular dystrophies. Mutations in the sarcoglycan proteins, caveolin-3 and dysferlin, lead to limb girdle muscular dystrophies. The laminin a2-chain is mutated in a subtype of congenital muscular dystrophy without structural brain anomalies, as is a7-integrin.</div><div class=\"graphic_footnotes\">BMD: Becker muscular dystrophy; CMD: congenital muscular dystrophy; COOH: carboxy-terminal domain; CR: cysteine-rich domain; DMD: Duchenne muscular dystrophy; HH: two helices of the coiled-coil domain; LGMD: limb-girdle muscular dystrophy; MM: Miyoshi myopathy; NH2: amino-terminal domain; Syn: syntrophin-binding domain.</div><div class=\"graphic_reference\">Courtesy of Dr. K. O'Brien and Dr. L. Kunkel, Children's Hospital, Boston, MA.</div><div id=\"graphicVersion\">Graphic 66588 Version 1.0</div></div></div>"},"66589":{"type":"graphic_diagnosticimage","displayName":"PA sling CT","title":"CT scan demonstrates a pulmonary artery sling","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">CT scan demonstrates a pulmonary artery sling</div><div class=\"cntnt\"><img style=\"width:519px; height:394px;\" src=\"images/PULM/66589_PA_sling_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left pulmonary artery originates from the right pulmonary artery, courses anterior to the right bronchial tree, and ascends posterior to the trachea and anterior to the esophagus before crossing to the left side to enter the left hilar region.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66589 Version 4.0</div></div></div>"},"66591":{"type":"graphic_table","displayName":"EUS criteria lymph nodes","title":"Endoscopic ultrasound (EUS) criteria for assessment of lymph nodes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound (EUS) criteria for assessment of lymph nodes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Benign</td> <td class=\"subtitle1\">Malignant</td> </tr> <tr> <td>Size (width)</td> <td>&#60;10 mm</td> <td>&#62;10 mm</td> </tr> <tr> <td>Shape</td> <td>Elongated</td> <td>Round</td> </tr> <tr> <td>Border</td> <td>Irregular</td> <td>Smooth</td> </tr> <tr> <td>Echogenicity</td> <td>Echorich</td> <td>Echopoor</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Catalano, MF, Sivak, MV Jr, Rice, T, et al, Gastrointest Endosc 1994; 40:442 and Bhutani, MS, Hawes, RH, Hoffman, BJ, Gastrointest Endosc 1997; 45:474.</div><div id=\"graphicVersion\">Graphic 66591 Version 4.0</div></div></div>"},"66592":{"type":"graphic_picture","displayName":"Complex atyp hyperplas endomet1","title":"Atypical endometrial hyperplasia (complex)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atypical endometrial hyperplasia (complex)</div><div class=\"cntnt\"><img style=\"width:504px; height:374px;\" src=\"images/OBGYN/66592_Complex_atyp_hyperplas_endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The glandular epithelium here is extremely atypical, but residual endometrial stroma separates all glands in this field. Because of the severity of the atypia, a specimen such as this should be examined thoroughly to rule out the concomitant presence of carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Silverberg SG, Kurman RJ. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. AFIP Atlas of Tumor Pathology, version 2.0, American Registry of Pathology, Washington DC 1995.</div><div id=\"graphicVersion\">Graphic 66592 Version 3.0</div></div></div>"},"66593":{"type":"graphic_picture","displayName":"Ligasure device","title":"LigaSure™ device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LigaSure&#8482; device</div><div class=\"cntnt\"><img style=\"width:432px; height:346px;\" src=\"images/SURG/66593_Ligasure_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LigaSure&#8482; device being used to divide ileocolic artery in laparoscopic colectomy.</div><div class=\"graphic_reference\">Courtesy of Jon Gould, MD.</div><div id=\"graphicVersion\">Graphic 66593 Version 3.0</div></div></div>"},"66596":{"type":"graphic_table","displayName":"Indications for upper gastrointestinal endoscopy","title":"Indications for upper gastrointestinal endoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for upper gastrointestinal endoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnostic examination</td> </tr> <tr> <td class=\"indent1\">Upper abdominal symptoms that fulfill any of the following criteria:<br /> <ul> <li>Are unresponsive to empiric therapy </li> <li>Are associated with alarm symptoms </li> <li>New-onset symptoms in a patient greater than 50 years of age </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dysphagia</td> </tr> <tr> <td class=\"indent1\">Odynophagia</td> </tr> <tr> <td class=\"indent1\">Persistent or recurrent esophageal reflux despite therapy</td> </tr> <tr> <td class=\"indent1\">Persistent vomiting of unknown cause</td> </tr> <tr> <td class=\"indent1\">Active or recent upper GI bleeding</td> </tr> <tr> <td class=\"indent1\">Presumed chronic blood loss and iron deficiency anemia if any of the following are present:<br /> <ul> <li>There is clinical suspicion of an upper GI source </li> <li>Colonoscopy is negative </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lesion seen on upper GI tract imaging</td> </tr> <tr> <td class=\"indent1\">Acute caustic ingestion</td> </tr> <tr> <td class=\"indent1\">When sampling of tissue or fluid is indicated</td> </tr> <tr> <td class=\"indent1\">Evaluation of diarrhea in a patient suspected of having small bowel disease (eg, celiac disease)</td> </tr> <tr> <td class=\"indent1\">Intraoperative evaluation of anatomic reconstructions</td> </tr> <tr> <td class=\"subtitle1_single\">Screening/surveillance</td> </tr> <tr> <td class=\"indent1\">Dysplasia surveillance in patients with Barrett's esophagus</td> </tr> <tr> <td class=\"indent1\">Gastric cancer screening in selected patients*</td> </tr> <tr> <td class=\"indent1\">Screening for upper GI malignancies in patients with polyposis syndromes or Lynch syndrome</td> </tr> <tr> <td class=\"indent1\">Screening for esophageal varices in patients with portal hypertension</td> </tr> <tr> <td class=\"indent1\">Screening for squamous cell carcinoma in patients with a history of caustic ingestions</td> </tr> <tr> <td class=\"indent1\">Examination to identify upper GI pathology that might influence the treatment of other disorders (eg, evaluating a patient with a history of upper GI bleeding prior to initiating anticoagulation)</td> </tr> <tr> <td class=\"subtitle1_single\">Therapeutic</td> </tr> <tr> <td class=\"indent1\">Treatment of bleeding upper GI tract lesions</td> </tr> <tr> <td class=\"indent1\">Prophylactic variceal banding</td> </tr> <tr> <td class=\"indent1\">Removal of foreign bodies</td> </tr> <tr> <td class=\"indent1\">Placement of feeding or drainage tubes</td> </tr> <tr> <td class=\"indent1\">Removal of selected polypoid lesions*</td> </tr> <tr> <td class=\"indent1\">Dilation of stenotic lesions</td> </tr> <tr> <td class=\"indent1\">Management of achalasia</td> </tr> <tr> <td class=\"indent1\">Palliation of stenoses due to neoplasms</td> </tr> <tr> <td class=\"indent1\">Endoscopic therapy of intestinal metaplasia</td> </tr> <tr> <td class=\"indent1\">Management of operative complications (eg, dilation of anastomotic strictures)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal.<br />* See text for details.</div><div class=\"graphic_reference\">Data for table collected from: Appropriate use of GI endoscopy. Gastrointest Endosc 2012; 75:1127.</div><div id=\"graphicVersion\">Graphic 66596 Version 4.0</div></div></div>"},"66597":{"type":"graphic_figure","displayName":"Ca-PTH dynamics lithium","title":"Mean (±SD) calcium-PTH dynamics in normal subjects and patients receiving lithium carbonate","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Mean (±SD) calcium-PTH dynamics in normal subjects and patients receiving lithium carbonate</div><div class=\"cntnt\"><img style=\"width:455px; height:335px;\" src=\"images/ENDO/66597_Ca-PTH_dynamics_lithium.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The curves were generated by measurements of serum PTH 30 minutes after serum ionized calcium concentrations had been raised or lowered by administration of calcium or citrate, respectively. The serum calcium-PTH curve is shifted to the right in the lithium-treated patients, and the set point is 5.10 mg/dL (1.28 mmol/L), as compared with 4.86 mg/dL (1.22 mmol/L) in the normal subjects.</div><div class=\"graphic_footnotes\">SD: standard deviation; PTH: parathyroid hormone; iPTH: intact PTH; SCa<SUB innerHtml>i</SUB>: serum ionized calcium.</div><div class=\"graphic_reference\">Adapted from: Haden ST, Stoll AL, McCormick S, et al. Alterations in parathyroid dynamics in lithium-treated subjects.&nbsp;J Clin Endocrinol Metab 1997; 82:2844.</div><div id=\"graphicVersion\">Graphic 66597 Version 5.0</div></div></div>"},"66598":{"type":"graphic_figure","displayName":"Continent ileostomy","title":"The continent ileostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The continent ileostomy</div><div class=\"cntnt\"><img style=\"width:392px; height:374px;\" src=\"images/GAST/66598_Continent_ileostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ileal pouch is formed from a loop of ileum, folded on itself as a U, and sutured along with antimesenteric borders. The limbs are then incised, exposing the mucosa, and the nipple valve is fashioned. The pouch is closed and positioned as shown underneath the abdominal wall. Note that the stoma is flush with the skin.</div><div class=\"graphic_reference\">Adapted from Pemberton, JH, Phillips, SF. Ileostomy and its alternatives. In: Gastrointestinal and Liver Disease, 6th ed, vol 2, Feldman, M, Sleisenger, MH, Scharschmidt, BF (Eds), WB Saunders Company, Philadelphia 1998. p. 1764. <br> Reproduced with permission from Mayo Foundation, Copyright ©1999. Mayo does not endorse any organizations or non-Mayo products that may appear in this Website. Materials copyrighted by Mayo may be reprinted for personal use only. Permission to reprint or electronically reproduce any document in part or in its entirety for any other reason is expressly prohibited, unless prior written consent is obtained from Mayo.</div><div id=\"graphicVersion\">Graphic 66598 Version 1.0</div></div></div>"},"66602":{"type":"graphic_figure","displayName":"Parotid gl facial nerve","title":"Parotid gland and the facial nerve","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Parotid gland and the facial nerve</div><div class=\"cntnt\"><img style=\"width:538px; height:308px;\" src=\"images/ONC/66602_Parotid_gl_facial_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relationship of the facial nerve and the parotid gland.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, PhD, FRSM, FIAC &amp; Dalley AF II, PhD. Clinical Oriented Anatomy (4th ed). Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &#169;1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66602 Version 2.0</div></div></div>"},"66606":{"type":"graphic_figure","displayName":"Electrolyte patterns EGD PFT","title":"Median electrolyte concentrations versus time in secretin-stimulated duodenal aspirates obtained through an endoscope","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Median electrolyte concentrations versus time in secretin-stimulated duodenal aspirates obtained through an endoscope</div><div class=\"cntnt\"><img style=\"width:547px; height:378px;\" src=\"images/GAST/66606_Electrolyte_patterns_EGD_PF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Concentration patterns simulate the traditional secretory curves observed with traditional pancreatic function testing using gastroduodenal collection tubes.</div><div class=\"graphic_reference\">Courtesy of Cleveland Clinic Foundation.</div><div id=\"graphicVersion\">Graphic 66606 Version 2.0</div></div></div>"},"66607":{"type":"graphic_picture","displayName":"Fundic gland polyp Light","title":"Fundic gland polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fundic gland polyp</div><div class=\"cntnt\"><img style=\"width:446px; height:268px;\" src=\"images/GAST/66607_Fundic_gland_polyp_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a fundic gland polyp shows normal gastric corpus-type epithelium, arranged in a disorderly and microcystic configuration.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 66607 Version 1.0</div></div></div>"},"66608":{"type":"graphic_diagnosticimage","displayName":"Serous cystadenoma","title":"Pancreatic serous cystadenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic serous cystadenoma</div><div class=\"cntnt\"><img style=\"width:405px; height:286px;\" src=\"images/GAST/66608_Serous_cystadenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT showing a serous cystadenoma of the pancreas. Note central calcification of stellate scar (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Kevin McGrath, MD.</div><div id=\"graphicVersion\">Graphic 66608 Version 5.0</div></div></div>"},"66610":{"type":"graphic_figure","displayName":"ABL1 and BCR genes in CML","title":"ABL1 and BCR genes in chronic myeloid leukemia","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">ABL1 and BCR genes in chronic myeloid leukemia</div><div class=\"cntnt\"><img style=\"width:466px; height:407px;\" src=\"images/HEME/66610_ABL_and_BCR_genes_in_CML.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A schematic representation of the ABL1 gene on chromosome 9 (A) and the BCR gene on chromosome 22 (B). All exons (red/blue boxes) have been scaled to the same size for clarity. Exon numbers are indicated above the coding sequence and the breakpoint cluster nomenclature is placed below the M-bcr (b1-b5). Introns are represented by the intervening lines. The various breakpoint regions are identified by double-headed arrows. The schematic fusion transcripts for the typical M-, m-, and &#181;-bcr are illustrated (C), while the translocation product is demonstrated on the right.</div><div id=\"graphicVersion\">Graphic 66610 Version 4.0</div></div></div>"},"66613":{"type":"graphic_table","displayName":"DSM-IV-TR criteria for social anxiety disorder","title":"DSM-IV-TR criteria for social anxiety disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV-TR criteria for social anxiety disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>A marked and persistent fear of one or more social or performance situations involving exposure to unfamiliar people or possible scrutiny by others.</td> </tr> <tr> <td>The person fears that he or she will act in a way (or show symptoms of anxiety) that will be humiliating or embarrassing.</td> </tr> <tr> <td>Exposure to the feared social situation almost invariably provokes anxiety, which may take the form of a panic attack.</td> </tr> <tr> <td>The person recognizes that the fear is excessive or unreasonable.</td> </tr> <tr> <td>The feared social or performance situations are avoided or endured with intense anxiety or distress.</td> </tr> <tr> <td>The condition interferes significantly with the person's normal routine, occupational (or academic) functioning, or social activities or relationships, or there is marked distress about having the phobia.</td> </tr> <tr> <td>The fear or avoidance is not due to the direct physiological effects of a substance or a general medical condition and is not better accounted for by another mental disorder.</td> </tr> <tr> <td>If a general medical condition or another mental disorder is present, the social or performance fear is unrelated to it (eg, the fear is not of trembling in Parkinson's disease).</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">22</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=80973&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Specify the disorder as \"generalized\" if fears include most social situations.</div><div class=\"graphic_reference\">Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (Copyright 2000). American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 66613 Version 8.0</div></div></div>"},"66614":{"type":"graphic_figure","displayName":"Duodenojejunostomy","title":"Duodenojejunostomy","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Duodenojejunostomy</div><div class=\"cntnt\"><img style=\"width:522px; height:664px;\" src=\"images/SURG/66614_Duodenojejunostomy_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Duodenojejunostomy is accomplished without (A) or with (B) division of the 4th portion of the duodenum.</div><div id=\"graphicVersion\">Graphic 66614 Version 2.0</div></div></div>"},"66615":{"type":"graphic_figure","displayName":"DIEP flap breast reconstruction","title":"DIEP flap breast reconstruction","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">DIEP flap breast reconstruction</div><div class=\"cntnt\"><img style=\"width:522px; height:686px;\" src=\"images/SURG/66615_DIEP-flap-breast-reconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The most commonly used perforator flap for breast reconstruction is the deep inferior epigastric perforator (DIEP) flap. The DIEP uses the lower abdominal island of skin and fat and spares the rectus abdominis muscle. Although the underlying muscle must be split to dissect out the perforating vessels, the muscle itself is not included in the transfer. The deep inferior epigastric artery and vein, which provide the vascular supply for the free flap, are anastomosed to local recipient vessels, using either the internal mammary or thoracodorsal arteries and veins.</div><div id=\"graphicVersion\">Graphic 66615 Version 3.0</div></div></div>"},"66616":{"type":"graphic_figure","displayName":"Exclusion of the distal esophagus","title":"Exclusion of the distal esophagus","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Exclusion of the distal esophagus</div><div class=\"cntnt\"><img style=\"width:471px; height:447px;\" src=\"images/SURG/66616_Exclusion_of_the_distal_esophagus_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the mobilized distal esophagus being prepared for division. By excluding the distal esophagus, gastric contents are prevented from contaminating the mediastinum through a perforated thoracic esophagus.</div><div id=\"graphicVersion\">Graphic 66616 Version 4.0</div></div></div>"},"66617":{"type":"graphic_table","displayName":"2010 TNM staging STS","title":"TNM staging for soft tissue sarcoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging for soft tissue sarcoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Primary tumor (T) </td> </tr> <tr> <td>TX</td> <td colspan=\"4\">Primary tumor cannot be assessed </td> </tr> <tr> <td>T0</td> <td colspan=\"4\">No evidence of primary tumor </td> </tr> <tr> <td class=\"sublist1_start\">T1 </td> <td class=\"sublist_other_start\" colspan=\"4\">Tumor 5 cm or less in greatest dimension<sup>* </sup></td> </tr> <tr> <td class=\"sublist1\">T1a </td> <td class=\"sublist_other_start\" colspan=\"4\">Superficial tumor </td> </tr> <tr> <td class=\"sublist1\">T1b </td> <td class=\"sublist_other_start\" colspan=\"4\">Deep tumor </td> </tr> <tr> <td class=\"sublist1_start\">T2 </td> <td class=\"sublist_other_start\" colspan=\"4\">Tumor more than 5 cm in greatest dimension<sup>* </sup></td> </tr> <tr> <td class=\"sublist1\">T2a </td> <td class=\"sublist_other_start\" colspan=\"4\">Superficial tumor </td> </tr> <tr> <td class=\"sublist1\">T2b </td> <td class=\"sublist_other_start\" colspan=\"4\">Deep tumor </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Regional lymph nodes (N) </td> </tr> <tr> <td>NX</td> <td colspan=\"4\">Regional lymph nodes cannot be assessed </td> </tr> <tr> <td>N0</td> <td colspan=\"4\">No regional lymph node metastasis </td> </tr> <tr> <td>N1<sup>&#182;</sup></td> <td colspan=\"4\">Regional lymph node metastasis </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Distant metastasis (M) </td> </tr> <tr> <td>M0</td> <td colspan=\"4\">No distant metastasis </td> </tr> <tr> <td>M1</td> <td colspan=\"4\">Distant metastasis </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Histologic grade (G)<sup>&#916;</sup> </td> </tr> <tr> <td>GX</td> <td colspan=\"4\">Grade cannot be assessed </td> </tr> <tr> <td>G1</td> <td colspan=\"4\">Grade 1 </td> </tr> <tr> <td>G2</td> <td colspan=\"4\">Grade 2 </td> </tr> <tr> <td>G3</td> <td colspan=\"4\">Grade 3 </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Anatomic stage/prognostic groups </td> </tr> <tr> <td rowspan=\"2\">Stage IA </td> <td>T1a</td> <td>N0</td> <td>M0</td> <td>G1, GX</td> </tr> <tr> <td>T1b</td> <td>N0</td> <td>M0</td> <td>G1, GX</td> </tr> <tr> <td rowspan=\"2\">Stage IB </td> <td>T2a</td> <td>N0</td> <td>M0</td> <td>G1, GX</td> </tr> <tr> <td>T2b</td> <td>N0</td> <td>M0</td> <td>G1, GX</td> </tr> <tr> <td rowspan=\"2\">Stage IIA </td> <td>T1a</td> <td>N0</td> <td>M0</td> <td>G2, G3</td> </tr> <tr> <td>T1b</td> <td>N0</td> <td>M0</td> <td>G2, G3</td> </tr> <tr> <td rowspan=\"2\">Stage IIB </td> <td>T2a</td> <td>N0</td> <td>M0</td> <td>G2</td> </tr> <tr> <td>T2b</td> <td>N0</td> <td>M0</td> <td>G2</td> </tr> <tr> <td rowspan=\"2\">Stage III </td> <td>T2a, T2b</td> <td>N0</td> <td>M0</td> <td>G3</td> </tr> <tr> <td>Any T</td> <td>N1</td> <td>M0</td> <td>Any G</td> </tr> <tr> <td>Stage IV</td> <td>Any T</td> <td>Any N</td> <td>M1</td> <td>Any G</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">* Superficial tumor is located exclusively above the superficial fascia without invasion of the fascia; deep tumor is located either exclusively beneath the superficial fascia, superficial to the fascia with invasion of or through the fascia, or both superficial yet beneath the fascia.<br />¶&nbsp;Presence of positive nodes (N1) in M0 tumors is considered Stage III.<br />Δ The French National Federation of the Centers for the Fight Against Cancer (FNCLCC) System preferred.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 66617 Version 13.0</div></div></div>"},"66620":{"type":"graphic_table","displayName":"Congen melanocytic nevi FAQ","title":"Frequently asked questions regarding congenital melanocytic nevi","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequently asked questions regarding congenital melanocytic nevi</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Small- and medium-sized CMN</td> <td class=\"subtitle1\">Large CMN</td> </tr> <tr> <td>1. What is the lifetime risk for developing melanoma?</td> <td>Most likely &#60;1 percent</td> <td>Approximately 5 percent (highest risk if CMN has final size &#62;40 cm and truncal location)</td> </tr> <tr class=\"divider_top\"> <td>2. Where do melanomas develop?</td> <td>Within the CMN; in the CNS if multiple CMN (&#8805;3; usually numerous) and NCM</td> <td>Within the CMN; CNS (especially if risk factors for NCM &ndash; see below); other (eg, retroperitoneum)</td> </tr> <tr class=\"divider_top\"> <td>3. If melanoma develops within the CMN, where does it start?</td> <td>Dermal-epidermal junction &#62;dermis</td> <td>Dermis/subcutis &#62;dermal-epidermal junction</td> </tr> <tr class=\"divider_top\"> <td>4. When do most melanomas develop?</td> <td>At or after puberty</td> <td>Approximately 50 percent prior to age 5 years; remainder thereafter</td> </tr> <tr class=\"divider_top\"> <td>5. Who is at increased risk for NCM?</td> <td>Individuals with multiple CMN (&#8805;3; usually numerous)</td> <td>Those with multiple satellite nevi and/or a CMN with final size &#62;40 cm, usually with a posterior axial location</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">6. What factors play a role in observation versus excision?</td> <td>&#8226; Cosmetic concerns or functional issues</td> <td rowspan=\"6\">Location, size, and involvement of deeper structures (eg, fascia, muscle) can make complete excision technically difficult or impossible; aggressive surgery to remove the CMN should be postponed in patients with symptomatic NCM</td> </tr> <tr> <td>&#8226; Anxiety</td> </tr> <tr> <td>&#8226; Awareness/medical sophistication</td> </tr> <tr> <td>&#8226; Natural history of lesion</td> </tr> <tr> <td class=\"sublist1_start\">&#8226; Factors that affect ease of monitoring:</td> </tr> <tr> <td class=\"sublist1\"> <p>- Location (arm versus buttock)</p> <p>- Degree of pigmentation (tan versus black)</p> <p>- Thickness and topography (thin and uniform versus thick and multinodular)</p> <p>- Degree of hypertrichosis (minimal versus very dense)</p> </td> </tr> <tr class=\"divider_top\"> <td>7. What methods are typically utilized for excision?</td> <td>Simple or staged excision; the latter can substantially reduce the size of the scar, especially for medium-sized CMN</td> <td>Staged excision with use of tissue expanders or (occasionally) skin grafting</td> </tr> <tr class=\"divider_top\"> <td>8. What other treatment options are available for cosmetic improvement?</td> <td>Curettage (only during the neonatal period), lasers (eg, pigment-directed, ablative), dermabrasion; these procedures do not remove deep melanocytes</td> <td>Curettage (only during the neonatal period), lasers (eg, pigment-directed, ablative), dermabrasion; these procedures do not remove deep melanocytes</td> </tr> <tr class=\"divider_top\"> <td>9. What techniques can be used to monitor CMN clinically?</td> <td>Visual inspection and palpation; dermoscopy; baseline photographs</td> <td>Visual inspection and palpation (eg, to detect indurated areas that may signify proliferation of deeper melanocytes); dermoscopy; baseline photographs</td> </tr> <tr class=\"divider_top\"> <td>10. What complications other than melanoma and NCM can develop?</td> <td>Cosmetic and psychosocial issues</td> <td>Cosmetic and psychosocial issues; bulkiness (often due to neurotization); induration; pruritus; skin fragility; other malignancies (eg, rhabdomyosarcoma)</td> </tr> <tr class=\"divider_top\"> <td>11. What imaging and consultations should be considered?</td> <td>MRI of brain &#177; spine for patients at risk for NCM (see above); dermatologist if concerning changes arise or excision is considered</td> <td>MRI of brain &#177; spine (the latter especially if CMN overlies posterior axis) for patients at risk for NCM (see above); dermatologist; neurologist for those with signs/symptoms of NCM; plastic surgeon; psychologist</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMN: congenital melanocytic nevus; NCM: neurocutaneous melanosis.</div><div class=\"graphic_reference\">Adapted with permission from: Marghoob AA. Congenital melanocytic nevi. Evaluation and management. Dermatol Clin 2002; 20:607. Copyright &#169; 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 66620 Version 2.0</div></div></div>"},"66622":{"type":"graphic_table","displayName":"Empirical dosing of emergency antidotes","title":"Empirical dosing of emergency antidotes to adult patients in extremis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empirical dosing of emergency antidotes to adult patients in extremis*</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Suspected toxin (or similar agent)</td>\r\n                    <td class=\"subtitle1\">Antidote</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cyanide</td>\r\n                    <td>5 g hydroxocobalamin IV, repeat x 1 (alternative is nitrite/thiosulfate kit)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Methemoglobinemia</td>\r\n                    <td>2 mL/kg 2 percent methylene blue IV over 5 minutes</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Digoxin</td>\r\n                    <td>2 to 5 vials digoxin antibody (Fab) fragments IV</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Calcium channel blocker</td>\r\n                    <td>20 mL 10 percent calcium chloride IV, repeat x 2; 0.5 to 1 units/kg/hour insulin (and dextrose) IV</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Local anesthetic</td>\r\n                    <td>1.5 mL/kg of 20 percent intralipid bolus IV, may repeat several times (alternatively, after bolus infuse 0.25 mL/kg per minute for 30 minutes; maximum dose 10 mL/kg)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sodium channel blockade</td>\r\n                    <td>100 mL of 7.5 percent to 8.4 percent sodium bicarbonate IV, repeat x 2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cholinergic agent</td>\r\n                    <td>2 mg atropine IV , doubled every 3 minutes as needed</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Isoniazid</td>\r\n                    <td>5 g pyridoxine over 10 minutes or until seizures stop; remainder over 4 hours</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chloroquine</td>\r\n                    <td>2 mg/kg diazepam IV over 30 minutes</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">* Additional details about antidotes and further treatment of the poisons listed in this table can be found in the specific reviews discussing these poisonings.</div><div id=\"graphicVersion\">Graphic 66622 Version 5.0</div></div></div>"},"66623":{"type":"graphic_table","displayName":"Esophageal foreign bodies","title":"Location of, and predisposing factors for, foreign bodies in the esophagus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Location of, and predisposing factors for, foreign bodies in the esophagus</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Location</td>\n<td class=\"subtitle1\">Frequency</td>\n<td class=\"subtitle1\">Predisposing condition</td>\n</tr>\n\n<tr>\n<td rowspan=\"3\">Proximal one-third</td>\n<td rowspan=\"3\">Rare</td>\n<td>Central nervous system lesions</td>\n</tr>\n\n<tr>\n<td>Zenker's diverticulum</td>\n</tr>\n\n<tr>\n<td>Cervical web</td>\n</tr>\n\n<tr>\n<td rowspan=\"5\">Middle one-third</td>\n<td rowspan=\"5\">Frequent</td>\n<td>Cancer (primary or extrinsic)</td>\n</tr>\n\n<tr>\n<td>Eosinophilic esophagitis</td>\n</tr>\n\n<tr>\n<td>Radiation stricture</td>\n</tr>\n\n<tr>\n<td>Traction esophageal diverticula</td>\n</tr>\n\n<tr>\n<td>Spastic dysmotility</td>\n</tr>\n\n<tr>\n<td rowspan=\"7\">Distal one-third</td>\n<td rowspan=\"7\">Common</td>\n<td>Peptic stricture</td>\n</tr>\n\n<tr>\n<td>Eosinophilic esophagitis</td>\n</tr>\n\n<tr>\n<td>Esophageal mucosal ring</td>\n</tr>\n\n<tr>\n<td>Cancer</td>\n</tr>\n\n<tr>\n<td>Achalasia</td>\n</tr>\n\n<tr>\n<td>Pulsion esophageal diverticula</td>\n</tr>\n\n<tr>\n<td>Spastic dysmotility</td>\n</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 66623 Version 2.0</div></div></div>"},"66624":{"type":"graphic_figure","displayName":"Tachygastria","title":"Tachygastria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tachygastria</div><div class=\"cntnt\"><img style=\"width:373px; height:128px;\" src=\"images/GAST/66624_Tachygastria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrogastrography of the gastric antrum shows a brief period of tachygastria between six and seven minutes, followed by a compensatory pause, and then return of normal pacemaker function with three contractions per minute.</div><div class=\"graphic_reference\">Adapted from: Chen JD, Pan J, McCallum RW. Clinical significance of gastric myoelectrical dysrhythmias. Dig Dis Sci 1995; 13:275.</div><div id=\"graphicVersion\">Graphic 66624 Version 3.0</div></div></div>"},"66625":{"type":"graphic_picture","displayName":"Acrokeratosis paraneoplastica hand","title":"Acrokeratosis paraneoplastica (Bazex's syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acrokeratosis paraneoplastica (Bazex's syndrome)</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/66625_Acrokera_paraneoplas_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, scaly papules are present on the hands.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66625 Version 4.0</div></div></div>"},"66626":{"type":"graphic_picture","displayName":"Maculopapular sarcoidosis","title":"Maculopapular sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maculopapular sarcoidosis</div><div class=\"cntnt\"><img style=\"width:287px; height:324px;\" src=\"images/DERM/66626_Maculopapular_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maculopapular sarcoidosis. Typical lesion consisting of small papules arising from a slightly indurated skin-colored patch.</div><div id=\"graphicVersion\">Graphic 66626 Version 1.0</div></div></div>"},"66627":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa nodule and sinus tracts unroofed","title":"Hidradenitis suppurativa nodule and sinus tracts unroofed","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa nodule and sinus tracts unroofed</div><div class=\"cntnt\"><img style=\"width:432px; height:270px;\" src=\"images/SURG/66627_Finalsurgicalextentedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the completely unroofed inflamed hidradenitis suppurativa nodule and multiple sinus tracts. Note the skin edges are beveled and the base is scraped clean of debris by rough gauze grattage. Hemostasis is controlled using ferric chloride, and the wound is cleansed with hydrogen peroxide and covered with petrolatum dressing.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 66627 Version 5.0</div></div></div>"},"66628":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound images of normal three vessel umbilical cord","title":"Prenatal ultrasound images of normal three vessel umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound images of normal three vessel umbilical cord</div><div class=\"cntnt\"><img style=\"width:512px; height:433px;\" src=\"images/OBGYN/66628_Norm_thr_vessel_umbil_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Transverse view of a normal umbilical cord shows the characteristic &quot;Mickey mouse&quot; appearance with two arteries (a) and one vein (v) surrounded by the Wharton's jelly. Upper panel, conventional two-dimensional ultrasound. Middle panel, color Doppler ultrasound shows blood flow in different directions (arteries in red, vein in blue). Lower panel, power Doppler ultrasound highlights the presence of angle-independent blood flow signals.<br> (Panel B) Longitudinal view of a three-vessel umbilical cord shows the arteries (a) looping around the vein (v). Upper panel, conventional two-dimensional ultrasound. Lower panel, color Doppler ultrasound (arteries in red, vein in blue).</div><div id=\"graphicVersion\">Graphic 66628 Version 4.0</div></div></div>"},"66629":{"type":"graphic_figure","displayName":"Grading of hirsutism","title":"Grading of severity of hirsutism in women","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Grading of severity of hirsutism in women</div><div class=\"cntnt\"><img style=\"width:602px; height:384px;\" src=\"images/ENDO/66629_Grading_of_hirsutism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ferriman-Gallwey hirsutism scoring system. Each of the nine body areas that is most sensitive to androgen is assigned a score from 0 (no hair) to 4 (frankly virile), and these are summed to provide a hormonal hirsutism score. \"Focal\" hirsutism (score 1 to 7) is a common normal variant, whereas generalized hirsutism (score of 8 or more) is abnormal in the general United States population. The normal score is lower in Asian populations and higher in Mediterranean populations.</div><div class=\"graphic_reference\">Reproduced with permission from: Hatch R, Rosenfield RS, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140:815. Copyright &copy; 1981 Elsevier.</div><div id=\"graphicVersion\">Graphic 66629 Version 8.0</div></div></div>"},"66631":{"type":"graphic_table","displayName":"Studies of ERCP complications","title":"Overall complications of endoscopic sphincterotomy and related mortality","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overall complications of endoscopic sphincterotomy and related mortality</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Author</td>\n\n      <td>Cotton et al 1991</td>\n\n      <td>Freeman et al 1996</td>\n\n      <td>Rabenstein et al 1998</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Study</td>\n\n      <td>Retrospective multicenter review</td>\n\n      <td>Prospective multicenter study</td>\n\n      <td>Prospective monocenter study</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Patients</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Number</td>\n\n      <td>7729</td>\n\n      <td>2347</td>\n\n      <td>746</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Pancreatitis</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Number</td>\n\n      <td>148</td>\n\n      <td>127</td>\n\n      <td>35</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Percent</td>\n\n      <td>1.9</td>\n\n      <td>5.4</td>\n\n      <td>4.7</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Bleeding</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Number</td>\n\n      <td>234</td>\n\n      <td>48</td>\n\n      <td>16</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Percent</td>\n\n      <td>3.0</td>\n\n      <td>2.0</td>\n\n      <td>2.1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Sepsis</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Number</td>\n\n      <td>129</td>\n\n      <td>35</td>\n\n      <td>10</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Percent</td>\n\n      <td>1.7</td>\n\n      <td>1.5</td>\n\n      <td>1.4</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Perforation</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Number</td>\n\n      <td>76</td>\n\n      <td>8</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Percent</td>\n\n      <td>1.0</td>\n\n      <td>0.3</td>\n\n      <td>0.1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Other</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Number</td>\n\n      <td>49</td>\n\n      <td>24</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Percent</td>\n\n      <td>0.6</td>\n\n      <td>1.1</td>\n\n      <td>0.3</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Totals</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Number</td>\n\n      <td>636</td>\n\n      <td>229</td>\n\n      <td>63</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Percent</td>\n\n      <td>8.2</td>\n\n      <td>9.8</td>\n\n      <td>8.4</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Deaths</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Number</td>\n\n      <td>103</td>\n\n      <td>10</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Percent</td>\n\n      <td>1.3</td>\n\n      <td>0.4</td>\n\n      <td>0.7</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 66631 Version 1.0</div></div></div>"},"66634":{"type":"graphic_figure","displayName":"CRS Pathophysiology","title":"Pathophysiology of cardiorenal syndrome","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of cardiorenal syndrome</div><div class=\"cntnt\"><img style=\"width:505px; height:700px;\" src=\"images/CARD/66634_CRSPathophysiology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ACEI: angiotensin converting enzyme inhibitor; ARBs: angiotensin II receptor blockers; CO: cardiac output; CVP: central venous pressure; LVEDP: left ventricular end-diastolic pressure; ETs: endothelins; NO: nitric oxide; NP: natriuretic peptides; NSAIDs: nonsteroidal antiinflammatory drugs; RAAS: renal angiotensin aldosterone system; SNS: sympathetic nervous system; SV: stroke volume; GFR: glomerular filtration rate.</div><div id=\"graphicVersion\">Graphic 66634 Version 6.0</div></div></div>"},"66635":{"type":"graphic_diagnosticimage","displayName":"CT guided bone bx ant sacrum","title":"CT-guided bone biopsy of a sacral metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT-guided bone biopsy of a sacral metastasis</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/ONC/66635_CT_guided_bone_bx_ant_sacru.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Safe access to biopsy of this bone metastasis in the anterior sacrum required an unusually long transiliac approach. The patient is lying prone and the needle is inserted through the buttock.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Daniel Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 66635 Version 3.0</div></div></div>"},"66636":{"type":"graphic_diagnosticimage","displayName":"MRI vertebral mets melanoma","title":"Melanoma vertebral metastases","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melanoma vertebral metastases</div><div class=\"cntnt\"><img style=\"width:160px; height:405px;\" src=\"images/ONC/66636_MRI_vertebral_mets_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal section of a T2-weighted magnetic resonance imaging (MRI) study of the spine showing diffuse vertebral metastases from melanoma (arrows). The signal is bright relative to the surrounding fat because of the relatively lower fat content of the metastatic foci compared to normal bone marrow.</div><div class=\"graphic_reference\">Courtesy of Kevin Donohoe, MD.</div><div id=\"graphicVersion\">Graphic 66636 Version 3.0</div></div></div>"},"66637":{"type":"graphic_picture","displayName":"Microscopic findings of PSP","title":"Microscopic neuropathology of progressive supranuclear palsy (PSP)","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Microscopic neuropathology of progressive supranuclear palsy (PSP)</div><div class=\"cntnt\"><img style=\"width:559px; height:577px;\" src=\"images/NEURO/66637_Microscopic_findings_PSP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient was diagnosed clinicaly with PSP-parkinsonism, a variant of classic PSP. The substantia nigra (A-E) shows neuronal loss and gliosis. Several surviving neurons contain globose neurofibrillary tangles (NFTs) (A, arrows). Tau immunostaining (B) demonstrates the NFTs (arrows) and numerous thread-like processes. The globose NFT expands the cytoplasmic profile of residual neurons (A-C) and its characteristic coiled &quot;ball of yarn configuration&quot; is highlighted by routine silver preparations (D) and tau (E). Tau-immunoreactive neuroglial lesions are widespread and include NFTs (arrows), pretangles (arrowhead), tufted astrocytes (thin arrows), and threads in neocortex (F) and striatum (G). Selective anti-4R tau decorates a tufted astrocyte in the subthalamic nucleus (H) and an oligodendroglial coiled body (I) in the internal capsule, as well as numerous thread-like deposits.</div><div class=\"graphic_footnotes\">A, C: hematoxylin-eosin; B, E-G: anti-tau; D: Bielschowsky; H, I: anti-4R tau; A, B: original magnification x200; C-E, H, I: original magnification x600; F, G: original magnification x400.</div><div class=\"graphic_reference\">Reproduced with permission from: Golbe LI, Boeve BF, Keegan BM, Parisi JE. An 81-year-old man with imbalance and memory impairment. Neurology 2007; 68:1147. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66637 Version 7.0</div></div></div>"},"66638":{"type":"graphic_figure","displayName":"Tennis racquet grip size measurement","title":"Determining grip size for tennis racquet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Determining grip size for tennis racquet</div><div class=\"cntnt\"><img style=\"width:442px; height:460px;\" src=\"images/EM/66638_Tennis_grip_measurement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Nirschl criteria suggest that appropriate grip size is determined by the distance from the middle of the proximal palmar crease of the hand to the distal tip of the ring finger in inches.</div><div class=\"graphic_reference\">Adapted from: Nirschl RP. The etiology and treatment of tennis elbow. J Sports Med 1974; 2:308.</div><div id=\"graphicVersion\">Graphic 66638 Version 4.0</div></div></div>"},"66639":{"type":"graphic_picture","displayName":"Hepatobiliary cystadenoma","title":"Hepatobiliary cystadenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatobiliary cystadenoma</div><div class=\"cntnt\"><img style=\"width:353px; height:287px;\" src=\"images/GAST/66639_Hepatobiliary_cystadenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Ultrasound shows a large cystic lesion with septations and slightly irregular wall. Panel B: CT scan demonstrates the same cyst occupying most of the left hepatic lobe. Panel C: Histologic appearance: Low power magnification showing the wall of the cyst composed of a layer of loose vascular, spindle cell stroma lined by tall columnar epithelium. Note polypoid projections (hematoxylin and eosin, original magnification: x 400). Panel D: Closer view demonstrates the layer of simple columnar epithelium with focal areas of pseudostratification. No cellular atypia or pleomorphism is noted (hematoxylin and eosin, original magnification: x 2000).</div><div class=\"graphic_reference\">Reproduced with permission from: Regev, A, Reddy, KR, Berho, M, et al. Large cystic lesions of the liver in adults: A 15-year experience in a tertiary center. J Am Coll Surg 2001; 193:36. Copyright © 2001 American College of Surgeons.</div><div id=\"graphicVersion\">Graphic 66639 Version 3.0</div></div></div>"},"66640":{"type":"graphic_picture","displayName":"Tretinoin APL differentiation","title":"Acute promyelocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute promyelocytic leukemia</div><div class=\"cntnt\"><img style=\"width:384px; height:252px;\" src=\"images/HEME/66640_Tretinoin_APL_differentiati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During treatment with tretinoin, malignant promyelocytes in acute promyelocytic leukemia (APL) begin to differentiate to neutrophils. The cells acquire secondary granules, and the nuclear chromatin becomes condensed.</div><div class=\"graphic_reference\">Courtesy of Richard A Larson, MD.</div><div id=\"graphicVersion\">Graphic 66640 Version 4.0</div></div></div>"},"66642":{"type":"graphic_picture","displayName":"Occlusion of superotemporal branch retinal vein","title":"Occlusion of the superotemporal branch retinal vein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Occlusion of the superotemporal branch retinal vein</div><div class=\"cntnt\"><img style=\"width:370px; height:369px;\" src=\"images/PC/66642_Occl_superotemporal_branch.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66642 Version 3.0</div></div></div>"},"66643":{"type":"graphic_picture","displayName":"Superficial onychomycosis","title":"Onychomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Onychomycosis</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/PC/66643_Superficial_onychomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White superficial onychomycosis caused by&nbsp;<EM>Trichophyton mentagrophytes</EM>.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 66643 Version 3.0</div></div></div>"},"66646":{"type":"graphic_table","displayName":"Dealing with lead paint PI","title":"Ways to prevent exposure to lead in paint","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ways to prevent exposure to lead in paint</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Clean up loose paint chips right away</td> </tr> <tr> <td>Wipe off loose paint using damp cloths or rags that you throw away after using</td> </tr> <tr> <td>Block access to chipping paint with furniture</td> </tr> <tr> <td>Put contact paper over chipping paint</td> </tr> <tr> <td>Hose off the porch or put down a blanket or rug where children play</td> </tr> <tr> <td>Seal or block off areas with small amounts of chipping paint</td> </tr> <tr> <td class=\"sublist1_start\">Do <strong>not </strong>use unsafe ways of removing paint:</td> </tr> <tr> <td class=\"sublist1\">- Do <strong>not </strong>sand off paint without a HEPA (a special type of filter) attachment</td> </tr> <tr> <td class=\"sublist1\">- Do <strong>not </strong>burn off paint with an open flame</td> </tr> <tr> <td class=\"sublist1\">- Do <strong>not </strong>use chemicals to remove paint</td> </tr> <tr> <td>When hiring contractors to remove lead paint, use only people who are \"certified abatement contractors\"</td> </tr> <tr> <td>Make sure family and belongings (such as cushioned furniture) are protected during lead removal (called \"abatement\")</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Environmental Protection Agency. Additional information available at: <a href=\"http://www.epa.gov/lead/\" target=\"_blank\">http://www.epa.gov/lead/</a>.</div><div id=\"graphicVersion\">Graphic 66646 Version 4.0</div></div></div>"},"66648":{"type":"graphic_diagnosticimage","displayName":"Elliptical method for calculating abdominal circumference","title":"Elliptical method for calculating abdominal circumference","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Elliptical method for calculating abdominal circumference</div><div class=\"cntnt\"><img style=\"width:504px; height:340px;\" src=\"images/OBGYN/66648_Ellip_calc_abd_circ.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AC: abdominal circumference.</div><div class=\"graphic_reference\">Courtesy of Jennifer T Ahn, MD.</div><div id=\"graphicVersion\">Graphic 66648 Version 4.0</div></div></div>"},"66651":{"type":"graphic_table","displayName":"Lugano classification for staging of lymphomas","title":"Lugano classification for staging of lymphomas (derived from Ann Arbor staging with Cotswolds modifications)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lugano classification for staging of lymphomas (derived from Ann Arbor staging with Cotswolds modifications)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Stage I</strong>&nbsp;&#8212; Involvement of a single lymph node region (eg, cervical, axillary, inguinal, mediastinal) or lymphoid structure such as the spleen, thymus, or Waldeyer's ring.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Stage II</strong>&nbsp;&#8212;&nbsp;Involvement of two or more lymph node regions or lymph node structures on the same side of the diaphragm. Hilar nodes should be considered to be \"lateralized\" and when involved on both sides, constitute stage II disease. For the purpose of defining the number of anatomic regions, all nodal disease within the mediastinum is considered to be a single lymph node region, and hilar involvement constitutes an additional site of involvement. The number of anatomic regions should be indicated by a subscript (eg, II-3).</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Stage III</strong>&nbsp;&#8212; Involvement of lymph node regions or lymphoid structures on both sides of the diaphragm. This may be subdivided stage III-1 or III-2: stage III-1 is used for patients with involvement of the spleen or splenic hilar, celiac, or portal nodes; and stage III-2 is used for patients with involvement of the paraaortic, iliac, inguinal, or mesenteric nodes.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Stage IV</strong>&nbsp;&#8212; Diffuse or disseminated involvement of one or more extranodal organs or tissue beyond that designated E, with or without associated lymph node involvement.</td> </tr> <tr class=\"divider_bottom\"> <td>All cases are subclassified to indicate the absence (A) or presence (B) of the systemic symptoms of significant unexplained fever, night sweats, or unexplained weight loss exceeding 10% of body weight during the six months prior to diagnosis.</td> </tr> <tr class=\"divider_bottom\"> <td>The designation \"E\" refers to extranodal contiguous extension (ie, proximal or contiguous extranodal disease) that can be encompassed within an irradiation field appropriate for nodal disease of the same anatomic extent. More extensive extranodal disease is designated stage IV.</td> </tr> <tr class=\"divider_bottom\"> <td>Bulky disease: A single nodal mass, in contrast to multiple smaller nodes, of 10 cm or &#8805;<span style=\"font-size: 16px; font-family: calibri;\">&#8531;</span>&nbsp;of the transthoracic diameter at any level of thoracic vertebrae as determined by CT; record the longest measurement by CT scan. The term \"X\" (used in the Ann Arbor staging system) is no longer necessary.</td> </tr> <tr class=\"divider_bottom\"> <td>The subscript \"RS\" is used to designate the stage at the time of relapse.&nbsp;</td> </tr> <tr> <td>Patients can be clinically or pathologically staged. Splenectomy, liver biopsy, lymph node biopsy, and/or bone marrow biopsy are mandatory for the establishment of pathological stage. The pathologic stage at a given site is denoted by a subscript (eg, M = bone marrow, H = liver, L = lung, O = bone, P = pleura, and D = skin).</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:&nbsp;<br /><OL>&#xD;&#xA;<LI>Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630.</LI>&#xD;&#xA;<LI>Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059.</LI></OL></div><div id=\"graphicVersion\">Graphic 66651 Version 7.0</div></div></div>"},"66652":{"type":"graphic_waveform","displayName":"Invasive hemodynamic tracing HCM with LVOT obstruction 2","title":"HCM with left ventricular outflow tract obstruction at rest","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">HCM with left ventricular outflow tract obstruction at rest</div><div class=\"cntnt\"><img style=\"width:490px; height:291px;\" src=\"images/CARD/66652_HCMobstructionatrest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown from top to bottom are four surface ECG leads and the left ventricular (LV) and aortic (Ao) pressure tracings from a patient with hypertrophic cardiomyopathy. The maximum LV systolic pressure is 230 mmHg; the Ao pressure, measured simultaneously with the maximum LV pressure, is 85 mmHg, thereby resulting in an LV outflow gradient of 145 mmHg. The LV systolic pressure varies by 20 to 30 mmHg with each beat (alternans), a finding occasionally found in HCM. The aortic pulse pressure is narrow (25 mmHg), and the pressure tracing reveals the spike-and-dome configuration of LV outflow obstruction.</div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy.</div><div class=\"graphic_reference\">Courtesy of Lameh Fananapazir, MD.</div><div id=\"graphicVersion\">Graphic 66652 Version 4.0</div></div></div>"},"66653":{"type":"graphic_figure","displayName":"Pegvisomant acromegaly IGF-1","title":"Effect of pegvisomant on serum IGF-1 concentrations","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Effect of pegvisomant on serum IGF-1 concentrations</div><div class=\"cntnt\"><img style=\"width:530px; height:332px;\" src=\"images/ENDO/66653_PegvisomantacromegalyIGF1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results in 90 patients with acromegaly who were treated with the growth hormone receptor antagonist pegvisomant for 12 to 24 months. The open circles represent the pretreatment values and the closed circles the lowest post-treatment values. The shaded areas represent the normal ranges for age.</div><div class=\"graphic_footnotes\">IGF-1: insulin-like growth factor-1.</div><div class=\"graphic_reference\">Adapted from: van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358:1754.</div><div id=\"graphicVersion\">Graphic 66653 Version 2.0</div></div></div>"},"66655":{"type":"graphic_diagnosticimage","displayName":"Normal follicle","title":"Normal follicle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal follicle</div><div class=\"cntnt\"><img style=\"width:432px; height:375px;\" src=\"images/OBGYN/66655_Normal_follicle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound image of the left ovary. A normal-appearing left ovary containing a simple anechoic clear cyst, which is consistent with a follicle. A small amount of ovarian tissue is identified surrounding the follicle, as indicated by the arrow.</div><div class=\"graphic_reference\">Reproduced with permission from: Thomas D Shipp, MD. Copyright ©Thomas D Shipp, MD.</div><div id=\"graphicVersion\">Graphic 66655 Version 3.0</div></div></div>"},"66656":{"type":"graphic_picture","displayName":"ALL monotonous view","title":"Acute lymphoblastic leukemia in bone marrow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute lymphoblastic leukemia in bone marrow</div><div class=\"cntnt\"><img style=\"width:437px; height:288px;\" src=\"images/HEME/66656_ALL_monotonous_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of this bone marrow aspirate shows a monotonous collection of blast forms, in a patient with acute lymphoblastic leukemia (ALL). Even at this magnification, the cells can be seen to have a high nuclear:cytoplasmic ratio and prominent nucleoli (arrows).</div><div id=\"graphicVersion\">Graphic 66656 Version 2.0</div></div></div>"},"66659":{"type":"graphic_picture","displayName":"Hood silicone stent studded","title":"Studded hood silicone stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Studded hood silicone stent</div><div class=\"cntnt\"><img style=\"width:428px; height:238px;\" src=\"images/PULM/66659_Hood_silicone_stent_studded.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Studded silicone Hood tracheobronchial stent with cut-off for right main bronchus.</div><div id=\"graphicVersion\">Graphic 66659 Version 2.0</div></div></div>"},"66660":{"type":"graphic_diagnosticimage","displayName":"Hamate body fracture","title":"Hamate body fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hamate body fracture</div><div class=\"cntnt\"><img style=\"width:324px; height:270px;\" src=\"images/EM/66660_Hamate_body_fracture_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This oblique radiograph of the wrist shows a comminuted dorsal hamate body fracture (arrows). The base of the fifth metacarpal is indicated by the dashed arrow.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 66660 Version 5.0</div></div></div>"},"66661":{"type":"graphic_figure","displayName":"Mastectomy incisions for central breast tumors","title":"Mastectomy incisions for central breast tumors","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Mastectomy incisions for central breast tumors</div><div class=\"cntnt\"><img style=\"width:499px; height:598px;\" src=\"images/SURG/66661_Mastectinciscentbrtum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Design of the classic Stewart elliptical incision for central and subareolar primary lesions of the breast. The medial extent of the incision ends at the margin of the sternum. The lateral extent of the skin incision should overlie the anterior margin of the latissimus dorsi. The design of the skin incision should incorporate the primary neoplasm en bloc with margins that are 1 to 2 cm from the cranial and caudal edges of the tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: Bland KI. Modified radical mastectomy and total (simple) mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66661 Version 7.0</div></div></div>"},"66663":{"type":"graphic_diagnosticimage","displayName":"Melioidosis septicemia","title":"Chest radiograph of melioidosis with fulminant septicemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of melioidosis with fulminant septicemia</div><div class=\"cntnt\"><img style=\"width:288px; height:352px;\" src=\"images/ID/66663_Melioidosis_septicemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with a fulminant presentation of melioidosis with septicemia.</div><div class=\"graphic_reference\">Courtesy of Bart Currie, FRACP.</div><div id=\"graphicVersion\">Graphic 66663 Version 4.0</div></div></div>"},"66664":{"type":"graphic_movie","displayName":"M-mode echocardiogram of AR","title":"M-mode echocardiogram of aortic regurgitation in a patient with bicupsid aortic valve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of aortic regurgitation in a patient with bicupsid aortic valve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/66664_aormmdecconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:318px; height:240px;\" src=\"images/CARD/66664_aormmdec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echo in a patient with a bicuspid aortic valve. Note eccentricity of aortic valve and thickened leaflets.</div><div id=\"graphicVersion\">Graphic 66664 Version 4.0</div></div></div>"},"66665":{"type":"graphic_figure","displayName":"Etonogestrel implant","title":"Etonogestrel implant","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Etonogestrel implant</div><div class=\"cntnt\"><img style=\"width:573px; height:265px;\" src=\"images/OBGYN/66665_Implanon_rod.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Implanon is 40 mm in length and 2 mm in diameter. It is composed of a solid core of Evatane with the crystals of etonogestrel imbedded within the core. Surrounding the core is a thin layer of evatane (0.06 mm thick) that controls the rate which etonogestrel is released. The rigidity of the implant pertains to its ease of removal and resistance to fracture during removal.</div><div class=\"graphic_reference\">Reproduced with permission from: Organon USA, Inc.</div><div id=\"graphicVersion\">Graphic 66665 Version 3.0</div></div></div>"},"66666":{"type":"graphic_diagnosticimage","displayName":"MR image appendicitis in pregnancy","title":"Magnetic resonance image of appendicitis in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of appendicitis in pregnancy</div><div class=\"cntnt\"><img style=\"width:396px; height:391px;\" src=\"images/OBGYN/66666_MR_appendicitis_pregnancy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2 weighted magnetic resonance image of a woman with appendicitis at 9 weeks of gestation. The appendix was fluid-filled and measured 7 mm (arrow). The gestational sac (gs) is seen lower in the pelvis.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 66666 Version 2.0</div></div></div>"},"66669":{"type":"graphic_picture","displayName":"Metagonimiasis adult worm","title":"Metagonimiasis adult worm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metagonimiasis adult worm</div><div class=\"cntnt\"><img style=\"width:410px; height:310px;\" src=\"images/ID/66669_Metagonimiasis_adult_worm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult&nbsp;<EM>Metagonimus yokogawai</EM>. In this figure, the following structures are labeled: oral sucker (OS), pharynx (PH), intestine (IN), genitoacetabulum (GA), ovary (OV), the large, paired testes (TE), and eggs within the uterus (UT).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Metagonimiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/metagonimiasis/index.html\">http://www.cdc.gov/dpdx/metagonimiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 66669 Version 5.0</div></div></div>"},"66670":{"type":"graphic_diagnosticimage","displayName":"Type II endoleak after endovascular aortic repair","title":"Type II endoleak after endovascular aortic repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Type II endoleak after endovascular aortic repair</div><div class=\"cntnt\"><img style=\"width:392px; height:456px;\" src=\"images/SURG/66670_Type_II_endoleak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Super-selective angiogram demonstrating a type II endoleak originating from the inferior mesenteric artery in a patient with an enlarging aneurysm sac after EVAR.</div><div class=\"graphic_footnotes\">EVAR: endovascular aneurysm repair.</div><div id=\"graphicVersion\">Graphic 66670 Version 3.0</div></div></div>"},"66671":{"type":"graphic_picture","displayName":"Confluent and reticulated papillomatosis","title":"Confluent and reticulated papillomatosis of Gougerot and Carteaud","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Confluent and reticulated papillomatosis of Gougerot and Carteaud</div><div class=\"cntnt\"><img style=\"width:444px; height:342px;\" src=\"images/DERM/66671_CR_papillomatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented, scaly papules and plaques on the trunk, which become reticulated toward the periphery, are present.</div><div class=\"graphic_reference\">Figure used with permission from Andrew Montemarano, DO. Reproduced from: Wolff K, Goldsmith LA, Katz S, et al. Fitzpatrick's Dermatology in General Medicine, 7th ed, McGraw-Hill Professional 2008. Copyright © 2008 Andrew Montemarano, DO.</div><div id=\"graphicVersion\">Graphic 66671 Version 3.0</div></div></div>"},"66672":{"type":"graphic_picture","displayName":"UV lesions IV","title":"Urticarial vasculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticarial vasculitis</div><div class=\"cntnt\"><img style=\"width:326px; height:502px;\" src=\"images/ALLRG/66672_UV_lesions_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urticarial patches with central ecchymosis.</div><div id=\"graphicVersion\">Graphic 66672 Version 2.0</div></div></div>"},"66673":{"type":"graphic_figure","displayName":"Incising posterior cul-de-sac","title":"Incising the posterior pelvic cul-de-sac during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incising the posterior pelvic cul-de-sac during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:306px; height:460px;\" src=\"images/OBGYN/66673_Incising_posterior_cul_de_s.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scissors are used to enter the vagina through the posterior cul-de-sac.</div><div id=\"graphicVersion\">Graphic 66673 Version 3.0</div></div></div>"},"66675":{"type":"graphic_picture","displayName":"Central retinal vein occlusion","title":"Central retinal vein occlusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central retinal vein occlusion</div><div class=\"cntnt\"><img style=\"width:383px; height:383px;\" src=\"images/PC/66675_Central_retinal_vein_occ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraretinal hemorrhages and cotton wool&nbsp;spots&nbsp;in all four quadrants on funduscopic examination.</div><div id=\"graphicVersion\">Graphic 66675 Version 4.0</div></div></div>"},"66676":{"type":"graphic_diagnosticimage","displayName":"Chronic PE PA I","title":"Chronic pulmonary embolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic pulmonary embolism</div><div class=\"cntnt\"><img style=\"width:354px; height:308px;\" src=\"images/PULM/66676_Chronic_PE_PA_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary angiogram shows mosaic oligemia with localization of pulmonary blood flow to the lower lobes. This may be regarded as a Westermark's sign with oligemia affecting the subtended pulmonary parenchyma of the upper lobes.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66676 Version 3.0</div></div></div>"},"66678":{"type":"graphic_diagnosticimage","displayName":"Intravenous leiomyomatosis MRI","title":"Intravenous leiomyomatosis: Magnetic resonance image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intravenous leiomyomatosis: Magnetic resonance image</div><div class=\"cntnt\"><img style=\"width:432px; height:314px;\" src=\"images/OBGYN/66678_IntraleiomyomatosisMRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascular invasive leiomyoma. Sagittal T2-weighted image demonstrates large low signal intensity mass (arrow) growing into inferior vena cava (arrowhead).</div><div class=\"graphic_reference\">Reproduced with permission from: Leyendecker JR, Brown JJ. Practical Guide to Abdominal and Pelvic MRI. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66678 Version 3.0</div></div></div>"},"66679":{"type":"graphic_waveform","displayName":"Repetitive monomorphic VT","title":"Telemetry recording (lead II) from a patient with RMVT","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Telemetry recording (lead II) from a patient with RMVT</div><div class=\"cntnt\"><img style=\"width:503px; height:438px;\" src=\"images/CARD/66679_Repetitive_monomorphic_VT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repetitive monomorphic ventricular tachycardia (RMVT) is characterized by frequent short &quot;salvos&quot; or bursts of monomorphic nonsustained VT. The bursts may vary in duration, but all demonstrate the same QRS morphology.</div><div id=\"graphicVersion\">Graphic 66679 Version 2.0</div></div></div>"},"66680":{"type":"graphic_picture","displayName":"Sweet syndrome - histopathology","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/DERM/66680_Sweets_syndr_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dense neutrophilic infiltrate in Sweet syndrome.</div><div id=\"graphicVersion\">Graphic 66680 Version 2.0</div></div></div>"},"66681":{"type":"graphic_diagnosticimage","displayName":"T tube related bile leak","title":"T tube-related leak after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T tube-related leak after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:288px; height:322px;\" src=\"images/GAST/66681_T_tube_related_bile_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography reveals a leak emanating from the T-tube site (arrow). A stent has been placed.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 66681 Version 5.0</div></div></div>"},"66683":{"type":"graphic_diagnosticimage","displayName":"Moyamoya with intraventricular hemorrhage","title":"A 22-year-old woman with moyamoya disease and sudden severe headache","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">A 22-year-old woman with moyamoya disease and sudden severe headache</div><div class=\"cntnt\"><img style=\"width:478px; height:214px;\" src=\"images/NEURO/66683_Mymyintrvntrclrhmrrh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Non-contrast CT scan of the brain reveals blood in the frontal and occipital horns of the left lateral ventricle (arrows).<br />(B) Cerebral angiogram (lateral projection) demonstrates total occlusion of the left internal carotid artery and collateral flow from the external carotid system.<br />(C) Selective angiogram shows severe stenosis of the distal part of the right internal carotid artery. Note the collateral vascular networks around the stenotic area (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Nijasri Suwanwela, MD.</div><div id=\"graphicVersion\">Graphic 66683 Version 6.0</div></div></div>"},"66684":{"type":"graphic_diagnosticimage","displayName":"Intramedullary mets SCC","title":"Intramedullary metastatic cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intramedullary metastatic cancer</div><div class=\"cntnt\"><img style=\"width:320px; height:315px;\" src=\"images/ONC/66684_Intramedullary_mets_SCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lumbar MRI scan in a 57-year-old man with known squamous cell carcinoma of the ethmoid sinus with metastasis to the skull base. The sagittal enhanced images demonstrate a large, intradural metastasis at the L1 level (arrow). Surgical pathology was consistent with metastatic squamous cell carcinoma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of William Welch, MD.</div><div id=\"graphicVersion\">Graphic 66684 Version 3.0</div></div></div>"},"66685":{"type":"graphic_figure","displayName":"Lap band PI","title":"Gastric banding ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric banding </div><div class=\"cntnt\"><img style=\"width:422px; height:365px;\" src=\"images/PI/66685_Lap_band_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows how the stomach looks after gastric banding.</div><div id=\"graphicVersion\">Graphic 66685 Version 4.0</div></div></div>"},"66686":{"type":"graphic_picture","displayName":"Cholesteatoma of the middle ear","title":"Cholesteatoma of the middle ear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholesteatoma of the middle ear</div><div class=\"cntnt\"><img style=\"width:320px; height:319px;\" src=\"images/PC/66686_Cholesteatoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholesteatoma (arrow) is a growth of desquamated, stratified, squamous epithelium.</div><div class=\"graphic_reference\">Reprinted with permission from Nikolas H Blevins, MD.</div><div id=\"graphicVersion\">Graphic 66686 Version 2.0</div></div></div>"},"66688":{"type":"graphic_diagnosticimage","displayName":"IDUS papillary projections","title":"Intraductal ultrasound showing papillary projections in the pancreatic duct","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Intraductal ultrasound showing papillary projections in the pancreatic duct</div><div class=\"cntnt\"><img style=\"width:452px; height:326px;\" src=\"images/GAST/66688_IDUS_ppllry_prjct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two papillary projections (arrows) identified by intraductal ultrasound of the pancreas raise the suspicion of malignant degeneration.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD, Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 66688 Version 4.0</div></div></div>"},"66689":{"type":"graphic_picture","displayName":"Lymphocytic gastritis Light","title":"Lymphocytic gastritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocytic gastritis</div><div class=\"cntnt\"><img style=\"width:401px; height:252px;\" src=\"images/GAST/66689_Lymphocytic_gastritis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power light micrograph of a gastric biopsy from a patient with lymphocytic gastritis. The dilated pits are separated by a cellular lamina propria containing a mixture of plasma cells and lymphocytes. The epithelium covering the surface and the superficial pits is disorganized and contains lymphocytes.</div><div class=\"graphic_reference\">From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 66689 Version 3.0</div></div></div>"},"66690":{"type":"graphic_table","displayName":"Preop evaluation questions","title":"Preoperative medical evaluation questions for a healthy patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preoperative medical evaluation questions for a healthy patient</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Questions</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>1. Do you usually get chest pain or breathlessness when you climb up two flights of stairs at normal speed?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>2. Do you have kidney disease?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>3. Has anyone in your family (blood relatives) had a problem following an anaesthetic?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>4. Have you ever had a heart attack?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>5. Have you ever been diagnosed with an irregular heartbeat?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>6. Have you ever had a stroke?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>7. If you have been put to sleep for an operation were there any anaesthetic problems?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>8. Do you suffer from epilepsy or seizures?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>9. Do you have any problems with pain, stiffness or arthritis in your neck or jaw?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>10. Do you have thyroid disease?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>11. Do you suffer from angina?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>12. Do you have liver disease?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>13. Have you ever been diagnosed with heart failure?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>14. Do you suffer from asthma?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>15. Do you have diabetes that requires insulin?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>16. Do you have diabetes that requires tablets only?</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>17. Do you suffer from bronchitis?</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Hilditch, WG, Asbury, AJ, Jack, E, McGrane, S. Validation of a pre-anaesthetic screening questionnaire. Anaesthesia 2003; 58:874.</div><div id=\"graphicVersion\">Graphic 66690 Version 1.0</div></div></div>"},"66692":{"type":"graphic_diagnosticimage","displayName":"Staphylococcal empyema CT","title":"Bilateral empyema due to staphylococcus aureus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral empyema due to staphylococcus aureus</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/PULM/66692_StaphylococcalempyemaCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows bilateral loculations of effusion with adjacent consolidated or compressed lung.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66692 Version 4.0</div></div></div>"},"66693":{"type":"graphic_waveform","displayName":"RA PCW pressures VT","title":"Changes in pressure waveforms with VT","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Changes in pressure waveforms with VT</div><div class=\"cntnt\"><img style=\"width:461px; height:329px;\" src=\"images/CARD/66693_RA_PCW_pressures_VT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure waveforms with ventricular tachycardia (VT). Top left: Right atrial (RA) pressure tracing shows prominent &quot;v&quot; wave. Top right: With restoration of sinus rhythm, there is a slight reduction in the mean RA pressure; the &quot;v&quot; wave is attenuated and a normal RA pressure waveform is seen. A similar response can be seen in the pulmonary capillary wedge (PCW) pressure tracing. Bottom left: During sinus rhythm, the mean PCW pressure is 18 mmHg and there is a &quot;v&quot; wave of 24 mmHg. Bottom right: During ventricular tachycardia, the mean PCW pressure increases to 24 mmHg with &quot;v&quot; waves of 40 mmHg.</div><div class=\"graphic_reference\">Courtesy of Morton Kern, MD.</div><div id=\"graphicVersion\">Graphic 66693 Version 2.0</div></div></div>"},"66694":{"type":"graphic_diagnosticimage","displayName":"CSVT in a two-week old infant","title":"Extensive cerebral sinovenous thrombosis in a two-week old term infant with hypernatremic dehydration, lethargy, and a bulging fontanelle","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Extensive cerebral sinovenous thrombosis in a two-week old term infant with hypernatremic dehydration, lethargy, and a bulging fontanelle</div><div class=\"cntnt\"><img style=\"width:599px; height:467px;\" src=\"images/PEDS/66694_CS_thromb_2wk_inf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Head CT (A) depicts acute venous thrombus as hyperdense signal involving sagittal and straight sinuses. Brain magnetic resonance venogram (B and C) depicts absent flow-related signal involving left transverse, entire superior sagittal, and straight sinuses. Acute clot appears as hyperintense signal (D) on sagittal T1-weighted sequences. Diffusion-weighted MRI sequences (E and F) show extensive acute ischemic changes in bilateral subcortical white matter, internal capsule, corpus callosum and thalamus (arrows). In addition, thalamic hemorrhage is present (asterisk).</div><div class=\"graphic_reference\">Courtesy of Rebecca Ichord, MD.</div><div id=\"graphicVersion\">Graphic 66694 Version 2.0</div></div></div>"},"66701":{"type":"graphic_table","displayName":"Homesickness prevention tips for hospital staff","title":"Homesickness-prevention strategies for hospital staff members working with children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Homesickness-prevention strategies for hospital staff members working with children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Coach parents before admission not to deceive their child about the purpose and timing of hospitalization. Although the honest truth may be upsetting or startling to some children, coping with the reality of their situation now prevents uncomfortable surprises later. Children who feel \"tricked\" into hospitalization lose confidence in the reliability of their caregivers and therapists, and this both increases homesickness and lessens trust.</td> </tr> <tr> <td>2. Orientation to the unit is one key to good adjustment. When children feel as if they have some control over the novel hospital environment, they may be less fearful and homesick. Depending on the child's condition, a tour of the unit, labeled photographs of staff members, big calendars, daily schedules, and introductions to the other kids on the unit can all help children feel comfortable and oriented in their new environment.</td> </tr> <tr> <td>3. When possible, staff members should convey a consistent message about length of stay. Conflicting messages from adults in charge reduces children's global confidence in caregivers. Unpredictability leads to anxiety. If one staff member says, \"You'll be here about two weeks,\" and another says, \"You'll be here about three weeks,\" children are likely to feel distressed and homesick.</td> </tr> <tr> <td>4. When hospitalization follows a traumatic event in which multiple family members were involved, family members may be in different parts of the hospital or even different hospitals. This can induce homesickness and separation anxiety. When possible, staff members should help children make contact, by telephone or in person, with dispersed family members.</td> </tr> <tr> <td>5. A child's mental status during hospitalization can change dramatically, even in the course of a day. Often, these changes involve a distorted sense of time and a fluctuating awareness of the caregivers' presence. These factors can cause homesickness. Continue efforts to orient the child. Pictures of the family, large clocks and calendars, lights on in rooms during the day, and frequent reminders often help reorient homesick children.</td> </tr> <tr> <td>6. Changes and uncertainties in caregiver visitations can cause homesickness. Caregivers should be apprised of the importance of frequent, reliable contact with their children. Staff members should encourage caregivers to call and give ample warning if they are unable to make a scheduled visit.</td> </tr> <tr> <td>7. Sometimes hospitalized children feel left alone, and this can cause homesickness. Especially early in a hospital stay, before the child knows the staff and routine, even five minutes alone can be frightening. Try to keep children apprised of the day's schedule and give ample warning if there are going to be times when the child is left alone, however briefly.</td> </tr> <tr> <td>8. To ease parental separation anxiety, staff members should forewarn parents when their child will be moved to a different room. Parents are unsettled to come to visiting hours and enter their child's room, only to find it empty or occupied by a stranger. For the same reasons that children need to feel prepared for upcoming events, so do parents.</td> </tr> <tr> <td>9. When possible, minimize discharge uncertainty. Children have an easier time coping with homesickness when they have a fixed-length hospital stay to manage. By the same token, avoid changing a child's discharge date if at all possible. Once staff members state an exact date out loud, children (and parents) have a tendency to fixate on that date. Changing the promised date can provoke homesickness. It may be best to tell children and families that discharge dates are hard to predict and to give them a range of plausible dates.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 119, Pages 192-201, Copyright © 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 66701 Version 15.0</div></div></div>"},"66702":{"type":"graphic_figure","displayName":"Construction of a loop colostomy - everting proximal limb","title":"Construction of a loop colostomy - everting proximal limb","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of a loop colostomy - everting proximal limb</div><div class=\"cntnt\"><img style=\"width:360px; height:268px;\" src=\"images/SURG/66702_Loop-colostomy-evert-prox.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts maturing a loop colostomy with a defunctionalized distal limb. The colotomy is made circumferentially, leaving 20 percent of the back wall of the loop colostomy intact. The mucosa of the proximal limb is everted.</div><div id=\"graphicVersion\">Graphic 66702 Version 1.0</div></div></div>"},"66704":{"type":"graphic_figure","displayName":"The p-i concept of T cell activation in drug hypersensitivity","title":"The p-i concept of T cell activation in drug hypersensitivity","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">The p-i concept of T cell activation in drug hypersensitivity</div><div class=\"cntnt\"><img style=\"width:534px; height:441px;\" src=\"images/ALLRG/66704_p_i_concept.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A drug may bind with a sufficiently high affinity to some of the many polymorphic TCR or HLA molecules. &#xD;&#xA;<OL>&#xD;&#xA;<LI>The drug may fit into a certain TCR with sufficient affinity to initiate signaling by that cell. An additional interaction with the HLA molecule is required for full activation.</LI>&#xD;&#xA;<LI>The drug may bind preferentially to the HLA molecule, in particular to the HLA peptide-binding groove. This binding may occur&nbsp;with certain HLA alleles only, explaining the striking HLA association of some drug hypersensitivity reactions.&nbsp;The drug binding to the HLA protein&nbsp;changes the configuration of the HLA-peptide complex&nbsp;to make it look like an altered (\"allo\") HLA peptide complex. Allo-alleles are highly stimulatory and elicit strong T cell&nbsp;responses. As a result, the ensuing T cell stimulation in some severe drug reactions has features of an alloimmune response.&nbsp;Alternatively, the drug (eg, abacavir) may bind to the HLA-B*57:01 molecule and thereby alter the peptide-binding properties of this HLA allele. The usual B*57:01 binding peptides are displaced by other (novel) peptides. The presentation of new peptides may induce a kind of an autoimmune or alloimmune response.</LI></OL></div><div class=\"graphic_footnotes\">HLA: human-leukocyte antigen; APC: antigen-presenting cell; TCR: T cell receptor.</div><div class=\"graphic_reference\">Original figure modified and updated for this publication. Celik G, Pichler WJ, Adkinson NF Jr. Drug Allergy. In: Middleton's Allergy Principles &amp; Practice, 7th ed, Adkinson NF, et al (Ed), Mosby Elsevier, Philadelphia 2009. Illustration used with the permission of Elsevier Inc. All rights reserved.<br /></div><div id=\"graphicVersion\">Graphic 66704 Version 7.0</div></div></div>"},"66705":{"type":"graphic_picture","displayName":"RBC in sideroblastic anemia","title":"Peripheral blood smears in sideroblastic anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smears in sideroblastic anemia</div><div class=\"cntnt\"><img style=\"width:384px; height:531px;\" src=\"images/HEME/66705_RBC_in_sideroblastic_anemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smears from two patients with sideroblastic anemia. Top panel: Mild degree of changes, consisting mainly of a small number of hypochromic red cells. Bottom panel: Severe changes, including hypochromia, microcytosis, and many misshapen red cells. (Wright's stain)</div><div class=\"graphic_reference\">Courtesy of Sylvia Bottomley, MD.</div><div id=\"graphicVersion\">Graphic 66705 Version 2.0</div></div></div>"},"66708":{"type":"graphic_figure","displayName":"COPD Venn diagram","title":"Chronic obstructive pulmonary disease","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Chronic obstructive pulmonary disease</div><div class=\"cntnt\"><img style=\"width:498px; height:342px;\" src=\"images/PULM/66708_COPD_Venn_diagram.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This nonproportional Venn diagram shows subsets of patients with chronic bronchitis, emphysema, and asthma (black circles). The subsets defined as COPD are shaded gray. Subset areas are not proportional to actual relative subset sizes. Asthma is, by definition, associated with reversible airflow obstruction; in variant asthma, special maneuvers may be necessary to make the obstruction evident. Patients with asthma whose airflow obstruction is completely reversible (subset 9) are not considered to have COPD. In many cases it is virtually impossible to differentiate patients with asthma whose airflow obstruction does not remit completely from persons with chronic bronchitis and emphysema who have partially reversible airflow obstruction with airway hyperreactivity. Thus, patients with unremitting asthma are classified as having COPD (subsets 6, 7 and 8). Chronic bronchitis and emphysema with airflow obstruction usually occur together (subset 5), and some patients may have asthma associated with these two disorders (subset 8). Individuals with asthma exposed to chronic irritation, as from cigarette smoke, may develop chronic productive cough, a feature of chronic bronchitis (subset 6). Such patients are often referred to in the United States as having asthmatic bronchitis or the asthmatic form of COPD. Persons with chronic bronchitis or emphysema without airflow obstruction (subsets 1, 2 and 11) are not classified as having COPD. In order to emphasize that cough and sputum are abnormal, individuals with these symptoms and normal lung function were classified as GOLD Stage 0, at risk, in the original GOLD classification [1]. This stage was deleted in the 2006 revision because of uncertainties about whether it is progressive [2]. Patients with airway obstruction due to diseases with known etiology or specific pathology, such as cystic fibrosis or obliterative bronchiolitis (subset 10), are not generally included in the definition of COPD.</div><div class=\"graphic_reference\">1. Data from: Global initiative for chronic obstructive lung disease (GOLD). Workshop report: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: Update 2005.<br>2. Data from: Global initiative for chronic obstructive lung disease (GOLD). Workshop report: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: Update 2006.</div><div id=\"graphicVersion\">Graphic 66708 Version 1.0</div></div></div>"},"66709":{"type":"graphic_diagnosticimage","displayName":"Gravitational changes on HRCT","title":"Normal HRCT of lung with positional changes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal HRCT of lung with positional changes</div><div class=\"cntnt\"><img style=\"width:319px; height:255px;\" src=\"images/PULM/66709_Gravitational_changes_on_HR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HRCT of lung with normal gravitational changes that lead to an increase in&nbsp;attenuation in the posterobasal and laterobasal segment of the lower lobes (arrows). A repeat prone scan would clearly demonstrate the transient, positional nature of this opacity.</div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66709 Version 3.0</div></div></div>"},"66711":{"type":"graphic_picture","displayName":"Lacunar cells and mummified Reed-Sternberg cell","title":"Lacunar cells and mummified Reed-Sternberg cell","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Lacunar cells and mummified Reed-Sternberg cell</div><div class=\"cntnt\"><img style=\"width:506px; height:756px;\" src=\"images/HEME/66711_LacuncellmumRdSternbrg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several \"lacunar cells\" are present. They are characterized by multilobated nuclei, small nucleoli, and abundant, pale cytoplasm that often \"retracts\" during tissue fixation and sectioning, leaving the nucleus in what appears to be an empty space (lacune). \"Mummified cells\" are neoplastic cells that contain condensed cytoplasm and pyknotic reddish nuclei. A \"mummified\" Reed-Sternberg cell is in the upper left corner.</div><div class=\"graphic_reference\">Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al. Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66711 Version 7.0</div></div></div>"},"66713":{"type":"graphic_picture","displayName":"Fungal Etest","title":"Etest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Etest</div><div class=\"cntnt\"><img style=\"width:371px; height:445px;\" src=\"images/ID/66713_Fungal_Etest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Etest method is based upon the establishment of a stable concentration gradient of an antimicrobial agent following diffusion from a plastic strip into an agar medium. When an Etest strip is placed upon an agar plate that has been inoculated with a test organism and incubated for 24 to 48 hours, an ellipse of growth inhibition occurs, and the intersection of the ellipse with the numeric scale on the strip provides an indication of the minimum inhibitory concentration (MIC).</div><div class=\"graphic_reference\">Courtesy of Michael Pfaller, MD.</div><div id=\"graphicVersion\">Graphic 66713 Version 1.0</div></div></div>"},"66715":{"type":"graphic_movie","displayName":"Pericardial effusion four chamber echocardiogram","title":"Pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/66715_4chperefconv.mp4\" style=\"width:360px;height:272px\"></div><img style=\"width:269px; height:438px;\" src=\"images/CARD/66715_4chperef.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical 4-chamber view from a 2-D echocardiogram shows a large pericardial effusion surrounding the heart. The heart has a swinging motion during the cardiac cycle, and there is slight compression of the right atrium early in diastole, suggesting early tamponade.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 66715 Version 3.0</div></div></div>"},"66716":{"type":"graphic_picture","displayName":"Early FSGS tip lesion light","title":"Tip lesion in early FSGS","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tip lesion in early FSGS</div><div class=\"cntnt\"><img style=\"width:394px; height:254px;\" src=\"images/NEPH/66716_Early_FGS_Tip_lesion_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph shows a tip lesion (arrow), which is considered to be an early change in primary focal segmental glomerulosclerosis. This lesion is characterized by epithelial cell injury and foam cell accumulation; note the enlarged cells with foamy cytoplasm in the lumen of the affected capillary. The lesion occurs at the \"tip\" of the glomerulus near the beginning of the proximal tubule.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 66716 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"66718":{"type":"graphic_figure","displayName":"Push through method for fish-hook removal","title":"Push-through method of fish-hook removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Push-through method of fish-hook removal</div><div class=\"cntnt\"><img style=\"width:307px; height:495px;\" src=\"images/EM/66718_Pushthroughmethod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A. Anesthetize the skin adjacent to the hook. B. Push the hook forward until the barb comes back through the skin. C. With eye protection in place, clip the barb of the hook with wirecutters. D. Back the remaining portion of the hook out of the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Diekema DS. Fishhook removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66718 Version 10.0</div></div></div>"},"66719":{"type":"graphic_table","displayName":"Slit lamp examination materials and equipment","title":"Materials and equipment that facilitate the slit lamp examination and their uses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Materials and equipment that facilitate the slit lamp examination and their uses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Item</td> <td class=\"subtitle1\">Function</td> </tr> <tr> <td>Fluorescein strip*</td> <td>Identification of corneal epithelial defect (small amount) or micro perforation (Seidel's test)</td> </tr> <tr> <td>Anesthetic drops*</td> <td>Corneal anesthesia</td> </tr> <tr> <td>Cotton tipped applicator*</td> <td>Movement of lids, lid eversion,&nbsp;foreign body&nbsp;or contact lens removal</td> </tr> <tr> <td>Cotton pledgette</td> <td>Removal of tight fitting contact lens</td> </tr> <tr> <td>Burr drill</td> <td>Foreign body removal</td> </tr> <tr> <td>18&nbsp;gauge needle</td> <td>Foreign body removal</td> </tr> <tr> <td>Gauze or tissue*</td> <td>Wiping tears, secretions</td> </tr> <tr> <td>Eye rinse solution*</td> <td>Rinsing fluorescein, eye irrigation</td> </tr> <tr> <td>Contact lens removal device</td> <td>Contact lens removal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Have available for every slit lamp examination.</div><div id=\"graphicVersion\">Graphic 66719 Version 2.0</div></div></div>"},"66723":{"type":"graphic_picture","displayName":"X-linked ichthyosis","title":"X-linked ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">X-linked ichthyosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/66723_X-linked_ichthyosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">X-linked ichthyosis: legs, infant.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169;2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66723 Version 1.0</div></div></div>"},"66725":{"type":"graphic_table","displayName":"Rx malignant pleural effusion","title":"Management of malignant and paramalignant pleural effusions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of malignant and paramalignant pleural effusions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Option </td> <td class=\"subtitle1\">Comment </td> </tr> <tr> <td>Observation</td> <td>For asymptomatic effusions; most will progress and require therapy</td> </tr> <tr> <td>Therapeutic thoracentesis</td> <td>Prompt relief of dyspnea; most effusions recur unless underlying tumor responds to chemo- or radiotherapy</td> </tr> <tr> <td>Chest catheter drainage only</td> <td>Most effusions will recur after catheter removal</td> </tr> <tr> <td>Chest catheter drainage with chemical pleurodesis (eg, talc slurry)</td> <td>Variable response rate with&nbsp;60 to&nbsp;90 percent of patients responding to talc pleurodesis</td> </tr> <tr> <td>Thoracoscopy with talc insufflation</td> <td>Control of effusion with similar frequency as chest catheter drainage with talc pleurodesis</td> </tr> <tr> <td>Long-term indwelling pleural catheter</td> <td>Control of effusion and improved symptoms in most patients. Some patients may experience pleurodesis after&nbsp;two weeks (median 11 weeks)&nbsp;of catheter drainage, which allows catheter removal.</td> </tr> <tr> <td>Pleural abrasion or pleurectomy</td> <td>Requires thoracoscopy or thoracotomy. Effectively controls effusions in nearly all patients.</td> </tr> <tr> <td>Pleuroperitoneal shunt</td> <td>When other options have failed or are not indicated; may be useful for chylothorax</td> </tr> <tr> <td>Chemotherapy</td> <td>May be effective in some tumor types, such as breast cancer, lymphoma, and small cell lung cancer</td> </tr> <tr> <td>Radiotherapy</td> <td>Mediastinal radiation therapy may be effective in lymphoma and lymphomatous chylothorax</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66725 Version 2.0</div></div></div>"},"66727":{"type":"graphic_figure","displayName":"T cell receptor signaling","title":"T cell receptor signaling","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">T cell receptor signaling</div><div class=\"cntnt\"><img style=\"width:622px; height:436px;\" src=\"images/ALLRG/66727_Tcell_receptor_signaling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A schematic representation of the pathways activated after ligation of the TCR as well as some of the molecules involved in this process.</div><div class=\"graphic_footnotes\">TCR: T cell receptor; CD: cluster of differentiation; PI3K: phosphatidylinositol; AKT: a serine/threonine kinase, also known as protein kinase B; PAG: phosphoprotein associated with glycosphingolipid-enriched microdomains; Fyn: a tyrosinase kinase protooncogene; Csk: cytoplasmic tyrosine kinase; Lyp: lymphoid phosphatase; LCK: lymphocyte-specific protein-tyrosine kinase; ZAP70: zeta-chain-associated protein kinase; CBL: Casitas B-lineage lymphoma protooncogene; VAV: a protooncogene; Rac: RAS-related botulinum toxin substrate; Mekk1: mitogen-activated protein kinase extracellular signal-regulated kinase 1; JNK: C-Jun kinase (mitogen-activated protein kinase 8); p38: 38 KD protein (mitogen-activated protein kinase 14); ATF2: activating transcription factor 2; cdc42: cell division cycle 42; WASP: Wiskott-Aldrich syndrome protein; PAK: p21 activated kinase; LAT: linker for activation of T cells; ITK: interleukin-2-inducible T cell kinase; Gads: glutamate decarboxylase; Nck: an adapter protein; SLP76: SH2 domain-containing leukocyte protein 76; PLC1: phospholipase C, gamma-1; GRB2: growth factor receptor-bound protein 2; SOS: a guanine nucleotide exchange factor for Ras; DAG: diacylglycerol; rasGRP: rasGuanyl nucleotide-releasing protein; RAS: rat sarcoma viral oncogene homolog; Raf1: V-Raf1 murine leukemia viral oncogene homolog 1; MEK1/2: MAPK/ERK kinase 1; ERK1/2: extracellular signal-regulated kinase 1/2; ELK1: member of ET3 oncogene family; PKCθ: protein kinase theta; IKK: IKB kinase; IkB: inhibitor of Kappa light chain gene enhancer in B cells; NFKB: nuclear factor kappa-B; PIP<sub>2</sub>: phosphatidylinositol 4,5-biphosphate; IP<sub>3</sub>: inositol 1,4,5-triphosphate; IP3R: IP3 receptor; Ca<sup>2+</sup>: ionized calcium; STIM1: stromal interaction molecule 1; ORAI: orai calcium release-activated calcium modulator 1; NFAT: nuclear factor of activated T cells.</div><div id=\"graphicVersion\">Graphic 66727 Version 2.0</div></div></div>"},"66728":{"type":"graphic_picture","displayName":"Choledocholithiasis after OLT","title":"Common bile duct obstruction due to stones following liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common bile duct obstruction due to stones following liver transplantation</div><div class=\"cntnt\"><img style=\"width:276px; height:360px;\" src=\"images/GAST/66728_Choledocholithiasis_after_O.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatographic image shows stones and sludge (arrows) which have developed in the donor common bile duct (CBD) following liver transplantation. The patient presented with jaundice and was successfully treated with balloon dilation of the bile duct anastomosis and extraction of the stones.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 66728 Version 2.0</div></div></div>"},"66729":{"type":"graphic_table","displayName":"Causes severe atopic dermatitis","title":"Causes of severe or difficult-to-treat atopic dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of severe or difficult-to-treat atopic dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Incorrect diagnosis</td> </tr> <tr> <td class=\"sublist1_start\">Treatment failure</td> </tr> <tr> <td class=\"sublist1\">Medication used incorrectly</td> </tr> <tr> <td class=\"sublist2\">Treatment regimen is too complex</td> </tr> <tr> <td class=\"sublist2\">Inadequate instructions</td> </tr> <tr> <td class=\"sublist1\">Medication not used because of parental or patient fear of medication side effects</td> </tr> <tr> <td class=\"sublist1\">Medication not available</td> </tr> <tr> <td class=\"sublist2\">Due to high cost</td> </tr> <tr> <td class=\"sublist2\">Not on formulary</td> </tr> <tr> <td class=\"sublist2\">Not available in the pharmacy</td> </tr> <tr> <td>Allergic reaction to medication or skin care product (allergic contact dermatitis)</td> </tr> <tr> <td>Exposure to irritants</td> </tr> <tr> <td>Exposure to allergen (food or environmental)</td> </tr> <tr> <td>Severe disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66729 Version 3.0</div></div></div>"},"66735":{"type":"graphic_diagnosticimage","displayName":"Long axis scan of needle into subacromial-subdeltoid bursa","title":"Long axis scan of needle into subacromial-subdeltoid bursa","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Long axis scan of needle into subacromial-subdeltoid bursa</div><div class=\"cntnt\"><img style=\"width:540px; height:402px;\" src=\"images/RHEUM/66735_Long_ax_subacr_subdel_bursa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long axis scan following needle (arrowheads) into a subacromial-subdeltoid bursitis (yellow dotted line). The bevel of the needle is turned downwards to facilitate access into the bursa.</div><div class=\"graphic_reference\">Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &#169; 2012.</div><div id=\"graphicVersion\">Graphic 66735 Version 1.0</div></div></div>"},"66736":{"type":"graphic_table","displayName":"Warfarin and aspirin in AF","title":"Meta-analysis of randomized controlled trials of warfarin and aspirin for primary prevention of stroke in atrial fibrillation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Meta-analysis of randomized controlled trials of warfarin and aspirin for primary prevention of stroke in atrial fibrillation</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">\r\n  \r\n   Comparison\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">\r\n  \r\n   Stroke\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">\r\n  \r\n   Major bleeding\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Odds ratio, 95% CI\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   p value\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Odds ratio, 95 percent CI\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   p value\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\">\r\n  \r\n   Conventional dose warfarin versus placebo\r\n  \r\n   </td>\r\n  \r\n   <td>0.31 (0.19 to 0.50)</td>\r\n  \r\n   <td>&#60;0.001</td>\r\n  \r\n   <td>1.88 (0.88 to 4.0)</td>\r\n  \r\n   <td>0.10</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\">\r\n  \r\n   Aspirin versus placebo\r\n  \r\n   </td>\r\n  \r\n   <td>0.68 (0.46 to 1.02)</td>\r\n  \r\n   <td>0.06</td>\r\n  \r\n   <td>0.82 (0.37 to 1.78)</td>\r\n  \r\n   <td>&#62;0.2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\">\r\n  \r\n   Conventional dose warfarin versus aspirin\r\n  \r\n   </td>\r\n  \r\n   <td>0.66 (0.45 to 0.99)</td>\r\n  \r\n   <td>0.04</td>\r\n  \r\n   <td>1.61 (0.75 to 3.44)</td>\r\n  \r\n   <td>&#62;0.2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\">\r\n  \r\n   Conventional dose warfarin versus low dose warfarin\r\n  \r\n   </td>\r\n  \r\n   <td>0.52 (0.25 to 1.08)</td>\r\n  \r\n   <td>0.08</td>\r\n  \r\n   <td>2.21 (0.67 to 7.25)</td>\r\n  \r\n   <td>0.19</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\">\r\n  \r\n   Conventional dose warfarin versus low dose warfarin plus aspirin\r\n  \r\n   </td>\r\n  \r\n   <td>0.44 (0.14 to 1.39)</td>\r\n  \r\n   <td>0.16</td>\r\n  \r\n   <td>1.14 (0.55 to 2.36)</td>\r\n  \r\n   <td>&#62;0.2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\">\r\n  \r\n   Low dose warfarin versus aspirin\r\n  \r\n   </td>\r\n  \r\n   <td>1.01 (0.49 to 2.06)</td>\r\n  \r\n   <td>&#62;0.2</td>\r\n  \r\n   <td>1.04 (0.43 to 2.48)</td>\r\n  \r\n   <td>&#62;0.2</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_lgnd\"><strong>NOTE: The data in this table cannot be directly applied to clinical practice (an individual patient) since the decision to use warfarin or aspirin is importantly related to a patient's estimated risk of embolic events.</strong></div><div class=\"graphic_reference\">Adapted from McNamara RL, Tamariz LJ, Segal JB, Bass EB. Ann Intern Med 2004; 139:1018.</div><div id=\"graphicVersion\">Graphic 66736 Version 2.0</div></div></div>"},"66737":{"type":"graphic_table","displayName":"ACC AHA HRS fascic block","title":"ACC/AHA/HRS guideline summary: Indications for permanent pacing in chronic bifascicular block","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/HRS guideline summary: Indications for permanent pacing in chronic bifascicular block</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class I - There is evidence and/or general agreement that permanent pacing is indicated in patients with chronic bifascicular block in the following settings:</td> </tr> <tr> <td class=\"indent1\">&#8226; Advanced second-degree AV block or intermittent third-degree AV block. (Level of Evidence: B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Type II second-degree AV block. (Level of Evidence: B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Alternating bundle branch block. (Level of Evidence: C)</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIa - The weight of evidence or opinion is in favor of the usefulness of permanent pacing in patients with chronic bifascicular block in the following settings:</td> </tr> <tr> <td class=\"indent1\">&#8226; Syncope not demonstrated to be due to AV block when other likely causes have been excluded, specifically VT. (Level of Evidence: B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Incidental finding at electrophysiological study of a markedly prolonged HV interval (&#8805;100 msec) in asymptomatic patients. (Level of Evidence: B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Incidental finding at electrophysiological study of pacing-induced infra-His block that is not physiological. (Level of Evidence: B)</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIb - The weight of evidence or opinion is less well established for the usefulness of permanent pacing in patients with chronic bifascicular block in the following setting:</td> </tr> <tr> <td class=\"indent1\">&#8226; Neuromuscular diseases, such as myotonic muscular dystrophy, Erb dystrophy (limb-girdle muscular dystrophy), and peroneal muscular atrophy with bifascicular block or any fascicular block, with or without symptoms. (Level of Evidence: C)</td> </tr> <tr> <td class=\"subtitle1_single\">Class III - There is evidence and/or general agreement that permanent pacing for chronic bifascicular block is not useful in the following settings:</td> </tr> <tr> <td class=\"indent1\">&#8226; Fascicular block without AV block or symptoms. (Level of Evidence: B)</td> </tr> <tr> <td class=\"indent1\">&#8226; Fascicular block with first-degree AV block without symptoms. (Level of Evidence: B)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: atrioventricular; VT: ventricular tachycardia.</div><div class=\"graphic_reference\">Adapted from: Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.</div><div id=\"graphicVersion\">Graphic 66737 Version 5.0</div></div></div>"},"66739":{"type":"graphic_figure","displayName":"Excitation contraction","title":"Major steps of excitation-contraction coupling in mammalian working myocardium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Major steps of excitation-contraction coupling in mammalian working myocardium</div><div class=\"cntnt\"><img style=\"width:288px; height:173px;\" src=\"images/CARD/66739_Excitation_contraction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An inward calcium (Ca2+) current occurs during the action potential and this influx triggers a much greater release of Ca2+ from the sarcoplasmic reticulum. Cytosolic Ca2+ levels rise rapidly and Ca2+ binds to its myofilament receptor on troponin C, activating contractile protein tension generation which results from actin myosin cross bridging. Myocyte relaxation occurs when Ca2+ dissociated from troponin C and the actin-myosin bonds are broken. Ca2+ is taken up by the sarcoplasmic reticulum and is removed via a sodium (Na+)-Ca2+ exchange.</div><div id=\"graphicVersion\">Graphic 66739 Version 1.0</div></div></div>"},"66740":{"type":"graphic_figure","displayName":"Traction suture tongue","title":"Traction suture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traction suture</div><div class=\"cntnt\"><img style=\"width:398px; height:247px;\" src=\"images/PEDS/66740_Traction_suture_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A suture can be placed through the anterior portion of the anesthetized tongue to provide tongue traction and better positioning for repair of tongue lacerations.</div><div id=\"graphicVersion\">Graphic 66740 Version 1.0</div></div></div>"},"66741":{"type":"graphic_picture","displayName":"Phoropter","title":"Phoropter","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Phoropter</div><div class=\"cntnt\"><img style=\"width:504px; height:360px;\" src=\"images/PC/66741_Phoropter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A phoropter is an instrument containing different lenses used to bring the focus onto the retina.</div><div id=\"graphicVersion\">Graphic 66741 Version 2.0</div></div></div>"},"66742":{"type":"graphic_table","displayName":"BOS grading system","title":"Original and proposed classifications of BOS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Original and proposed classifications of BOS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Original classification</td> <td class=\"subtitle1\" colspan=\"2\">Current proposition</td> </tr> <tr> <td>BOS 0</td> <td>FEV<sub>1</sub> 80 percent or more of baseline</td> <td>BOS 0</td> <td>FEV<sub>1</sub> &#62;90 percent of baseline <strong>and</strong><br /> FEF<sub>25-75</sub> &#62;75 percent of baseline</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>BOS 0-p</td> <td>FEV<sub>1</sub> 81 to 90 percent of baseline <strong>and/or</strong><br /> FEF<sub>25-75</sub> &#8804;75 percent of baseline</td> </tr> <tr> <td>BOS 1</td> <td>FEV<sub>1</sub> 66 to 80 percent of baseline</td> <td>BOS 1</td> <td>FEV<sub>1</sub> 66 to 80 percent of baseline</td> </tr> <tr> <td>BOS 2</td> <td>FEV<sub>1</sub> 51 to 65 percent of baseline</td> <td>BOS 2</td> <td>FEV<sub>1</sub> 51 to 65 percent of baseline</td> </tr> <tr> <td>BOS 3</td> <td>FEV<sub>1</sub> 50 percent or less of baseline</td> <td>BOS 3</td> <td>FEV<sub>1</sub> 50 percent or less of baseline</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">After lung transplantation, \"baseline values\" for FEV<sub>1</sub> and FEF<sub>25-75</sub> are ascertained by taking the average of the two highest values obtained at least three weeks apart and without preceding bronchodilator inhalation. The baseline values may be adjusted upward if lung function improves in the months after transplantation.</div><div class=\"graphic_footnotes\">BOS: bronchiolitis obliterans syndrome; FEF<sub>25-75</sub>: mid-expiratory flow rate; FEV<sub>1</sub>: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Reproduced with permission from: Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297. Copyright &copy; 2006 The International Society for Heart and Lung Transplantation.</div><div id=\"graphicVersion\">Graphic 66742 Version 3.0</div></div></div>"},"66743":{"type":"graphic_diagnosticimage","displayName":"Fallots tetralogy PA","title":"Fallot's tetralogy with Blalock-Taussig anastomosis to the right pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fallot's tetralogy with Blalock-Taussig anastomosis to the right pulmonary artery</div><div class=\"cntnt\"><img style=\"width:352px; height:345px;\" src=\"images/PULM/66743_Fallots_tetralogy_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows hyperperfusion of the right lung with lateralization of pulmonary vascular flow and oligemia of the left lung. Several punctate, irregular vascular structures are seen in the left lung, likely reflecting bronchial collateralization.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66743 Version 3.0</div></div></div>"},"66747":{"type":"graphic_table","displayName":"Genetic causes of hypercholesterolemia","title":"Characteristic findings of different genetic causes of hypercholesterolemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristic findings of different genetic causes of hypercholesterolemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Disorder</td> <td class=\"subtitle1\" rowspan=\"2\">Estimated prevalence</td> <td class=\"subtitle1\" rowspan=\"2\">Characteristic lipid levels*</td> <td class=\"subtitle1\" colspan=\"2\">Clinical features</td> <td class=\"subtitle1\" rowspan=\"2\">Confirmatory studies</td> </tr> <tr> <td class=\"subtitle1\">&nbsp;In adults</td> <td class=\"subtitle1\">In children</td> </tr> <tr class=\"divider_bottom\"> <td>Heterozygous familial hypercholesterolemia</td> <td>1/200 to 1/500</td> <td> <ul> <li>Elevated TC and LDL-C </li> <li>LDL-C 190 to 450 mg/dL<sup>&#182;</sup> </li> <li>TG usually normal </li> </ul> </td> <td> <ul> <li>Tendon or tuberous xanthomata </li> <li>Xanthelasmas </li> <li>Corneal arcus </li> <li>Premature CHD </li> </ul> </td> <td> <ul> <li>Subclinical atherosclerosis </li> </ul> </td> <td> <ul> <li>Exclusion of secondary disorders of cholesterol </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Homozygous familial hypercholesterolemia</td> <td>1/1,000,000</td> <td> <ul> <li>Markedly elevated TC and LDL-C </li> <li>Untreated LDL-C &#62;500mg/dL </li> <li>TG usually normal </li> </ul> </td> <td> <ul> <li>Extensive xanthomata </li> <li>Severe and progressive atherosclerotic cardiovascular disease </li> </ul> </td> <td> <ul> <li>Cutaneous or tendon xanthomata often in the first year of life </li> <li>Premature CHD occurs in childhood if untreated </li> </ul> </td> <td> <ul> <li>Genetic testing for mutations in the LDLR, APOB, and PCSK9 genes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Familial combined hyperlipidemia (FCHL)</td> <td>1 to 2%</td> <td> <ul> <li>Phenotypically heterogeneous </li> <li>Elevated TC and/or TG </li> <li>LDL-C/apo B ratio &#60;1.2 </li> </ul> </td> <td> <ul> <li>Xanthelasma </li> <li>Corneal arcus </li> <li>Premature CHD </li> </ul> </td> <td> <ul> <li>Clinical manifestations are typically not seen during childhood </li> </ul> </td> <td> <ul> <li>Similar lipid profile in one first- or two second-degree relatives </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Familial hyperapobetalipoproteinemia</td> <td> <p>&#60;1%</p> Likely a variant of FCHL</td> <td> <ul> <li>Apo B &#62;135 mg/dL </li> <li>LDL-C &#60;160 mg/dL </li> <li>LDL-C/apo B ratio &#60;1.2 </li> </ul> </td> <td> <ul> <li>Xanthelasma </li> <li>Premature CHD </li> <li>Obesity </li> </ul> </td> <td> <ul> <li>Clinical manifestations other than obesity are typically not seen during childhood </li> </ul> </td> <td> <ul> <li>Similar lipid profile in at least two first- or second-degree relatives </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Polygenic hypercholesterolemia</td> <td>&#62;25%</td> <td> <ul> <li>Elevated TC and LDL-C </li> <li>TG usually normal </li> <li>LDL-C 130-250 mg/dL </li> </ul> </td> <td> <ul> <li>Premature CHD </li> <li>Tendon xanthomata are <strong>not</strong> seen </li> </ul> </td> <td> <ul> <li>Clinical manifestations are typically not seen during childhood </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td>Familial dysbetalipoproteinemia</td> <td>1/5,000</td> <td> <ul> <li>Elevated TC and TG </li> <li>VLDL/TG ratio &#62;0.3 </li> </ul> </td> <td> <ul> <li>Tuboeruptive xanthomata </li> <li>Xanthomata of the palmar creases </li> <li>Premature CHD </li> </ul> </td> <td> <ul> <li>Clinical manifestations are typically not seen during childhood </li> </ul> </td> <td> <ul> <li>Apo E isoform analysis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Summary of the clinical features of different lipid disorders.</div><div class=\"graphic_footnotes\">TC: total cholesterol; TG: triglycerides; LDL-C: low density lipoprotein cholesterol; apo B: apolipoprotein B; VLDL: very low density lipoprotein; CHD: coronary heart disease; LDLR: LDL receptor; PCSK9: proprotein convertase subtilisin kexin 9; FCHL: familial combined hyperlipidemia.<br />* Lipid levels presented in this table represent the typical ranges seen in each disorder, primarily in affected adults. In most of these disorders, there is considerable variability in these values and lipid levels alone generally cannot be used to confirm or exclude the diagnosis.<br />¶ In pediatric patients, an LDL-C&nbsp;cutoff value of ≥190 mg/dL is generally used to establish a diagnosis of heterozygous FH. However, in patients with a concerning family history (ie, first-degree relatives with hypercholesterolemia and/or early cardiovascular disease), it may be appropriate to use a lower cutoff value (eg, LDL of ≥160 mg/dL).</div><div id=\"graphicVersion\">Graphic 66747 Version 3.0</div></div></div>"},"66748":{"type":"graphic_picture","displayName":"C-ANCA pattern on indirect immunofluorescence","title":"C-ANCA pattern on indirect immunofluorescence","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">C-ANCA pattern on indirect immunofluorescence</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/66748_C_ANCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Demonstration of cytoplasmic antineutrophil cytoplasmic antibodies (C-ANCA) by indirect immunofluorescence with normal neutrophils. There is heavy staining in the cytoplasm while the multilobulated nuclei (clear zones) are nonreactive. These antibodies are usually directed against proteinase 3, and most patients have granulomatosis with polyangiitis.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 66748 Version 6.0</div></div></div>"},"66749":{"type":"graphic_figure","displayName":"Recirculation and HD delivery","title":"Figure showing the effect of dialyzer blood flow on urea clearance in the presence of low cardiac output and recirculation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Figure showing the effect of dialyzer blood flow on urea clearance in the presence of low cardiac output and recirculation</div><div class=\"cntnt\"><img style=\"width:446px; height:254px;\" src=\"images/NEPH/66749_Recirculation_hd_delive.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of increasing dialyzer blood flow (Qb) on total body urea clearance (Ktb) during hemodialysis. The top curve (Kd) represents the ideal curve in which all of the dialysis prescription is delivered. The lower curves reflect the progressive decrease in Ktb induced by the sequential addition of a low cardiac output (Qco = 5 L/min); plus a high access blood flow (Qac = 50% Qco); plus 15 percent access recirculation.</div><div class=\"graphic_footnotes\">K<SUB>tb</SUB>: total body urea clearance; Qb: blood flow; Kd: delivered dialyzer clearance; Q<SUB innerHtml>co</SUB>: cardiac output; Q<SUB innerHtml>ac</SUB>: access blood flow; AR: access recirculation.</div><div id=\"graphicVersion\">Graphic 66749 Version 4.0</div></div></div>"},"66751":{"type":"graphic_picture","displayName":"Gonococcal ophthalmia neonatorum","title":"Gonococcal ophthalmia neonatorum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gonococcal ophthalmia neonatorum</div><div class=\"cntnt\"><img style=\"width:504px; height:293px;\" src=\"images/PEDS/66751_Gonococcal_ophthalmia_neonat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: The Public Health Image Library, Centers for Disease Control and Prevention. Photo by Dr. J Pledger.</div><div id=\"graphicVersion\">Graphic 66751 Version 1.0</div></div></div>"},"66752":{"type":"graphic_waveform","displayName":"Ventricular demand pacemaker tutorial","title":"Ventricular demand pacemaker tutorial","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventricular demand pacemaker tutorial</div><div class=\"cntnt\"><img style=\"width:376px; height:118px;\" src=\"images/CARD/66752_Ventric_demand_pacer_tutori.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A single pacemaker spike (marked by red lines) is followed by a QRS complex which is wide and bizarre and resembles a ventricular beat. There are some normal intervening QRS complexes that suppress the pacemaker when they occur faster than the rate set for the pacemaker.</div><div id=\"graphicVersion\">Graphic 66752 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"66754":{"type":"graphic_picture","displayName":"Bald-faced hornets","title":"Bald-faced hornets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bald-faced hornets</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/66754_Bald-faced_hornets.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 66754 Version 1.0</div></div></div>"},"66755":{"type":"graphic_figure","displayName":"Vitamin K and warfarin","title":"Biochemical similarity between vitamin K and warfarin molecules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biochemical similarity between vitamin K and warfarin molecules</div><div class=\"cntnt\"><img style=\"width:291px; height:236px;\" src=\"images/HEME/66755_Vitamin_K_and_warfarin.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66755 Version 1.0</div></div></div>"},"66756":{"type":"graphic_diagnosticimage","displayName":"E point septal separation LVEF","title":"M-mode echocardiogram for estimating left ventricular function","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram for estimating left ventricular function</div><div class=\"cntnt\"><img style=\"width:263px; height:316px;\" src=\"images/CARD/66756_EpointseptalseparationL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiogram can be used as a confirmatory adjunct to two-dimensional evaluation of the left ventricle; the E point (of the mitral valve) septal separation (EPSS) is probably the most useful parameter. The M-mode echocardiogram was obtained prior to a myocardial infarction. The EPSS is 0, and the ejection fraction (EF) is normal. The panel on the right was obtained after the infarction; the EPSS is 13 mm and the EF is 40 percent. If EPSS is greater than 7 mm, there is a high likelihood that the EF is &lt;45 percent.</div><div class=\"graphic_footnotes\">Dia: diastole; Sys: systole; MV: mitral valve.</div><div id=\"graphicVersion\">Graphic 66756 Version 3.0</div></div></div>"},"66757":{"type":"graphic_figure","displayName":"Lactate threshold ","title":"Lactate threshold according to exercise intensity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lactate threshold according to exercise intensity</div><div class=\"cntnt\"><img style=\"width:387px; height:356px;\" src=\"images/PEDS/66757_Lactate_threshold.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At low to moderate exercise intensity, lactate production is matched by clearance, and blood lactate concentration increases only slightly. As exercise intensity increases (between stages 3 and 4), lactate production exceeds clearance, and lactate concentration begins to increase exponentially. The lactate threshold occurs just before the exponential rise in an individual's potential for high-level endurance performance.</div><div id=\"graphicVersion\">Graphic 66757 Version 4.0</div></div></div>"},"66758":{"type":"graphic_table","displayName":"Syndromes with hearing loss","title":"Selected genetic syndromes associated with hearing loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected genetic syndromes associated with hearing loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Syndrome </td> <td class=\"subtitle1\">Features </td> <td class=\"subtitle1\">Caused by mutation </td> <td class=\"subtitle1\">Sensorineural </td> <td class=\"subtitle1\">Conductive </td> <td class=\"subtitle1\">Mixed </td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/193500\" spellcheck=\"true\" target=\"_blank\">Waardenburg syndrome</a> (AD)</td> <td>White forelock, heterochromic irides, broad mandible, deafness</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/276900\" spellcheck=\"true\" target=\"_blank\">Usher syndrome</a> (AR)</td> <td>Retinitis pigmentosa, ataxia, deafness</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/274600\" spellcheck=\"true\" target=\"_blank\">Pendred syndrome</a> (AR)</td> <td>Familial goiter, dysfunctional iodide organization, deafness</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/301050\" spellcheck=\"true\" target=\"_blank\">Alport syndrome</a> (XL, AR, AD)</td> <td>Nephritis, deafness, lens, defects, retinitis</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Craniofacial anomalies (eg, <a href=\"http://www.omim.org/entry/101200\" spellcheck=\"true\" target=\"_blank\">Apert syndrome</a>, <a href=\"http://www.omim.org/entry/101600\" spellcheck=\"true\" target=\"_blank\">Pfeiffer syndrome</a>, <a href=\"http://www.omim.org/entry/123500\" spellcheck=\"true\" target=\"_blank\">Crouzon syndrome</a>)</td> <td>Craniosynostosis, micrognathia, syndactyly</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/214800\" spellcheck=\"true\" target=\"_blank\">CHARGE</a> (AD, isolated cases)</td> <td>Choanal atresia, colobomas, heart defect, intellectual disability, genital hypoplasia, ear anomalies, deafness</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/164210\" spellcheck=\"true\" target=\"_blank\">Hemifacial microsomia </a>(oculo-auriculo-vertebral spectrum, Goldenhar syndrome) (sporadic, AD)</td> <td>Facial hypoplasia, ear anomalies, hemivertebrae, parotid gland dysfunction</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>X</td> </tr> <tr> <td>Mucopolysaccharidosis <a href=\"http://www.omim.org/entry/607014\" spellcheck=\"true\" target=\"_blank\">Hurler</a> (AR), <a href=\"http://www.omim.org/entry/309900\" spellcheck=\"true\" target=\"_blank\">Hunter </a>(XL), <a href=\"http://www.omim.org/entry/253200\" spellcheck=\"true\" target=\"_blank\">Maroteaux-Lamy</a> (AR)</td> <td>Coarse facies, stiff joints, intellectual disability, cloudy corneas</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/154500\" spellcheck=\"true\" target=\"_blank\">Treacher-Collins syndrome</a> (AD)</td> <td>Facial malformation, cleft palate, deafness</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/311300\" spellcheck=\"true\" target=\"_blank\">Otopalatodigital syndrome</a> (XL)</td> <td>Deafness, cleft palate, broad digits</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/108300\" spellcheck=\"true\" target=\"_blank\">Stickler syndrome</a> (AD)</td> <td>Cleft palate, micrognathia, myopia, cataracts, spondyloepiphyseal dysplasia, deafness</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/151100\" spellcheck=\"true\" target=\"_blank\">LEOPARD syndrome</a> (AD)</td> <td>Multiple lentigenes, pulmonic stenosis, hypertelorism, deafness, genital anomalies</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/244400\" spellcheck=\"true\" target=\"_blank\">Ciliary dyskinesia</a>&nbsp;(AR)</td> <td>Situs inversus, immobile cilia, heart defects, splenic anomalies, deafness</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/216400\" spellcheck=\"true\" target=\"_blank\">Cockayne syndrome</a> (AR)</td> <td>Retinal degeneration, senile-like changes, growth retardation, photosensitivity, deafness</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/100800\" spellcheck=\"true\" target=\"_blank\">Achondroplasia</a> (AD)</td> <td>Short limbs, hydrocephalus</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/113650\" spellcheck=\"true\" target=\"_blank\">Branchiootorenal syndrome</a> (AD)</td> <td>Branchial anomalies, ear malformations, renal anomalies</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/118100\" spellcheck=\"true\" target=\"_blank\">Klippel-Feil syndrome</a> (sporadic, AD, AR)</td> <td>Fused cervical vertebrae, webbed neck, deafness, congenital heart defect</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/126800\" spellcheck=\"true\" target=\"_blank\">Duane syndrome</a> (sporadic, AD)</td> <td>Ocular strabismus, ear anomalies, skeletal anomalies, cranial nerve palsies, deafness</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/154700\" spellcheck=\"true\" target=\"_blank\">Marfan syndrome</a> (AD)</td> <td>Lens subluxation, arachnodactyly, aortic aneurysm, hyperextensibility, deafness</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/157900\" spellcheck=\"true\" target=\"_blank\">Mobius syndrome</a> (sporadic, AD, AR)</td> <td>Cranial nerve palsies, limb anomalies, hypoglossia, micrognathia, deafness</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/191900\" spellcheck=\"true\" target=\"_blank\">Muckle-Wells syndrome</a> (AD)</td> <td>Amyloid nephropathy, urticaria, deafness</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/261800\" spellcheck=\"true\" target=\"_blank\">Pierre-Robin syndrome</a> (AR, XL)</td> <td>Micrognathia, cleft palate, glossoptosis, deafness</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/220400\" spellcheck=\"true\" target=\"_blank\">Jervell and Lange-Nielsen syndrome</a> (AR)</td> <td>Long QT, deafness</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/162200\" spellcheck=\"true\" target=\"_blank\">Neurofibromatosis type I</a> (AD)</td> <td>Neurofibromas, caf&#233;-au-lait spots, optic glioma</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/166200\" spellcheck=\"true\" target=\"_blank\">Osteogenesis imperfecta</a> (AD, AR)</td> <td>Fragile bones, blue sclera</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/130000\" spellcheck=\"true\" target=\"_blank\">Ehlers-Danlos</a> (AD, AR)</td> <td>Joint hyperextensibility, fragile skin</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> </tr> <tr> <td><a href=\"http://www.omim.org/entry/124900\" spellcheck=\"true\" target=\"_blank\">Konigsmark syndrome</a> (AD)</td> <td>Low-frequency hearing loss, macrothrombocytopenia</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Syndromes are listed roughly in order of relative frequency as a cause of hereditary hearing loss.</div><div class=\"graphic_footnotes\">AD: autosomal dominant inheritance; AR: autosomal recessive inheritance; XL: X-linked inheritance; CHARGE: Coloboma, Heart defect, Atresia choanae (also known as choanal atresia), Retarded growth and development, Genital abnormalities, and Ear abnormalities; LEOPARD: Lentigines, Electrocardiographic conduction abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retarded growth, Deafness.</div><div id=\"graphicVersion\">Graphic 66758 Version 5.0</div></div></div>"},"66759":{"type":"graphic_table","displayName":"TSC diagnostic criteria","title":"Diagnostic criteria for tuberous sclerosis complex","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for tuberous sclerosis complex</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Genetic diagnostic criteria</td> </tr> <tr> <td class=\"indent1\">The identification of either a <em>TSC1</em> or <em>TSC2</em> pathogenic mutation in DNA from normal tissue is sufficient to make a definite diagnosis of TSC. A pathogenic mutation is defined as a mutation that clearly inactivates the function of the TSC1 or TSC2 proteins (eg, nonsense mutation), prevents protein synthesis (eg, large deletion), or is a missense mutation whose effect on protein function has been established by functional assessment.</td> </tr> <tr> <td class=\"indent1\">Note that 10 to 25% of patients with TSC have no mutation identified by conventional genetic testing, and a normal result does not exclude TSC, or have any effect on the use of clinical diagnostic criteria to diagnose TSC.</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical diagnostic criteria</td> </tr> <tr> <td class=\"subtitle2_single\">Major clinical features:</td> </tr> <tr> <td class=\"indent1\">Hypomelanotic macules (&#8805;3, at least 5 mm diameter)</td> </tr> <tr> <td class=\"indent1\">Angiofibromas (&#8805;3) or fibrous cephalic plaque</td> </tr> <tr> <td class=\"indent1\">Ungual fibromas (&#8805;2)</td> </tr> <tr> <td class=\"indent1\">Shagreen patch (connective tissue nevus)</td> </tr> <tr> <td class=\"indent1\">Multiple retinal hamartomas</td> </tr> <tr> <td class=\"indent1\">Cortical dysplasias (includes tubers and cerebral white matter radial migration lines)</td> </tr> <tr> <td class=\"indent1\">Subependymal nodules</td> </tr> <tr> <td class=\"indent1\">Subependymal giant cell astrocytoma</td> </tr> <tr> <td class=\"indent1\">Cardiac rhabdomyoma</td> </tr> <tr> <td class=\"indent1\">Lymphangioleiomyomatosis (LAM)*</td> </tr> <tr> <td class=\"indent1\">Angiomyolipomas (&#8805;2)*</td> </tr> <tr> <td class=\"subtitle2_single\">Minor clinical features:</td> </tr> <tr> <td class=\"indent1\">\"Confetti\" skin lesions (1 to 2 mm hypomelanotic macules)</td> </tr> <tr> <td class=\"indent1\">Dental enamel pits (&#8805;3)</td> </tr> <tr> <td class=\"indent1\">Intraoral fibromas (&#8805;2)</td> </tr> <tr> <td class=\"indent1\">Retinal achromic patch</td> </tr> <tr> <td class=\"indent1\">Multiple renal cysts</td> </tr> <tr> <td class=\"indent1\">Nonrenal hamartomas</td> </tr> <tr> <td class=\"subtitle2_single\">Definite TSC:</td> </tr> <tr> <td class=\"indent1\">Two major clinical features, or one major and two or more minor clinical features</td> </tr> <tr> <td class=\"subtitle2_single\">Possible TSC:</td> </tr> <tr> <td class=\"indent1\">Either one major clinical feature or two or more minor clinical features</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSC: tuberous sclerosis complex.<br />* A combination of LAM and angiomyolipomas without other features does not meet criteria for a definite diagnosis.</div><div class=\"graphic_reference\">Original figure modified for this publication. Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 2013; 49:243. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 66759 Version 14.0</div></div></div>"},"66760":{"type":"graphic_figure","displayName":"Fascial interposition during vasectomy illustration","title":"Fascial interposition during vasectomy illustration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fascial interposition during vasectomy illustration</div><div class=\"cntnt\"><img style=\"width:448px; height:394px;\" src=\"images/PC/66760_Vasal_disruption_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vas sheath is sutured over the prostatic vasal end.</div><div id=\"graphicVersion\">Graphic 66760 Version 2.0</div></div></div>"},"66761":{"type":"graphic_figure","displayName":"FEV1 and age in males","title":"FEV1 and age in healthy men","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">FEV1 and age in healthy men</div><div class=\"cntnt\"><img style=\"width:410px; height:298px;\" src=\"images/PULM/66761_FEV1_and_age_in_males.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Growth and decline of lung function in healthy males. Actual values are shown in the top panel and growth velocity in the bottom panel.</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Data from: Sherrill DL, Camilli A, Lebowitz MD. Am Rev Respir Dis 1989; 140:638.</div><div id=\"graphicVersion\">Graphic 66761 Version 2.0</div></div></div>"},"66762":{"type":"graphic_table","displayName":"Incubation period for rash I","title":"Incubation period for infectious diseases associated with fever and rash","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incubation period for infectious diseases associated with fever and rash</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent/disease</td> <td class=\"subtitle1\">Incubation period</td> </tr> <tr> <td><em>Arcanobacterium haemolyticum</em></td> <td>Unknown</td> </tr> <tr> <td>Atypical measles</td> <td>7 to 14 days</td> </tr> <tr> <td><em>Blastomyces dermatitidis</em></td> <td>30 to 45 days</td> </tr> <tr> <td>Boutonneuse fever (<em>Rickettsia conorii</em>)</td> <td>6 to 10 days</td> </tr> <tr> <td>Cat scratch disease</td> <td>7 to 14 days</td> </tr> <tr> <td>Chancroid</td> <td>1 to 35 days</td> </tr> <tr> <td>Chickenpox </td> <td>10 to 20 days</td> </tr> <tr> <td>Chikungunya&nbsp;</td> <td>3 to 7 days</td> </tr> <tr> <td><em>Chlamydia psittaci</em></td> <td>5 to 21 days</td> </tr> <tr> <td><em>Coccidioides immitis</em></td> <td>7 to 21 days</td> </tr> <tr> <td>Coxsackie/echovirus</td> <td>2 to 9 days</td> </tr> <tr> <td>Cutaneous larva migrans</td> <td>2 to 4 days</td> </tr> <tr> <td>Dengue</td> <td>3 to 14 days</td> </tr> <tr> <td>Disseminated gonococcal infection</td> <td>5 days to several months</td> </tr> <tr> <td>Ehrlichiosis</td> <td>7 to 21 days</td> </tr> <tr> <td><em>Escherichia coli</em> 0157:H7</td> <td>3 to 8 days</td> </tr> <tr> <td>Epstein-Barr virus (mononucleosis)</td> <td>30 to 50 days</td> </tr> <tr> <td>Gnathostomiasis</td> <td>3 to 12 months</td> </tr> <tr> <td>Granuloma inguinale</td> <td>8 to 80 days</td> </tr> <tr> <td>Hepatitis B</td> <td>45 to 160 days</td> </tr> <tr> <td>Hepatitis C</td> <td>14 to 180 days</td> </tr> <tr> <td>Herpes simplex (genital)</td> <td>2 to 7 days</td> </tr> <tr> <td>Human immunodeficiency virus (HIV)</td> <td>28 to 180 days</td> </tr> <tr> <td>Kawasaki syndrome</td> <td>Unknown</td> </tr> <tr> <td>Leishmaniasis</td> <td>14 to 56 days</td> </tr> <tr> <td>Loiasis</td> <td>6 to 12 months</td> </tr> <tr> <td>Lyme disease</td> <td>3 to 30 days</td> </tr> <tr> <td>Lymphogranuloma venerum (LGV)</td> <td>3 to 21 days</td> </tr> <tr> <td><em>Mycobacterium leprae</em></td> <td>&#62;1 year</td> </tr> <tr> <td><em>Mycobacterium marinum</em></td> <td>14 to 56 days</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div id=\"graphicVersion\">Graphic 66762 Version 4.0</div></div></div>"},"66763":{"type":"graphic_picture","displayName":"Acute ISN Low power","title":"Low power light micrograph of kidney biopsy of a patient with severe acute interstitial nephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low power light micrograph of kidney biopsy of a patient with severe acute interstitial nephritis</div><div class=\"cntnt\"><img style=\"width:360px; height:234px;\" src=\"images/NEPH/66763_Acute_ISN_Low_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of severe acute interstitial nephritis showing diffuse interstitial inflammatory infiltrate. One normal glomerulus is present at the top of the slide.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 66763 Version 2.0</div></div></div>"},"66764":{"type":"graphic_figure","displayName":"Stroke treatment delay and outcome","title":"Stroke treatment delay and outcome","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">Stroke treatment delay and outcome</div><div class=\"cntnt\"><img style=\"width:619px; height:497px;\" src=\"images/NEURO/66764_Strokeonsetrxdelay.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation of stroke onset to start of treatment (OTT) with treatment effect after adjustment for prognostic variables assessed by A) day 90 modified Rankin score 0-1 versus 2-6 (interaction p=0.0269, n=3530 [excluding EPITHET data p=0.0116, n=3431]); B) global test that incorporates modified Rankin score 0-1 versus 2-6, Barthel Index score 95-100 versus 90 or lower and NIHSS score 0-1 versus 2 or more (interaction p=0.0111, n=3535 [excluding EPITHET data p=0.0049, n=3436]); C) mortality (interaction p=0.0444, n=3530 [excluding EPITHET data p=0.0582, n=3431]); and D) parenchymal hemorrhage type 2 (interaction p=0.4140, n=3531 [excluding EPITHET data p=0.4578, n=3431]). Thus, for parenchymal hemorrhage type 2, the fitted line is not statistically distinguishable from a horizontal line. For each graph, the adjusted odds ratio is shown with the 95% CIs. CIs from the models will differ from those shown in the tables because the model uses data from all patients treated within 0-360 min whereas the categorized analyses in the tables are based on subsets of patients: the modeled CIs are deemed to be more reliable.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Lees, KR, Bluhmki, E, von Kummer, R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695. Illustration used with permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 66764 Version 2.0</div></div></div>"},"66765":{"type":"graphic_figure","displayName":"Fetal circulation 1","title":"Fetal circulation","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Fetal circulation</div><div class=\"cntnt\"><img style=\"width:502px; height:651px;\" src=\"images/OBGYN/66765_Fetal_circulation_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The degree of oxygen saturation is indicated by shading, as explained in the figure key.</div><div id=\"graphicVersion\">Graphic 66765 Version 4.0</div></div></div>"},"66767":{"type":"graphic_picture","displayName":"Vertical talus","title":"Vertical talus deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vertical talus deformity</div><div class=\"cntnt\"><img style=\"width:380px; height:279px;\" src=\"images/PEDS/66767_Vertical_talus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vertical talus deformity (rockerbottom foot) in an infant.</div><div class=\"graphic_reference\">Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.</div><div id=\"graphicVersion\">Graphic 66767 Version 2.0</div></div></div>"},"66768":{"type":"graphic_table","displayName":"Hymenoptera characteristics","title":"Characteristics of Hymenoptera (bees and wasps) ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of Hymenoptera (bees and wasps) </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Common name</td> <td class=\"subtitle1\">Typical number of adults in a nest</td> <td class=\"subtitle1\">Solitary, but many can occur in the same area</td> <td class=\"subtitle1\">Will sting in defense of the nest</td> <td class=\"subtitle1\">Will not sting unless pinched or handled</td> <td class=\"subtitle1\">Nest</td> <td class=\"subtitle1\">Principal food</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Bees</td> </tr> <tr> <td class=\"indent1\">Honey bee</td> <td>Thousands</td> <td>&nbsp;</td> <td>&#8730;</td> <td>&nbsp;</td> <td>Wax combs in hollow trees, building voids, or manmade hives; Africanized honey bees will nest in many types of cavities</td> <td>Pollen and honey made from nectar</td> </tr> <tr> <td class=\"indent1\">Bumble bee</td> <td>Dozens</td> <td>&nbsp;</td> <td>&#8730;</td> <td>&nbsp;</td> <td>Wax pots in the ground or other cavities</td> <td>Pollen and honey made from nectar</td> </tr> <tr> <td class=\"indent1\">Carpenter bee</td> <td>One</td> <td>&#8730;</td> <td>&nbsp;</td> <td>&#8730;</td> <td>Tunnels in wood trim, fences, and decks</td> <td>Pollen and nectar</td> </tr> <tr> <td class=\"indent1\">Sweat bee</td> <td>One</td> <td>&#8730;</td> <td>&nbsp;</td> <td>&#8730;</td> <td>&nbsp;</td> <td>Pollen and nectar</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Wasps</td> </tr> <tr> <td class=\"indent1\">Yellow jackets</td> <td>Hundreds to thousands</td> <td>&nbsp;</td> <td>&#8730;</td> <td>&nbsp;</td> <td>Paper combs hidden by envelope and attached to vegetation or buildings, or in the ground or building voids</td> <td>Insects, nectar, ripe fruit; some species scavenge carrion and human food</td> </tr> <tr> <td class=\"indent1\">Paper wasps</td> <td>Dozens</td> <td>&nbsp;</td> <td>&#8730;</td> <td>&nbsp;</td> <td>A single, exposed (no envelope) paper comb with cells open at the bottom</td> <td>Insects (often caterpillars), nectar</td> </tr> <tr> <td class=\"indent1\">European hornet</td> <td>Hundreds</td> <td>&nbsp;</td> <td>&#8730;</td> <td>&nbsp;</td> <td>Brittle, brown combs, with or without envelope, in hollow trees or building voids</td> <td>Insects (often bees and yellow jackets), ripe fruit, sap</td> </tr> <tr> <td class=\"indent1\">Cicada killers</td> <td>One</td> <td>&#8730;</td> <td>&nbsp;</td> <td>&#8730;</td> <td>Burrows in the ground</td> <td>Cicadas</td> </tr> <tr> <td class=\"indent1\">Mud daubers</td> <td>One</td> <td>&#8730;</td> <td>&nbsp;</td> <td>&#8730;</td> <td>Mud lumps or tubes in sheltered areas</td> <td>Spiders</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66768 Version 3.0</div></div></div>"},"66769":{"type":"graphic_figure","displayName":"Infected hair follicle PI","title":"Infected hair follicle","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Infected hair follicle</div><div class=\"cntnt\"><img style=\"width:504px; height:391px;\" src=\"images/PI/66769_Infected-hair-follicle-PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66769 Version 1.0</div></div></div>"},"66770":{"type":"graphic_diagnosticimage","displayName":"Tissue Doppler normal LV","title":"Tissue Doppler echocardiographic image of normal left ventricle","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Tissue Doppler echocardiographic image of normal left ventricle</div><div class=\"cntnt\"><img style=\"width:455px; height:290px;\" src=\"images/CARD/66770_TissueDopplernormalLV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tissue Doppler image, obtained from the parastenal long-axis view, shows normal left ventricular systolic function. Panel A shows the color-coded two-dimensional tissue Doppler image; panel B shows the corresponding color-M-mode tissue Doppler image for a single cardiac cycle; and panel C is the time-velocity plot of the posterior wall of the color-M-mode tissue Doppler image.</div><div class=\"graphic_footnotes\">S: peak systolic velocity; E: peak early diastolic velocity; A: peak atrial velocity.</div><div id=\"graphicVersion\">Graphic 66770 Version 4.0</div></div></div>"},"66772":{"type":"graphic_table","displayName":"Causes of macrocytosis","title":"Causes and mechanisms of macrocytosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes and mechanisms of macrocytosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Abnormalities of DNA metabolism </td> </tr> <tr> <td>Vitamin B12 (cobalamin) deficiency</td> </tr> <tr> <td>Folate deficiency</td> </tr> <tr> <td class=\"sublist1_start\">Drugs </td> </tr> <tr> <td class=\"sublist1\">Antiretroviral therapies for HIV infection (eg, zidovudine)</td> </tr> <tr> <td class=\"sublist1\">Azathioprine or 6-mercaptopurine&nbsp; </td> </tr> <tr> <td class=\"sublist1\">Capecitabine </td> </tr> <tr> <td class=\"sublist1\">Cladribine</td> </tr> <tr> <td class=\"sublist1\">Cytosine arabinoside </td> </tr> <tr> <td class=\"sublist1\">Hydroxyurea</td> </tr> <tr> <td class=\"sublist1\">Imatinib, sunitinib</td> </tr> <tr> <td class=\"sublist1\">Methotrexate</td> </tr> <tr> <td class=\"subtitle1_single\">Shift to immature or stressed red cells </td> </tr> <tr> <td>Reticulocytosis</td> </tr> <tr> <td>Action of erythropoietin - skip macrocytes, stress erythrocytosis</td> </tr> <tr> <td>Aplastic anemia/Fanconi anemia</td> </tr> <tr> <td>Pure red cell aplasia</td> </tr> <tr> <td class=\"subtitle1_single\">Primary bone marrow disorders </td> </tr> <tr> <td>Myelodysplastic syndromes</td> </tr> <tr> <td>Congenital dyserythropoietic anemias</td> </tr> <tr> <td>Some sideroblastic anemias</td> </tr> <tr> <td>Large granular lymphocyte (LGL) leukemia</td> </tr> <tr> <td class=\"subtitle1_single\">Lipid abnormalities </td> </tr> <tr> <td>Liver disease</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td class=\"subtitle1_single\">Mechanism unknown </td> </tr> <tr> <td>Alcohol abuse</td> </tr> <tr> <td>Multiple myeloma and other plasma cell disorders</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66772 Version 3.0</div></div></div>"},"66773":{"type":"graphic_table","displayName":"Drug and toxin induced ECG abnormalities","title":"Drug- and toxin-induced electrocardiographic abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug- and toxin-induced electrocardiographic abnormalities</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Bradycardia/AV blockade</td> </tr> <tr> <td>Beta blockers</td> </tr> <tr> <td>Calcium channel blockers</td> </tr> <tr> <td class=\"sublist1_start\">Cardiac glycosides</td> </tr> <tr> <td class=\"sublist1\">Digoxin</td> </tr> <tr> <td class=\"sublist1\">Digitoxin</td> </tr> <tr> <td class=\"sublist1\">Red squill</td> </tr> <tr> <td class=\"sublist1\">Digitalis lanata</td> </tr> <tr> <td class=\"sublist1\">Digitalis purpurea</td> </tr> <tr> <td class=\"sublist1\">Bufotenin</td> </tr> <tr> <td class=\"sublist1\">Oleander</td> </tr> <tr> <td class=\"sublist1_start\">Alpha-adrenergic agonists</td> </tr> <tr> <td class=\"sublist1\">Phenylpropanolamine</td> </tr> <tr> <td class=\"sublist1\">Clonidine</td> </tr> <tr> <td class=\"sublist1\">Imidazolines</td> </tr> <tr> <td class=\"sublist1_start\">Cholinergics</td> </tr> <tr> <td class=\"sublist1\">Organophosphates</td> </tr> <tr> <td class=\"sublist1\">Carbamates</td> </tr> <tr> <td>Opioids</td> </tr> <tr> <td>Sedative-hypnotics</td> </tr> <tr> <td>Magnesium</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Supraventricular tachycardia</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td class=\"sublist1\">Methylphenidate</td> </tr> <tr> <td class=\"sublist1\">Ephedrine</td> </tr> <tr> <td class=\"sublist1\">Pseudoephedrine</td> </tr> <tr> <td class=\"sublist1\">Albuterol</td> </tr> <tr> <td class=\"sublist1\">Dobutamine</td> </tr> <tr> <td class=\"sublist1\">Epinephrine</td> </tr> <tr> <td class=\"sublist1\">Dopamine</td> </tr> <tr> <td class=\"sublist1_start\">Anticholinergics</td> </tr> <tr> <td class=\"sublist1\">Antihistamines</td> </tr> <tr> <td class=\"sublist1\">TCAs</td> </tr> <tr> <td class=\"sublist1\">Phenothiazines</td> </tr> <tr> <td class=\"sublist1\">Clozapine</td> </tr> <tr> <td class=\"sublist1\">Atropine</td> </tr> <tr> <td class=\"sublist1\">Scopolamine</td> </tr> <tr> <td>Thyroid hormone</td> </tr> <tr> <td>Cellular asphyxiants</td> </tr> <tr> <td>Carbon monoxide</td> </tr> <tr> <td>Drug withdrawal states</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Ventricular tachycardia</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1_start\">Antidepressants</td> </tr> <tr> <td class=\"sublist1\">TCAs</td> </tr> <tr> <td class=\"sublist1_start\">Antipsychotics</td> </tr> <tr> <td class=\"sublist1\">Phenothiazines</td> </tr> <tr> <td class=\"sublist1_start\">Chlorinated hydrocarbons</td> </tr> <tr> <td class=\"sublist1\">Chloral hydrate</td> </tr> <tr> <td class=\"sublist1\">Solvents</td> </tr> <tr> <td>Fluoride</td> </tr> <tr> <td>Cardiac glycosides</td> </tr> <tr> <td>Potassium</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">QRS and QT interval prolongation</td> </tr> <tr> <td>Antidepressants</td> </tr> <tr> <td>Antipsychotics</td> </tr> <tr> <td class=\"sublist1_start\">Antihistamines</td> </tr> <tr> <td class=\"sublist1\">Diphenhydramine</td> </tr> <tr> <td class=\"sublist1\">Astemizole</td> </tr> <tr> <td class=\"sublist1\">Terfenadine</td> </tr> <tr> <td class=\"sublist1_start\">Antiarrhythmics</td> </tr> <tr> <td class=\"sublist1\">Quinidine</td> </tr> <tr> <td class=\"sublist1\">Disopyramide</td> </tr> <tr> <td class=\"sublist1\">Procainamide</td> </tr> <tr> <td class=\"sublist1\">Propafenone</td> </tr> <tr> <td class=\"sublist1\">Flecainide, encainide</td> </tr> <tr> <td class=\"sublist1\">Amiodarone</td> </tr> <tr> <td class=\"sublist1\">Calcium channel blockers (rare)</td> </tr> <tr> <td class=\"sublist1\">Beta blockers (rare)</td> </tr> <tr> <td>Propoxyphene</td> </tr> <tr> <td>Organophosphate insecticides</td> </tr> <tr> <td class=\"sublist1_start\">Antimicrobials</td> </tr> <tr> <td class=\"sublist1\">Amantadine</td> </tr> <tr> <td class=\"sublist1\">Azithromycin</td> </tr> <tr> <td class=\"sublist1\">Chloroquine</td> </tr> <tr> <td class=\"sublist1\">Erythromycin</td> </tr> <tr> <td class=\"sublist1\">Pentamidine</td> </tr> <tr> <td class=\"sublist1\">Quinine</td> </tr> <tr> <td class=\"sublist1\">Quinolones (eg, ciprofloxacin)</td> </tr> <tr> <td>Arsenic</td> </tr> <tr> <td>Thallium</td> </tr> <tr> <td>Fluoride</td> </tr> <tr> <td>Citrate</td> </tr> <tr> <td>Lithium</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66773 Version 7.0</div></div></div>"},"66775":{"type":"graphic_picture","displayName":"Pulmonary LAM microscopy Low","title":"Microscopic features of lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microscopic features of lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:250px; height:225px;\" src=\"images/PULM/66775_Pulmonary_LAM_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low magnification photomicrograph showing a portion of a cystic space in lymphangioleiomyomatosis. The periphery of the cystic space consists of alveolar septa and peribronchiolar interstitium that has been expanded by a population of spindle cells.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 66775 Version 2.0</div></div></div>"},"66776":{"type":"graphic_table","displayName":"Clinical features of myocarditis","title":"Clinical features of myocarditis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of myocarditis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Excessive fatigue or exercise intolerance</td> </tr> <tr> <td>Chest pain</td> </tr> <tr> <td>Unexplained sinus tachycardia</td> </tr> <tr> <td>S3, S4, or summation gallop</td> </tr> <tr> <td>Abnormal electrocardiogram</td> </tr> <tr> <td>Abnormal echocardiogram</td> </tr> <tr> <td>New cardiomegaly on chest radiograph</td> </tr> <tr> <td>Atrial or ventricular arrhythmia</td> </tr> <tr> <td>Partial or complete heart block, new-onset bundle branch block</td> </tr> <tr> <td>New-onset or worsening&nbsp;heart failure</td> </tr> <tr> <td>Acute pericarditis</td> </tr> <tr> <td>Cardiogenic shock</td> </tr> <tr> <td>Sudden cardiac&nbsp;death</td> </tr> <tr> <td>Respiratory distress/tachypnea</td> </tr> <tr> <td>Hepatomegaly</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66776 Version 5.0</div></div></div>"},"66777":{"type":"graphic_table","displayName":"Basic and advanced pediatric life support courses","title":"Basic and advanced pediatric life support courses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic and advanced pediatric life support courses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Name of course</td> <td class=\"subtitle1\">Approximate cost</td> <td class=\"subtitle1\">Available online?</td> </tr> <tr> <td>Basic Life Support (BLS)</td> <td>$15-$30</td> <td>Yes</td> </tr> <tr> <td>Pediatric Advanced Life Support (PALS)</td> <td>$149-$280</td> <td>Yes</td> </tr> <tr> <td>Advanced Pediatric Life Support (APLS)</td> <td>$250-$350</td> <td>No</td> </tr> <tr> <td>Emergency Nurse Pediatric Course (ENPC)</td> <td> <p>$180 (Emergency Nurse Association member)</p> <p>$240-$300 (non-member)</p> </td> <td>No</td> </tr> <tr> <td>Advanced Cardiac Life Support (ACLS)</td> <td>$200-$275</td> <td>Yes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66777 Version 1.0</div></div></div>"},"66778":{"type":"graphic_picture","displayName":"Fordyce spots - lip","title":"Fordyce spots","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fordyce spots</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/66778_Fordyce_spots_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small yellow papules are present on the lip.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66778 Version 3.0</div></div></div>"},"66781":{"type":"graphic_picture","displayName":"Acrokeratosis paraneoplastica - multiple sites","title":"Acrokeratosis paraneoplastica","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Acrokeratosis paraneoplastica</div><div class=\"cntnt\"><img style=\"width:520px; height:390px;\" src=\"images/ONC/66781_Eryt_paps_plaqs_finger_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, scaly papules and plaques on finger (A), periungual region (B), right ear (C), and right elbow (D). Arrows point to most involved areas.</div><div class=\"graphic_reference\">Reproduced with permission from: Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): Association with liposarcoma. J Am Acad Dermatol 2006; 55:1103. Copyright © 2006 The American Academy of Dermatology.</div><div id=\"graphicVersion\">Graphic 66781 Version 5.0</div></div></div>"},"66786":{"type":"graphic_diagnosticimage","displayName":"Pancreatic necrosis drainage CT","title":"Infected pancreatic necrosis percutaneous drainage","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Infected pancreatic necrosis percutaneous drainage</div><div class=\"cntnt\"><img style=\"width:504px; height:358px;\" src=\"images/GAST/66786_Pancreatic_necrosis_drainag.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan showing a percutaneous drain catheter (arrow) inserted into a necrotic pancreatic fluid collection for drainage and lavage.</div><div class=\"graphic_reference\">Courtesy of Dia T Simmons, MD, Santhi Swaroop Vege, MD, and Suresh T Chari, MD.</div><div id=\"graphicVersion\">Graphic 66786 Version 3.0</div></div></div>"},"66788":{"type":"graphic_figure","displayName":"Aortic regurgitation hemodynamics","title":"Aortic regurgitation hemodynamics","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Aortic regurgitation hemodynamics</div><div class=\"cntnt\"><img style=\"width:542px; height:334px;\" src=\"images/CARD/66788_Aortic_regurgitation_hemody.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aortic regurgitation. Note upsloping LV diastolic pressure and wide pulse pressure.</div><div id=\"graphicVersion\">Graphic 66788 Version 1.0</div></div></div>"},"66789":{"type":"graphic_picture","displayName":"Ultrasound guided biopsy machine","title":"Ultrasound guided biopsy machine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound guided biopsy machine</div><div class=\"cntnt\"><img style=\"width:384px; height:576px;\" src=\"images/SURG/66789_US_guided_biopsy_machine.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Used with permission of GE Healthcare.</div><div id=\"graphicVersion\">Graphic 66789 Version 1.0</div></div></div>"},"66791":{"type":"graphic_table","displayName":"Example of epinephrine infusion - Pediatric 20 kg","title":"Example of epinephrine infusion - Pediatric 20 kg","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of epinephrine infusion - Pediatric 20 kg</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"6\">Example of preparation of epinephrine infusion for refractory symptoms of anaphylaxis for pediatric patient of 20 kg body weight for emergency/critical care units</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"6\"> <p>Final concentration: Epinephrine 10 mcg/mL</p> Add 1 mg (1000 mcg) of epinephrine to 100 mL bag of 0.9% normal saline (NS) or 5% dextrose water (D5W)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Preparation</td> </tr> <tr> <td colspan=\"6\"> <ol> <li><strong>CHECK</strong> vial strength. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\"> <ol start=\"2\"> <li>To prepare epinephrine infusion for a final concentration of <strong>10</strong> mcg/mL, dilute <strong>10 mL</strong> of <strong>0.1 mg/mL</strong> epinephrine (may also be labeled 1:10,000) in <strong>100 mL</strong> bag of 0.9% NS or D5W <strong>OR</strong> <strong>1 mL</strong> of <strong>1 mg/mL</strong> epinephrine (may also be labeled 1:1000) in <strong>100 mL</strong> bag of 0.9% NS or D5W.*</li> </ol> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Administration</td> </tr> <tr> <td class=\"indent1\" colspan=\"6\"> <ul> <li>Infuse an initial dose of 0.1 mcg/kg/minute using a programmable infusion pump and titrate, as needed, while continuously monitoring the patient's cardiac rhythm and blood pressure. </li> <li>For detail on titrating the infusion based upon response, refer to the UpToDate topic on emergency treatment of anaphylaxis. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"3\">Pediatric dose for 20 kg child</td> <td class=\"subtitle2\" colspan=\"3\">Administration rate for infusion pump to deliver pediatric dose shown</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle3\">mcg per kg per minute</td> <td class=\"subtitle3\" rowspan=\"12\">Multiply by patient weight<br /> (20 kg)</td> <td class=\"subtitle3\">mcg per minute</td> <td class=\"subtitle3\">mL per <em>minute</em> for 20 kg child</td> <td class=\"subtitle3\" rowspan=\"12\">Multiply by 60 minutes</td> <td class=\"subtitle3\">mL per <em>hour</em> for 20 kg child</td> </tr> <tr> <td class=\"centered\">0.05</td> <td class=\"centered\">1</td> <td class=\"centered\">0.1</td> <td class=\"centered\">6</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">0.1</td> <td class=\"centered\">2</td> <td class=\"centered\">0.2</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"centered\">0.2</td> <td class=\"centered\">4</td> <td class=\"centered\">0.4</td> <td class=\"centered\">24</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">0.3</td> <td class=\"centered\">6</td> <td class=\"centered\">0.6</td> <td class=\"centered\">36</td> </tr> <tr> <td class=\"centered\">0.4</td> <td class=\"centered\">8</td> <td class=\"centered\">0.8</td> <td class=\"centered\">48</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">0.5</td> <td class=\"centered\">10</td> <td class=\"centered\">1</td> <td class=\"centered\">60</td> </tr> <tr> <td class=\"centered\">0.6</td> <td class=\"centered\">12</td> <td class=\"centered\">1.2</td> <td class=\"centered\">72</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">0.7</td> <td class=\"centered\">14</td> <td class=\"centered\">1.4</td> <td class=\"centered\">84</td> </tr> <tr> <td class=\"centered\">0.8</td> <td class=\"centered\">16</td> <td class=\"centered\">1.6</td> <td class=\"centered\">96</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">0.9</td> <td class=\"centered\">18</td> <td class=\"centered\">1.8</td> <td class=\"centered\">108</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td class=\"centered\">20</td> <td class=\"centered\">2</td> <td class=\"centered\">120</td> </tr> <tr> <td colspan=\"6\"> <ul> <li>The above table is provided as an example. There are other acceptable concentrations. </li> <li>Intravenous epinephrine, like all vasopressors, can cause life-threatening hypertension, cardiac ischemia, and ventricular arrhythmias. It should be administered ONLY by clinicians trained and experienced in dose titration of intravenous epinephrine using continuous noninvasive electronic monitoring of heart rate and blood pressure. </li> <li>Epinephrine is an ischemia causing agent and vesicant. Monitor infusion site for extravasation. Central venous catheter administration is preferred when available.&nbsp;Refer to the&nbsp;Lexicomp drug reference for information on managing extravasation including infiltration of phentolamine. </li> <li>To reduce the risk of making a medication error, we suggest that centers have available an institutionally approved protocol for epinephrine infusion that includes steps on how to prepare and administer the infusion and standard concentration(s). </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Unused diluted solutions should be discarded within 24 hours or less of preparation, depending on local standards.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gahart BL, Nazareno AR, Ortega MQ. Gahart's 2016 Intravenous Medications: A Handbook for Nurses and Health Professionals, 32nd ed, Elsevier-Mosby, St. Louis, MO 2016.</li>&#xD;&#xA;    <li>Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 66791 Version 10.0</div></div></div>"},"66792":{"type":"graphic_picture","displayName":"Nummular eczema legs 2","title":"Nummular eczema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nummular eczema</div><div class=\"cntnt\"><img style=\"width:320px; height:382px;\" src=\"images/DERM/66792_Nummulareczemalegs2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">&quot;Coin-shaped&quot; patches and plaques are located on the legs.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66792 Version 4.0</div></div></div>"},"66793":{"type":"graphic_figure","displayName":"Stroke mortality related to BP and age","title":"Stroke mortality related to blood pressure and age","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Stroke mortality related to blood pressure and age</div><div class=\"cntnt\"><img style=\"width:530px; height:390px;\" src=\"images/NEPH/66793_Stroke_mortality_v_BP_and_a.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stroke mortality rate, pictured on a log scale with 95% confidence intervals (CI), in each decade of age in relation to the estimated usual systolic and diastolic blood pressure at the start of that decade. Stroke mortality increases with both higher pressures and older ages. For diastolic pressure, each age-specific regression line ignores the left-hand point (ie, at slightly less than 75 mmHg), for which the risk lies significantly above the fitted regression line (as indicated by the broken line below 75 mmHg).</div><div class=\"graphic_reference\">Data from Prospective Studies Collaboration, Lancet 2002; 360:1903.</div><div id=\"graphicVersion\">Graphic 66793 Version 4.0</div></div></div>"},"66794":{"type":"graphic_diagnosticimage","displayName":"Interstitial pneumonitis CXR","title":"Interstitial pneumonitis","html":"<div class=\"graphic normal\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Interstitial pneumonitis</div><div class=\"cntnt\"><img style=\"width:468px; height:264px;\" src=\"images/ID/66794_Interstitial_pneumonitis_CX.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with interstitial pneumonitis six months after liver transplantation. Diffuse, bilateral infiltrates and marked hypoxemia are consistent with <EM>Pneumocystis&nbsp;jirovecii </EM>pneumonia.</div><div class=\"graphic_reference\">Courtesy of Jay Fishman, MD.</div><div id=\"graphicVersion\">Graphic 66794 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"66795":{"type":"graphic_movie","displayName":"TEE left atrial appendage thrombus and spontaneous echo contrast ","title":"Transesophageal echocardiography (TEE) showing left atrial appendage thrombus and spontaneous echo contrast ","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography (TEE) showing left atrial appendage thrombus and spontaneous echo contrast </div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/66795_teethla2conv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:267px; height:207px;\" src=\"images/CARD/66795_teethla2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiogram shows a large mobile thrombus in the left atrial appendage, extending into the body of the left atrium. Spontaneous echo contrast can be seen in the left atrium.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 66795 Version 6.0</div></div></div>"},"66796":{"type":"graphic_figure","displayName":"Circadian silent ischemia","title":"Circadian pattern of silent ischemia","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Circadian pattern of silent ischemia</div><div class=\"cntnt\"><img style=\"width:559px; height:407px;\" src=\"images/CARD/66796_Circadian_silent_ischemia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 24-hour distribution of silent ischemic events during continuous electrocardiographic monitoring parallels the circadian pattern of heart rate (HR) and systolic blood pressure (SBP). Note the simultaneous and significant increases in both the double product and silent ischemic events between 6:00 and 7:00 AM.</div><div class=\"graphic_reference\">Data from: Deedwania PC, Nelson J. Circulation 1990; 82:1296.</div><div id=\"graphicVersion\">Graphic 66796 Version 2.0</div></div></div>"},"66799":{"type":"graphic_table","displayName":"Uricemia excretion","title":"Causes of hyperuricemia due to decreased uric acid clearance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hyperuricemia due to decreased&nbsp;uric acid&nbsp;clearance</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical disorders</td> </tr> <tr> <td class=\"indent1\">Chronic renal insufficiency of any form</td> </tr> <tr> <td class=\"indent1\">Lead nephropathy (saturnine gout)</td> </tr> <tr> <td class=\"indent1\">Effective volume depletion (eg, fluid losses, heart failure)</td> </tr> <tr> <td class=\"indent1\">Diabetic or starvation ketoacidosis</td> </tr> <tr> <td class=\"indent1\">Lactic acidosis</td> </tr> <tr> <td class=\"indent1\">Preeclampsia</td> </tr> <tr> <td class=\"indent1\">Obesity</td> </tr> <tr> <td class=\"indent1\">Hyperparathyroidism</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Chronic beryllium disease</td> </tr> <tr> <td class=\"subtitle1_single\">Rare monogenic disorders causing decreased uric acid clearance</td> </tr> <tr> <td class=\"indent1\">Autosomal dominant tubulointerstitial kidney disease caused by <em>UMOD </em>pathogenic variants</td> </tr> <tr> <td class=\"indent1\">Glomerulocystic kidney disease</td> </tr> <tr> <td class=\"subtitle1_single\">Common variants in genes encoding transporters that regulate renal or gut uric acid clearance (numerous; genes with largest reported effect are shown)</td> </tr> <tr> <td class=\"indent1\"><em>SLC2A9</em></td> </tr> <tr> <td class=\"indent1\"><em>ABCG2</em></td> </tr> <tr> <td class=\"indent1\"><em>SLC17A1</em></td> </tr> <tr> <td class=\"indent1\"><em>SLC22A11</em></td> </tr> <tr> <td class=\"indent1\"><em>PDZK1</em></td> </tr> <tr> <td class=\"indent1\"><em>SLC16A9</em></td> </tr> <tr> <td class=\"indent1\"><em>SLC22A12</em></td> </tr> <tr> <td class=\"subtitle1_single\">Drug- or diet-induced</td> </tr> <tr> <td class=\"indent1\">Diuretics (thiazides and loop diuretics)</td> </tr> <tr> <td class=\"indent1\">Cyclosporine and tacrolimus</td> </tr> <tr> <td class=\"indent1\">Low-dose salicylates</td> </tr> <tr> <td class=\"indent1\">Ethambutol</td> </tr> <tr> <td class=\"indent1\">Pyrazinamide</td> </tr> <tr> <td class=\"indent1\">Ethanol</td> </tr> <tr> <td class=\"indent1\">Levodopa</td> </tr> <tr> <td class=\"indent1\">Methoxyflurane</td> </tr> <tr> <td class=\"indent1\">Laxative abuse (alkalosis)</td> </tr> <tr> <td class=\"indent1\">Salt restriction</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66799 Version 7.0</div></div></div>"},"66800":{"type":"graphic_figure","displayName":"FOXP3 org mutations","title":"Mutations in IPEX - Gene organization and selected mutations in FOXP3 and associated functional domains of the gene product","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Mutations in IPEX - Gene organization and selected mutations in FOXP3 and associated functional domains of the gene product</div><div class=\"cntnt\"><img style=\"width:574px; height:219px;\" src=\"images/ALLRG/66800_FOXP3_org_mutations.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FOXP3, a member of the forkhead box P (FOXP) family of transcription factors, encodes a 431 amino acid protein fundamental to the differentiation of CD4+ regulatory T cells (T<SUB>Reg</SUB>). In addition to the forkhead DNA-binding domain that interacts with the interleukin-2 (IL-2) promoter and other target genes, FOXP3 also contains an N-terminal proline-rich domain which regulates transcription. A zinc finger motif may be involved in protein-DNA interactions, while a leucine zipper domain mediates homo and heterodimerization with FOXP3 and other FOXP transcription factors. Except for the zinc finger motif, mutations have been described in patients with IPEX in each of these coding regions.</div><div class=\"graphic_footnotes\">IPEX: immune dysregulation, polyendocrinopathy, enteropathy, X-linked.<br />Black: exon -1, part of the untranslated 5' region.<br />White: 3' untranslated region.<br />Gray: untranslated regions prior to start and stop codons.<br />Blue: translated regions of protein not included in functional domains.<br />Other colored regions on gene correspond to domain names as listed.<br />*: Loci associated with disease causing mutations.</div><div id=\"graphicVersion\">Graphic 66800 Version 4.0</div></div></div>"},"66802":{"type":"graphic_picture","displayName":"Pathologic skin picking face","title":"Psychogenic excoriations of the face","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Psychogenic excoriations of the face</div><div class=\"cntnt\"><img style=\"width:468px; height:296px;\" src=\"images/DERM/66802_Pathologic_skin_pick_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Excoriations and sharply demarcated superficial ulcerations on the face of a woman with pathologic skin picking.</div><div id=\"graphicVersion\">Graphic 66802 Version 1.0</div></div></div>"},"66804":{"type":"graphic_picture","displayName":"Mucinous neoplasm panc Gross II","title":"Pancreatic mucinous cystadenoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pancreatic mucinous cystadenoma</div><div class=\"cntnt\"><img style=\"width:504px; height:333px;\" src=\"images/GAST/66804_Mucinous_neoplasm_panc_Gr1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross appearance of a mucinous cystadenoma of the pancreas and attached spleen.</div><div class=\"graphic_reference\">Courtesy of Michael L Steer, MD.</div><div id=\"graphicVersion\">Graphic 66804 Version 2.0</div></div></div>"},"66805":{"type":"graphic_table","displayName":"Hemorrhagic cystitis drugs","title":"Chemotherapeutic drugs causing hemorrhagic cystitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapeutic drugs causing hemorrhagic cystitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agents</td> <td class=\"subtitle1\">Effect</td> <td class=\"subtitle1\">Caveats</td> </tr> <tr> <td>Cyclophosphamide, Ifosfamide</td> <td>Hemorrhagic cystitis</td> <td>Uroprotection with mesna, saline and continuous bladder irrigation</td> </tr> <tr> <td>Busulfan</td> <td>Hemorrhagic cystitis</td> <td>Seen with prolonged systemic therapy; long delay of onset</td> </tr> <tr> <td>Thiotepa</td> <td>Irritation and rarely hemorrhagic cystitis</td> <td>Intravesical</td> </tr> <tr> <td>Doxorubicin</td> <td>Reversible&nbsp;hemorrhagic cystitis in 20 to 30 percent</td> <td>Intravesical</td> </tr> <tr> <td>Mitomycin</td> <td>Cystitis in 15 percent </td> <td>Intravesical</td> </tr> <tr> <td>Fludarabine</td> <td>Rare hemorrhagic cystitis</td> <td>&nbsp;</td> </tr> <tr> <td>Chlorambucil</td> <td>Rare cases of sterile cystitis</td> <td>&nbsp;</td> </tr> <tr> <td>Cabazitaxel</td> <td>Hemorrhagic cystitis in 17 percent; severe (grade 3 or 4) in 2 to 3 percent</td> <td> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td>Dacarbazine, temozolomide</td> <td>Rare hemorrhagic cystitis</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66805 Version 8.0</div></div></div>"},"66807":{"type":"graphic_table","displayName":"Fussiness and pediatric symptom scores acute mountain sickness","title":"Children's Lake Louise acute mountain sickness scoring system: Fussiness and pediatric symptom scores","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Children's Lake Louise acute mountain sickness scoring system: Fussiness and pediatric symptom scores</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Amount of unexplained fussiness</strong>*</td> <td>0 - No fussiness</td> </tr> <tr> <td>1 to 5 - Intermittent fussiness</td> </tr> <tr class=\"divider_bottom\"> <td>6 - Constant fussiness</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Intensity of fussiness</strong><sup>&#182;</sup></td> <td>0 - No fussiness</td> </tr> <tr> <td>1 to 5 - Moderate fussiness</td> </tr> <tr class=\"divider_bottom\"> <td>6 - Hard crying and extreme fussiness</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Eating</strong></td> <td>0 - Normal</td> </tr> <tr> <td>1 - Slightly less than normal</td> </tr> <tr> <td>2 - Much less than normal</td> </tr> <tr class=\"divider_bottom\"> <td>3 - Vomiting or not eating</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Playfulness</strong></td> <td>0 - Normal</td> </tr> <tr> <td>1 - Playing slightly less</td> </tr> <tr> <td>2 - Playing much less than normal</td> </tr> <tr class=\"divider_bottom\"> <td>3 - Not playing</td> </tr> <tr> <td rowspan=\"4\"><strong>Sleeping</strong></td> <td>0 - Normal</td> </tr> <tr> <td>1 - Slightly less or more than normal</td> </tr> <tr> <td>2 - Much less or more than normal</td> </tr> <tr> <td>3 - Not able to sleep</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Children are scored by combining amount of unexplained fussiness with intensity of fussiness to obtain a total mean fussiness score (0-12). This score is then added to the pediatric symptom score (0-9). Total score &ge;7 (including a fussiness score &ge;4 and pediatric symptom score &ge;3) is considered to be diagnostic of acute mountain sickness.</div><div class=\"graphic_footnotes\">* Intermittent fussiness is graded subjectively by the parent from 0 (No fussiness) to 6 (Constant fussiness).<br />¶ Intensity of fussiness is graded subjectively by the parent from 0 (No fussiness) to 6 (Hard crying and extreme fussiness).</div><div class=\"graphic_reference\">Adapted from: Yaron M, Waldman N, Niermeyer S, et al. The diagnosis of acute mountain sickness in preverbal children. Arch Pediatr Adolesc Med 1998; 152:683.</div><div id=\"graphicVersion\">Graphic 66807 Version 4.0</div></div></div>"},"66808":{"type":"graphic_table","displayName":"Breast cancer and ovarian cancer genes","title":"Major genes associated with breast and ovarian cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major genes associated with breast and ovarian cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Associated syndrome</td> <td class=\"subtitle1\">Major associated&nbsp;abnormalities</td> </tr> <tr> <td><em>BRCA1</em></td> <td>Hereditary&nbsp;breast cancer and ovarian cancer</td> <td>Breast, ovarian, fallopian tube, male breast, pancreas, prostate cancers</td> </tr> <tr> <td><em>BRCA2</em></td> <td>Hereditary&nbsp;breast cancer and ovarian cancer</td> <td>Breast, ovarian, fallopian tube, male breast, pancreas, prostate cancers</td> </tr> <tr> <td><em>TP53</em></td> <td>Li-Fraumeni</td> <td>Breast cancer, soft tissue and bone sarcomas, leukemia, brain cancer, adrenocortical cancer, choroid plexus&nbsp;cancer, bronchoalveolar lung cancer</td> </tr> <tr> <td><em>PTEN</em></td> <td>Cowden/PTEN hamartoma</td> <td>Hamartomas, papillomas of the lips and mucous membranes, acral skin keratoses, trichillemmomas of skin, macrocephaly, breast cancer,&nbsp;endometrial cancer, non-medullary thyroid cancer, colon cancer, renal cell cancer</td> </tr> <tr> <td><em>CDH1</em></td> <td>Hereditary diffuse gastric cancer</td> <td>Lobular breast cancer, diffuse gastric cancer</td> </tr> <tr> <td><em>STK11</em></td> <td>Peutz-Jeghers</td> <td>Hamartomatous gastrointestinal tract polyps; characteristic mucocutaneous pigmentation; cancers of the breast, small bowel, stomach, colorectal, pancreas, lung,&nbsp;&nbsp;endometrium and&nbsp;ovary; sex cord tumor</td> </tr> <tr> <td> <p>Mismatch repair genes (<em>MSH2,&nbsp;MLH1, MSH6, PMS2</em>)</p> <p><em>EPCAM</em> gene</p> </td> <td>&nbsp;Lynch (hereditary nonpolyposis colon cancer)</td> <td>Colon, endometrial, ovarian, stomach cancers</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66808 Version 15.0</div></div></div>"},"66809":{"type":"graphic_figure","displayName":"Reverse transcriptase PCR","title":"Reverse-transcriptase polymerase chain reaction (RT-PCR)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reverse-transcriptase polymerase chain reaction (RT-PCR)</div><div class=\"cntnt\"><img style=\"width:384px; height:539px;\" src=\"images/PC/66809_Reverse_transcriptase_PCR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The reverse-transcription polyermase chain reaction (PCR) assay works as follows: within target cells, genomic DNA (top) is naturally transcribed into messenger RNA (mRNA); this can be subsequently isolated using a variety of techniques. mRNA is then converted into complementary DNA (cDNA) by an RNA- dependent DNA polymerase, termed reverse transcriptase. Next, the cDNA is changed into double-stranded DNA, becoming the template for a subsequent PCR reaction. After the amplification reaction, the product can be visualized by gel electrophoresis (bottom).</div><div id=\"graphicVersion\">Graphic 66809 Version 1.0</div></div></div>"},"66811":{"type":"graphic_diagnosticimage","displayName":"Brain MRI and CT of Huntington disease","title":"Brain MRI and CT of Huntington disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI and CT of Huntington disease</div><div class=\"cntnt\"><img style=\"width:388px; height:514px;\" src=\"images/NEURO/66811_MRI_CT_Huntington.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On brain MRI, T1-weighted (A) and T2-weighted (B) axial images show caudate atrophy and enlargement of the frontal horns. On CT, an axial image (C) from another patient shows similar findings.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Eric D. Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 66811 Version 4.0</div></div></div>"},"66813":{"type":"graphic_diagnosticimage","displayName":"Enlarged esophagus Chagas","title":"Esophageal dilation in Chagas disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal dilation in Chagas disease</div><div class=\"cntnt\"><img style=\"width:271px; height:315px;\" src=\"images/CARD/66813_Enlarged_esophagus_Chagas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest x-ray obtained immediately (left panel) and five minutes after (right panel) a barium swallow in a patient with chronic Chagas disease shows modest esophageal dilatation and full retention of the contrast at five minutes.</div><div id=\"graphicVersion\">Graphic 66813 Version 2.0</div></div></div>"},"66814":{"type":"graphic_figure","displayName":"Transcervical CVS PI","title":"Technique for transcervical chorionic villus sampling (CVS)","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Technique for transcervical chorionic villus sampling (CVS)</div><div class=\"cntnt\"><img style=\"width:534px; height:483px;\" src=\"images/PI/66814_Transcervical_CVS_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the transcervical CVS technique, the physician guides a cannula (a small tube used for collection of the chorionic villi) through the vagina into the placenta under ultrasound guidance.</div><div id=\"graphicVersion\">Graphic 66814 Version 2.0</div></div></div>"},"66815":{"type":"graphic_table","displayName":"Exercise Rx growing pains","title":"Muscle stretching regimen for growing pains in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscle stretching regimen for growing pains in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Quadriceps</td> </tr> <tr> <td class=\"sublist2_start\">Patient prone</td> </tr> <tr> <td class=\"sublist2\">Flex heel to buttock and hold</td> </tr> <tr> <td class=\"sublist2\">Lift thigh off table to stretch</td> </tr> <tr> <td class=\"subtitle1_single\">Hamstrings</td> </tr> <tr> <td class=\"sublist2_start\">Patient supine</td> </tr> <tr> <td class=\"sublist2\">Lift leg by heel</td> </tr> <tr> <td class=\"sublist2\">Hold knee straight</td> </tr> <tr> <td class=\"sublist2\">Flex hip to stretch</td> </tr> <tr> <td class=\"subtitle1_single\">Calf</td> </tr> <tr> <td class=\"sublist2_start\">Patient prone</td> </tr> <tr> <td class=\"sublist2\">Knee flexed to 90 degrees</td> </tr> <tr> <td class=\"sublist2\">Push foot down to stretch</td> </tr> <tr> <td class=\"sublist2_start\">Patient supine</td> </tr> <tr> <td class=\"sublist2\">Knee straight</td> </tr> <tr> <td class=\"sublist2\">Push foot up to stretch</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Regimen to be performed by parents twice per day. Each stretch is held for 10 to 20 seconds and repeated 10 to 20 times for each leg.</div><div class=\"graphic_reference\">Adapted from: Baxter MP, Dulberg C. \"Growing pains\" in childhood--a proposal for treatment. J Pediatr Orthop 1988; 8:402.</div><div id=\"graphicVersion\">Graphic 66815 Version 4.0</div></div></div>"},"66817":{"type":"graphic_picture","displayName":"Fibroid pseudocapsule","title":"Hysteroscopic myomectomy: Leiomyoma pseudocapsule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic myomectomy: Leiomyoma pseudocapsule</div><div class=\"cntnt\"><img style=\"width:350px; height:346px;\" src=\"images/OBGYN/66817_Fibroid_pseudocapsule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysteroscopic shelling out of the pseudocapsule surrounding a myoma.</div><div class=\"graphic_reference\">Courtesy of Linda D Bradley, MD.</div><div id=\"graphicVersion\">Graphic 66817 Version 2.0</div></div></div>"},"66818":{"type":"graphic_figure","displayName":"G6PD mutations and class","title":"Location of point mutations in the glucose-6-phosphate dehydrogenase molecule and associated DNA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Location of point mutations in the glucose-6-phosphate dehydrogenase molecule and associated DNA</div><div class=\"cntnt\"><img style=\"width:376px; height:267px;\" src=\"images/HEME/66818_G6PD_mutations_and_class.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">G6PD deficiency Distribution along the glucose-6-phosphate dehydrogenase (G6PD) sequence of point mutations causing G6PD deficiency in three groups of patients: class 1 (severe deficiency with nonspherocytic hemolytic anemia), class II (severe deficiency with intermittent hemolysis), and class III (moderate to mild deficiency). The three classes tend to have different distributions. In particular, class I mutants tend to be clustered in the region of the putative glucose-6-phosphate binding site (cDNA nucleotides 613-615; amino acid 205) and the putative NADP-binding site (nucleotides 1156-1161; amino acids 386 and 387).</div><div class=\"graphic_reference\">Data from Beutler, E, Blood 1994; 84:3613.</div><div id=\"graphicVersion\">Graphic 66818 Version 2.0</div></div></div>"},"66819":{"type":"graphic_figure","displayName":"Capillary hemodynamics I","title":"Capillary hemodynamic forces","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Capillary hemodynamic forces</div><div class=\"cntnt\"><img style=\"width:320px; height:150px;\" src=\"images/PULM/66819_Capillary_hemodynamics_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the capillary and interstitial fluid hydraulic (P) and oncotic (n) pressures controlling fluid movement across the capillary wall between the plasma and the interstitial fluid. The arrows point in the direction of fluid movement induced by each of the forces.</div><div class=\"graphic_footnotes\">cap: capillary; if: interstitial fluid.</div><div id=\"graphicVersion\">Graphic 66819 Version 2.0</div></div></div>"},"66820":{"type":"graphic_picture","displayName":"Lymphoblastic lymphoma High","title":"Mediastinal lymphoblastic lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal lymphoblastic lymphoma</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/PULM/66820_Lymphoblastic_lymphoma_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph of a mediastinal lymphoblastic lymphoma shows blastic-appearing cells with a high nuclear-to-cytoplasmic ratio, and a high mitotic index. (Hematoxylin and eosin, magnification 100x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 66820 Version 1.0</div></div></div>"},"66821":{"type":"graphic_table","displayName":"pMDI priming requirements","title":"Priming requirements for specific pressurized metered dose inhalers (pMDIs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Priming requirements for specific pressurized metered dose inhalers (pMDIs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">US trade name</td> <td class=\"subtitle1\">Time to prime</td> <td class=\"subtitle1\">Number of sprays*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Short-acting bronchodilators</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Albuterol (salbutamol) HFA</td> <td>ProAir HFA</td> <td>New and when not used for more than two weeks</td> <td>Three</td> </tr> <tr> <td>Proventil HFA</td> <td>New and when not used for more than two weeks</td> <td>Four</td> </tr> <tr> <td>Ventolin HFA</td> <td>New and when not used for more than three weeks or if dropped</td> <td>Four</td> </tr> <tr> <td class=\"indent1\">Levalbuterol (levosalbutamol) HFA</td> <td>Xopenex HFA</td> <td>New and when not used for more than three days</td> <td>Four</td> </tr> <tr> <td class=\"indent1\">Ipratropium bromide HFA</td> <td>Atrovent HFA</td> <td>New and when not used for more than three days</td> <td>Two</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Ipratropium bromide and albuterol combination</td> <td rowspan=\"2\">Combivent Respimat</td> <td>New and when not used for more than three weeks</td> <td>Repeated sprays toward ground until an aerosol cloud is visible; then repeat three more sprays</td> </tr> <tr> <td>When not used for more than three days up to three weeks</td> <td>Once</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Inhaled glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Beclomethasone HFA</td> <td>QVAR</td> <td>New and when not used for more than 10 days</td> <td>Two</td> </tr> <tr> <td class=\"indent1\">Ciclesonide</td> <td>Alvesco</td> <td>New and when not used for more than 10 days</td> <td>Three</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Fluticasone HFA</td> <td rowspan=\"2\">Flovent HFA</td> <td>New</td> <td>Four</td> </tr> <tr> <td>Not used more than seven days or if dropped</td> <td>One</td> </tr> <tr> <td class=\"indent1\">Flunisolide HFA</td> <td>Aerospan</td> <td>New and when not used for more than 14 days</td> <td>Two</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Combination glucocorticoid and LABA MDIs</td> </tr> <tr> <td class=\"indent1\">Budesonide combined with formoterol</td> <td>Symbicort HFA</td> <td>New and when not used more than seven days or if dropped</td> <td>Two</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Fluticasone combined with salmeterol</td> <td rowspan=\"2\">Advair HFA</td> <td>New</td> <td>Four</td> </tr> <tr> <td>Not used more than four weeks or if dropped</td> <td>Two</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Instructions for priming from approved product information in United States. Priming instructions for other pressurized meter-dose inhalers available in other countries may vary. Consult local product information.</div><div class=\"graphic_footnotes\">HFA: hydrofluoroalkane; LABA: long-acting beta-agonist; MDI: meter-dose inhaler.<br />* Instruct patients to point the mouthpiece away from their face when releasing priming or test sprays into the air.</div><div class=\"graphic_reference\">Data from: United States approved prescribing information available at US National Institute of Health DailyMed website <a href=\"http://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/about.cfm</a> (accessed April 21, 2014).</div><div id=\"graphicVersion\">Graphic 66821 Version 11.0</div></div></div>"},"66822":{"type":"graphic_figure","displayName":"Surgical treatment of hypothenar space abscess","title":"Surgical treatment of hypothenar space abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgical treatment of hypothenar space abscess</div><div class=\"cntnt\"><img style=\"width:380px; height:560px;\" src=\"images/SURG/66822_Surg_tx_hypothen_space_absc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep fascial space infections are surgical emergencies and there is no role for nonoperative treatment. The approach to a hypothenar space abscess is depicted here.</div><div id=\"graphicVersion\">Graphic 66822 Version 1.0</div></div></div>"},"66823":{"type":"graphic_figure","displayName":"Zones of open globe injury","title":"Zones of open globe injury","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Zones of open globe injury</div><div class=\"cntnt\"><img style=\"width:540px; height:347px;\" src=\"images/EM/66823_Zones_of_open_globe_injury.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66823 Version 2.0</div></div></div>"},"66826":{"type":"graphic_figure","displayName":"Male urinary tract","title":"Anatomy of the male urinary tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the male urinary tract</div><div class=\"cntnt\"><img style=\"width:307px; height:408px;\" src=\"images/NEPH/66826_Male_urinary_tract.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: O'Neill, WC. Atlas of renal ultrasonography, 1st ed, W.B. Saunders Company, Philadelphia 2000. Copyright ©2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 66826 Version 1.0</div></div></div>"},"66827":{"type":"graphic_figure","displayName":"2nd trimester total/intact hCG levels","title":"Second trimester total/intact human chorionic gonadotropin (hCG) levels ","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Second trimester total/intact human chorionic gonadotropin (hCG) levels </div><div class=\"cntnt\"><img style=\"width:510px; height:493px;\" src=\"images/OBGYN/66827_2ndtritotlintcthCGlvls.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Median maternal serum levels in unaffected pregnancies calculated from in-house data at Women and Infants Hospital, Providence, Rhode Island. These data are representative and not intended or appropriate for use in other laboratories.</div><div class=\"graphic_footnotes\">IU: international units.</div><div class=\"graphic_reference\">Courtesy of Glenn E Palomaki, PhD.</div><div id=\"graphicVersion\">Graphic 66827 Version 2.0</div></div></div>"},"66828":{"type":"graphic_figure","displayName":"Atypical atrioventricular nodal reentrant tachycardia","title":"Atypical atrioventricular nodal reentrant tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical atrioventricular nodal reentrant tachycardia</div><div class=\"cntnt\"><img style=\"width:279px; height:424px;\" src=\"images/CARD/66828_ECG_uncommon_AVNRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are three simultaneous ECG leads (I, II, and III) during an uncommon or atypical form of an atrioventricular nodal reentrant tachycardia (AVNRT) in which antegrade conduction to the ventricle is via the fast pathway and retrograde atrial activation is by the slow pathway. As a result of delayed atrial activation, there is a long RP and short PR interval and a negative P wave in the inferior leads II and III.</div><div id=\"graphicVersion\">Graphic 66828 Version 2.0</div></div></div>"},"66829":{"type":"graphic_picture","displayName":"Robot surg ports","title":"Robotic surgical ports","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Robotic surgical ports</div><div class=\"cntnt\"><img style=\"width:504px; height:349px;\" src=\"images/OBGYN/66829_Robot_surg_ports.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Marie Fidela R Paraiso, MD.</div><div id=\"graphicVersion\">Graphic 66829 Version 1.0</div></div></div>"},"66831":{"type":"graphic_picture","displayName":"Achondroplasia 2","title":"Achondroplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Achondroplasia</div><div class=\"cntnt\"><img style=\"width:328px; height:502px;\" src=\"images/PEDS/66831_Achondroplasia_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This infant with achondroplasia has tibial bowing, frontal bossing, rhizomelia (the proximal limb segment, is shorter than the distal segment), and brachydactyly (short fingers).</div><div class=\"graphic_reference\">Photo courtesy of Paul S Matz, MD. Reproduced from: Chung EK, Boom JA, Datto GA, Matz PS (Eds). Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006.</div><div id=\"graphicVersion\">Graphic 66831 Version 1.0</div></div></div>"},"66832":{"type":"graphic_picture","displayName":"AP forearm technique","title":"Anteroposterior (AP) forearm radiograph technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anteroposterior (AP) forearm radiograph technique</div><div class=\"cntnt\"><img style=\"width:279px; height:396px;\" src=\"images/EM/66832_APforearmtechnique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Technique for neutral rotation AP radiograph with wrist neutral, forearm pronated, elbow flexed 90 degrees, and shoulder abducted 90 degrees.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66832 Version 13.0</div></div></div>"},"66833":{"type":"graphic_figure","displayName":"Therapies hot flashes","title":"Therapies hot flashes","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Therapies hot flashes</div><div class=\"cntnt\"><img style=\"width:599px; height:412px;\" src=\"images/ENDO/66833_Therapies_hot_flashes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hot flash score changes from baseline for a series of eight randomized, placebo-controlled trials, plus a trial in which women were randomized to venlafaxine (75 mg/day) versus a single dose (400 mg) of intramuscular medroxyprogesterone acetate. Six week data shown for the latter trial.</div><div class=\"graphic_reference\">Reproduced with permission from: Loprinzi CL, Barton DL, Sloan JA, et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause 2008; 15:655. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66833 Version 10.0</div></div></div>"},"66834":{"type":"graphic_figure","displayName":"Thyroid anatomy PI","title":"Thyroid and parathyroid glands","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Thyroid and parathyroid glands</div><div class=\"cntnt\"><img style=\"width:505px; height:500px;\" src=\"images/PI/66834_Thyroid_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thyroid is a butterfly-shaped gland in the middle of the neck. It sits just below the larynx (voice box). The thyroid makes two hormones, called T3 and T4, which control how the body uses and stores energy. The parathyroid glands are four small glands behind the thyroid. They make a hormone called parathyroid hormone, which helps control the amount of calcium in the blood.</div><div class=\"graphic_footnotes\">T3: triiodothyronine; T4: thyroxine.</div><div id=\"graphicVersion\">Graphic 66834 Version 9.0</div></div></div>"},"66835":{"type":"graphic_figure","displayName":"Closure vaginal mucosa","title":"Closure of the vaginal mucosa during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Closure of the vaginal mucosa during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:414px; height:369px;\" src=\"images/OBGYN/66835_Closure_vaginal_mucosa.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66835 Version 2.0</div></div></div>"},"66836":{"type":"graphic_table","displayName":"Amelogenesis imperfecta","title":"Clinical and hereditary characteristics of amelogenesis imperfecta","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and hereditary characteristics of amelogenesis imperfecta</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Clinical appearance</td> <td class=\"subtitle1\">Enamel thickness</td> <td class=\"subtitle1\">Radiographic appearance</td> <td class=\"subtitle1\">Inheritance</td> </tr> <tr> <td>Hypoplastic<br /> (type 1)</td> <td>Crown size varies from small to normal, small teeth may lack proximal contacts, color varies from normal to opaque white/yellow-brown</td> <td>Varies from thin and smooth to normal thickness with grooves, furrows, or pits</td> <td>Enamel has normal to slightly reduced contrast, thin</td> <td>Autosomal dominant, recessive, or X-linked</td> </tr> <tr class=\"divider_top\"> <td>Hypomaturation<br /> (type 2)</td> <td>Varies from creamy opaque to marked yellow or brown, surface of teeth soft and rough, dental sensitivity and open bite common</td> <td>Normal thickness with enamel that often chips and abrades easily</td> <td>Enamel has contrast similar to dentin, unerupted crowns have normal morphology</td> <td>Autosomal dominant, recessive, or X-linked</td> </tr> <tr class=\"divider_top\"> <td>Hypocalcified<br /> (type 3)</td> <td>Opaque white to yellow-brown, soft and rough enamel surface, dental sensitivity and open bite common, heavy calculus formation common</td> <td>Normal thickness with enamel that often chips and abrades easily</td> <td>Enamel has contrast similar to or &#60;dentin, unerupted crowns have normal morphology</td> <td>Autosomal dominant, recessive</td> </tr> <tr class=\"divider_top\"> <td>Hypomaturation/ hypoplasia/ taurodontism<br /> (type 4)</td> <td>White/yellow-brown mottled, teeth can appear small and lack proximal contact</td> <td>Reduced, hypomineralized areas and pits</td> <td>Enamel contrast normal to slightly &#62;dentin, large pulp chambers</td> <td>Autosomal dominant</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:986. Copyright 2000 W.B. Saunders Company.</div><div id=\"graphicVersion\">Graphic 66836 Version 5.0</div></div></div>"},"66837":{"type":"graphic_picture","displayName":"Multicyst dysplastic kidney","title":"Multicystic dysplastic kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multicystic dysplastic kidney</div><div class=\"cntnt\"><img style=\"width:400px; height:321px;\" src=\"images/PEDS/66837_Multicyst_dysplastic_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of: Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 66837 Version 2.0</div></div></div>"},"66838":{"type":"graphic_figure","displayName":"Partial airway collapse","title":"Partial airway collapse","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Partial airway collapse</div><div class=\"cntnt\"><img style=\"width:486px; height:229px;\" src=\"images/PULM/66838_Partial_airway_collapse.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Model of counterbalancing forces that influence airway patency</div><div class=\"graphic_reference\">Adapted with permission from Thach, B. Neuromuscular control of the upper airway. In: Beckerman, R, Brouillette, R, Hunt, C (Eds), Respiratory Control Disorders in Infants and Children, Baltimore, Williams &amp; Wilkins, 1990, p. 47.</div><div id=\"graphicVersion\">Graphic 66838 Version 1.0</div></div></div>"},"66839":{"type":"graphic_figure","displayName":"Myofascial pain points anterior","title":"Anterior trigger points associated with the myofascial pain syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior trigger points associated with the myofascial pain syndrome</div><div class=\"cntnt\"><img style=\"width:368px; height:476px;\" src=\"images/RHEUM/66839_Myofascial_pain_points_ante.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpation of a trigger point (black dots) in patients with the myofascial pain syndrome may cause pain at a distant point. This zone of reference (gray area) is usually quite characteristic for each trigger point.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 66839 Version 1.0</div></div></div>"},"66840":{"type":"graphic_figure","displayName":"Incisional hernia","title":"Incisional hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incisional hernia</div><div class=\"cntnt\"><img style=\"width:313px; height:335px;\" src=\"images/SURG/66840_Incisional_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An incisional hernia occurs when bowel protrudes through a defect or weakness resulting from a surgical incision. It appears as a bulge near a surgical scar on the abdomen.</div><div class=\"graphic_reference\">Reproduced with permission from: Weber, J, Kelley, J. Health Assessment in Nursing, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66840 Version 1.0</div></div></div>"},"66841":{"type":"graphic_diagnosticimage","displayName":"Femoral nerve block ultrasound","title":"Femoral nerve block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Femoral nerve block ultrasound</div><div class=\"cntnt\"><img style=\"width:514px; height:313px;\" src=\"images/SURG/66841_Fem_nerve_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With ultrasound guidance, the transducer is placed in the inguinal crease, and the hyperechoic femoral nerve lateral to the hypoechoic pulsatile common femoral artery is identified.</div><div class=\"graphic_footnotes\">n.: nerve.</div><div id=\"graphicVersion\">Graphic 66841 Version 5.0</div></div></div>"},"66842":{"type":"graphic_table","displayName":"Extrahepatic manifestations HCV","title":"Prevalence of clinical extrahepatic manifestations in 321 patients with chronic HCV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of clinical extrahepatic manifestations in 321 patients with chronic HCV infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">N (percent)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Skin involvement</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Purpura</td>\n\n      <td>21 (7)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Raynaud phenomenon</td>\n\n      <td>21 (7)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Cutaneous vasculitis</td>\n\n      <td>19 (6)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Pruritus</td>\n\n      <td>20 (6)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Psoriasis</td>\n\n      <td>6 (20)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Porphyria cutanea tarda</td>\n\n      <td>3 (1)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Lichen planus</td>\n\n      <td>3 (1)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> At least one skin manifestation</td>\n\n      <td>55 (17)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Rheumatologic involvement</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Arthralgia</td>\n\n      <td>60 (19)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Arthritis</td>\n\n      <td>6 (2)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Myalgia</td>\n\n      <td>31 (2)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Neurologic involvement</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Sensory neuropathy</td>\n\n      <td>28 (9)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Motor neuropathy</td>\n\n      <td>15 (5)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Miscellaneous</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Sicca syndrome (mouth)</td>\n\n      <td>40 (12)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Sicca syndrome (eye)</td>\n\n      <td>32 (10)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Hypertension </td>\n\n      <td>32 (10)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> Uveitis</td>\n\n      <td>2 (1)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Overall</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"> At least one extrahepatic clinical&nbsp;manifestation</td>\n\n      <td>122 (38)&nbsp;</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from: Cacoub P, Renou C, Rosenthal E, et al. Medicine 2000; 79:47.</div><div id=\"graphicVersion\">Graphic 66842 Version 2.0</div></div></div>"},"66844":{"type":"graphic_table","displayName":"Thoracic defects causing hydrops","title":"Thoracic abnormalities associated with hydrops fetalis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thoracic abnormalities associated with hydrops fetalis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>\t<p>Congenital pulmonary airway malformation (CPAM)</p>\n\t<p>(formerly known as congenital cystic adenomatoid malformation, CCAM)</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Diaphragmatic hernia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pulmonary sequestration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chylothorax</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lymphangiectasia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Neoplasms</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bronchogenic cyst</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=44656&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Thoracic_defects_causing_hy.htm</title></head></div><div id=\"graphicVersion\">Graphic 66844 Version 2.0</div></div></div>"},"66845":{"type":"graphic_table","displayName":"Lymphoma staging PI","title":"Staging classification for Hodgkin and non-Hodgkin lymphomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Staging classification for Hodgkin and non-Hodgkin lymphomas</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_left\">\n   Stage I\n   </td>\n   <td>Involvement of a single lymph node region (stage I)</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_left\">\n   Stage II\n   </td>\n   <td>Involvement of two or more lymph node regions or lymphatic structures on the same side of the diaphragm alone (stage II)</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_left\">\n   Stage III\n   </td>\n   <td>Involvement of lymph node regions on both sides of the diaphragm (stage III)</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_left\">\n   Stage IV\n   </td>\n   <td>Involvement of one or more organs or tissues outside the lymphatic system, with or without involvement of nearby lymph nodes</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">12.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48801&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Ann_Arbor_staging_PI.htm</title></head></div><div class=\"graphic_lgnd\">The letters A and B are used to indicate if certain symptoms occurred in the six months before diagnosis. A person is said to have &quot;B symptoms&quot; if he or she had: unexplained fever (higher than 100.4 F or 38 C), night sweats, or unexplained weight loss during the six months prior to diagnosis. For example a person with stage II disease who had B symptoms has stage IIB disease.<br>In contrast, a person without B symptoms has stage IIA disease.</div><div class=\"graphic_reference\">Adapted from: Carbone, PP, et al, Cancer Res 1971; 31:1860 and Lister, TA, et al, J Clin Oncol 1989; 7:1630.</div><div id=\"graphicVersion\">Graphic 66845 Version 2.0</div></div></div>"},"66846":{"type":"graphic_figure","displayName":"Atlantoaxial anatomy","title":"Upper cervical vertebrae, assembled: posterosuperior view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper cervical vertebrae, assembled: posterosuperior view</div><div class=\"cntnt\"><img style=\"width:430px; height:256px;\" src=\"images/PEDS/66846_Atlantoaxial_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atlantoaxial anatomy. The first two cervical vertebrae are specialized bones that function as an important unit. The atlas (C1) articulates with the occiput of the skull superiorly and with the axis (C2) inferiorly.</div><div id=\"graphicVersion\">Graphic 66846 Version 1.0</div></div></div>"},"66847":{"type":"graphic_table","displayName":"Noninfectious causes generalized lymphadenopathy in children","title":"Noninfectious causes of generalized lymphadenopathy in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Noninfectious causes of generalized lymphadenopathy in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Selected clinical features that may be present</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neoplastic</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Primary</strong></td> </tr> <tr> <td class=\"indent2\">Hodgkin lymphoma</td> <td>Usually manifests as cervical lymphadenopathy; adenopathy may be unilateral; respiratory distress can occur</td> </tr> <tr> <td class=\"indent2\">Non-Hodgkin lymphoma</td> <td>Rapidly enlarging diffuse adenopathy, abdominal pain, vomiting; adenopathy is usually bilateral; respiratory distress can occur</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Metastatic</strong></td> </tr> <tr> <td class=\"indent2\">Acute lymphocytic or myelogenous leukemia</td> <td>Ill appearance, bleeding, hepatosplenomegaly, anemia, thrombocytopenia; occipital nodes often prominent</td> </tr> <tr> <td class=\"indent2\">Neuroblastoma</td> <td>Abdominal mass; opsoclonus-myoclonus, proptosis, periorbital ecchymoses, nasal obstruction, Horner syndrome, subcutaneous nodules, secretory diarrhea</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Rhabdomyosarcoma</td> <td>Proptosis; nasal, aural, or sinus obstruction; Horner syndrome; hematuria; urinary obstruction; constipation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Immunologic</td> </tr> <tr> <td class=\"indent1\">Vasculitis syndromes (systemic lupus erythematosus, rheumatoid arthritis)</td> <td>Patients may have generalized adenopathy during the acute phase of illness</td> </tr> <tr> <td class=\"indent1\">Serum sickness</td> <td>Rash, splenomegaly, myalgia, arthritis</td> </tr> <tr> <td class=\"indent1\">Autoimmune hemolytic anemia</td> <td>Lymphadenopathy coincides with hemolysis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chronic granulomatous disease</td> <td>Recurrent infection, skin abscesses, suppurative adenitis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Metabolic</td> </tr> <tr> <td class=\"indent1\">Gaucher disease</td> <td>Hepatosplenomegaly, anemia, thrombocytopenia, osteopenia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Niemann-Pick disease</td> <td>Hepatosplenomegaly, loss of neurologic function</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Drugs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Phenytoin, phenobarbital, carbamazepine, isoniazid, aspirin, barbiturates, penicillin, tetracycline, iodides, sulfonamides, allopurinol, and phenylbutazone</td> <td>Severe maculopapular rash, fever, hepatosplenomegaly, jaundice, anemia, leukopenia, and plasmacytosis occurring during or after the lymphadenopathy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> <td>Multisystem granulomatous disease; generalized adenopathy with prominent cervical involvement</td> </tr> <tr> <td class=\"indent1\">Hemophagocytic lymphohistiocytosis</td> <td>Fever, hepatosplenomegaly, neurologic symptoms, rash</td> </tr> <tr> <td class=\"indent1\">Castleman disease</td> <td>Fever, hepatosplenomegaly, polyclonal hypergammaglobulinemia</td> </tr> <tr> <td class=\"indent1\">Langerhans cell histiocytosis</td> <td>Rash (brown to purplish papules), mucosal lesions, lytic bone lesions, proptosis, diabetes insipidus</td> </tr> <tr> <td class=\"indent1\">Kikuchi-Fujimoto disease</td> <td>Cervical and supraclavicular adenopathy, fever, fatigue, weight loss, anemia, and leukopenia</td> </tr> <tr> <td class=\"indent1\">Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy)</td> <td>Chronic bilateral cervical adenopathy is characteristic; other nodal groups are involved in most cases; fever, anemia, leukocytosis, elevated ESR, and hypergammaglobulinemia</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> <td>Tachycardia, hypertension, diaphoresis, weight loss, goiter, hyperreflexia</td> </tr> <tr> <td class=\"indent1\">Papular acrodermatitis (Gianotti-Crosti syndrome)</td> <td>Rash on face, buttocks, limbs, palms, and soles; hepatomegaly</td> </tr> <tr> <td class=\"indent1\">Progressive transformation of germinal centers</td> <td>Found in 10 percent of nodes with reactive hyperplasia; sometimes associated with prior diagnosis of Hodgkin lymphoma and rarely before the diagnosis of Hodgkin lymphoma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Malley R. Lymphadenopathy. In: Textbook of Pediatric Emergency Medicine, 5<SUP>th</SUP> ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.421. </LI>&#xD;&#xA;<LI>Scagni P, Peisino MG, Bianchi M, et al. Kikuchi-Fujimoto disease is a rare cause of lymphadenopathy and fever of unknown origin in children. J Pediatr Hematol Oncol 2005; 27:337. </LI>&#xD;&#xA;<LI>Osborne BM, Butler JJ, Gresik MV. Progressive transformation of germinal centers: Comparison of 23 pediatric patients to the adult population. Modern Pathology 1992; 5:135. </LI></OL></div><div id=\"graphicVersion\">Graphic 66847 Version 11.0</div></div></div>"},"66848":{"type":"graphic_diagnosticimage","displayName":"Fishtail deformity","title":"Fishtail deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fishtail deformity</div><div class=\"cntnt\"><img style=\"width:272px; height:396px;\" src=\"images/EM/66848_Fishtaildeformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An angular fishtail deformity has persisted in this 14-year-old boy who sustained a lateral condylar fracture that was treated operatively six years previously.</div><div class=\"graphic_reference\">Reproduced with permission from: Sawyer JR, Beaty JH. Lateral Condylar and Capitellar Fractures of the Distal Humerus. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66848 Version 14.0</div></div></div>"},"66850":{"type":"graphic_table","displayName":"Causes of a colonic mass","title":"Causes of a colonic mass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of a colonic mass</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Malignant lesions</td> </tr> <tr> <td class=\"indent1\">Adenocarcinoma</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> </tr> <tr> <td class=\"indent1\">Carcinoid tumor</td> </tr> <tr> <td class=\"indent1\">Kaposi sarcoma</td> </tr> <tr> <td class=\"indent1\">Prostate cancer</td> </tr> <tr> <td class=\"subtitle1_single\">Benign lesions</td> </tr> <tr> <td class=\"indent1\">Crohn's colitis</td> </tr> <tr> <td class=\"indent1\">Diverticulitis</td> </tr> <tr> <td class=\"indent1\">Endometriosis</td> </tr> <tr> <td class=\"indent1\">Solitary rectal ulcer</td> </tr> <tr> <td class=\"indent1\">Lipoma</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Amebiasis</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Fungal infection</td> </tr> <tr> <td class=\"indent1\">Extrinsic lesion</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66850 Version 3.0</div></div></div>"},"66854":{"type":"graphic_picture","displayName":"Centruroides exilicauda 3","title":"Centruroides exilicauda (bark scorpion)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Centruroides exilicauda (bark scorpion)</div><div class=\"cntnt\"><img style=\"width:432px; height:346px;\" src=\"images/EM/66854_C_exilicauda_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mitchell Ross, MD.</div><div id=\"graphicVersion\">Graphic 66854 Version 2.0</div></div></div>"},"66855":{"type":"graphic_table","displayName":"Cisplatin 80 plus etoposide for small cell lung cancer","title":"Cisplatin (80 mg/m<SUP>2</SUP>) plus etoposide for small cell lung cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cisplatin (80 mg/m<SUP>2</SUP>) plus etoposide for small cell lung cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Every 21 days for four cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cisplatin</td> <td>80 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (NS) and administer over 60 minutes. Do not administer with aluminum needles or sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Etoposide</td> <td>100 mg/m<sup>2</sup> IV daily</td> <td>Dilute in 500 mL NS* or 5% dextrose in water (D5W) to final concentration &#60;0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur.</td> <td>Days 1, 2, and 3</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine prophylaxis not indicated. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of neutropenic fever is 8%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial.<sup>[1]</sup> A lower starting dose of etoposide may be needed for patients with renal or liver impairment.<sup>[3]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Basic metabolic panel (creatinine and electrolytes) and liver function tests prior to each cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>A dose reduction of 25% for both etoposide and cisplatin is recommended for grade 4 neutropenia, febrile neutropenia, or grade 4 thrombocytopenia in the prior cycle.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other severe non-hematologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Etoposide and cisplatin should be withheld or doses decreased depending on clinical judgement. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lara PN, et al. J Clin Oncol 2009; 27:2530.</LI>&#xD;&#xA;<LI>Takada M, et al. J Clin Oncol 2002; 20:3054.</LI>&#xD;&#xA;<LI>Etoposide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed December 8, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 66855 Version 23.0</div></div></div>"},"66857":{"type":"graphic_picture","displayName":"Nebulizer and spacer use","title":"Nebulizer and spacer use","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nebulizer and spacer use</div><div class=\"cntnt\"><img style=\"width:383px; height:548px;\" src=\"images/ALLRG/66857_Nebulizer_and_spacer_use_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Girl using a nebulizer with a mask.<br> (B) Boy using a metered-dose inhaler with spacer.</div><div class=\"graphic_reference\">Reproduced with permission from: Klossner NJ, Hatfield NT. Introductory Maternity and Pediatric Nursing, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2009. Copyright &#169; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66857 Version 1.0</div></div></div>"},"66859":{"type":"graphic_picture","displayName":"Pelosi technique 4","title":"Closure using Pelosi technique","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Closure using Pelosi technique</div><div class=\"cntnt\"><img style=\"width:546px; height:500px;\" src=\"images/OBGYN/66859_Closure_Pelosi_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Exteriorization of the uterus through the abdominal incision is easily accomplished.<br />(B) Following completion of the hysterotomy closure, the self-retaining retractor is removed.<br />(C) The visceral and parietal peritoneum are not closed.<br />(D) No suture approximation of the rectus muscles is performed. The fascia is closed in a continuous, non-locking fashion with delayed-absorbable sutures placed at least one cm from the fascial wound edge (arrows).<br />(E) The subcutaneous tissue is not closed except when this layer is ≥2 cm thick. The skin is closed with subcuticular sutures, or (F) metal staples.</div><div class=\"graphic_reference\">Courtesy of Marco Pelosi, MD and Marco Pelosi III, MD.</div><div id=\"graphicVersion\">Graphic 66859 Version 3.0</div></div></div>"},"66861":{"type":"graphic_table","displayName":"Resrch meth depres term ill","title":"Research assessment methods for depression in terminally ill patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Research assessment methods for depression in terminally ill patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnostic classification systems</td> </tr> <tr> <td class=\"indent1\">Diagnostic and Statistical Manual, 4th edition<sup>[1]</sup> (DSM-IV)</td> </tr> <tr> <td class=\"indent1\">Endicott Substitution Criteria<sup>[2]</sup></td> </tr> <tr> <td class=\"indent1\">Research Diagnostic Criteria<sup>[3]</sup> (RDC)</td> </tr> <tr> <td class=\"subtitle1_single\">Structured diagnostic interviews</td> </tr> <tr> <td class=\"indent1\">Schedule for Affective Disorders and Schizophrenia<sup>[4]</sup> (SADS)*</td> </tr> <tr> <td class=\"indent1\">Diagnostic Interview Schedule<sup>[5]</sup> (DIS)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Structured Clinical Interview for DSM-III-R<sup>[6]</sup> (SCID)</td> </tr> <tr> <td class=\"subtitle1_single\">Screening instruments - self-report</td> </tr> <tr> <td class=\"indent1\">General Health Questionnaire-30<sup>[7]</sup> (GHQ)</td> </tr> <tr> <td class=\"indent1\">Hospital Anxiety and Depression Scale<sup>[8]</sup> (HADS)</td> </tr> <tr> <td class=\"indent1\">Beck Depression Inventory, Short Form<sup>[9]</sup> (BDI-SF)</td> </tr> <tr> <td class=\"indent1\">Zung Self-Rating Depression Scale<sup>[10-14]</sup></td> </tr> <tr> <td class=\"indent1\">Rotterdam Symptom Checklist<sup>[15]</sup></td> </tr> <tr> <td class=\"indent1\">Carroll Depression Rating Scale<sup>[16]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Designed for use with RDC criteria.<br />¶ Designed for use with DSM-III criteria. Diagnostic and Statistical Manual, 3rd edition (DSM-III).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC: Author, 1994.</LI>&#xD;&#xA;<LI>Endicott, J. Cancer 1984; 53:2243.</LI>&#xD;&#xA;<LI>Spitzer, RL, et al. Arch Gen Psychiatry 1978; 10:1.</LI>&#xD;&#xA;<LI>Endicott, J, et al. Arch Gen Psychiatry 1978; 35:837.</LI>&#xD;&#xA;<LI>Robins, LN, et al. Arch Gen Psychiatry 1981; 38:381.</LI>&#xD;&#xA;<LI>Spitzer, RL, Williams, JBW, Gibbon, M, First, MB. Structured Clinical Interview for DSM-III-R. American Psychiatric Press, Washington DC 1990.</LI>&#xD;&#xA;<LI>Goldberg, DP. Manual of the General Health Questionnaire. NFER Publishing, Windsor, England 1978.</LI>&#xD;&#xA;<LI>Zigmond, AS, et al. Acta Psychiatr Scand 1983; 67:361.</LI>&#xD;&#xA;<LI>Beck, AT, et al. Postgrad Med 1972; 52:81.</LI>&#xD;&#xA;<LI>Passik, SD, et al. J Clin Oncol 1998; 16:1594.</LI>&#xD;&#xA;<LI>Dugan, W, et al. Psychooncology 1998; 7:483.</LI>&#xD;&#xA;<LI>Passik, SD, et al. J Pain Symptom Manage 2000; 19:329.</LI>&#xD;&#xA;<LI>Passik, SD, et al. J Pain Symptom Manage 2001; 21:273.</LI>&#xD;&#xA;<LI>McDonald, MV, et al. Oncol Nurs Forum 1999; 26:593.</LI>&#xD;&#xA;<LI>de Haes, JC, et al. Br J Cancer 1990; 62:1034.</LI>&#xD;&#xA;<LI>Carroll, BJ, et al. Br J Psychiatry 1981; 138:194.</LI></OL></div><div id=\"graphicVersion\">Graphic 66861 Version 2.0</div></div></div>"},"66864":{"type":"graphic_table","displayName":"Paraphimosis reduction tips","title":"Paraphimosis reduction: Procedure tips","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paraphimosis reduction: Procedure tips</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Patients with hair tourniquet or other constricting bands have physical findings that are very similar to paraphimosis.</td> </tr> <tr> <td>2. Patients with glans penis ischemia with necrosis require emergent urologic consultation and preparation for invasive reduction utilizing procedural sedation in the ED or general anesthesia in the OR.</td> </tr> <tr> <td>3. Adequate pain control is essential for the cooperation necessary to achieve a successful reduction at the bedside.</td> </tr> <tr> <td>4. Most young boys are best served with procedural sedation for paraphimosis reduction.</td> </tr> <tr> <td>5.&nbsp;Methods to reduce swelling&nbsp;require a significant amount of time (eg, 30 to&nbsp;60 minutes)&nbsp;to have an important impact on foreskin and glans penis swelling and should<strong> not</strong> be used when penile necrosis is evident.</td> </tr> <tr> <td>6. The compression time during a successful manual reduction of a paraphimosis often exceeds 5 minutes if adjuncts such as ice, compression bandages, or osmotic agents are <strong>not</strong> used.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For more detail, refer to UpToDate topics on treatment of paraphimosis. </div><div class=\"graphic_footnotes\">ED: emergency department; OR: operating room.</div><div id=\"graphicVersion\">Graphic 66864 Version 5.0</div></div></div>"},"66865":{"type":"graphic_table","displayName":"Causes of hypercalcemia","title":"Causes of hypercalcemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypercalcemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Parathyroid mediated</td> </tr> <tr> <td class=\"indent1\"><strong>Primary hyperparathyroidism (sporadic)</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Inherited variants</strong></td> </tr> <tr> <td class=\"indent2\">Multiple endocrine neoplasia (MEN) syndromes</td> </tr> <tr> <td class=\"indent2\">Familial isolated hyperparathyroidism</td> </tr> <tr> <td class=\"indent2\">Hyperparathyroidism-jaw tumor syndrome</td> </tr> <tr> <td class=\"indent1\"><strong>Familial hypocalciuric hypercalcemia</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Tertiary hyperparathyroidism (renal failure)</strong></td> </tr> <tr> <td class=\"subtitle1_single\">Non-parathyroid mediated</td> </tr> <tr> <td class=\"indent1\"><strong>Hypercalcemia of malignancy</strong></td> </tr> <tr> <td class=\"indent2\">PTHrp</td> </tr> <tr> <td class=\"indent2\">Increased calcitriol (activation of extrarenal 1 alpha-hydroxylase)</td> </tr> <tr> <td class=\"indent2\">Osteolytic bone metastases and local cytokines</td> </tr> <tr> <td class=\"indent1\"><strong>Vitamin D intoxication</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Chronic granulomatous disorders</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Increased calcitriol (activation of extrarenal 1-alpha-hydroxylase)</td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td class=\"indent1\">Thiazide diuretics</td> </tr> <tr> <td class=\"indent1\">Lithium</td> </tr> <tr> <td class=\"indent1\">Teriparatide</td> </tr> <tr> <td class=\"indent1\">Abaloparatide</td> </tr> <tr> <td class=\"indent1\">Excessive vitamin A</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Theophylline toxicity</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Acromegaly</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"indent1\">Adrenal insufficiency</td> </tr> <tr> <td class=\"indent1\">Immobilization</td> </tr> <tr> <td class=\"indent1\">Parenteral nutrition</td> </tr> <tr> <td class=\"indent1\">Milk-alkali syndrome</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTHrp: PTH-related peptide.</div><div class=\"graphic_reference\">Adapted from: Khairallah W, Fawaz A, Brown EM, and El-Hajj Fuleihan G. Hypercalcemia and diabetes insipidus in a patient previously treated with lithium. Nat Clin Pract Nephrol 2007; 3:397.</div><div id=\"graphicVersion\">Graphic 66865 Version 10.0</div></div></div>"},"66867":{"type":"graphic_picture","displayName":"Barretts high-grade AF","title":"Autofluorescence image of Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Autofluorescence image of Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:507px; height:226px;\" src=\"images/GAST/66867_Barretts_high-grade_AF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White light endoscopic view of Barrett's esophagus (left panel) showing a focal lesion (arrow) with high grade dysplasia. Corresponding autofluorescence image (right panel) showing the focal lesion (arrow). This lesion was first detected by autofluorescence and only retrospectively seen with white light imaging.</div><div class=\"graphic_reference\">Reproduced from: KARA, et al. Gastrointestinal Endoscopy 2005; 61:679.</div><div id=\"graphicVersion\">Graphic 66867 Version 1.0</div></div></div>"},"66869":{"type":"graphic_diagnosticimage","displayName":"Pseudomonas empyema CT","title":"Pseudomonas empyema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudomonas empyema</div><div class=\"cntnt\"><img style=\"width:360px; height:322px;\" src=\"images/PULM/66869_Pseudomonas_empyema_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large left sided empyema due to Pseudomonas aeruginosa. Posterior collection of pleural effusion compresses the left lung and displaces the cardiomediastinal silhouette to the right.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 66869 Version 2.0</div></div></div>"},"66872":{"type":"graphic_diagnosticimage","displayName":"Ultrasound deltoids post trauma","title":"Ultrasound deltoids post trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound deltoids post trauma</div><div class=\"cntnt\"><img style=\"width:450px; height:345px;\" src=\"images/NEURO/66872_US-deltoids_pt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are axial images of both deltoids in a patient who sustained trauma to the area 10 years previously. The muscles have sustained significant injury and it is difficult to identify any significant muscle architecture in the images. Instead, bright calcific deposits are seen that cast shadows and contribute to the obscuration of the bone edge of the humerus (H) below. Muscle calcification can be seen as a residual of trauma or inflammatory myopathy.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 66872 Version 4.0</div></div></div>"},"66873":{"type":"graphic_figure","displayName":"Adult ear","title":"Anatomy of the adult ear","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Anatomy of the adult ear</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/PC/66873_Adult-ear.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66873 Version 3.0</div></div></div>"},"66874":{"type":"graphic_figure","displayName":"Elbow joint articulations","title":"Elbow joint articulations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elbow joint articulations</div><div class=\"cntnt\"><img style=\"width:433px; height:521px;\" src=\"images/EM/66874_Elbow_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The elbow is a complex hinge joint composed of three separate articulations: ulnohumeral (large purple circle), radiohumeral (small purple circle), and radioulnar (red circle). The radiohumeral and ulnohumeral articulations combine to provide hinge movement (purple arrows)and supination and pronation of the forearm is facilitated by pivoting at the radioulnar articulation (red arrows).</div><div id=\"graphicVersion\">Graphic 66874 Version 2.0</div></div></div>"},"66875":{"type":"graphic_picture","displayName":"Discordant twin placenta","title":"Discordant twin placenta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Discordant twin placenta</div><div class=\"cntnt\"><img style=\"width:432px; height:316px;\" src=\"images/OBGYN/66875_Discordant_twin_placenta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chorioamnionitis and meconium in twin 1, normal twin 2.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 66875 Version 1.0</div></div></div>"},"66876":{"type":"graphic_diagnosticimage","displayName":"Branching cals","title":"Mammogram grouped calcifications B","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mammogram grouped calcifications B</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ONC/66876_Branching_cals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnified craniocaudal mammogram showing linear branching calcifications in a segmental distribution (red arrow). Grouped microcalcifications such as these are highly suggestive of carcinoma, and the linear branching is suggestive of a ductal lesion. Biopsy confirmed a high-grade ductal carcinoma in situ (DCIS).</div><div class=\"graphic_reference\">Courtesy of Lisa E Esserman, MD.</div><div id=\"graphicVersion\">Graphic 66876 Version 3.0</div></div></div>"},"66877":{"type":"graphic_diagnosticimage","displayName":"Sonogram complete mole","title":"Sonogram of a complete hydatidiform mole","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sonogram of a complete hydatidiform mole</div><div class=\"cntnt\"><img style=\"width:307px; height:331px;\" src=\"images/ONC/66877_Sonogram_complete_mole.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fetus is absent and the hydropic vesicle changes of the trophoblast have the typical grapelike appearance.</div><div class=\"graphic_reference\">Courtesy of Beryl Benacerraf, MD.</div><div id=\"graphicVersion\">Graphic 66877 Version 2.0</div></div></div>"},"66878":{"type":"graphic_diagnosticimage","displayName":"Chondroblastoma extension","title":"Chondroblastoma with epiphyseal and metaphyseal extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondroblastoma with epiphyseal and metaphyseal extension</div><div class=\"cntnt\"><img style=\"width:278px; height:443px;\" src=\"images/PEDS/66878_Chondroblastoma_extension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterpostero plain radiograph of the knee. Observe the large chondroblastoma affecting the tibial epiphysis, with extension into the metaphysis. Observe the sharp zone of transition and clearly defined margins of this lesion. Chondroblastoma and giant cell tumor are the two most common neoplasms to affect the epiphysis.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 66878 Version 2.0</div></div></div>"},"66879":{"type":"graphic_table","displayName":"LD psychoeducation evaluation","title":"Tests of psychoeducational and neuropsychologic assessment to evaluate children with learning disabilities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tests of psychoeducational and neuropsychologic assessment to evaluate children with learning disabilities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Intellectual/cognitive ability</td> </tr> <tr> <td>Differential Ability Scales - Second Edition (DAS-II)</td> </tr> <tr> <td>Kaufman Assessment Battery for Children - Second Edition (KABC-II)</td> </tr> <tr> <td>Leiter International Performance Scale - Revised (Leiter-R)</td> </tr> <tr> <td>Stanford-Binet Intelligence Scale - Fifth Edition (SB-V)</td> </tr> <tr> <td>Wechsler Abbreviated Scale of Intelligence (WASI)</td> </tr> <tr> <td>Wechsler Intelligence Scale for Children - Fourth Edition (WISC-4)</td> </tr> <tr> <td>Wechsler Preschool and Primary Scales of Intelligence - Fourth Edition (WPPSI-IV)</td> </tr> <tr> <td>Woodcock-Johnson Tests of Cognitive Abilities - Third Edition (WJ III)</td> </tr> <tr> <td class=\"subtitle1_single\">Academic achievement </td> </tr> <tr> <td>Gray Oral Reading Test - Fourth Edition (GORT-4)</td> </tr> <tr> <td>Kaufman Test of Educational Achievement - Second Edition (KTEA-II) Comprehensive Form</td> </tr> <tr> <td>Peabody Individual Achievement Test - Revised - Normative Update (PIAT-R/NU)</td> </tr> <tr> <td>Test of Written Language - Fourth Edition (TOWL-4)</td> </tr> <tr> <td>Wechsler Individual Achievement Test - Second Edition (WIAT-III)</td> </tr> <tr> <td>Wide Range Achievement Test - Fourth Edition (WRAT4)</td> </tr> <tr> <td>Woodcock-Johnson Tests of Achievement - Third Edition (WJ III)</td> </tr> <tr> <td class=\"subtitle1_single\">Perceptual, visual-motor, and motor</td> </tr> <tr> <td>Beery-Buktenica Developmental Test of Visual-Motor Integration - Fifth Edition (Beery-VMI)</td> </tr> <tr> <td>Finger tapping test</td> </tr> <tr> <td>Grooved pegboard test</td> </tr> <tr> <td>Hooper Visual Organization Test (VOT)</td> </tr> <tr> <td>Purdue Pegboard</td> </tr> <tr> <td>Rey-Osterrieth Complex Figure Test (ROCF)</td> </tr> <tr> <td>Sensory-Perceptual examination</td> </tr> <tr> <td>Wide Range Assessment of Visual Motor Ability (WRAVMA)</td> </tr> <tr> <td class=\"subtitle1_single\">Language </td> </tr> <tr> <td>Boston Naming Test (BNT)</td> </tr> <tr> <td>Clinical Evaluation of Language Fundamentals - Fourth Edition (CELF-4)</td> </tr> <tr> <td>Comprehensive Test of Phonological Processing - Second Edition (CTOPP-2)</td> </tr> <tr> <td>Expressive Vocabulary Test (EVT)</td> </tr> <tr> <td>Peabody Picture Vocabulary Test - Third Edition (PPVT-IV)</td> </tr> <tr> <td>Preschool Language Scale (PLS-4)</td> </tr> <tr> <td>Test of&nbsp;Word Reading Efficiency, Second Edition (TOWRE-2)</td> </tr> <tr> <td>Token Test for Children, Revised (TTFC-II)</td> </tr> <tr> <td class=\"subtitle1_single\">Attention</td> </tr> <tr> <td>Conners' Continuous Performance Test II (CPT-II)</td> </tr> <tr> <td>Gordon Diagnostic System (GDS)</td> </tr> <tr> <td>Children's Paced Auditory Serial Addition Test (CHIPASAT)</td> </tr> <tr> <td>Random A's test</td> </tr> <tr> <td>Test of Everyday Attention for Children (TEA-Ch)</td> </tr> <tr> <td>Test of Variables of Attention (TOVA)</td> </tr> <tr> <td class=\"subtitle1_single\">Memory</td> </tr> <tr> <td>California Verbal Learning Test for Children (CVLT-C)</td> </tr> <tr> <td>Children's Auditory Verbal Learning Test - 2 (CAVLT-2)</td> </tr> <tr> <td>Children's Memory Scale (CMS)</td> </tr> <tr> <td>Test of Memory and Learning - Second Edition (TOMAL-2)</td> </tr> <tr> <td>Wide Range Assessment of Memory and Learning - Second Edition (WRAML2)</td> </tr> <tr> <td class=\"subtitle1_single\">Executive function</td> </tr> <tr> <td>Children's Category Test (CCT)</td> </tr> <tr> <td>Delis-Kaplan Executive Functioning System (D-KEFS)</td> </tr> <tr> <td>Go/No-Go inhibition task</td> </tr> <tr> <td>Stroop Color-Word interference task</td> </tr> <tr> <td>Tower of London</td> </tr> <tr> <td>Trail Making Test (TMT)</td> </tr> <tr> <td>Verbal fluency test</td> </tr> <tr> <td>Wisconsin Card Sorting Test (WCST)</td> </tr> <tr> <td class=\"subtitle1_single\">Emotional/Behavioral</td> </tr> <tr> <td>Adaptive Behavior Assessment System - Second Edition (ABAS-II)</td> </tr> <tr> <td>Behavior Assessment System for Children, Second edition (BASC-2)</td> </tr> <tr> <td>Child Behavior Checklist (CBCL)</td> </tr> <tr> <td>Conners' Rating Scales - Revised (CRS-R)</td> </tr> <tr> <td>Vineland Adaptive Behavior Rating Scales, Second edition (Vineland-II)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Personal Communication: Kevin R Krull, PhD, ABPP, Judith Z Feigin, EdD, 2003; Learning Support Center, Texas Children's Hospital, Houston, Texas.</div><div id=\"graphicVersion\">Graphic 66879 Version 4.0</div></div></div>"},"66882":{"type":"graphic_picture","displayName":"Schatzki ring healed CPC Endosc","title":"Schatzki's ring healed","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schatzki's ring healed</div><div class=\"cntnt\"><img style=\"width:252px; height:215px;\" src=\"images/GAST/66882_Schatzki_ring_healed_CPC_En.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the distended distal esophagus revealing complete healing of the superficial ulceration with a ring of thin membrane occluding 70 percent of the distal esophageal lumen. This is the characteristic endoscopic view of a Schatzki ring.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Douglas A. Horst, MD.</div><div id=\"graphicVersion\">Graphic 66882 Version 1.0</div></div></div>"},"66884":{"type":"graphic_table","displayName":"Clinical features that suggest a diagnosis on intial evaluation","title":"Clinical features that suggest a diagnosis on initial evaluation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features that suggest a diagnosis on initial evaluation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neurally mediated syncope:</td> </tr> <tr> <td>Absence of heart disease</td> </tr> <tr> <td>Long history of recurrent syncope</td> </tr> <tr> <td>After sudden unexpected unpleasant sight, sound, smell or pain</td> </tr> <tr> <td>Prolonged standing or crowded, hot places</td> </tr> <tr> <td>Nausea, vomiting associated with syncope</td> </tr> <tr> <td>During a meal or post-prandial</td> </tr> <tr> <td>With head rotation or pressure on carotid sinus (as in tumours, shaving, tight collars)</td> </tr> <tr> <td>After exertion</td> </tr> <tr> <td class=\"subtitle1_single\">Syncope due to OH:</td> </tr> <tr> <td>After standing up</td> </tr> <tr> <td>Temporal relationship with start or changes of dosage of vasodepressive drugs leading to hypotension</td> </tr> <tr> <td>Prolonged standing especially in crowded, hot places</td> </tr> <tr> <td>Presence of autonomic neuropathy or Parkinsonism</td> </tr> <tr> <td>Standing after exertion</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular syncope:</td> </tr> <tr> <td>Presence of definite structural heart disease</td> </tr> <tr> <td>Family history of unexplained sudden death or channelopathy</td> </tr> <tr> <td>During exertion, or supine</td> </tr> <tr> <td>Abnormal ECG</td> </tr> <tr> <td>Sudden onset palpitation immediately followed by syncope</td> </tr> <tr> <td class=\"sublist1_start\">ECG findings suggesting arrhythmic syncope:</td> </tr> <tr> <td class=\"sublist1\">- Bifascicular block (defined as either LBBB or RBBB combined with left anterior or left posterior fascicular block)</td> </tr> <tr> <td class=\"sublist1\">- Other intraventricluar conduction abnormalities (QRS duration &#8805;0.12 s)</td> </tr> <tr> <td class=\"sublist1\">- Mobitz I second degree AV block</td> </tr> <tr> <td class=\"sublist1\">- Asymptomatic inappropriate sinus bradycardia (&#60;50 bpm), sinoatrial block or sinus pause &#8805;3 s in the absence of negatively chronotropic medications</td> </tr> <tr> <td class=\"sublist1\">- Non-sustained VT</td> </tr> <tr> <td class=\"sublist1\">- Pre-excited QRS complexes</td> </tr> <tr> <td class=\"sublist1\">- Long or short QT intervals</td> </tr> <tr> <td class=\"sublist1\">- Early repolarization</td> </tr> <tr> <td class=\"sublist1\">- RBBB pattern with ST-elevation in leads V1-V3 (Brugada syndrome)</td> </tr> <tr> <td class=\"sublist1\">- Negative T waves in right precordial leads, epsilon waves and ventricular late potentials suggestive of ARVC</td> </tr> <tr> <td class=\"sublist1\">- Q waves suggesting myocardial infarction</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ARVC: arrhythmogenic right ventricular cardiomyopathy; AV: atrioventricular; LBBB: left bundle branch block; OH: orthostatic hypotension; RBBB: right bundle branch block; VT: ventricular tachycardia.</div><div class=\"graphic_reference\">Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright © 2009 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 66884 Version 7.0</div></div></div>"},"66885":{"type":"graphic_figure","displayName":"United States map of TB case rates 2010-2012","title":"Reported new tuberculosis cases, by county - United States, National Tuberculosis Surveillance System, 2010-2012","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Reported new tuberculosis cases, by county - United States, National Tuberculosis Surveillance System, 2010-2012</div><div class=\"cntnt\"><img style=\"width:550px; height:415px;\" src=\"images/ID/66885_TB_case_rates_map.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data are current as of March 6, 2013. Data for 2012 are provisional.</div><div class=\"graphic_footnotes\">TB: tuberculosis.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention (CDC). Trends in Tuberculosis - United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:201.</div><div id=\"graphicVersion\">Graphic 66885 Version 5.0</div></div></div>"},"66886":{"type":"graphic_picture","displayName":"Erythroplasia of Queyrat","title":"Erythroplasia of Queyrat","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythroplasia of Queyrat</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/ONC/66886_Erythroplasia_Queyrat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 66886 Version 3.0</div></div></div>"},"66887":{"type":"graphic_figure","displayName":"Criteria for basal cell carcinoma","title":"Dermoscopic criteria for basal cell carcinoma: Dermoscopic structures and histopathologic correlation<sup>[1-4]</sup>","html":"<div class=\"graphic\"><div style=\"width: 641px\" class=\"figure\"><div class=\"ttl\">Dermoscopic criteria for basal cell carcinoma: Dermoscopic structures and histopathologic correlation<sup>[1-4]</sup></div><div class=\"cntnt\"><img style=\"width:621px; height:833px;\" src=\"images/DERM/66887_Crit_basal_cell_carcin_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Argenziano G, Chimenti S, Talamini R, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.</li>&#xD;&#xA;    <li>Braun RP, Oliviero M, Kopf AW, Saurat JH. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol 2005; 52:109.</li>&#xD;&#xA;    <li>Braun RP, Rabinovitz HS, Krischer J, et al. Dermoscopy of pigmented seborrheic keratosis: a morphological study. Arch Dermatol 2002; 138:1556.</li>&#xD;&#xA;    <li>Scope A, Benvenuto-Andrade C, Agero AL, Marghoob AA. Nonmelanocytic lesions defying the two-step dermoscopy algorithm. Dermatol Surg 2006; 32:1398.</li>&#xD;&#xA;    <li>Navarrete-Dechent C, Bajaj S, Marchetti MA, et al. Association of Shiny White Blotches and Strands With Nonpigmented Basal Cell Carcinoma: Evaluation of an Additional Dermoscopic Diagnostic Criterion. JAMA Dermatol 2016; 152:546.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 66887 Version 4.0</div></div></div>"},"66888":{"type":"graphic_table","displayName":"Muscle strength grading scale","title":"Muscle strength grading scale*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscle strength grading scale*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade </td> <td class=\"subtitle1\">Demonstrated strength</td> </tr> <tr> <td>5</td> <td>Muscle contracts normally against full resistance.</td> </tr> <tr> <td>4</td> <td>Muscle strength is reduced but muscle contraction can still move joint against resistance<sup>&#182;</sup>.</td> </tr> <tr> <td>3</td> <td>Muscle strength is further reduced such that the joint can be moved only against gravity with the examiner's resistance completely removed.</td> </tr> <tr> <td>2</td> <td>Muscle can move only if the resistance of gravity is removed (eg, in the horizontal plane).</td> </tr> <tr> <td>1</td> <td>Only a trace of movement is seen or felt or fasciculations are present.</td> </tr> <tr> <td>0</td> <td>No movement.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This scale relies on full patient effort and cooperation. Thus, patients who are unable to follow instructions due to young age, cognitive deficits, or decreased level of consciousness cannot be tested in this manner.<br />¶ This system is relatively less sensitive for the evaluation of mild weakness. To compensate for this, the addition of 4+ and 4- categories are sometimes added to the scale.</div><div id=\"graphicVersion\">Graphic 66888 Version 3.0</div></div></div>"},"66891":{"type":"graphic_figure","displayName":"Gene switching in Borrelia spp","title":"Switch in serotype Y to serotype B by a relapsing fever Borrelia spp","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Switch in serotype Y to serotype B by a relapsing fever Borrelia spp</div><div class=\"cntnt\"><img style=\"width:487px; height:192px;\" src=\"images/ID/66891_Gene_switching_in_Borrelia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A serotype Y cell with two linear plasmids. The one on the top bears several different vmp genes that are silent. These are vmpP, vmpY, vmpB, and vmpG. The second linear plasmid has a second copy of the vmpY. It is at the end of the plasmid and is expressed off a promoter (P) at the site. The serotype identity of the cell is determined by the vmp gene on the second plasmid. In the switch, one of the silent vmp genes on the first plasmid--in this case vmpB--replaces the vmp gene at the expression site on the second plasmid. There is no loss of a silent vmp gene during the switch. Now that the vmp gene is replaced on the second plasmid, the cell's identity is serotype B.</div><div class=\"graphic_reference\">Courtesy of Alan Barbour, MD.</div><div id=\"graphicVersion\">Graphic 66891 Version 2.0</div></div></div>"},"66895":{"type":"graphic_picture","displayName":"Pigmented nails Addison's PI","title":"Hyperpigmentation of nails in primary adrenal insufficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperpigmentation of nails in primary adrenal insufficiency</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/PI/66895_Pigmented_nails_Addisons_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fingers of a 28-year-old white woman with Addison's disease (underneath) compared with those of a normal woman (top). There is hyperpigmentation of the skin and increased pigmentation of the distal half of the nails that occurred during the period of adrenal insufficiency. The proximal half of the nails are hypopigmented, a reflection of the reduction in ACTH (corticotropin)&nbsp;secretion after the institution of glucocorticoid therapy.</div><div class=\"graphic_reference\">Courtesy of David N Orth, MD.</div><div id=\"graphicVersion\">Graphic 66895 Version 2.0</div></div></div>"},"66896":{"type":"graphic_figure","displayName":"Life cycle of Onchocerca volvulus","title":"Life cycle of <EM>Onchocerca volvulus</EM>","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Life cycle of <EM>Onchocerca volvulus</EM></div><div class=\"cntnt\"><img style=\"width:611px; height:492px;\" src=\"images/ID/66896_Lifecycle_O_volvulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a blood meal, an infected blackfly (genus <EM>Simulium</EM>) introduces third-stage filarial larvae onto the skin of the human host, where they penetrate into the bite wound <STRONG>(1)</STRONG>. In subcutaneous tissues, the larvae <STRONG>(2)</STRONG> develop into adult filariae, which commonly reside in nodules in subcutaneous connective tissues <STRONG>(3)</STRONG>. Adults can live in the nodules for approximately 15 years. Some nodules may contain numerous male and female worms. Females measure 33 to 50 cm in length and 270 to 400 micron in diameter, while males measure 19 to 42 mm by 130 to 210 micron. In the subcutaneous nodules, the female worms are capable of producing microfilariae for approximately&nbsp;nine years. The microfilariae, measuring 220 to 360 micron by 5 to 9 micron and unsheathed, have a life span that may reach&nbsp;two years. They are occasionally found in peripheral blood, urine, and sputum but are typically found in the skin and in the lymphatics of connective tissues <STRONG>(4)</STRONG>. A blackfly ingests the microfilariae during a blood meal <STRONG>(5)</STRONG>. After ingestion, the microfilariae migrate from the blackfly's midgut through the hemocoel to the thoracic muscles <STRONG>(6)</STRONG>. There, the microfilariae develop into first-stage larvae <STRONG>(7)</STRONG> and subsequently into third-stage infective larvae <STRONG>(8)</STRONG>. The third-stage infective larvae migrate to the blackfly's proboscis <STRONG>(9)</STRONG> and can infect another human when the fly takes a blood meal <STRONG>(1)</STRONG>.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. Available at: <A href=\"http://www.cdc.gov/dpdx/onchocerciasis/index.html\">http://www.cdc.gov/dpdx/onchocerciasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 66896 Version 6.0</div></div></div>"},"66897":{"type":"graphic_table","displayName":"Toxic epidermal necrolysis SCORTEN criteria","title":"SCORTEN score for Stevens-Johnson syndrome/toxic epidermal necrolysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">SCORTEN score for Stevens-Johnson syndrome/toxic epidermal necrolysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Independent prognosis factors</td> <td class=\"subtitle1\">Weight</td> </tr> <tr> <td>Age</td> <td>&#8805;40 years</td> <td>1</td> </tr> <tr> <td>Malignancy*</td> <td>Yes</td> <td>1</td> </tr> <tr> <td>Body surface area detached</td> <td>&#8805;10%</td> <td>1</td> </tr> <tr> <td>Tachycardia</td> <td>&#8805;120/min</td> <td>1</td> </tr> <tr> <td>Serum urea</td> <td>&#62;10 mmol/L</td> <td>1</td> </tr> <tr> <td>Serum glucose</td> <td>&#62;14 mmol/L</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Serum bicarbonate</td> <td>&#60;20 mmol/L</td> <td>1</td> </tr> <tr> <td colspan=\"2\"><strong>SCORTEN#</strong></td> <td><strong>7</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SCORTEN: score of toxic epidermal necrolysis.<br />* Malignancy: evolving cancer and hematologic malignancies.</div><div class=\"graphic_reference\">Adapted with permission from: Gu&eacute;gan S, Bastuji-Garin S, Poszepczynska-Guign&eacute; E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126:272. Copyright &copy; Macmillan Publishers Ltd.</div><div id=\"graphicVersion\">Graphic 66897 Version 6.0</div></div></div>"},"66898":{"type":"graphic_table","displayName":"Bilirubin albumin ratio BW","title":"Bilirubin/albumin (mg/g) ratio as a criterion for exchange transfusion in preterm infants based upon birth weight","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bilirubin/albumin (mg/g) ratio as a criterion for exchange transfusion in preterm infants based upon birth weight</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Birth weight, g</td> <td class=\"subtitle1\">B/A range, mg/g (molar)</td> </tr> <tr> <td>&#60;1250</td> <td>4 to 5.2 (0.3 to 0.42)</td> </tr> <tr> <td>1250 to 1499</td> <td>5.2 to 6 (0.42 to 0.5)</td> </tr> <tr> <td>1500 to 1999</td> <td>6 to 6.8 (0.5 to 0.58)</td> </tr> <tr> <td>2000 to 2499</td> <td>6.8 to 7 (0.78 to 0.8)</td> </tr> <tr> <td>&#62;2500</td> <td>&#8805;7 (0.8)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">B/A: bilirubin/albumin ratio.</div><div class=\"graphic_reference\">Data from: Ahlfors CE, Amin SB, Parker AE. Unbound bilirubin predicts abnormal automated auditory brainstem response in a diverse newborn population. J Perinatol 2009; 29:305.</div><div id=\"graphicVersion\">Graphic 66898 Version 4.0</div></div></div>"},"66900":{"type":"graphic_table","displayName":"Causes Meniere disease","title":"Conditions that may cause symptoms of Meniere disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions that may cause symptoms of Meniere disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Hyper/hypothyroidism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diabetes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Central nervous system disease (eg, cerebral vascular\ninsufficiency, aneurysm, multiple sclerosis, concussive syndrome,\ntumor, pseudotumor cerebri)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Recurrent vestibular neuronitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Autoimmune disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Neurosyphilis</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 66900 Version 2.0</div></div></div>"},"66901":{"type":"graphic_picture","displayName":"Pelagia noctiluca print","title":"Pelagia noctiluca print","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelagia noctiluca print</div><div class=\"cntnt\"><img style=\"width:216px; height:287px;\" src=\"images/PC/66901_Pelagia_noctiluca_print.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Junghanss, T, Bodio, M. Medically important venomous animals: Biology, prevention, first aid, and clinical management. CID 2006; 32:1309. Copyright &#169; 2006 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 66901 Version 1.0</div></div></div>"},"66904":{"type":"graphic_picture","displayName":"Primary biliary cholangitis II","title":"Primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:432px; height:279px;\" src=\"images/GAST/66904_Primary_biliary_cirrhosis1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of liver biopsy in primary biliary cholangitis in the same patient showing a marked mononuclear cell infiltrate surrounding and destroying a bile duct.</div><div class=\"graphic_reference\">Courtesy of Sanjiv Chopra, MD.</div><div id=\"graphicVersion\">Graphic 66904 Version 2.0</div></div></div>"},"66906":{"type":"graphic_table","displayName":"Neonatal GBS infection rx","title":"Antimicrobial therapy for group B streptococcal infections in neonates and young infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial therapy for&nbsp;group B streptococcal infections in neonates and young infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Site(s) of infection</td> <td class=\"subtitle1\">Empiric therapy*</td> <td class=\"subtitle1\">Definitive therapy<sup>&#182;</sup></td> <td class=\"subtitle1\">Duration of therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Early-onset (from birth <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">through day 6)</span></td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;Bacteremia/sepsis/pneumonia</td> <td> <p>Ampicillin 150 mg/kg every 12 hours</p> <p><strong>PLUS</strong></p> <p>Gentamicin 4 mg/kg every 24 hours for infants born at &#8805;35 weeks gestation; 3 mg/kg every 24 hours for infants born at &#60;35 weeks gestation</p> </td> <td>Penicillin G: 50,000 to 100,000 units/kg per day divided every&nbsp;12 hours</td> <td>&nbsp;10 days</td> </tr> <tr class=\"divider_bottom\"> <td>Meningitis&nbsp;</td> <td> <p>Ampicillin 100 to 150 mg/kg every&nbsp;8 hours</p> <p><strong>PLUS</strong></p> <p>Gentamicin 4 mg/kg every 24 hours for infants born at &#8805;35 weeks gestation; 3 mg/kg every 24 hours for infants born at &#60;35 weeks gestation</p> </td> <td>Penicillin G: 250,000 to 450,000 units/kg per day divided every 8 hours</td> <td>14 to 21 days<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Late-onset (beyond day 6 after birth)</td> </tr> <tr class=\"divider_bottom\"> <td>Bacteremia without a focus</td> <td> <p>Ampicillin, nafcillin, or vancomycin</p> <p><strong>PLUS</strong></p> Gentamicin or cefotaxime<sup>&#9674;</sup></td> <td> <p>Penicillin G</p> 75,000 to 150,000 units/kg per day divided every 8 hours</td> <td>10 days</td> </tr> <tr class=\"divider_bottom\"> <td>Meningitis</td> <td> <p>Ampicillin and/or vancomycin</p> <p><strong>PLUS</strong></p> Gentamicin or cefotaxime<sup>&#9674;</sup></td> <td> <p>Penicillin G</p> 450,000 to 500,000 units/kg per day divided every 6 hours</td> <td>14 to 21 days<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Cellulitis/adenitis</td> <td> <p>Nafcillin or vancomycin</p> <p><strong>PLUS</strong></p> Gentamicin or cefotaxime<sup>&#9674;</sup></td> <td> <p>Penicillin G</p> 75,000 to 150,000 units/kg per day divided every 8 hours</td> <td>10 to 14 days</td> </tr> <tr class=\"divider_bottom\"> <td>Septic arthritis</td> <td> <p>Nafcillin or vancomycin</p> <p><strong>PLUS</strong></p> Cefotaxime<sup>&#9674;</sup></td> <td> <p>Penicillin G</p> 75,000 to 150,000 units/kg per day divided every 8 hours</td> <td>14 to 21 days</td> </tr> <tr class=\"divider_bottom\"> <td>Osteomyelitis</td> <td> <p>Nafcillin or vancomycin</p> <p><strong>PLUS</strong></p> Cefotaxime<sup>&#9674;</sup></td> <td> <p>Penicillin G</p> 75,000 to 150,000 units/kg per day divided every 8 hours</td> <td>21 to 28 days</td> </tr> <tr> <td>Urinary tract infection</td> <td> <p>Ampicillin, nafcillin, or vancomycin</p> <p><strong>PLUS</strong></p> Gentamicin or cefotaxime<sup>&#9674;</sup></td> <td> <p>Penicillin G</p> 75,000 to 150,000 units/kg per day divided every 8 hours</td> <td>10 days</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The antibiotic doses listed above are for use in neonates and young infants weighing ≥1 kg with normal renal function. For additional dosing detail, refer to the Lexicomp pediatric and neonatal drug information monographs included within UpToDate.</div><div class=\"graphic_footnotes\">GBS: group B streptococcus; CSF: cerebrospinal fluid; IV: intravenous.<br />* Selection will depend on age and&nbsp;presumed source of infection (maternal, hospital, or community). Local susceptibility patterns should also be considered.<br />¶ Transition from empiric to definitive therapy should&nbsp;occur once GBS is identified by culture; clinical improvement is evident; and for meningitis, CSF is sterile at 24 to 48 hours of therapy.<br />Δ&nbsp;Fourteen days is sufficient for uncomplicated cases of GBS meningitis.<br />◊ If cefotaxime is not available, alternative agents include ceftazidime or&nbsp;ceftriaxone.&nbsp;Ceftriaxone should <STRONG>not</STRONG> to be used in infants with clinically significant hyperbilirubinemia or those receiving concurrent IV calcium (including parenteral nutrition).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW (Ed), American Academy of Pediatrics, 2015. p.745.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Tables of antibacterial drug dosages, Table 4.2. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.882.</LI>&#xD;&#xA;<LI>Medications. In: Guidelines for Acute Care of the Neonate, 22nd Ed, Adams JM, Fernandes CJ (Eds), Baylor College of Medicine, Houston, TX 2014. p.89.</LI>&#xD;&#xA;<LI>Rao SC, Srinivasjois R, Hagen R, et al. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2011 Nov 9(11).</LI></OL></div><div id=\"graphicVersion\">Graphic 66906 Version 9.0</div></div></div>"},"66913":{"type":"graphic_table","displayName":"Skin thermal relaxation time","title":"Thermal relaxation times","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thermal relaxation times</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Target</td> <td class=\"subtitle1\">Thermal relaxation time</td> </tr> <tr> <td>200 &#181;m hair follicle</td> <td>20 msec</td> </tr> <tr> <td>100 &#181;m port wine stain blood vessel</td> <td>5 msec</td> </tr> <tr> <td>50 &#181;m blood vessel</td> <td>1 msec</td> </tr> <tr> <td>50 &#181;m of epidermis</td> <td>1 msec</td> </tr> <tr> <td>7 &#181;m erythrocyte</td> <td>20 &#181;sec</td> </tr> <tr> <td>1 &#181;m melanosome</td> <td>1 &#181;sec</td> </tr> <tr> <td>0.1 &#181;m tattoo particle</td> <td>10 nsec</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66913 Version 1.0</div></div></div>"},"66914":{"type":"graphic_figure","displayName":"Classification of phalangeal condylar fractures","title":"Classification of phalangeal condylar fractures ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classification of phalangeal condylar fractures </div><div class=\"cntnt\"><img style=\"width:385px; height:417px;\" src=\"images/SURG/66914_Class_condylar_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Condylar fractures are classified into three types:<br /><UL>&#xD;&#xA;<LI>Type I - Non-displaced unicondylar fractures </LI>&#xD;&#xA;<LI>Type II - Displaced unicondylar fractures </LI>&#xD;&#xA;<LI>Type III - Comminuted bicondylar fractures </LI></UL></div><div id=\"graphicVersion\">Graphic 66914 Version 5.0</div></div></div>"},"66915":{"type":"graphic_figure","displayName":"Transducer position for parasternal short axis view","title":"Transducer position for obtaining the parasternal short axis view of the heart","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transducer position for obtaining the parasternal short axis view of the heart</div><div class=\"cntnt\"><img style=\"width:378px; height:362px;\" src=\"images/CARD/66915_Transducer_short_axis_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown is the transducer position and beam plane used for two-dimensional imaging of the heart in the short axis. In this view the plane of the cut runs through or just below the minor axis of the left ventricle.</div><div class=\"graphic_footnotes\">IL: inferolateral left ventricular wall; IW: inferior or diaphragmatic wall of the left ventricle; S: interventricular septum; PM: papillary muscles; PMPM: posteromedial; ALPM: anterolateral.</div><div id=\"graphicVersion\">Graphic 66915 Version 5.0</div></div></div>"},"66916":{"type":"graphic_table","displayName":"Methanol and ethylene glycol intoxication - Rapid overview","title":"Methanol and ethylene glycol intoxication: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methanol and ethylene glycol intoxication: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td>Early toxicity: CNS sedation and inebriation similar to ethanol intoxication</td> </tr> <tr> <td>Late toxicity: metabolic acidosis with elevated anion gap; compensatory tachypnea/hyperpnea; coma in severe cases, accompanied by ocular toxicity (methanol) or renal failure (ethylene glycol)</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic testing</td> </tr> <tr> <td>Arterial or venous blood gas (to determine extent of acidosis)</td> </tr> <tr> <td>Basic chemistry (to determine anion gap and renal function)</td> </tr> <tr> <td>Serum osmolality (to help determine diagnosis)</td> </tr> <tr> <td>Serum ethanol concentration (to help determine osmolal gap)</td> </tr> <tr> <td>Serum calcium concentration (to rule out ethylene-glycol associated hypocalcemia)</td> </tr> <tr> <td>Serum methanol, ethylene glycol, and isopropanol concentrations (to establish diagnosis)</td> </tr> <tr> <td>Urinalysis (for oxalate crystals)</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Secure airway as necessary in severely intoxicated patients</td> </tr> <tr> <td>Treat hypotension with intravenous crystalloid, followed by standard vasopressors as necessary</td> </tr> <tr> <td>Block alchohol dehydrogenase with <strong>fomepizole</strong>, 15 mg/kg IV loading dose, followed by 10 mg/kg q 12 h x 4 doses. If patient requires further treatment after this regimen, increase dose to 15 mg/kg every 12 hours</td> </tr> <tr> <td>If fomepizole is unavailable or patient has a known allergy, block alcohol dehydrogenase with ethanol, 10 mL/kg of a 10 percent ethanol solution, followed by 1 mL/kg of 10 percent ethanol solution infused per hour. Titrate to serum ethanol concentration of 100 mg/dL.</td> </tr> <tr> <td>Administer <strong>sodium bicarbonate</strong>, 1 to 2 meq/kg bolus followed by infusion of 132 meq NaHCO3 in 1 L D5W to run at 200 to 250 mL/hour for patients with pH below 7.3</td> </tr> <tr> <td>For patients with known or suspected methanol poisoning, administer <strong>folic acid</strong>, 50 mg IV every six hours</td> </tr> <tr> <td>For patients with known or suspected ethylene glycol poisoning, administer <strong>thiamine</strong>, 100 mg IV, and administer <strong>pyridoxine</strong>, 50 mg IV</td> </tr> <tr> <td>If the diagnosis is uncertain but clinical suspicion is high, the clinician should initiate antidotal treatment with alcohol dehydrogenase blockade and consultation for hemodialysis</td> </tr> <tr> <td class=\"subtitle1_single\">Hemodialysis is indicated in severe toxicity, which we define as follows:</td> </tr> <tr> <td>Metabolic acidosis, regardless of drug level</td> </tr> <tr> <td>Elevated serum methanol or ethylene glycol levels (more than 50 mg/dL; or methanol 15.6 mmol/L, ethylene glycol 8.1 mmol/L), unless arterial pH is above 7.3</td> </tr> <tr> <td>Evidence of end-organ damage (eg, visual changes, renal failure)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 66916 Version 10.0</div></div></div>"},"66918":{"type":"graphic_picture","displayName":"Gram stain CSF 1 with answer","title":"Streptococcus pneumoniae in cerebrospinal fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Streptococcus pneumoniae in cerebrospinal fluid</div><div class=\"cntnt\"><img style=\"width:369px; height:240px;\" src=\"images/ID/66918_Gram_stain_CSF_1_with_answe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and gram-positive diplococci. <EM>Streptococcus pneumoniae</EM> grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 66918 Version 3.0</div></div></div>"},"66919":{"type":"graphic_table","displayName":"Diseases associated with HTLV-1 infection","title":"Diseases associated with HTLV-1 infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases associated with HTLV-1 infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Major</td>\n</tr>\n<tr>\n<td>Adult T-cell leukemia/lymphoma (ATLL)</td>\n</tr>\n<tr>\n<td>HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Minor</td>\n</tr>\n<tr>\n<td>Infective dermatitis</td>\n</tr>\n<tr>\n<td>Uveitis</td>\n</tr>\n<tr>\n<td>Arthropathy</td>\n</tr>\n<tr>\n<td>Sjogren's syndrome</td>\n</tr>\n<tr>\n<td>Raynaud syndrome</td>\n</tr>\n<tr>\n<td>Polymyositis</td>\n</tr>\n<tr>\n<td>Pulmonary lymphocytic alveolitis</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 66919 Version 2.0</div></div></div>"},"66920":{"type":"graphic_picture","displayName":"Nocardia on modified AFB stain","title":"<EM>Nocardia </EM>on a modified acid-fast stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Nocardia </EM>on a modified acid-fast stain</div><div class=\"cntnt\"><img style=\"width:375px; height:252px;\" src=\"images/ID/66920_Nocardia_on_modified_AFB_st.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Modified acid-fast (Kinyoun) stain of <EM>Nocardia </EM>showing the characteristic branching filamentous rods that are partially acid fast. <EM>Actinomyces</EM> do not exhibit acid fastness.</div><div class=\"graphic_reference\">Courtesy of Stanley W Chapman, MD.</div><div id=\"graphicVersion\">Graphic 66920 Version 3.0</div></div></div>"},"66921":{"type":"graphic_movie","displayName":"Mitral stenosis as heard at the base","title":"Mitral stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/66921_msbaseconv.mp4\" style=\"width:520px;height:414px\"></div><img style=\"width:510px; height:264px;\" src=\"images/CARD/66921_msbase.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram and phonocardiogram of mitral stenosis as heard at the base. Following S2 (aortic and pulmonic valve closure) is the opening of the stenotic mitral valve (snap) and a low pitched, faint mid diastolic murmur of mitral stenosis.</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 66921 Version 3.0</div></div></div>"},"66923":{"type":"graphic_figure","displayName":"Cerebral autoregulation","title":"Normal cerebral autoregulation and its disturbance during acute ischemic stroke","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Normal cerebral autoregulation and its disturbance during acute ischemic stroke</div><div class=\"cntnt\"><img style=\"width:451px; height:400px;\" src=\"images/NEURO/66923_Cerebral_autoregulation.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Mounzer Kassab.</div><div id=\"graphicVersion\">Graphic 66923 Version 1.0</div></div></div>"},"66925":{"type":"graphic_table","displayName":"Anatomic causes pancreatitis","title":"Anatomic abnormalities associated with pancreatitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anatomic abnormalities associated with pancreatitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Congenital</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Biliary anomalies</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Biliary cyst</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Anomalous pancreaticobiliary junction</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Pancreatic anomalies</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Pancreas divisum</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Annular pancreas</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Short pancreas</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Cystic dilatation of the pancreatic duct (pancreatocele)</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Duodenal anomalies</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Duodenal or gastric duplication cysts</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Duodenal diverticulum</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Acquired</td>\n</tr>\n<tr>\n<td>Parasitic infestation</td>\n</tr>\n<tr>\n<td>Sphincter of Oddi dysfunction</td>\n</tr>\n<tr>\n<td>Pancreatic trauma</td>\n</tr>\n<tr>\n<td>Acquired Immunodeficiency Syndrome</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 66925 Version 2.0</div></div></div>"},"66926":{"type":"graphic_diagnosticimage","displayName":"IPMN ERCP","title":"Intraductal papillary mucinous neoplasm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraductal papillary mucinous neoplasm</div><div class=\"cntnt\"><img style=\"width:360px; height:326px;\" src=\"images/GAST/66926_IPMN_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images obtained during endoscopic retrograde cholangiopancreatography in a 61-year-old patient with steatorrhea, weight loss, and diabetes. The left panel shows an endoscopic image of the papilla, which has a gaping \"fisheye\" appearance and is exuding mucin. The pancreatogram shows a dilated pancreatic duct and side branches with intraluminal filling defects. The patient underwent a pancreaticoduodenectomy, which confirmed an intraductal papillary mucinous neoplasm.</div><div class=\"graphic_reference\">Courtesy of Maurits Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 66926 Version 3.0</div></div></div>"},"66928":{"type":"graphic_figure","displayName":"Laparosc tranvaginal entry","title":"Transvaginal entry and insufflation for laparoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transvaginal entry and insufflation for laparoscopy</div><div class=\"cntnt\"><img style=\"width:444px; height:273px;\" src=\"images/OBGYN/66928_Laparosc_tranvaginal_entry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal Veress needle insertion. Place a tenaculum on the posterior lip of the cervix and elevate the cervix. This exposes the posterior fornix and places the vaginal mucosa under tension.</div><div class=\"graphic_reference\">LifeART image copyright ©2009 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 66928 Version 2.0</div></div></div>"},"66929":{"type":"graphic_figure","displayName":"Delivery of posterior arm","title":"The effect of the Barnum maneuver in reducing the obstructing part of the fetal shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The effect of the Barnum maneuver in reducing the obstructing part of the fetal shoulder</div><div class=\"cntnt\"><img style=\"width:231px; height:442px;\" src=\"images/OBGYN/66929_Delivery_of_posterior_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The operator has already inserted a hand into the vagina and delivered the posterior arm by sweeping it across the fetal chest, and thus delivered the posterior shoulder as well (not shown). A 13-cm bisacromial diameter becomes an 11-cm axillo-acromial diameter upon delivery of the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: Poggi SH, Spong CY, Allen AH. Prioritizing posterior arm delivery during severe shoulder dystocia. Obstet Gynecol 2003; 101:1068. Copyright © 2003 American College of Obstetricians and Gynecologists.</div><div id=\"graphicVersion\">Graphic 66929 Version 2.0</div></div></div>"},"66930":{"type":"graphic_table","displayName":"Endoscopic therapeutic modality","title":"Indication for endoscopic therapy in the treatment of the three basic types of endobronchial stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indication for endoscopic therapy in the treatment of the three basic types of endobronchial stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Endobronchial lesion</td> <td class=\"subtitle1\">Extrinsic lesion</td> <td class=\"subtitle1\">Mixed lesion</td> </tr> <tr> <td>Laser</td> <td>+</td> <td>&ndash;</td> <td>+</td> </tr> <tr> <td>Electrocautery</td> <td>+</td> <td>&ndash;</td> <td>+</td> </tr> <tr> <td>Cryotherapy</td> <td>+*</td> <td>&ndash;</td> <td>+*</td> </tr> <tr> <td>Brachytherapy</td> <td>+*</td> <td>-</td> <td>+*</td> </tr> <tr> <td>APC</td> <td>+</td> <td>&ndash;</td> <td>+</td> </tr> <tr> <td>PDT</td> <td>+*</td> <td>&ndash;</td> <td>+*</td> </tr> <tr> <td>Stents</td> <td>&ndash;</td> <td>+</td> <td>+<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">APC: argon plasma coagulator; PDT: photodynamic therapy.<br />* Contraindicated in impending respiratory failure.<br />¶ Indicated if postinterventional airway lumen is &lt;50 percent of normal.</div><div class=\"graphic_reference\">Bolliger, CT, Mathur, PN, Beamis, JF, et al. Eur Respir J 2002; 2002; 19:369.</div><div id=\"graphicVersion\">Graphic 66930 Version 2.0</div></div></div>"},"66931":{"type":"graphic_picture","displayName":"Synovial tissue in RA","title":"Synovial tissue in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Synovial tissue in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:416px; height:290px;\" src=\"images/RHEUM/66931_Synovial_tissue_in_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of synovial tissue in RA showing prominent hyperplasia of the synovial lining layer. The inflammatory infiltrate in the sublining is comprised predominantly of lymphocytes, plasma cells, and macrophages (hematoxylin and eosin).</div><div class=\"graphic_reference\">Courtesy of Ellen M Gravallese, MD.</div><div id=\"graphicVersion\">Graphic 66931 Version 1.0</div></div></div>"},"66932":{"type":"graphic_diagnosticimage","displayName":"CT scan showing walled off pancreatic necrosis","title":"CT scan showing walled off pancreatic necrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan showing walled off pancreatic necrosis</div><div class=\"cntnt\"><img style=\"width:349px; height:584px;\" src=\"images/SURG/66932_Walled_off_pancr_necrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast enhanced CT scan showing walled off pancreatic necrosis in both axial (A) and coronal (B) projections. This morphologic variant of necrosis is well suited to minimally invasive methods of debridement.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 66932 Version 7.0</div></div></div>"},"66933":{"type":"graphic_figure","displayName":"Collateral circulation around the shoulder","title":"Collateral circulation around the shoulder","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Collateral circulation around the shoulder</div><div class=\"cntnt\"><img style=\"width:521px; height:549px;\" src=\"images/SURG/66933_Collateral-circulation-shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thyrocervical trunk, dorsal scapular artery, and internal thoracic artery provide important collateral channels of blood flow to the ipsilateral brain and upper extremity when a significant stenosis or occlusion of the brachiocephalic or subclavian artery is present.</div><div id=\"graphicVersion\">Graphic 66933 Version 4.0</div></div></div>"},"66934":{"type":"graphic_figure","displayName":"Psoas compartment block ","title":"Psoas compartment block with nerve stimulator-guidance","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Psoas compartment block with nerve stimulator-guidance</div><div class=\"cntnt\"><img style=\"width:504px; height:650px;\" src=\"images/SURG/66934_Psoas_compartment_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For nerve stimulator-guided psoas compartment block, the needle insertion site can be localized in one of two ways: &#xD;&#xA;<UL>&#xD;&#xA;<LI>In method 1, the needle is inserted 4 cm lateral to the midline along a line drawn from the iliac crest to the L4&nbsp;spinous processes in the midline of the back. </LI>&#xD;&#xA;<LI>In method 2, the needle insertion site is found by first drawing a line (line 1) connecting the iliac crests. The PSIS is identified and the lumbar spinous processes are marked. A second line (line 2) is drawn through the PSIS parallel to a third line (line 3) connecting the spinous processes. The needle is inserted 1 cm cephalad to the junction of the lateral third and medial two-thirds of a line between the lines 2 and 3 at the level of L4. </LI></UL></div><div class=\"graphic_footnotes\">PSIS: posterior superior iliac spine.</div><div id=\"graphicVersion\">Graphic 66934 Version 9.0</div></div></div>"},"66935":{"type":"graphic_figure","displayName":"Prevalence of hypertension in men and women in US","title":"Prevalence of hypertension in the United States","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Prevalence of hypertension in the United States</div><div class=\"cntnt\"><img style=\"width:556px; height:522px;\" src=\"images/NEPH/66935_PrevhtninmenwomeninUS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence of hypertension in men (upper graph) and women (lower graph) according to age and race/ethnicity in the United States from the National Health and Nutrition Examination Survey (NHANES). Hypertension occurs earlier and more frequently in non-Hispanic blacks.</div><div class=\"graphic_reference\">Data from: Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043.</div><div id=\"graphicVersion\">Graphic 66935 Version 11.0</div></div></div>"},"66936":{"type":"graphic_picture","displayName":"Gram stain peritoneal answer","title":"Mixed flora from a ruptured viscus: Gram stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mixed flora from a ruptured viscus: Gram stain</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ID/66936_Gramstainperitonealanswe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of peritoneal fluid (x1000) shows several different organisms, including Gram positive cocci in chains, Gram positive rods, plump enteric Gram negative bacilli, and thinner Gram negative rods. Mixed fecal flora grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 66936 Version 3.0</div></div></div>"},"66940":{"type":"graphic_waveform","displayName":"ECG digoxin toxicity in AF 4","title":"Single-lead electrocardiogram (ECG) showing atrial fibrillation and a junctional pacemaker with a 4:3 Wenckebach exit block","html":"<div class=\"graphic normal\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing atrial fibrillation and a junctional pacemaker with a 4:3 Wenckebach exit block</div><div class=\"cntnt\"><img style=\"width:539px; height:76px;\" src=\"images/CARD/66940_Digitalis_toxicity_in_AF_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 4 electrocardiograms in this sequence demonstrate increasing severity of digoxin toxicity in a patient with atrial fibrillation.<br />In this strip, the result is group beating characterized by three beats with decreasing R-R intervals. On physical examination, this seemingly irregular rhythm might lead to the mistaken diagnosis of an irregularly irregular response to atrial fibrillation, rather than arrhythmia associated with severe digoxin toxicity. This patient presented with this ECG; the preceding electrocardiograms reflected (in reverse order) the sequence of recovery as the effect of digoxin wore off.</div><div class=\"graphic_reference\">The four electrocardiograms are adapted from: Childers R, Med Clin North Am 1976; 60:3.</div><div id=\"graphicVersion\">Graphic 66940 Version 7.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"66942":{"type":"graphic_picture","displayName":"Chronic GVHD - poikiloderma","title":"Chronic graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/66942_Chronic_GVHD_poikiloderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poikilodermatous changes in chronic graft-versus-host disease. Mottled pigmentation and erythema are present on the extremity.</div><div id=\"graphicVersion\">Graphic 66942 Version 1.0</div></div></div>"},"66943":{"type":"graphic_table","displayName":"Sulfite-containing foods","title":"Sulfite-containing foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sulfite-containing foods</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">High content</td> </tr> <tr> <td class=\"indent1\">Dried fruit (excluding dark raisins and prunes)</td> </tr> <tr> <td class=\"indent1\">Lemon juice (nonfrozen)</td> </tr> <tr> <td class=\"indent1\">Lime juice (nonfrozen)</td> </tr> <tr> <td class=\"indent1\">Wine</td> </tr> <tr> <td class=\"indent1\">Molasses</td> </tr> <tr> <td class=\"indent1\">Sauerkraut juice</td> </tr> <tr> <td class=\"indent1\">Grape juice (white, white sparkling, pink sparkling, red sparkling)</td> </tr> <tr> <td class=\"subtitle1_single\">Moderate content</td> </tr> <tr> <td class=\"indent1\">Dried potatoes</td> </tr> <tr> <td class=\"indent1\">Wine vinegar</td> </tr> <tr> <td class=\"indent1\">Gravies, sauces</td> </tr> <tr> <td class=\"indent1\">Fruit topping</td> </tr> <tr> <td class=\"indent1\">Maraschino cherries</td> </tr> <tr> <td class=\"indent1\">Pectin</td> </tr> <tr> <td class=\"indent1\">Shrimp (fresh)</td> </tr> <tr> <td class=\"indent1\">Sauerkraut</td> </tr> <tr> <td class=\"indent1\">Pickled peppers</td> </tr> <tr> <td class=\"indent1\">Pickled cocktail onions</td> </tr> <tr> <td class=\"indent1\">Pickles/relishes</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Low content (&#60;10 ppm)*</td> </tr> <tr> <td class=\"indent1\">Corn starch</td> </tr> <tr> <td class=\"indent1\">Hominy</td> </tr> <tr> <td class=\"indent1\">Frozen potatoes</td> </tr> <tr> <td class=\"indent1\">Maple syrup</td> </tr> <tr> <td class=\"indent1\">Imported jams and jellies</td> </tr> <tr> <td class=\"indent1\">Fresh mushrooms</td> </tr> <tr> <td class=\"indent1\">Malt vinegar</td> </tr> <tr> <td class=\"indent1\">Dried cod</td> </tr> <tr> <td class=\"indent1\">Canned potatoes</td> </tr> <tr> <td class=\"indent1\">Beer</td> </tr> <tr> <td class=\"indent1\">Dry soup mix</td> </tr> <tr> <td class=\"indent1\">Soft drinks</td> </tr> <tr> <td class=\"indent1\">Instant tea</td> </tr> <tr> <td class=\"indent1\">Pizza dough (frozen)</td> </tr> <tr> <td class=\"indent1\">Pie dough</td> </tr> <tr> <td class=\"indent1\">Sugar (especially beet sugar)</td> </tr> <tr> <td class=\"indent1\">Gelatin</td> </tr> <tr> <td class=\"indent1\">Coconut</td> </tr> <tr> <td class=\"indent1\">Fresh fruit salad</td> </tr> <tr> <td class=\"indent1\">Domestic jams and jellies</td> </tr> <tr> <td class=\"indent1\">Crackers</td> </tr> <tr> <td class=\"indent1\">Cookies</td> </tr> <tr> <td class=\"indent1\">Grapes</td> </tr> <tr> <td class=\"indent1\">High fructose corn syrup</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Foods with low sulfite content have not been implicated in inducing reactions in sulfite-sensitive individuals.</div><div class=\"graphic_reference\">Courtesy of Ronald A Simon, MD.</div><div id=\"graphicVersion\">Graphic 66943 Version 5.0</div></div></div>"},"66945":{"type":"graphic_algorithm","displayName":"Patient management","title":"Flow chart for the evaluation and management of choledocholithiasis","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Flow chart for the evaluation and management of choledocholithiasis</div><div class=\"cntnt\"><img style=\"width:532px; height:366px;\" src=\"images/GAST/66945_Patient_management.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBD: common bile duct; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; IOC: intraoperative cholangiogram; MRCP: magnetic resonance cholangiopancreatography.</div><div class=\"graphic_reference\">Reproduced from: ASGE Standards of Practice Committee. The role of endoscopy in the evaluation of suspected choledocholithiasis. Gastrointest Endosc 2010; 71:1. Copyright &copy; 2010. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 66945 Version 2.0</div></div></div>"},"66947":{"type":"graphic_picture","displayName":"Dolichovespula nest","title":"Dolichovespula nest","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dolichovespula nest</div><div class=\"cntnt\"><img style=\"width:504px; height:413px;\" src=\"images/ALLRG/66947_Dolichovespula_nest.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 66947 Version 1.0</div></div></div>"},"66948":{"type":"graphic_table","displayName":"Periop psychotropics","title":"Perioperative management of psychotropic agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perioperative management of psychotropic agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name or class of drug</td> <td class=\"subtitle1\">Clinical considerations</td> <td class=\"subtitle1\">Recommended strategy for surgery with brief NPO state</td> <td class=\"subtitle1\">Recommended strategy for surgery with prolonged NPO state</td> </tr> <tr> <td>Antipsychotics</td> <td>Some agents are associated with QT prolongation and occasionally cause hypotension or arrythmias.</td> <td>Continue therapy up to and including day of surgery in patients with high risk of developing psychoses.</td> <td> <p>Continue therapy up to and including day of surgery. Parenteral formulations are available for haloperidol, chlorpromazine, aripriprazole, olanzapine, and ziprasidone.</p> If prolonged NPO state is anticipated, depot formulations (eg, haloperidol decanoate) could be considered, to begin well before surgery in consultation with psychopharmacologist.</td> </tr> <tr> <td>Benzodiazepines</td> <td>Abrupt withdrawal can result in agitation, hypertension, delirium, and seizures.</td> <td>Continue therapy up to and including day of surgery.</td> <td>Continue therapy up to and including day of surgery. Parenteral diazepam, lorazepam, and chlordiazepoxide are available for prolonged NPO state.</td> </tr> <tr> <td>Buspirone</td> <td>No known adverse effects.</td> <td>Continue therapy up to and including day of surgery.</td> <td>Continue therapy up to and including day of surgery. No parenteral substitution available but parenteral diazepam, lorazepam, or chlordiazepoxide can be used for prolonged NPO state.</td> </tr> <tr> <td>Lithium</td> <td>Continuation may prolong the effect of muscle relaxants and, due to impaired renal concentrating ability, can cause hypovolemia and hypernatremia.</td> <td>Continue therapy up to and including day of surgery with close monitoring of electrolytes and volume status.</td> <td>Resume with oral intake. No parenteral substitution available. When needed, may use parenteral valproate or a second-generation antipsychotic.</td> </tr> <tr> <td>Monoamine oxidase (MAO)&nbsp;inhibitors</td> <td>If continued and direct acting sympathomimetic agents like ephedrine are used during anesthesia, can result in severe hypertension. If agents like meperidine or dextromethorphan are used, can result in \"serotonin syndrome.\"</td> <td>For emergency procedures, a MAO-safe anesthetic technique should be used. For other surgeries, anesthesiologist and psychiatrist should collaborate and decide either to use MAO-safe anesthetic technique or discontinue the medication. If discontinued should be stopped for two weeks prior to surgery.</td> <td>Resume with oral intake. No parenteral substitution available.</td> </tr> <tr> <td>Serotonin reuptake inhibitors</td> <td>Increased risk of bleeding.</td> <td>Discontinue therapy three weeks prior to surgery in patients undergoing high-risk procedures (such as certain CNS procedures).</td> <td>Resume with oral intake. No parenteral substitution available.</td> </tr> <tr> <td>Tricyclic antidepressants</td> <td>Continuation may increase the potential for arrythmias. Abrupt withdrawal can lead to insomnia, nausea, headache, increased salivation, and increased sweating.</td> <td>Continue therapy up to and including day of surgery for patients on high doses. Patients on low doses and in whom perioperative arrhythmia is a concern should discontinue for seven days prior to surgery.</td> <td>Resume with oral intake. No parenteral substitution available.</td> </tr> <tr> <td>Valproic acid</td> <td>No known adverse effects.</td> <td>Continue therapy up to and including day of surgery.</td> <td>Continue therapy up to and including day of surgery. Resume with oral intake. A parenteral formulation (valproate sodium) is available.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NPO: nil per os (nothing by mouth); CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 66948 Version 6.0</div></div></div>"},"66950":{"type":"graphic_algorithm","displayName":"Approach to bone disorders in HIV","title":"Approach to bone disease in patients with human immunodeficiency virus (HIV) infection","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Approach to bone&nbsp;disease in patients with human immunodeficiency virus (HIV) infection</div><div class=\"cntnt\"><img style=\"width:644px; height:711px;\" src=\"images/ID/66950_ApprbonedisorderHIVedt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMD: bone mineral density; DXA: dual-energy x-ray absorptiometry; FRAX: Fracture Risk Assessment Tool; ART: antiretroviral therapy.</div><div class=\"graphic_reference\">Reproduced from: McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937, by permission of Oxford University Press. Copyright © 2010.</div><div id=\"graphicVersion\">Graphic 66950 Version 16.0</div></div></div>"},"66951":{"type":"graphic_diagnosticimage","displayName":"MRI of normal fetal bowel","title":"Magnetic resonance images of normal fetal bowel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance images of normal fetal bowel</div><div class=\"cntnt\"><img style=\"width:436px; height:653px;\" src=\"images/OBGYN/66951_MRI_fetal_bowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal fetal bowel at 24 weeks of gestation&nbsp;(A and B) and 27 weeks of gestation (C and D).<br />(A) T2w coronal image shows high signal fluid filled loops of bowel throughout the abdomen. Minimal low signal meconium can be seen in the pelvis.<br />(B) T1w coronal image better demonstrates high signal meconium filling the rectosigmoid and descending colon.<br />(C) T2w coronal image shows low signal meconium in the rectosigmoid.<br />(D) T1w coronal image better demonstrates high signal meconium filling the rectosigmoid.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 66951 Version 4.0</div></div></div>"},"66952":{"type":"graphic_picture","displayName":"Focal nodular hyperplasia Light","title":"Focal nodular hyperplasia of the liver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal nodular hyperplasia of the liver</div><div class=\"cntnt\"><img style=\"width:405px; height:251px;\" src=\"images/GAST/66952_Focal_nodular_hyperplasia_L.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy specimen showing fibrosis closely mimicking cirrhosis. Note the large feeder artery typical of FNH (arrow).</div><div class=\"graphic_reference\">Courtesy of Frank A Mitros, MD.</div><div id=\"graphicVersion\">Graphic 66952 Version 2.0</div></div></div>"},"66953":{"type":"graphic_picture","displayName":"Mixed flora on blood agar","title":"Growth of mixed flora on blood agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Growth of mixed flora on blood agar</div><div class=\"cntnt\"><img style=\"width:379px; height:252px;\" src=\"images/ID/66953_Mixed_flora_on_blood_agar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Expectorated sputum showing different colonial morphologies on blood agar which represents mixed flora; this result is common even in the absence of a bacterial lower tract respiratory infection.</div><div class=\"graphic_reference\">Courtesy of Melvin P Weinstein, MD.</div><div id=\"graphicVersion\">Graphic 66953 Version 2.0</div></div></div>"},"66955":{"type":"graphic_picture","displayName":"Contact derm vulva","title":"Contact dermatitis vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contact dermatitis vulva</div><div class=\"cntnt\"><img style=\"width:331px; height:405px;\" src=\"images/OBGYN/66955_Contact_derm_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from&#160;Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 66955 Version 3.0</div></div></div>"},"66959":{"type":"graphic_diagnosticimage","displayName":"Plain film destructive arthropathy","title":"Destructive arthritis in mixed connective tissue disease (MCTD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Destructive arthritis in mixed connective tissue disease (MCTD)</div><div class=\"cntnt\"><img style=\"width:212px; height:355px;\" src=\"images/RHEUM/66959_Plain_film_destructive_arth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hand radiograph in the same patient as the previous picture shows a florid destructive arthropathy with digital osteolysis and deformity.</div><div class=\"graphic_reference\">Courtesy of Robert M Bennett, MD.</div><div id=\"graphicVersion\">Graphic 66959 Version 3.0</div></div></div>"},"66962":{"type":"graphic_picture","displayName":"CPAM type 2 histology","title":"Histology of type 2 congenital pulmonary airway malformation (CPAM)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of type 2 congenital pulmonary airway malformation (CPAM)</div><div class=\"cntnt\"><img style=\"width:432px; height:284px;\" src=\"images/PEDS/66962_CCAM_type_2_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic specimen of a type 2 congenital pulmonary airway malformation (CPAM). The lesion is composed of structures resembling terminal bronchioles and is lined by low columnar to cuboidal epithelium. These structures are separated by small amounts of connective tissue. In this example, alveolar structures are not apparent.</div><div class=\"graphic_reference\">Courtesy of Christopher M Oermann, MD, and Claire Langston, MD</div><div id=\"graphicVersion\">Graphic 66962 Version 4.0</div></div></div>"},"66964":{"type":"graphic_figure","displayName":"Anatomy of the penis","title":"Anatomy of the penis","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Anatomy of the penis</div><div class=\"cntnt\"><img style=\"width:527px; height:572px;\" src=\"images/PC/66964_Anatomy_of_the_penis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66964 Version 1.0</div></div></div>"},"66965":{"type":"graphic_picture","displayName":"Pyogenic granuloma gingival mucosa","title":"Pyogenic granuloma of the gingival mucosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma of the gingival mucosa</div><div class=\"cntnt\"><img style=\"width:397px; height:546px;\" src=\"images/PC/66965_Pyogenicgranulomaging.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucosal pyogenic granuloma in a 26-year-old woman in her fourth month of pregnancy. Excessive tissue growth is impeding proper teeth contact and chewing.</div><div id=\"graphicVersion\">Graphic 66965 Version 6.0</div></div></div>"},"66966":{"type":"graphic_figure","displayName":"Cortisol in the critically ill","title":"Cortisol levels in normal subjects and the critically ill","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Cortisol levels in normal subjects and the critically ill</div><div class=\"cntnt\"><img style=\"width:500px; height:326px;\" src=\"images/PULM/66966_Cortisol_in_the_critically.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted with permission from: Vermes I, Beishuizen A, Hampsink RM, Haanen C. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab 1995; 80:1238. Copyright &#169; 1995 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 66966 Version 5.0</div></div></div>"},"66967":{"type":"graphic_figure","displayName":"Delayed organophos agents","title":"Agents associated with organophosphorous induced delayed neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Agents associated with organophosphorous induced delayed neuropathy</div><div class=\"cntnt\"><img style=\"width:375px; height:160px;\" src=\"images/PULM/66967_Delayed_organophos_agents.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 66967 Version 2.0</div></div></div>"},"66969":{"type":"graphic_table","displayName":"Criteria for PBS","title":"Definitions and diagnostic criteria of interstitial cystitis/painful bladder syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions and diagnostic criteria of interstitial cystitis/painful bladder syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">American Urological Association (2011)<sup>[1]</sup></td> </tr> <tr> <td>\"An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks' duration, in the absence of infection or other identifiable causes.\"</td> </tr> <tr> <td class=\"subtitle1_single\">International Continence Society (ICS) definition of painful bladder disorders (2002)<sup>[2]</sup></td> </tr> <tr> <td>Painful bladder syndrome is \"the complaint of suprapubic pain related to bladder filling, accompanied by other symptoms such as increased daytime and nighttime frequency, in the absence of proven urinary infection or other obvious pathology... The ICS believes this to be a preferable term to 'interstitial cystitis.' Interstitial cystitis is a specific diagnosis and requires confirmation by typical cystoscopic and histological features.\"</td> </tr> <tr> <td class=\"subtitle1_single\">National Institute for Diabetes and Diseases of the Kidney Criteria (1990)*<sup>[3]</sup></td> </tr> <tr> <td class=\"sublist1_start\">A diagnosis of&nbsp;interstitial cystitis&nbsp;can be made when patients have (1) bladder pain or urinary urgency AND (2) glomerulations or Hunner's ulcer during cystoscopy/hydrodistension AND (3) none of the exclusions listed below:</td> </tr> <tr> <td class=\"sublist1\">Awake cystometric capacity &#62;350 mL using a fill rate of 30 to 100 mL/minute</td> </tr> <tr> <td class=\"sublist1\">Absence of intense urge to void at 100 mL gas or 150 mL liquid</td> </tr> <tr> <td class=\"sublist1\">Involuntary detrusor contractions on cystometry</td> </tr> <tr> <td class=\"sublist1\">Urinary frequency less than&nbsp;eight voids per day</td> </tr> <tr> <td class=\"sublist1\">Absence of nocturia</td> </tr> <tr> <td class=\"sublist1\">Duration of symptoms less than&nbsp;nine months</td> </tr> <tr> <td class=\"sublist1\">Age less than 18 years</td> </tr> <tr> <td class=\"sublist1\">Cystitis (bacterial, chemical, post-irradiation), prostatitis, vulvitis (herpes) or vaginitis</td> </tr> <tr> <td class=\"sublist1\">Bladder, uterine, cervical, vaginal or urethral cancer</td> </tr> <tr> <td class=\"sublist1\">Bladder or lower ureteral calculi</td> </tr> <tr> <td class=\"sublist1\">Urethral diverticulum</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These criteria are not clinically useful but have been used in research studies.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Hanno PM, Burks DA, Clemens JQ, et al. J Urol 2011; 185:2162. </li>&#xD;&#xA;    <li>Abrams P, Cardozo L, Fall M, et al. Neurourol Urodyn 2002; 21:167. </li>&#xD;&#xA;    <li>Wein AJ, Hanno PM, Gillenwater JY. In: Interstitial Cystitis: An introduction to the problem. Hanno PM, Staskin DR, Krane RJ, Wein AJ, (Eds), Interstitial Cystitis: Springer-Verlag, 1990. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 66969 Version 6.0</div></div></div>"},"66971":{"type":"graphic_table","displayName":"Cutaneous reactions monoclonal antibodies","title":"Cutaneous reactions associated with non-EGFR targeting monoclonal antibodies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cutaneous reactions associated with non-EGFR targeting monoclonal antibodies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Rituximab</td> <td>Infusion reactions;&nbsp;paraneoplastic pemphigus; Stevens-Johnson syndrome</td> </tr> <tr> <td>Alemtuzumab</td> <td>Infusion reactions; viral reactivation</td> </tr> <tr> <td>Bevacizumab</td> <td>Infusion reactions</td> </tr> <tr> <td>Trastuzumab</td> <td>Infusion reactions</td> </tr> <tr> <td>Ofatumumab</td> <td>Infusion reactions, rash, urticaria, hyperhidrosis</td> </tr> <tr> <td>Obinutuzumab</td> <td>Infusion reactions</td> </tr> <tr> <td>Daratumumab</td> <td>Infusion reactions </td> </tr> <tr> <td>Olaratumab&nbsp;</td> <td>Infusion reactions </td> </tr> <tr> <td>Ramucirumab</td> <td>Infusion reactions, rash</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EGFR: epidermal growth factor receptor.</div><div id=\"graphicVersion\">Graphic 66971 Version 7.0</div></div></div>"},"66972":{"type":"graphic_table","displayName":"Causes unconjugated hyperbilirubinemia","title":"Causes of unconjugated hyperbilirubinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of unconjugated hyperbilirubinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bilirubin overproduction</td> </tr> <tr> <td class=\"sublist1_start\">Extravascular hemolysis</td> </tr> <tr> <td class=\"sublist1\">Extravasation of blood into tissues</td> </tr> <tr> <td class=\"sublist1\">Hypersplenism</td> </tr> <tr> <td class=\"sublist1_start\">Intravascular hemolysis</td> </tr> <tr> <td class=\"sublist1\">Inherited red blood cell disorders</td> </tr> <tr> <td class=\"sublist2\">Glucose-6-phosphate dehydrogenase deficiency*</td> </tr> <tr> <td class=\"sublist2\">Sickle cell disease*</td> </tr> <tr> <td class=\"sublist2\">Thalassemia</td> </tr> <tr> <td class=\"sublist2\">Hereditary spherocytosis</td> </tr> <tr> <td class=\"sublist2\">Hereditary elliptocytosis</td> </tr> <tr> <td class=\"sublist1\">Infection: malaria, bacterial sepsis*</td> </tr> <tr> <td class=\"sublist1\">Autoimmune hemolytic anemia</td> </tr> <tr> <td class=\"sublist1\">Microangiopathic hemolytic anemia</td> </tr> <tr> <td class=\"sublist1\">Drug induced hemolytic anemia</td> </tr> <tr> <td class=\"subtitle1_single\">Impaired hepatic bilirubin uptake</td> </tr> <tr> <td>Heart failure</td> </tr> <tr> <td>Portosystemic shunts</td> </tr> <tr> <td>Some patients with Gilbert syndrome</td> </tr> <tr> <td>Certain drugs-rifamycin, probenecid, flavaspadic acid, bunamiodyl</td> </tr> <tr> <td class=\"subtitle1_single\">Impaired bilirubin conjugation</td> </tr> <tr> <td class=\"sublist1_start\">Inherited</td> </tr> <tr> <td class=\"sublist1\">Crigler-Najjar syndrome</td> </tr> <tr> <td class=\"sublist1\">Gilbert syndrome*</td> </tr> <tr> <td class=\"sublist1_start\">Acquired</td> </tr> <tr> <td class=\"sublist1\">Neonates: physiologic hyperbilirubinemia,* breast-milk jaundice*</td> </tr> <tr> <td class=\"sublist1\">Hyperthyroidism (mechanism unclear)</td> </tr> <tr> <td class=\"sublist1\">Ethinyl estradiol</td> </tr> <tr> <td class=\"sublist1\">Antibiotics-novobiocin, gentamicin (above therapeutic range)</td> </tr> <tr> <td class=\"sublist1\">Liver diseases</td> </tr> <tr> <td class=\"sublist2\">Chronic persistent hepatitis</td> </tr> <tr> <td class=\"sublist2\">Advanced cirrhosis</td> </tr> <tr> <td class=\"indent2\">Wilson disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Common causes.</div><div class=\"graphic_reference\">Data from: Mandl KD. Jaundice-Unconjugated Hyperbilirubinemia. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.400.</div><div id=\"graphicVersion\">Graphic 66972 Version 6.0</div></div></div>"},"66973":{"type":"graphic_figure","displayName":"Refractive errors emmetropia myopia and hyperopia","title":"Refractive errors: Emmetropia (A), myopia (B), and hyperopia (C)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Refractive errors: Emmetropia (A), myopia (B), and hyperopia (C)</div><div class=\"cntnt\"><img style=\"width:246px; height:414px;\" src=\"images/PC/66973_Refractive_errors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>A) </STRONG>Emmetropia - eye with normal vision.<BR><STRONG>B)</STRONG> Myopia - nearsighted eye.<BR><STRONG>C)</STRONG> Hyperopia - farsighted eye.</div><div class=\"graphic_reference\">Reproduced with permission from Yanoff M, Duker JS. Ophthalmology, Mosby 1999. Copyright © 1999 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 66973 Version 2.0</div></div></div>"},"66974":{"type":"graphic_algorithm","displayName":"A scheme for classifying iodinated contrast","title":"A scheme for classifying iodinated contrast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A scheme for classifying iodinated contrast</div><div class=\"cntnt\"><img style=\"width:422px; height:242px;\" src=\"images/ALLRG/66974_Classifying_scheme_RCM.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RCM: radiocontrast media.</div><div id=\"graphicVersion\">Graphic 66974 Version 9.0</div></div></div>"},"66977":{"type":"graphic_table","displayName":"Types of suture material","title":"Classification of common suture materials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of common suture materials</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Type\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Generic name\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">\r\n  \r\n   Absorbable\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Natural fibers\r\n  \r\n   </td>\r\n  \r\n   <td>Plain catgut</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chromic catgut</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"5\">\r\n  \r\n   Synthetics\r\n  \r\n   </td>\r\n  \r\n   <td>Polyglycolic acid (Dexon)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Polyglactin 910 (Vicryl)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Polydioxanone (PDS)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Polyglyconate (Maxon)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Poliglecaprone (Moncryl)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">\r\n  \r\n   Permanent\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"3\">\r\n  \r\n   Natural fibers\r\n  \r\n   </td>\r\n  \r\n   <td>Cotton</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Linen</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Silk</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"5\">\r\n  \r\n   Synthetics\r\n  \r\n   </td>\r\n  \r\n   <td>Polyamide (Nylon)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Polypropylene (Prolene)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Polybutester (Novafil)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Polyester (Mersilene)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Coated polyester (Ti-cron, Tevdek)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Metal\r\n  \r\n   </td>\r\n  \r\n   <td>Stainless steel (Flexon)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Silver</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 66977 Version 2.0</div></div></div>"},"66979":{"type":"graphic_picture","displayName":"Pannus invading cartilage in RA","title":"Pannus invading cartilage in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pannus invading cartilage in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:431px; height:271px;\" src=\"images/RHEUM/66979_Pannus_invading_cartilage_i.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Articular surface of a joint obtained at the time of joint replacement surgery from a patient with rheumatoid arthritis. Pannus has replaced articular cartilage (left) and is invading the remaining cartilage (right, hematoxylin and eosin).</div><div class=\"graphic_reference\">Courtesy of Ellen M Gravallese, MD.</div><div id=\"graphicVersion\">Graphic 66979 Version 1.0</div></div></div>"},"66980":{"type":"graphic_diagnosticimage","displayName":"Spontaneous echo contrast seen in the left atrium on TEE","title":"Spontaneous echo contrast seen in the left atrium on transesophageal echocardiogram ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spontaneous echo contrast seen in the left atrium on transesophageal echocardiogram </div><div class=\"cntnt\"><img style=\"width:360px; height:286px;\" src=\"images/CARD/66980_Spontaneous_echo_contrast_E.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiography showing spontaneous echo contrast (or \"smoke\") in an enlarged left atrium (LA). This finding is a marker for stasis and is associated with a higher risk of thrombus formation and thromboembolism.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 66980 Version 5.0</div></div></div>"},"66981":{"type":"graphic_picture","displayName":"Ocular cicatricial pemphigoid stage 4","title":"Stage 4 ocular cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Stage 4 ocular cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:496px; height:348px;\" src=\"images/DERM/66981_Ocular_cicatricial_stage_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">End stage disease, with complete dry eye and &quot;leatherization&quot; of the ocular surface with corneal scarring.</div><div id=\"graphicVersion\">Graphic 66981 Version 1.0</div></div></div>"},"66982":{"type":"graphic_movie","displayName":"Apical 4 chamber effusion RV collapse","title":"Apical 4 chamber view of effusion and RV collapse","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Apical 4 chamber view of effusion and RV collapse</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/66982_Apical4chambeffRVmovie.mp4\" style=\"width:496px;height:368px\"></div><img style=\"width:504px; height:388px;\" src=\"images/EM/66982_Apical4chambeffRVimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compare this video clip to the apical four chamber view of normal cardiac function and note the collapse of the right ventricle.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 66982 Version 1.0</div></div></div>"},"66983":{"type":"graphic_figure","displayName":"Lymphocyte subset analysis by flow cytometry II","title":"Lymphocyte subset analysis by flow cytometry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocyte subset analysis by flow cytometry</div><div class=\"cntnt\"><img style=\"width:417px; height:300px;\" src=\"images/ALLRG/66983_Lympho_subset_anal_II_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow cytometric profile of an individual's peripheral blood affected by severe combined immunodeficiency (SCID) (T-B-NK-).</div><div id=\"graphicVersion\">Graphic 66983 Version 4.0</div></div></div>"},"66984":{"type":"graphic_diagnosticimage","displayName":"Hepatic adenomas CT","title":"Hepatic adenomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic adenomas</div><div class=\"cntnt\"><img style=\"width:324px; height:284px;\" src=\"images/GAST/66984_Hepatic_adenomas_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A computed tomography (CT) scan of the liver demonstrates two complex masses in the liver. Adenomas are usually solitary tumors. Multiple adenomas are commonly present in patients with glycogen storage disease.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 66984 Version 3.0</div></div></div>"},"66990":{"type":"graphic_table","displayName":"IPEX lab eval","title":"Findings on preliminary and advanced studies consistent with IPEX","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Findings on preliminary and advanced studies consistent with IPEX</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Findings</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Preliminary laboratories</td> </tr> <tr> <td class=\"indent1\">CBC with differential</td> <td>Eosinophilia, cytopenias</td> </tr> <tr> <td class=\"indent1\">Serum glucose + antiislet antibodies</td> <td>Refractory type 1 DM</td> </tr> <tr> <td class=\"indent1\">Thyroid function tests + antithyroid antibodies</td> <td>Immune-mediated thyroiditis</td> </tr> <tr> <td class=\"indent1\">Antienterocyte antibody</td> <td>May be present in autoimmune enteropathy</td> </tr> <tr> <td class=\"indent1\">IgE</td> <td>Elevated</td> </tr> <tr> <td class=\"indent1\">IgA, IgM, IgG</td> <td>IgA may be elevated, others usually normal</td> </tr> <tr> <td class=\"indent1\">RAST for food antigens</td> <td>Elevated</td> </tr> <tr> <td class=\"indent1\">T and B cell subsets</td> <td>Usually normal</td> </tr> <tr> <td class=\"indent1\">T cell proliferation</td> <td>Usually normal</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Advanced studies</td> </tr> <tr> <td class=\"indent1\">FOXP3 gene sequencing</td> <td>Mutations establish definitive diagnosis</td> </tr> <tr> <td class=\"indent1\">Endoscopic biopsy</td> <td>Villous atrophy with lymphocyte infiltration</td> </tr> <tr> <td class=\"indent1\">Skin biopsy</td> <td>Lymphocytic infiltration</td> </tr> <tr> <td class=\"indent1\">T<sub>Reg</sub> quantitative and functional studies</td> <td>T<sub>Reg</sub> deficiency</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IPEX: immune dysregulation, polyendocrinopathy, enteropathy, X-linked; CBC: complete blood count; DM: diabetes mellitus; IgE: immunoglobulin E; IgA: immunoglobulin A; IgM: immunoglobulin M; IgG: immunoglobulin G; RAST: radioallergosorbent tests; FOXP3: forkhead box P3 transcription factor; T<sub>Reg</sub>: regulatory T cell subset.</div><div id=\"graphicVersion\">Graphic 66990 Version 3.0</div></div></div>"},"66991":{"type":"graphic_table","displayName":"Table intrinsic muscles of the hand","title":"Intrinsic muscles of the hand","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intrinsic muscles of the hand</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Muscle</td> <td class=\"subtitle1\">Proximal attachment</td> <td class=\"subtitle1\">Distal attachment</td> <td class=\"subtitle1\">Innervation*</td> <td class=\"subtitle1\">Main action</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Thenar muscles</td> </tr> <tr> <td class=\"indent1\">Opponens pollicis</td> <td rowspan=\"5\">Flexor retinaculum and tubercles of scaphoid and trapezium</td> <td>Lateral side of first metacarpal</td> <td rowspan=\"4\">Recurrent branch of median nerve (<strong>C8</strong>, T1)</td> <td>To oppose thumb, it draws first metacarpal medially to center of palm and rotates it medially</td> </tr> <tr> <td class=\"indent1\">Abductor pollicis brevis</td> <td rowspan=\"4\">Lateral side of base of proximal phalanx of thumb</td> <td>Abducts thumb; helps oppose it</td> </tr> <tr> <td class=\"indent1\">Flexor pollicis brevis</td> <td>Flexes thumb</td> </tr> <tr> <td class=\"indent2\">Superficial head</td> <td rowspan=\"5\">Adducts thumb toward lateral border of palm</td> </tr> <tr> <td class=\"indent2\">Deep head</td> <td rowspan=\"4\">Deep branch of ulnar nerve (C8, <strong>T1</strong>)</td> </tr> <tr> <td class=\"indent1\">Adductor pollicis</td> <td rowspan=\"2\">Bases of second and third metacarpals, capitate, adjacent carpals</td> <td rowspan=\"3\">Medial side of base of proximal phalanx of thumb</td> </tr> <tr> <td class=\"indent2\">Oblique head</td> </tr> <tr> <td class=\"indent2\">Transverse head</td> <td>Anterior surface of shaft of third metacarpal</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Hypothenar muscles</td> </tr> <tr> <td class=\"indent1\">Abductor digiti minimi</td> <td>Pisiform</td> <td rowspan=\"2\">Medial side of base of proximal phalanx of fifth finger</td> <td rowspan=\"3\">Deep branch of ulnar nerve (C8, <strong>T1</strong>)</td> <td>Abducts fifth finger; assists in flexion of its proximal phalanx</td> </tr> <tr> <td class=\"indent1\">Flexor digiti minimi brevis</td> <td rowspan=\"2\">Hook of hamate and flexor retinaculum</td> <td>Flexes proximal phalanx of fifth finger</td> </tr> <tr> <td class=\"indent1\">Opponens digiti minimi</td> <td>Medial border of fifth metacarpal</td> <td>Draws fifth metacarpal anterior and rotates it, bringing fifth finger into opposition with thumb</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Short muscles</td> </tr> <tr> <td class=\"indent1\">Lumbricals</td> <td rowspan=\"2\">Lateral two tendons of flexor digitorum profundus (as unipennate muscles)</td> <td rowspan=\"3\">Lateral sides of extensor expansions of second through fifth fingers</td> <td rowspan=\"2\">Median nerve (C8, <strong>T1</strong>)</td> <td rowspan=\"3\">Flex metacarpophalangeal joints; extend interphalangeal joints of second through fifth fingers</td> </tr> <tr> <td class=\"indent2\">First and second</td> </tr> <tr> <td class=\"indent2\">Third and fourth</td> <td>Medial three tendons of flexor digitorum profundus (as bipennate muscles)</td> <td rowspan=\"3\">Deep branch of ulnar nerve (C8, <strong>T1</strong>)</td> </tr> <tr> <td class=\"indent1\">Dorsal interossei, first through fourth</td> <td>Adjacent sides of two metacarpals (as bipennate muscles)</td> <td>Bases of proximal phalanges; extensor expansions of second through fourth fingers</td> <td>Abduct second through fourth fingers from axial line; act with lumbricals in flexing metacarpophalangeal joints and extending interphalangeal joints</td> </tr> <tr> <td class=\"indent1\">Palmar interossei, first through third</td> <td>Palmar surfaces of second, fourth, and fifth metacarpals (as unipennate muscles)</td> <td>Bases of proximal phalanges; extensor expansions of second, fourth, and fifth fingers</td> <td>Adduct second, fourth, and fifth fingers toward axial line; assist lumbricals in flexing metacarpophalangeal joints and extending interphalangeal joints; extensor expansions of second-fourth fingers</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The spinal cord segmental innervation is indicated (eg, \"<strong>C8</strong>, T1\" means that the nerves supplying the opponens pollicis are derived from the eighth cervical segment and first thoracic segment of the spinal cord). Numbers in boldface (<strong>C8</strong>) indicate the main segmental innervation. Damage to one or more of the listed spinal cord segments or to the motor nerve roots arising from them results in paralysis of the muscles concerned.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66991 Version 15.0</div></div></div>"},"66992":{"type":"graphic_diagnosticimage","displayName":"MRI of Grade I medial collateral ligament injury","title":"MRI of Grade I medial collateral ligament injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of Grade&nbsp;I medial collateral ligament injury</div><div class=\"cntnt\"><img style=\"width:380px; height:380px;\" src=\"images/EM/66992_MCL_grade1_injury_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MCL is macroscopically intact, but there is overlying bright signal (arrowheads), reflecting superficial edema associated with the presence of torn fibers. In Grade 1 sprains, the edema is seen only superficially. The MCL is of normal thickness and is closely applied to the cortical bone.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MCL: medial collateral ligament.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD.</div><div id=\"graphicVersion\">Graphic 66992 Version 4.0</div></div></div>"},"66994":{"type":"graphic_figure","displayName":"Biclonal pattern immunofix","title":"Biclonal gammopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biclonal gammopathy</div><div class=\"cntnt\"><img style=\"width:299px; height:358px;\" src=\"images/HEME/66994_Biclonal_pattern_immunofix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the immunofixation pattern of a single serum specimen with antisera to heavy chain determinants of IgA, IgG, and IgM, and to kappa and lambda light chain determinants. It shows a discrete IgG band (seen as a dark band) and a discrete lambda band with similar mobility, indicative of the presence of an IgG lambda monoclonal protein. There is also an IgM kappa monoclonal protein.</div><div id=\"graphicVersion\">Graphic 66994 Version 2.0</div></div></div>"},"66996":{"type":"graphic_figure","displayName":"Mutations in the Wiskott-Aldrich syndrome - WAS gene","title":"Mutations in the Wiskott-Aldrich syndrome (WAS) gene","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Mutations in the Wiskott-Aldrich syndrome (WAS) gene</div><div class=\"cntnt\"><img style=\"width:609px; height:379px;\" src=\"images/ALLRG/66996_WASmutations.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>WAS </EM>gene mutations causing both classic Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Types of mutations are based upon molecular analysis.</div><div class=\"graphic_footnotes\">WIP: WASP interacting protein; PH: Pleckstrin homology; CRIB: Cdc42- and Rac-interactive binding; GBD: GTPase-binding domain; SH3: Src homology 3; Arp2/3: actin-related protein 2/3; del: deletion.</div><div class=\"graphic_reference\">Data from:&nbsp;<br /><OL>&#xD;&#xA;<LI>Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): Hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004; 104:4010.</LI>&#xD;&#xA;<LI>Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006; 117:725. </LI>&#xD;&#xA;<LI>Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: Clinical characteristics, long-term outcome, and treatment options. Blood 2010; 115:3231.</LI></OL></div><div id=\"graphicVersion\">Graphic 66996 Version 6.0</div></div></div>"},"66997":{"type":"graphic_figure","displayName":"Zipper fastener release","title":"Zipper fastener penile entrapment release","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Zipper fastener penile entrapment release</div><div class=\"cntnt\"><img style=\"width:306px; height:527px;\" src=\"images/EM/66997_Zipperfastenerrelease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once the median bar is cut through with wire cutters, the fastener falls apart and the entrapped skin is easily removed from the zipper.</div><div class=\"graphic_reference\">Reproduced with permission from: Fein JA, Zderic SA. Management of zipper injuries. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 66997 Version 10.0</div></div></div>"},"66998":{"type":"graphic_figure","displayName":"Pleural flap buttress of thoracic esophageal perforation repair","title":"Pleural flap buttress of thoracic esophageal perforation repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural flap buttress of thoracic esophageal perforation repair</div><div class=\"cntnt\"><img style=\"width:282px; height:306px;\" src=\"images/SURG/66998_Parietal-pleura-patch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a parietal pleural patch used to repair a perforation in the distal esophagus.</div><div id=\"graphicVersion\">Graphic 66998 Version 3.0</div></div></div>"},"66999":{"type":"graphic_table","displayName":"Normal range for coagulation tests in children","title":"Normal range for coagulation tests by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal range for coagulation tests by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Coagulation tests</td> <td class=\"subtitle1\" colspan=\"7\">Age</td> </tr> <tr> <td class=\"subtitle2\"> <p>Day 1 of life</p> <p>Mean (boundary)</p> </td> <td class=\"subtitle2\"> <p>Day 3 of life</p> <p>Mean (boundary)</p> </td> <td class=\"subtitle2\"> <p>1 to 12 months</p> <p>Mean (boundary)</p> </td> <td class=\"subtitle2\"> <p>1 to 5 year</p> <p>Mean (boundary)</p> </td> <td class=\"subtitle2\"> <p>6 to 10 year</p> <p>Mean (boundary)</p> </td> <td class=\"subtitle2\"> <p>11 to 16 year</p> <p>Mean (boundary)</p> </td> <td class=\"subtitle2\"> <p>Adult</p> <p>Mean (boundary)</p> </td> </tr> <tr> <td>PT(s)*</td> <td>15.6 (14.4-16.4)<sup>&#182;</sup></td> <td>14.9 (13.5-16.4)<sup>&#182;</sup></td> <td>13.1 (11.5-15.3)</td> <td>13.3 (12.1-14.5)<sup>&#182;</sup></td> <td>13.4 (11.7-15.1)<sup>&#182;</sup></td> <td>13.8 (12.7-16.1)<sup>&#182;</sup></td> <td>13 (11.5-14.5)</td> </tr> <tr> <td>INR</td> <td>1.26 (1.15-1.35)<sup>&#182;</sup></td> <td>1.2 (1.05-1.35)<sup>&#182;</sup></td> <td>1 (0.86-1.22)</td> <td>1.03 (0.92-1.14)<sup>&#182;</sup></td> <td>1.04 (0.87-1.2)<sup>&#182;</sup></td> <td>1.08 (0.97-1.3)<sup>&#182;</sup></td> <td>1 (0.8-1.2)</td> </tr> <tr> <td>APTT(s)*</td> <td>38.7 (34.3-44.8)<sup>&#182;</sup></td> <td>36.3 (29.5-42.2)<sup>&#182;</sup></td> <td>39.3 (35.1-46.3)<sup>&#182;</sup></td> <td>37.7 (33.6-46.3)<sup>&#182;</sup></td> <td>37.3 (31.8-43.7)<sup>&#182;</sup></td> <td>39.5 (33.9-46.1)<sup>&#182;</sup></td> <td>33.2 (28.6-38.2)</td> </tr> <tr> <td>Fibrinogen (g/L)</td> <td>2.8 (1.92-3.74)</td> <td>3.3 (2.83-4.01)</td> <td>2.42 (0.82-3.83)<sup>&#182;</sup></td> <td>2.82 (1.62-4.01)<sup>&#182;</sup></td> <td>3.04 (1.99-4.09)</td> <td>3.15 (2.12-4.33)</td> <td>3.1 (1.9-4.3)</td> </tr> <tr> <td>Factor II (U/mL)</td> <td>0.54 (0.41-0.69)<sup>&#182;</sup></td> <td>0.62 (0.5-0.73)<sup>&#182;</sup></td> <td>0.9 (0.62-1.03)<sup>&#182;</sup></td> <td>0.89 (0.7-1.09)<sup>&#182;</sup></td> <td>0.89 (0.67-1.1)<sup>&#182;</sup></td> <td>0.9 (0.61-1.07)<sup>&#182;</sup></td> <td>1.1 (0.78-1.38)</td> </tr> <tr> <td>Factor V (U/mL)</td> <td>0.81 (0.64-1.03)<sup>&#182;</sup></td> <td>1.22 (0.92-1.54)</td> <td>1.13 (0.94-1.41)</td> <td>0.97 (0.67-1.27)<sup>&#182;</sup></td> <td>0.99 (0.56-1.41)<sup>&#182;</sup></td> <td>0.89 (0.67-1.41)<sup>&#182;</sup></td> <td>1.18 (0.78-1.52)</td> </tr> <tr> <td>Factor VII (U/mL)</td> <td>0.7 (0.52-0.88)<sup>&#182;</sup></td> <td>0.86 (0.67-1.07)<sup>&#182;</sup></td> <td>1.28 (0.83-1.6)</td> <td>1.11 (0.72-1.5)<sup>&#182;</sup></td> <td>1.13 (0.7-1.56)<sup>&#182;</sup></td> <td>1.18 (0.69-2)</td> <td>1.29 (0.61-1.99)</td> </tr> <tr> <td>Factor VIII (U/mL)</td> <td>1.82 (1.05-3.29)</td> <td>1.59 (0.83-2.74)</td> <td>0.94 (0.54-1.45)<sup>&#182;</sup></td> <td>1.1 (0.36-1.85)<sup>&#182;</sup></td> <td>1.17 (0.52-1.82)<sup>&#182;</sup></td> <td>1.2 (0.59-2)<sup>&#182;</sup></td> <td>1.6 (0.52-2.9)</td> </tr> <tr> <td>vWF (U/mL)</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> <td>0.82 (0.6-1.2)</td> <td>0.95 (0.44-1.44)</td> <td>1 (0.46-1.53)</td> <td>0.92 (0.5-1.58)</td> </tr> <tr> <td>Factor IX (U/mL)</td> <td>0.48 (0.35-0.56)<sup>&#182;</sup></td> <td>0.72 (0.44-0.97)<sup>&#182;</sup></td> <td>0.71 (0.43-1.21)<sup>&#182;</sup></td> <td>0.85 (0.44-1.27)<sup>&#182;</sup></td> <td>0.96 (0.48-1.45)<sup>&#182;</sup></td> <td>1.11 (0.64-2.16)<sup>&#182;</sup></td> <td>1.3 (0.59-2.54)</td> </tr> <tr> <td>Factor X (U/mL)</td> <td>0.55 (0.46-0.67)<sup>&#182;</sup></td> <td>0.6 (0.46-0.75)<sup>&#182;</sup></td> <td>0.95 (0.77-1.22)<sup>&#182;</sup></td> <td>0.98 (0.72-1.25)<sup>&#182;</sup></td> <td>0.97 (0.68-1.25)<sup>&#182;</sup></td> <td>0.91 (0.53-1.22)<sup>&#182;</sup></td> <td>1.24 (0.96-1.71)</td> </tr> <tr> <td>Factor XI (U/mL)</td> <td>0.3 (0.7-0.41)<sup>&#182;</sup></td> <td>0.57 (0.24-0.79)<sup>&#182;</sup></td> <td>0.89 (0.62-1.25)<sup>&#182;</sup></td> <td>1.13 (0.65-1.62)</td> <td>1.13 (0.65-1.62)</td> <td>1.11 (0.65-1.39)</td> <td>1.12 (0.67-1.96)</td> </tr> <tr> <td>Factor XII (U/mL)</td> <td>0.58 (0.43-0.8)<sup>&#182;</sup></td> <td>0.53 (0.14-0.8)<sup>&#182;</sup></td> <td>0.79 (0.2-1.35)<sup>&#182;</sup></td> <td>0.85 (0.36-1.35)<sup>&#182;</sup></td> <td>0.81 (0.26-1.37)<sup>&#182;</sup></td> <td>0.75 (0.14-1.17)<sup>&#182;</sup></td> <td>1.15 (0.35-2.07)</td> </tr> <tr> <td>XIIIa (U/mL)</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> <td>1.08 (0.72-1.43)<sup>&#182;</sup></td> <td>1.09 (0.65-1.51)<sup>&#182;</sup></td> <td>0.99 (0.57-1.4)</td> <td>1.05 (0.55-1.55)</td> </tr> <tr> <td>XIIIs (U/mL)</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> <td>1.13 (0.69-1.56)<sup>&#182;</sup></td> <td>1.16 (0.77-1.54)<sup>&#182;</sup></td> <td>1.02 (0.6-1.43)</td> <td>0.97 (0.57-1.37)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All factors except fibrinogen are expressed as units per milliliter, where pooled plasma contains 1.0 U/mL. All data are expressed as the mean, followed by the upper and lower boundary encompassing 95 percent of the population. Between 20 and 67 samples were assayed for each value for each age group. Some measurements were skewed due to a disproportionate number of high values. The lower limit, which excludes the lower 2.5 percent of the population, is given.</div><div class=\"graphic_footnotes\">PT: prothrombin time; APTT: activated partial thromboplastin time; VIII: factor VIII procoagulant; vWF: von Willebrand factor; n/a: data not available.<br />* Normal range for PT and aPTT should be based upon the standards set by individual clinical laboratories.<br />¶ Denotes values that are significantly different from adults.</div><div class=\"graphic_reference\">Data on vWF, XIIIa and XIIIs from: Andrew M, Vegh P, Johnston M, et al. Maturation of the Hemostatic System During Childhood. Blood 1992; 80:1999.<br />Remaining data from: Monagle P, Barnes C, Ignjatovic V, Furmedge J, et al. Developmental Haemostasis. Thrombosis and Haemostasis 2006; 95:362.</div><div id=\"graphicVersion\">Graphic 66999 Version 5.0</div></div></div>"}};